false
--12-31
Q3
0000830656
http://fasb.org/us-gaap/2023#ProductAndServiceOtherMember
http://fasb.org/us-gaap/2023#ProductAndServiceOtherMember
http://fasb.org/us-gaap/2023#ProductAndServiceOtherMember
http://fasb.org/us-gaap/2023#ProductAndServiceOtherMember
0000830656
2023-01-01
2023-09-30
0000830656
2023-11-10
0000830656
2023-09-30
0000830656
2022-12-31
0000830656
us-gaap:ConvertibleDebtMember
2023-09-30
0000830656
us-gaap:ConvertibleDebtMember
2022-12-31
0000830656
us-gaap:RelatedPartyMember
2023-09-30
0000830656
us-gaap:RelatedPartyMember
2022-12-31
0000830656
PBIO:SeriesDConvertiblePreferredStockMember
2023-09-30
0000830656
PBIO:SeriesDConvertiblePreferredStockMember
2022-12-31
0000830656
PBIO:SeriesGConvertiblePreferredStockMember
2023-09-30
0000830656
PBIO:SeriesGConvertiblePreferredStockMember
2022-12-31
0000830656
PBIO:SeriesHConvertiblePreferredStockMember
2023-09-30
0000830656
PBIO:SeriesHConvertiblePreferredStockMember
2022-12-31
0000830656
PBIO:SeriesH2ConvertiblePreferredStockMember
2023-09-30
0000830656
PBIO:SeriesH2ConvertiblePreferredStockMember
2022-12-31
0000830656
PBIO:SeriesJConvertiblePreferredStockMember
2023-09-30
0000830656
PBIO:SeriesJConvertiblePreferredStockMember
2022-12-31
0000830656
PBIO:SeriesKConvertiblePreferredStockMember
2023-09-30
0000830656
PBIO:SeriesKConvertiblePreferredStockMember
2022-12-31
0000830656
PBIO:SeriesAAConvertiblePreferredStockMember
2023-09-30
0000830656
PBIO:SeriesAAConvertiblePreferredStockMember
2022-12-31
0000830656
PBIO:SeriesBBConvertiblePreferredStockMember
2023-09-30
0000830656
PBIO:SeriesBBConvertiblePreferredStockMember
2022-12-31
0000830656
PBIO:SeriesCCConvertiblePreferredStockMember
2023-09-30
0000830656
PBIO:SeriesCCConvertiblePreferredStockMember
2022-12-31
0000830656
2023-07-01
2023-09-30
0000830656
2022-07-01
2022-09-30
0000830656
2022-01-01
2022-09-30
0000830656
2021-12-31
0000830656
2022-09-30
0000830656
us-gaap:PreferredStockMember
2022-12-31
0000830656
us-gaap:CommonStockMember
2022-12-31
0000830656
us-gaap:WarrantMember
2022-12-31
0000830656
us-gaap:AdditionalPaidInCapitalMember
2022-12-31
0000830656
us-gaap:RetainedEarningsMember
2022-12-31
0000830656
us-gaap:PreferredStockMember
2023-03-31
0000830656
us-gaap:CommonStockMember
2023-03-31
0000830656
us-gaap:WarrantMember
2023-03-31
0000830656
us-gaap:AdditionalPaidInCapitalMember
2023-03-31
0000830656
us-gaap:RetainedEarningsMember
2023-03-31
0000830656
2023-03-31
0000830656
us-gaap:PreferredStockMember
2023-06-30
0000830656
us-gaap:CommonStockMember
2023-06-30
0000830656
us-gaap:WarrantMember
2023-06-30
0000830656
us-gaap:AdditionalPaidInCapitalMember
2023-06-30
0000830656
us-gaap:RetainedEarningsMember
2023-06-30
0000830656
2023-06-30
0000830656
us-gaap:PreferredStockMember
2021-12-31
0000830656
us-gaap:CommonStockMember
2021-12-31
0000830656
us-gaap:WarrantMember
2021-12-31
0000830656
us-gaap:AdditionalPaidInCapitalMember
2021-12-31
0000830656
us-gaap:RetainedEarningsMember
2021-12-31
0000830656
us-gaap:PreferredStockMember
2022-03-31
0000830656
us-gaap:CommonStockMember
2022-03-31
0000830656
us-gaap:WarrantMember
2022-03-31
0000830656
us-gaap:AdditionalPaidInCapitalMember
2022-03-31
0000830656
us-gaap:RetainedEarningsMember
2022-03-31
0000830656
2022-03-31
0000830656
us-gaap:PreferredStockMember
2022-06-30
0000830656
us-gaap:CommonStockMember
2022-06-30
0000830656
us-gaap:WarrantMember
2022-06-30
0000830656
us-gaap:AdditionalPaidInCapitalMember
2022-06-30
0000830656
us-gaap:RetainedEarningsMember
2022-06-30
0000830656
2022-06-30
0000830656
us-gaap:PreferredStockMember
2023-01-01
2023-03-31
0000830656
us-gaap:CommonStockMember
2023-01-01
2023-03-31
0000830656
us-gaap:WarrantMember
2023-01-01
2023-03-31
0000830656
us-gaap:AdditionalPaidInCapitalMember
2023-01-01
2023-03-31
0000830656
us-gaap:RetainedEarningsMember
2023-01-01
2023-03-31
0000830656
2023-01-01
2023-03-31
0000830656
us-gaap:PreferredStockMember
2023-04-01
2023-06-30
0000830656
us-gaap:CommonStockMember
2023-04-01
2023-06-30
0000830656
us-gaap:WarrantMember
2023-04-01
2023-06-30
0000830656
us-gaap:AdditionalPaidInCapitalMember
2023-04-01
2023-06-30
0000830656
us-gaap:RetainedEarningsMember
2023-04-01
2023-06-30
0000830656
2023-04-01
2023-06-30
0000830656
us-gaap:PreferredStockMember
2023-07-01
2023-09-30
0000830656
us-gaap:CommonStockMember
2023-07-01
2023-09-30
0000830656
us-gaap:WarrantMember
2023-07-01
2023-09-30
0000830656
us-gaap:AdditionalPaidInCapitalMember
2023-07-01
2023-09-30
0000830656
us-gaap:RetainedEarningsMember
2023-07-01
2023-09-30
0000830656
us-gaap:PreferredStockMember
2022-01-01
2022-03-31
0000830656
us-gaap:CommonStockMember
2022-01-01
2022-03-31
0000830656
us-gaap:WarrantMember
2022-01-01
2022-03-31
0000830656
us-gaap:AdditionalPaidInCapitalMember
2022-01-01
2022-03-31
0000830656
us-gaap:RetainedEarningsMember
2022-01-01
2022-03-31
0000830656
2022-01-01
2022-03-31
0000830656
us-gaap:PreferredStockMember
2022-04-01
2022-06-30
0000830656
us-gaap:CommonStockMember
2022-04-01
2022-06-30
0000830656
us-gaap:WarrantMember
2022-04-01
2022-06-30
0000830656
us-gaap:AdditionalPaidInCapitalMember
2022-04-01
2022-06-30
0000830656
us-gaap:RetainedEarningsMember
2022-04-01
2022-06-30
0000830656
2022-04-01
2022-06-30
0000830656
us-gaap:PreferredStockMember
2022-07-01
2022-09-30
0000830656
us-gaap:CommonStockMember
2022-07-01
2022-09-30
0000830656
us-gaap:WarrantMember
2022-07-01
2022-09-30
0000830656
us-gaap:AdditionalPaidInCapitalMember
2022-07-01
2022-09-30
0000830656
us-gaap:RetainedEarningsMember
2022-07-01
2022-09-30
0000830656
us-gaap:PreferredStockMember
2023-09-30
0000830656
us-gaap:CommonStockMember
2023-09-30
0000830656
us-gaap:WarrantMember
2023-09-30
0000830656
us-gaap:AdditionalPaidInCapitalMember
2023-09-30
0000830656
us-gaap:RetainedEarningsMember
2023-09-30
0000830656
us-gaap:PreferredStockMember
2022-09-30
0000830656
us-gaap:CommonStockMember
2022-09-30
0000830656
us-gaap:WarrantMember
2022-09-30
0000830656
us-gaap:AdditionalPaidInCapitalMember
2022-09-30
0000830656
us-gaap:RetainedEarningsMember
2022-09-30
0000830656
2020-08-30
0000830656
PBIO:NexityGlobalSAMember
2023-01-01
2023-09-30
0000830656
PBIO:NexityGlobalSAMember
2023-09-30
0000830656
srt:MinimumMember
2023-09-30
0000830656
srt:MaximumMember
2023-09-30
0000830656
srt:NorthAmericaMember
2023-07-01
2023-09-30
0000830656
srt:NorthAmericaMember
2022-07-01
2022-09-30
0000830656
srt:NorthAmericaMember
2023-01-01
2023-09-30
0000830656
srt:NorthAmericaMember
2022-01-01
2022-09-30
0000830656
srt:EuropeMember
2023-07-01
2023-09-30
0000830656
srt:EuropeMember
2022-07-01
2022-09-30
0000830656
srt:EuropeMember
2023-01-01
2023-09-30
0000830656
srt:EuropeMember
2022-01-01
2022-09-30
0000830656
srt:AsiaMember
2023-07-01
2023-09-30
0000830656
srt:AsiaMember
2022-07-01
2022-09-30
0000830656
srt:AsiaMember
2023-01-01
2023-09-30
0000830656
srt:AsiaMember
2022-01-01
2022-09-30
0000830656
PBIO:HardwareMember
2023-07-01
2023-09-30
0000830656
PBIO:HardwareMember
2022-07-01
2022-09-30
0000830656
PBIO:HardwareMember
2023-01-01
2023-09-30
0000830656
PBIO:HardwareMember
2022-01-01
2022-09-30
0000830656
PBIO:ConsumablesMember
2023-07-01
2023-09-30
0000830656
PBIO:ConsumablesMember
2022-07-01
2022-09-30
0000830656
PBIO:ConsumablesMember
2023-01-01
2023-09-30
0000830656
PBIO:ConsumablesMember
2022-01-01
2022-09-30
0000830656
PBIO:ContractResearchServicesMember
2023-07-01
2023-09-30
0000830656
PBIO:ContractResearchServicesMember
2022-07-01
2022-09-30
0000830656
PBIO:ContractResearchServicesMember
2023-01-01
2023-09-30
0000830656
PBIO:ContractResearchServicesMember
2022-01-01
2022-09-30
0000830656
PBIO:SamplePreparationAccessoriesMember
2023-07-01
2023-09-30
0000830656
PBIO:SamplePreparationAccessoriesMember
2022-07-01
2022-09-30
0000830656
PBIO:SamplePreparationAccessoriesMember
2023-01-01
2023-09-30
0000830656
PBIO:SamplePreparationAccessoriesMember
2022-01-01
2022-09-30
0000830656
PBIO:TechnicalSupportExtendedServiceContractsMember
2023-07-01
2023-09-30
0000830656
PBIO:TechnicalSupportExtendedServiceContractsMember
2022-07-01
2022-09-30
0000830656
PBIO:TechnicalSupportExtendedServiceContractsMember
2023-01-01
2023-09-30
0000830656
PBIO:TechnicalSupportExtendedServiceContractsMember
2022-01-01
2022-09-30
0000830656
PBIO:AgrochemProductsMember
2023-07-01
2023-09-30
0000830656
PBIO:AgrochemProductsMember
2022-07-01
2022-09-30
0000830656
PBIO:AgrochemProductsMember
2023-01-01
2023-09-30
0000830656
PBIO:AgrochemProductsMember
2022-01-01
2022-09-30
0000830656
us-gaap:ShippingAndHandlingMember
2023-07-01
2023-09-30
0000830656
us-gaap:ShippingAndHandlingMember
2022-07-01
2022-09-30
0000830656
us-gaap:ShippingAndHandlingMember
2023-01-01
2023-09-30
0000830656
us-gaap:ShippingAndHandlingMember
2022-01-01
2022-09-30
0000830656
PBIO:OtherMember
2023-07-01
2023-09-30
0000830656
PBIO:OtherMember
2022-07-01
2022-09-30
0000830656
PBIO:OtherMember
2023-01-01
2023-09-30
0000830656
PBIO:OtherMember
2022-01-01
2022-09-30
0000830656
PBIO:TransferredAtAPointInTimeMember
2023-07-01
2023-09-30
0000830656
PBIO:TransferredAtAPointInTimeMember
2022-07-01
2022-09-30
0000830656
PBIO:TransferredAtAPointInTimeMember
2023-01-01
2023-09-30
0000830656
PBIO:TransferredAtAPointInTimeMember
2022-01-01
2022-09-30
0000830656
PBIO:TransferredOverAtTimeMember
2023-07-01
2023-09-30
0000830656
PBIO:TransferredOverAtTimeMember
2022-07-01
2022-09-30
0000830656
PBIO:TransferredOverAtTimeMember
2023-01-01
2023-09-30
0000830656
PBIO:TransferredOverAtTimeMember
2022-01-01
2022-09-30
0000830656
PBIO:TwoThousandAndTwentyThreeMember
2023-09-30
0000830656
PBIO:TwoThousandAndTwentyFourMember
2023-09-30
0000830656
PBIO:TopFiveCustomersMember
us-gaap:SalesRevenueNetMember
us-gaap:CustomerConcentrationRiskMember
2023-07-01
2023-09-30
0000830656
PBIO:TopFiveCustomersMember
us-gaap:SalesRevenueNetMember
us-gaap:CustomerConcentrationRiskMember
2022-07-01
2022-09-30
0000830656
PBIO:TopFiveCustomersMember
us-gaap:SalesRevenueNetMember
us-gaap:CustomerConcentrationRiskMember
2023-01-01
2023-09-30
0000830656
PBIO:TopFiveCustomersMember
us-gaap:SalesRevenueNetMember
us-gaap:CustomerConcentrationRiskMember
2022-01-01
2022-09-30
0000830656
PBIO:FederalAgenciesMember
us-gaap:SalesRevenueNetMember
us-gaap:CustomerConcentrationRiskMember
2023-07-01
2023-09-30
0000830656
PBIO:FederalAgenciesMember
us-gaap:SalesRevenueNetMember
us-gaap:CustomerConcentrationRiskMember
2022-07-01
2022-09-30
0000830656
PBIO:FederalAgenciesMember
us-gaap:SalesRevenueNetMember
us-gaap:CustomerConcentrationRiskMember
2023-01-01
2023-09-30
0000830656
PBIO:FederalAgenciesMember
us-gaap:SalesRevenueNetMember
us-gaap:CustomerConcentrationRiskMember
2022-01-01
2022-09-30
0000830656
PBIO:TopFiveCustomersMember
us-gaap:AccountsReceivableMember
us-gaap:CustomerConcentrationRiskMember
2023-01-01
2023-09-30
0000830656
PBIO:TopFiveCustomersMember
us-gaap:AccountsReceivableMember
us-gaap:CustomerConcentrationRiskMember
2022-01-01
2022-12-31
0000830656
PBIO:FederalAgenciesMember
us-gaap:AccountsReceivableMember
us-gaap:CustomerConcentrationRiskMember
2023-01-01
2023-09-30
0000830656
PBIO:FederalAgenciesMember
us-gaap:AccountsReceivableMember
us-gaap:CustomerConcentrationRiskMember
2022-01-01
2022-12-31
0000830656
PBIO:EmployeeStockOptionsMember
2023-01-01
2023-09-30
0000830656
PBIO:EmployeeStockOptionsMember
2022-01-01
2022-09-30
0000830656
us-gaap:ConvertibleDebtSecuritiesMember
2023-01-01
2023-09-30
0000830656
us-gaap:ConvertibleDebtSecuritiesMember
2022-01-01
2022-09-30
0000830656
PBIO:CommonStockWarrantsMember
2023-01-01
2023-09-30
0000830656
PBIO:CommonStockWarrantsMember
2022-01-01
2022-09-30
0000830656
PBIO:SeriesDConvertiblePreferredStockMember
2023-01-01
2023-09-30
0000830656
PBIO:SeriesDConvertiblePreferredStockMember
2022-01-01
2022-09-30
0000830656
PBIO:SeriesGConvertiblePreferredStockMember
2023-01-01
2023-09-30
0000830656
PBIO:SeriesGConvertiblePreferredStockMember
2022-01-01
2022-09-30
0000830656
PBIO:SeriesHConvertiblePreferredStockMember
2023-01-01
2023-09-30
0000830656
PBIO:SeriesHConvertiblePreferredStockMember
2022-01-01
2022-09-30
0000830656
PBIO:SeriesHTwoConvertiblePreferredStockMember
2023-01-01
2023-09-30
0000830656
PBIO:SeriesHTwoConvertiblePreferredStockMember
2022-01-01
2022-09-30
0000830656
PBIO:SeriesJConvertiblePreferredStockMember
2023-01-01
2023-09-30
0000830656
PBIO:SeriesJConvertiblePreferredStockMember
2022-01-01
2022-09-30
0000830656
PBIO:SeriesKConvertiblePreferredStockMember
2023-01-01
2023-09-30
0000830656
PBIO:SeriesKConvertiblePreferredStockMember
2022-01-01
2022-09-30
0000830656
PBIO:SeriesAAConvertiblePreferredStockMember
2023-01-01
2023-09-30
0000830656
PBIO:SeriesAAConvertiblePreferredStockMember
2022-01-01
2022-09-30
0000830656
PBIO:SeriesBBConvertiblePreferredStockMember
2023-01-01
2023-09-30
0000830656
PBIO:SeriesBBConvertiblePreferredStockMember
2022-01-01
2022-09-30
0000830656
PBIO:SeriesCCConvertiblePreferredStockMember
2023-01-01
2023-09-30
0000830656
PBIO:SeriesCCConvertiblePreferredStockMember
2022-01-01
2022-09-30
0000830656
PBIO:EmployeesOfficersMember
2023-01-01
2023-09-30
0000830656
PBIO:EmployeesOfficersMember
srt:MinimumMember
2023-01-01
2023-09-30
0000830656
PBIO:EmployeesOfficersMember
srt:MaximumMember
2023-01-01
2023-09-30
0000830656
us-gaap:CostOfSalesMember
2023-07-01
2023-09-30
0000830656
us-gaap:CostOfSalesMember
2022-07-01
2022-09-30
0000830656
us-gaap:CostOfSalesMember
2023-01-01
2023-09-30
0000830656
us-gaap:CostOfSalesMember
2022-01-01
2022-09-30
0000830656
us-gaap:ResearchAndDevelopmentExpenseMember
2023-07-01
2023-09-30
0000830656
us-gaap:ResearchAndDevelopmentExpenseMember
2022-07-01
2022-09-30
0000830656
us-gaap:ResearchAndDevelopmentExpenseMember
2023-01-01
2023-09-30
0000830656
us-gaap:ResearchAndDevelopmentExpenseMember
2022-01-01
2022-09-30
0000830656
us-gaap:SellingAndMarketingExpenseMember
2023-07-01
2023-09-30
0000830656
us-gaap:SellingAndMarketingExpenseMember
2022-07-01
2022-09-30
0000830656
us-gaap:SellingAndMarketingExpenseMember
2023-01-01
2023-09-30
0000830656
us-gaap:SellingAndMarketingExpenseMember
2022-01-01
2022-09-30
0000830656
us-gaap:GeneralAndAdministrativeExpenseMember
2023-07-01
2023-09-30
0000830656
us-gaap:GeneralAndAdministrativeExpenseMember
2022-07-01
2022-09-30
0000830656
us-gaap:GeneralAndAdministrativeExpenseMember
2023-01-01
2023-09-30
0000830656
us-gaap:GeneralAndAdministrativeExpenseMember
2022-01-01
2022-09-30
0000830656
us-gaap:EquitySecuritiesMember
2023-09-30
0000830656
us-gaap:EquitySecuritiesMember
us-gaap:FairValueInputsLevel1Member
2023-09-30
0000830656
us-gaap:EquitySecuritiesMember
us-gaap:FairValueInputsLevel2Member
2023-09-30
0000830656
us-gaap:EquitySecuritiesMember
us-gaap:FairValueInputsLevel3Member
2023-09-30
0000830656
us-gaap:FairValueInputsLevel1Member
2023-09-30
0000830656
us-gaap:FairValueInputsLevel2Member
2023-09-30
0000830656
us-gaap:FairValueInputsLevel3Member
2023-09-30
0000830656
us-gaap:EquitySecuritiesMember
2022-12-31
0000830656
us-gaap:EquitySecuritiesMember
us-gaap:FairValueInputsLevel1Member
2022-12-31
0000830656
us-gaap:EquitySecuritiesMember
us-gaap:FairValueInputsLevel2Member
2022-12-31
0000830656
us-gaap:EquitySecuritiesMember
us-gaap:FairValueInputsLevel3Member
2022-12-31
0000830656
us-gaap:FairValueInputsLevel1Member
2022-12-31
0000830656
us-gaap:FairValueInputsLevel2Member
2022-12-31
0000830656
us-gaap:FairValueInputsLevel3Member
2022-12-31
0000830656
PBIO:CorporateOfficeMember
2023-01-01
2023-09-30
0000830656
PBIO:MedfordLeaseMember
2023-01-01
2023-09-30
0000830656
PBIO:MedfordLeaseMember
2023-09-30
0000830656
PBIO:SparksLeaseMember
2021-08-08
2021-08-09
0000830656
PBIO:SparksLeaseMember
2023-09-30
0000830656
PBIO:BattelleMemorialInstituteMember
2014-01-01
2014-12-31
0000830656
PBIO:BattelleMemorialInstituteMember
2015-01-01
2015-12-31
0000830656
PBIO:BattelleMemorialInstituteMember
2016-01-01
2016-12-31
0000830656
PBIO:BattelleMemorialInstituteMember
2017-01-01
2017-12-31
0000830656
PBIO:BattelleMemorialInstituteMember
2018-01-01
2018-12-31
0000830656
PBIO:TargetDiscoveryIncMember
2012-04-01
2012-04-30
0000830656
PBIO:TargetDiscoveryIncMember
2022-01-01
2022-09-30
0000830656
PBIO:TargetDiscoveryIncMember
2023-01-01
2023-09-30
0000830656
us-gaap:ConvertibleDebtMember
2023-01-01
2023-09-30
0000830656
srt:MinimumMember
us-gaap:ConvertibleDebtMember
2023-01-01
2023-09-30
0000830656
srt:MaximumMember
us-gaap:ConvertibleDebtMember
2023-01-01
2023-09-30
0000830656
srt:MinimumMember
us-gaap:ConvertibleDebtMember
2023-09-30
0000830656
srt:MaximumMember
us-gaap:ConvertibleDebtMember
2023-09-30
0000830656
us-gaap:ConvertibleCommonStockMember
us-gaap:ConvertibleDebtMember
2023-09-30
0000830656
us-gaap:ConvertibleDebtMember
2023-09-30
0000830656
PBIO:PBIAgrochemIncMember
2023-09-30
0000830656
PBIO:ThreeLendersMember
2023-01-01
2023-09-30
0000830656
PBIO:ThreeLendersMember
PBIO:ForbearanceAgreementsMember
2023-01-01
2023-09-30
0000830656
PBIO:FourLendersMember
PBIO:ForbearanceAgreementsMember
2023-09-30
0000830656
PBIO:NewLoanMember
2023-09-30
0000830656
PBIO:NewLoanMember
2023-01-01
2023-09-30
0000830656
PBIO:TenLoansMember
2023-01-01
2023-09-30
0000830656
us-gaap:CommonStockMember
PBIO:TenLoansMember
2023-01-01
2023-09-30
0000830656
us-gaap:PreferredStockMember
PBIO:TenLoansMember
2023-01-01
2023-09-30
0000830656
PBIO:ShortTermNonConvertibleLoanMember
2023-01-01
2023-09-30
0000830656
PBIO:ShortTermNonConvertibleLoanMember
srt:MinimumMember
2023-09-30
0000830656
PBIO:ShortTermNonConvertibleLoanMember
srt:MaximumMember
2023-09-30
0000830656
us-gaap:ConvertibleDebtMember
2023-01-01
2023-09-30
0000830656
PBIO:ShortTermNonConvertibleLoanMember
2023-09-30
0000830656
PBIO:ShortTermNonConvertibleLoanMember
2022-12-31
0000830656
us-gaap:InvestorMember
2023-01-01
2023-09-30
0000830656
us-gaap:InvestorMember
2023-09-30
0000830656
us-gaap:InvestorMember
2022-01-01
2022-12-31
0000830656
us-gaap:InvestorMember
2022-12-31
0000830656
PBIO:OthersMember
srt:MinimumMember
2023-01-01
2023-09-30
0000830656
PBIO:OthersMember
srt:MaximumMember
2023-01-01
2023-09-30
0000830656
PBIO:OthersMember
srt:MinimumMember
2023-09-30
0000830656
PBIO:OthersMember
srt:MaximumMember
2023-09-30
0000830656
PBIO:OthersMember
2023-09-30
0000830656
PBIO:OthersMember
srt:MinimumMember
2022-01-01
2022-12-31
0000830656
PBIO:OthersMember
srt:MaximumMember
2022-01-01
2022-12-31
0000830656
PBIO:OthersMember
srt:MinimumMember
2022-12-31
0000830656
PBIO:OthersMember
srt:MaximumMember
2022-12-31
0000830656
PBIO:OthersMember
2022-12-31
0000830656
us-gaap:ConvertibleDebtMember
PBIO:FiveDayAverageVWAPMember
2023-09-30
0000830656
us-gaap:ConvertibleDebtMember
PBIO:SeriesAAPreferredStockMember
2023-01-01
2023-09-30
0000830656
PBIO:ConvertibleDebtOneMember
2023-01-01
2023-09-30
0000830656
PBIO:ConvertibleDebtTwoMember
2023-01-01
2023-09-30
0000830656
PBIO:ConvertibleDebtThreeMember
2023-01-01
2023-09-30
0000830656
PBIO:ConvertibleDebtFourMember
2023-01-01
2023-09-30
0000830656
srt:ChiefExecutiveOfficerMember
2023-09-30
0000830656
PBIO:NonConvertibleLoansMember
2023-09-30
0000830656
PBIO:NonConvertibleLoansMember
2022-12-31
0000830656
PBIO:MerchantDebtMember
2023-09-30
0000830656
PBIO:MerchantDebtMember
2022-12-31
0000830656
PBIO:SBAMember
2023-09-30
0000830656
PBIO:SBAMember
2022-12-31
0000830656
PBIO:PayrollProtectionProgramMember
2020-12-31
0000830656
PBIO:PaycheckProtectionProgrammeMember
2021-12-31
0000830656
PBIO:MerchantAgreementMember
srt:MinimumMember
2023-09-30
0000830656
PBIO:MerchantAgreementMember
srt:MaximumMember
2023-09-30
0000830656
PBIO:MerchantAgreementMember
2023-01-01
2023-09-30
0000830656
PBIO:MerchantAgreementMember
2022-01-01
2022-12-31
0000830656
PBIO:OfficersAndDirectorsMember
2023-09-30
0000830656
PBIO:OfficersAndDirectorsMember
2023-01-01
2023-09-30
0000830656
PBIO:OfficersAndDirectorsMember
2022-12-31
0000830656
PBIO:OfficersAndDirectorsMember
2022-01-01
2022-12-31
0000830656
PBIO:OtherRelatedPartiesMember
2023-09-30
0000830656
PBIO:OtherRelatedPartiesMember
2023-01-01
2023-09-30
0000830656
PBIO:OtherRelatedPartiesMember
2022-12-31
0000830656
PBIO:OtherRelatedPartiesMember
2022-01-01
2022-12-31
0000830656
us-gaap:RelatedPartyMember
2023-01-01
2023-09-30
0000830656
us-gaap:RelatedPartyMember
2022-01-01
2022-12-31
0000830656
us-gaap:RelatedPartyMember
2023-09-30
0000830656
us-gaap:RelatedPartyMember
2022-12-31
0000830656
us-gaap:RelatedPartyMember
srt:MinimumMember
2023-09-30
0000830656
us-gaap:RelatedPartyMember
srt:MaximumMember
2023-09-30
0000830656
us-gaap:PreferredStockMember
2023-09-30
0000830656
PBIO:SeriesBBConvertiblePreferredStockMember
2023-05-01
0000830656
PBIO:SeriesCCConvertiblePreferredStockMember
2023-05-01
0000830656
PBIO:SeriesBBPreferredStockMember
2023-09-30
0000830656
PBIO:SeriesBBPreferredStockMember
2023-01-01
2023-09-30
0000830656
PBIO:SeriesCCPreferredStockMember
2023-09-30
0000830656
PBIO:SeriesCCPreferredStockMember
2023-01-01
2023-09-30
0000830656
PBIO:SeriesBBRestrictedPreferredStockMember
2023-01-01
2023-09-30
0000830656
PBIO:SeriesCCRestrictedPreferredStockMember
2023-01-01
2023-09-30
0000830656
PBIO:SeriesBBPreferredStockMember
us-gaap:PreferredStockMember
2023-01-01
2023-09-30
0000830656
us-gaap:CommonStockMember
2023-01-01
2023-09-30
0000830656
PBIO:TwoThousandAndTwentyOneEquityIncentivePlanMember
2021-12-30
0000830656
PBIO:TwoThousandAndTwentyOneEquityIncentivePlanMember
2023-09-30
0000830656
PBIO:UnvestedStockBasedAwardsMember
2023-09-30
0000830656
PBIO:UnvestedStockBasedAwardsMember
2023-01-01
2023-09-30
0000830656
PBIO:StockOptionsMember
2023-09-30
0000830656
PBIO:StockOptionsMember
2023-01-01
2023-09-30
0000830656
PBIO:ExercisableOptionsMember
2023-01-01
2023-09-30
0000830656
us-gaap:WarrantMember
2023-04-13
0000830656
us-gaap:WarrantMember
2023-04-11
2023-04-13
0000830656
us-gaap:WarrantMember
2023-01-01
2023-09-30
0000830656
us-gaap:CommonStockMember
2022-01-01
2022-09-30
0000830656
PBIO:AccreditedInvestorAndConsultantsMember
2023-01-01
2023-09-30
0000830656
us-gaap:PaymentInKindPIKNoteMember
PBIO:CommonStockAndWarrantMember
2023-01-01
2023-09-30
0000830656
PBIO:IssuedForServicesRenderedMember
PBIO:CommonStockAndWarrantMember
2023-01-01
2023-09-30
0000830656
PBIO:IssuedForServicesRenderedMember
2023-01-01
2023-09-30
0000830656
PBIO:ConversionOfDebtMember
2023-01-01
2023-09-30
0000830656
PBIO:DebtSettlementMember
2023-01-01
2023-09-30
0000830656
PBIO:LenderMember
2023-09-30
0000830656
PBIO:DividendsPaidInKindMember
2023-01-01
2023-09-30
0000830656
PBIO:ConversionOfDebtMember
PBIO:CommonStockAndWarrantMember
2023-01-01
2023-09-30
0000830656
PBIO:DebtExtensionMember
2023-01-01
2023-09-30
0000830656
PBIO:NewCommonStockIssuancesMember
2023-01-01
2023-09-30
0000830656
PBIO:ConversionOfPreferredToCommonStockMember
2023-01-01
2023-09-30
0000830656
us-gaap:RestrictedStockMember
2022-01-01
2022-09-30
0000830656
PBIO:ConversionOfDebtMember
2022-01-01
2022-09-30
0000830656
us-gaap:PaymentInKindPIKNoteMember
2022-01-01
2022-09-30
0000830656
PBIO:IssuedForServicesRenderedMember
2022-01-01
2022-09-30
0000830656
us-gaap:CommonStockMember
PBIO:IssuedForServicesRenderedMember
2023-01-01
2023-09-30
0000830656
us-gaap:PaymentInKindPIKNoteMember
us-gaap:CommonStockMember
2023-01-01
2023-09-30
0000830656
us-gaap:PaymentInKindPIKNoteMember
us-gaap:CommonStockMember
2022-01-01
2022-09-30
0000830656
us-gaap:CommonStockMember
PBIO:NewConversionDebtMember
2022-01-01
2022-09-30
0000830656
us-gaap:CommonStockMember
PBIO:DebtExtensionMember
2022-01-01
2022-09-30
0000830656
PBIO:SeriesAAPreferredStockMember
PBIO:DebtExtensionMember
2022-01-01
2022-09-30
0000830656
PBIO:SeriesAAPreferredStockMember
2022-01-01
2022-09-30
0000830656
us-gaap:WarrantMember
2022-01-01
2022-09-30
0000830656
PBIO:SeriesAJuniorParticipatingPreferredStockMember
2023-09-30
0000830656
PBIO:SeriesAJuniorParticipatingPreferredStockMember
2022-12-31
0000830656
PBIO:SeriesAConvertiblePreferredStockMember
2023-09-30
0000830656
PBIO:SeriesAConvertiblePreferredStockMember
2022-12-31
0000830656
PBIO:SeriesBConvertiblePreferredStockMember
2023-09-30
0000830656
PBIO:SeriesBConvertiblePreferredStockMember
2022-12-31
0000830656
PBIO:SeriesCConvertiblePreferredStockMember
2023-09-30
0000830656
PBIO:SeriesCConvertiblePreferredStockMember
2022-12-31
0000830656
PBIO:SeriesEConvertiblePreferredStockMember
2023-09-30
0000830656
PBIO:SeriesEConvertiblePreferredStockMember
2022-12-31
0000830656
PBIO:StockOptionsMember
2022-12-31
0000830656
us-gaap:SubsequentEventMember
2023-11-05
0000830656
us-gaap:SubsequentEventMember
srt:MinimumMember
2023-11-05
0000830656
us-gaap:SubsequentEventMember
srt:MaximumMember
2023-11-05
0000830656
us-gaap:SubsequentEventMember
us-gaap:CommonStockMember
2023-10-01
2023-11-05
0000830656
PBIO:SeriesBBConvertiblePreferredStockMember
us-gaap:SubsequentEventMember
2023-10-01
2023-11-05
0000830656
srt:BoardOfDirectorsChairmanMember
us-gaap:SubsequentEventMember
PBIO:TwoThousandTwentyOneEquityPlanMember
2023-10-18
2023-10-18
0000830656
srt:BoardOfDirectorsChairmanMember
us-gaap:SubsequentEventMember
PBIO:TwoThousandTwentyOneEquityPlanMember
2023-10-18
0000830656
srt:BoardOfDirectorsChairmanMember
us-gaap:SubsequentEventMember
2023-10-18
2023-10-18
0000830656
srt:BoardOfDirectorsChairmanMember
us-gaap:SubsequentEventMember
2023-10-18
0000830656
PBIO:MrSchumacherMember
us-gaap:SubsequentEventMember
2023-10-18
2023-10-18
0000830656
PBIO:DrsTingMember
us-gaap:SubsequentEventMember
2023-10-18
2023-10-18
0000830656
PBIO:LazarevMember
us-gaap:SubsequentEventMember
2023-10-18
2023-10-18
0000830656
srt:ExecutiveOfficerMember
us-gaap:SubsequentEventMember
2023-10-18
0000830656
srt:ExecutiveOfficerMember
us-gaap:SubsequentEventMember
srt:MinimumMember
2023-10-18
0000830656
srt:ExecutiveOfficerMember
us-gaap:SubsequentEventMember
srt:MaximumMember
2023-10-18
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
PBIO:Integer
xbrli:pure
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
10-Q
(Mark
One)
☒
Quarterly Report Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
For
the quarterly period ended September 30, 2023
or
☐
Transition Report Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
For
the transition period from _____________ to _____________
Commission
File Number 001-38185
PRESSURE
BIOSCIENCES, INC.
(Exact
name of registrant as specified in its charter)
Massachusetts |
|
04-2652826 |
(State
or other jurisdiction of |
|
(I.R.S.
Employer |
incorporation
or organization) |
|
Identification
No.) |
14
Norfolk Avenue
South
Easton, Massachusetts |
|
02375 |
(Address
of principal executive offices) |
|
(Zip
Code) |
(508)
230-1828
(Registrant’s
telephone number, including area code)
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
N/A |
|
N/A
|
|
N/A |
Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days.
☒
Yes ☐ No
Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule
405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant
was required to submit such files).
☒
Yes ☐ No
Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting
company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,”
and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):
|
Large
accelerated filer |
☐ |
Accelerated
filer |
☐ |
|
Non-accelerated
Filer |
☒ |
Smaller
Reporting Company |
☒ |
|
Emerging
Growth Company |
☐ |
|
|
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate
by check mark whether the registrant is a shell company (as defined in Exchange Act Rule 12b-2 of the Exchange Act).
☐
Yes ☒ No
The
number of shares outstanding of the Issuer’s common stock as of November 10, 2023 was 21,726,433.
TABLE
OF CONTENTS
Pressure BioSciences, Inc. | September 30, 2023 10Q Report | 2 |
PART
I - FINANCIAL INFORMATION
Item
1. Financial Statements
PRESSURE
BIOSCIENCES, INC. AND SUBSIDIARIES
CONSOLIDATED
BALANCE SHEETS
(UNAUDITED)
| |
September 30, 2023 | | |
December 31, 2022 | |
ASSETS | |
| | | |
| | |
CURRENT ASSETS | |
| | | |
| | |
Cash and cash equivalents | |
$ | 5,263 | | |
$ | 3,865 | |
Accounts receivable | |
| 329,263 | | |
| 295,374 | |
Inventories, net of $905,759 and $982,973 reserve, respectively | |
| 467,155 | | |
| 686,383 | |
Prepaid expenses and other current assets | |
| 219,283 | | |
| 257,527 | |
Total current assets | |
| 1,020,964 | | |
| 1,243,149 | |
Investment in equity securities | |
| 77,918 | | |
| 63,638 | |
Property and equipment, net | |
| 91,409 | | |
| 103,351 | |
Right of use asset operating leases | |
| 159,424 | | |
| 282,095 | |
Intangible assets, net | |
| 252,404 | | |
| 317,308 | |
TOTAL ASSETS | |
$ | 1,602,119 | | |
$ | 2,009,541 | |
| |
| | | |
| | |
LIABILITIES AND STOCKHOLDERS’ DEFICIT | |
| | | |
| | |
CURRENT LIABILITIES | |
| | | |
| | |
Accounts payable | |
$ | 1,062,565 | | |
$ | 637,238 | |
Accrued employee compensation | |
| 376,760 | | |
| 167,247 | |
Accrued professional fees and other | |
| 2,722,666 | | |
| 2,497,762 | |
Accrued interest and dividends payable | |
| 4,576,350 | | |
| 10,803,983 | |
Deferred revenue | |
| 253,152 | | |
| 58,242 | |
Convertible debt, net of unamortized debt discounts of $744,393 and $455,517, respectively | |
| 18,222,120 | | |
| 17,823,669 | |
Other debt, net of unamortized discounts of $0 and $0, respectively | |
| 2,030,510 | | |
| 1,638,969 | |
Related party, net of unamortized debt discount of $514 and $7,915, respectively | |
| 647,986 | | |
| 634,885 | |
Right of use operating lease liability | |
| 66,259 | | |
| 142,171 | |
Total current liabilities | |
| 29,958,368 | | |
| 34,404,166 | |
LONG TERM LIABILITIES | |
| | | |
| | |
Long term debt | |
| 162,522 | | |
| 150,000 | |
Right of use operating lease liability long term | |
| 71,287 | | |
| 139,924 | |
Deferred revenue | |
| 10,645 | | |
| 1,822 | |
TOTAL LONG TERM LIABILITIES | |
| 244,454 | | |
| 291,746 | |
TOTAL LIABILITIES | |
| 30,202,822 | | |
| 34,695,912 | |
COMMITMENTS AND CONTINGENCIES (Note 4) | |
| - | | |
| - | |
STOCKHOLDERS’ DEFICIT | |
| | | |
| | |
Series D, G, H, H2, J, K, AA, BB, CC Convertible Preferred Stock, $.01 par value (Note 6) | |
| 100 | | |
| 1,098 | |
Preferred stock, value | |
| 100 | | |
| 1,098 | |
Common stock, $.01 par value; 100,000,000 shares authorized; 23,399,945 and 13,682,910 shares issued and outstanding on September 30, 2023 and December 31, 2022, respectively | |
| 234,000 | | |
| 136,829 | |
Warrants to acquire common stock | |
| 35,684,321 | | |
| 31,995,762 | |
Additional paid-in capital | |
| 93,973,646 | | |
| 69,006,145 | |
Accumulated deficit | |
| (158,492,770 | ) | |
| (133,826,205 | ) |
TOTAL STOCKHOLDERS’ DEFICIT | |
| (28,600,703 | ) | |
| (32,686,371 | ) |
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT | |
$ | 1,602,119 | | |
$ | 2,009,541 | |
The
accompanying notes are an integral part of these unaudited consolidated financial statements.
Pressure BioSciences, Inc. | September 30, 2023 10Q Report | 3 |
PRESSURE
BIOSCIENCES, INC. AND SUBSIDIARIES
CONSOLIDATED
STATEMENTS OF OPERATIONS
(UNAUDITED)
| |
2023 | | |
2022 | | |
2023 | | |
2022 | |
| |
For the Three Months Ended September 30, | | |
For the Nine Months Ended September 30, | |
| |
2023 | | |
2022 | | |
2023 | | |
2022 | |
Revenue: | |
| | | |
| | | |
| | | |
| | |
Products, services, other | |
$ | 413,009 | | |
$ | 144,032 | | |
$ | 1,665,412 | | |
$ | 1,122,169 | |
Total revenue | |
| 413,009 | | |
| 144,032 | | |
| 1,665,412 | | |
| 1,122,169 | |
Costs and expenses: | |
| | | |
| | | |
| | | |
| | |
Cost of products and services | |
| 229,457 | | |
| 126,203 | | |
| 844,684 | | |
| 742,707 | |
Research and development | |
| 288,345 | | |
| 262,370 | | |
| 1,004,437 | | |
| 716,685 | |
Selling and marketing | |
| 157,773 | | |
| 226,526 | | |
| 537,802 | | |
| 422,422 | |
General and administrative | |
| 1,030,243 | | |
| 892,293 | | |
| 5,290,564 | | |
| 2,591,644 | |
Total operating costs | |
| 1,705,818 | | |
| 1,507,392 | | |
| 7,677,487 | | |
| 4,473,458 | |
Operating loss | |
| (1,292,809 | ) | |
| (1,363,360 | ) | |
| (6,012,075 | ) | |
| (3,351,289 | ) |
| |
| | | |
| | | |
| | | |
| | |
Other (expense) income: | |
| | | |
| | | |
| | | |
| | |
Interest expense, net | |
| (4,338,759 | ) | |
| (2,034,021 | ) | |
| (14,112,098 | ) | |
| (6,448,771 | ) |
Unrealized gain (loss) on investment in equity securities | |
| (5,965 | ) | |
| (8,675 | ) | |
| 14,280 | | |
| (8,047 | ) |
Gain (loss) on extinguishment of liabilities | |
| - | | |
| (1,054,122 | ) | |
| 687,591 | | |
| (1,809,249 | ) |
Other income (expense) | |
| 7,588 | | |
| (2,059 | ) | |
| 11,820 | | |
| (904 | ) |
Total other expense | |
| (4,337,136 | ) | |
| (3,098,877 | ) | |
| (13,398,407 | ) | |
| (8,266,971 | ) |
Net loss | |
| (5,629,945 | ) | |
| (4,462,237 | ) | |
| (19,410,482 | ) | |
| (11,618,260 | ) |
Deemed dividends on extension of warrants | |
| - | | |
| - | | |
| (3,626,950 | ) | |
| - | |
Preferred stock dividends | |
| (632,054 | ) | |
| (431,709 | ) | |
| (1,629,133 | ) | |
| (1,295,566 | ) |
Net loss attributable to common shareholders | |
$ | (6,261,999 | ) | |
$ | (4,893,946 | ) | |
$ | (24,666,565 | ) | |
$ | (12,913,826 | ) |
Basic and diluted net loss per share attributable to common shareholders | |
$ | (0.29 | ) | |
$ | (0.44 | ) | |
$ | (1.21 | ) | |
$ | (1.24 | ) |
Weighted average common shares outstanding used in the basic and diluted net loss per share calculation | |
| 21,716,950 | | |
| 11,131,742 | | |
| 20,337,229 | | |
| 10,429,817 | |
The
accompanying notes are an integral part of these unaudited consolidated financial statements.
Pressure BioSciences, Inc. | September 30, 2023 10Q Report | 4 |
PRESSURE
BIOSCIENCES, INC. AND SUBSIDIARIES
CONSOLIDATED
STATEMENTS OF CASH FLOWS
(UNAUDITED)
| |
2023 | | |
2022 | |
| |
For the Nine Months Ended | |
| |
September 30, | |
| |
2023 | | |
2022 | |
CASH FLOWS FROM OPERATING ACTIVITIES: | |
| | | |
| | |
Net loss | |
$ | (19,410,482 | ) | |
$ | (11,618,260 | ) |
Adjustments to reconcile net loss to net cash used in operating activities: | |
| | | |
| | |
(Gain) on extinguishment of debt | |
| (687,591 | ) | |
| (10,000 | ) |
Non-cash lease expense | |
| 122,671 | | |
| 82,001 | |
Common stock and warrants issued for interest | |
| 3,715,204 | | |
| 2,196,278 | |
Depreciation and amortization | |
| 84,341 | | |
| 67,985 | |
Accretion of interest and amortization of debt discount | |
| 3,213,622 | | |
| 1,777,863 | |
Loss on extinguishment of accrued liabilities and debt | |
| - | | |
| 1,809,249 | |
Common stock and warrants issued for debt extension | |
| 1,671,573 | | |
| - | |
Preferred stock issued for debt extension | |
| 2,683,600 | | |
| - | |
Stock-based compensation expense | |
| 1,706,420 | | |
| 128,984 | |
(Gain)/Loss on investment in equity securities | |
| (14,280 | ) | |
| 8,047 | |
Common stock and warrants issued for services | |
| 1,978,645 | | |
| 367,370 | |
Preferred stock issued for services | |
| 617,200 | | |
| - | |
Changes in operating assets and liabilities: | |
| | | |
| | |
Accounts receivable | |
| (33,889 | ) | |
| (11,568 | ) |
Inventories | |
| 219,228 | | |
| (238,973 | ) |
Prepaid expenses and other assets | |
| 38,244 | | |
| 204,141 | |
Accounts payable | |
| 425,327 | | |
| 80,130 | |
Accrued employee compensation | |
| 209,513 | | |
| 104,258 | |
Operating lease liability | |
| (144,549 | ) | |
| (82,001 | ) |
Deferred revenue and other accrued expenses | |
| 1,551,380 | | |
| 2,083,239 | |
Net cash used in operating activities | |
| (2,053,823 | ) | |
| (3,051,257 | ) |
| |
| | | |
| | |
CASH FLOWS FROM INVESTING ACTIVITIES: | |
| | | |
| | |
Purchases of property plant and equipment | |
| (7,495 | ) | |
| (20,754 | ) |
Net cash used in investing activities | |
| (7,495 | ) | |
| (20,754 | ) |
| |
| | | |
| | |
CASH FLOWS FROM FINANCING ACTIVITIES: | |
| | | |
| | |
Sale of common stock for cash | |
| 150,000 | | |
| - | |
Proceeds from stock option exercises | |
| 81,111 | | |
| 17,443 | |
Net proceeds from convertible debt | |
| 4,336,665 | | |
| 3,428,249 | |
Net proceeds from non-convertible debt - third party | |
| 2,043,681 | | |
| 1,815,000 | |
Net proceeds from debt - related party | |
| 159,186 | | |
| 762,500 | |
Payments on convertible debt | |
| (2,462,269 | ) | |
| (1,086,946 | ) |
Payments on debt - related party | |
| (159,000 | ) | |
| (259,600 | ) |
Payments on non-convertible debt | |
| (2,086,658 | ) | |
| (1,506,066 | ) |
Net cash provided by financing activities | |
| 2,062,716 | | |
| 3,170,580 | |
| |
| | | |
| | |
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS | |
| 1,398 | | |
| 98,569 | |
CASH AND CASH EQUIVALENTS AT BEGINNING OF YEAR | |
| 3,865 | | |
| 132,311 | |
CASH AND CASH EQUIVALENTS AT END OF PERIOD | |
$ | 5,263 | | |
$ | 230,880 | |
The
accompanying notes are an integral part of these unaudited consolidated financial statements.
Pressure BioSciences, Inc. | September 30, 2023 10Q Report | 5 |
| |
2023 | | |
2022 | |
| |
For the Nine Months Ended | |
| |
September 30, | |
| |
2023 | | |
2022 | |
CASH FLOWS SUPPLEMENTAL INFORMATION | |
| | | |
| | |
Interest paid in cash | |
$ | 1,219,038 | | |
$ | 938,451 | |
NON CASH TRANSACTIONS: | |
| | | |
| | |
Early adoption of ASU 2020-06 | |
| - | | |
| 473,027 | |
Common stock issued with debt | |
| 1,293,270 | | |
| 512,593 | |
Discount from warrants issued with debt | |
| - | | |
| 93,576 | |
Common stock issued in lieu of cash for dividend | |
| 162,528 | | |
| 306,333 | |
Preferred stock issued with debt | |
| 539,487 | | |
| - | |
Preferred stock dividends | |
| 1,629,133 | | |
| 1,295,566 | |
Conversion of preferred stock for common stock | |
| 14,869 | | |
| 44 | |
Conversion of debt, interest, preferred stock dividend for preferred stock | |
| 10,017,212 | | |
| - | |
Conversion of debt and interest into common stock | |
| 509,033 | | |
| 350,500 | |
Conversion of common stock for preferred stock | |
| 6,240 | | |
| - | |
Extension of warrants for Series AA preferred stock | |
| 3,626,950 | | |
| - | |
The
accompanying notes are an integral part of these unaudited consolidated financial statements.
Pressure BioSciences, Inc. | September 30, 2023 10Q Report | 6 |
PRESSURE
BIOSCIENCES, INC. AND SUBSIDIARIES
CONSOLIDATED
STATEMENTS OF CHANGES IN STOCKHOLDERS’ DEFICIT
FOR
THE NINE MONTHS ENDED SEPTEMBER 30, 2023 AND SEPTEMBER 30, 2022
(UNAUDITED)
| |
Shares | | |
Amount | | |
Shares | | |
Amount | | |
Warrants | | |
Capital | | |
Deficit | | |
Deficit | |
| |
Combined Preferred Stock | | |
Common Stock | | |
Stock | | |
Additional Paid In | | |
Accumulated | | |
Total Stockholders’ | |
| |
Shares | | |
Amount | | |
Shares | | |
Amount | | |
Warrants | | |
Capital | | |
Deficit | | |
Deficit | |
BALANCE, December 31, 2022 | |
| 109,874 | | |
$ | 1,098 | | |
| 13,682,910 | | |
$ | 136,829 | | |
$ | 31,995,762 | | |
$ | 69,006,145 | | |
$ | (133,826,205 | ) | |
$ | (32,686,371 | ) |
Stock option exercise | |
| - | | |
| - | | |
| 117,552 | | |
| 1,176 | | |
| - | | |
| 79,935 | | |
| - | | |
| 81,111 | |
Stock-based compensation | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| 1,430,244 | | |
| - | | |
| 1,430,244 | |
Series AA Preferred Stock dividend | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| (431,807 | ) | |
| (431,807 | ) |
Issuance of common stock for services | |
| - | | |
| - | | |
| 990,500 | | |
| 9,905 | | |
| - | | |
| 1,409,430 | | |
| - | | |
| 1,419,335 | |
Issuance of common stock warrants for services | |
| - | | |
| - | | |
| - | | |
| - | | |
| 61,609 | | |
| - | | |
| - | | |
| 61,609 | |
Conversion of debt and interest for common stock | |
| - | | |
| - | | |
| 203,613 | | |
| 2,036 | | |
| - | | |
| 506,997 | | |
| - | | |
| 509,033 | |
Issuance of common stock for dividends paid-in-kind | |
| - | | |
| - | | |
| 73,694 | | |
| 737 | | |
| - | | |
| 101,698 | | |
| - | | |
| 102,435 | |
Issuance of common stock for interest paid-in-kind | |
| - | | |
| - | | |
| 1,111,081 | | |
| 11,111 | | |
| - | | |
| 1,694,123 | | |
| - | | |
| 1,705,234 | |
Common stock issued for debt extension | |
| - | | |
| - | | |
| 568,200 | | |
| 5,682 | | |
| - | | |
| 1,024,257 | | |
| - | | |
| 1,029,939 | |
Stock issued with debt | |
| - | | |
| - | | |
| 783,150 | | |
| 7,832 | | |
| - | | |
| 1,079,919 | | |
| - | | |
| 1,087,751 | |
Conversion of preferred stock for common stock | |
| (101,154 | ) | |
| (1,012 | ) | |
| 493,540 | | |
| 4,935 | | |
| - | | |
| (3,923 | ) | |
| - | | |
| - | |
Sale of Common Stock | |
| - | | |
| - | | |
| 40,000 | | |
| 400 | | |
| - | | |
| 99,600 | | |
| - | | |
| 100,000 | |
Net loss | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| (6,857,834 | ) | |
| (6,857,834 | ) |
Balance, March 31, 2023 | |
| 8,720 | | |
$ | 86 | | |
| 18,064,240 | | |
$ | 180,643 | | |
$ | 32,057,371 | | |
$ | 76,428,425 | | |
$ | (141,115,846 | ) | |
$ | (32,449,321 | ) |
Series AA/CC Preferred Stock dividend | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| (565,272 | ) | |
| (565,272 | ) |
Stock-based compensation | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| 135,554 | | |
| - | | |
| 135,554 | |
Issuance of common stock for services | |
| - | | |
| - | | |
| 147,500 | | |
| 1,475 | | |
| - | | |
| 170,925 | | |
| - | | |
| 172,400 | |
Extension of warrants for Series AA Preferred stock | |
| - | | |
| - | | |
| - | | |
| - | | |
| 3,626,950 | | |
| - | | |
| (3,626,950 | ) | |
| - | |
Common stock issued for debt extension | |
| - | | |
| - | | |
| 528,600 | | |
| 5,286 | | |
| - | | |
| 486,348 | | |
| - | | |
| 491,634 | |
Conversion of preferred stock for common stock | |
| (44 | ) | |
| - | | |
| 44,400 | | |
| 444 | | |
| - | | |
| (444 | ) | |
| - | | |
| - | |
Conversion of debt, accrued interest and accrued dividend for preferred stock | |
| 401 | | |
| 4 | | |
| - | | |
| - | | |
| - | | |
| 10,017,208 | | |
| - | | |
| 10,017,212 | |
Conversion of common stock to preferred stock | |
| 62 | | |
| 1 | | |
| (624,000 | ) | |
| (6,240 | ) | |
| - | | |
| 6,239 | | |
| - | | |
| - | |
Issuance of common stock for dividends paid-in-kind | |
| - | | |
| - | | |
| 69,073 | | |
| 690 | | |
| - | | |
| 59,403 | | |
| - | | |
| 60,093 | |
Issuance of common stock for interest paid-in-kind | |
| - | | |
| - | | |
| 1,034,000 | | |
| 10,340 | | |
| - | | |
| 1,286,106 | | |
| - | | |
| 1,296,446 | |
Stock issued with debt | |
| - | | |
| - | | |
| 302,092 | | |
| 3,021 | | |
| - | | |
| 153,653 | | |
| - | | |
| 156,674 | |
Sale of Common Stock | |
| - | | |
| - | | |
| 20,000 | | |
| 200 | | |
| - | | |
| 49,800 | | |
| - | | |
| 50,000 | |
Issuance of preferred stock for services | |
| 57 | | |
| 1 | | |
| - | | |
| - | | |
| - | | |
| 505,699 | | |
| - | | |
| 505,700 | |
Issuance of Preferred stock for debt extension | |
| 185 | | |
| 2 | | |
| - | | |
| - | | |
| - | | |
| 1,396,998 | | |
| - | | |
| 1,397,000 | |
Preferred stock issued with debt | |
| 58 | | |
| 1 | | |
| - | | |
| - | | |
| - | | |
| 539,486 | | |
| - | | |
| 539,487 | |
Net loss | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| (6,922,703 | ) | |
| (6,922,703 | ) |
BALANCE, June 30, 2023 | |
| 9,439 | | |
$ | 95 | | |
| 19,585,905 | | |
$ | 195,859 | | |
$ | 35,684,321 | | |
$ | 91,235,400 | | |
$ | (152,230,771 | ) | |
$ | (25,115,096 | ) |
Stock-based compensation | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| 140,622 | | |
| - | | |
| 140,622 | |
Series AA/CC Preferred Stock dividend | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| (632,054 | ) | |
| (632,054 | ) |
Issuance of common stock for services | |
| - | | |
| - | | |
| 492,500 | | |
| 4,926 | | |
| - | | |
| 320,375 | | |
| - | | |
| 325,301 | |
Common stock issued for debt extension | |
| - | | |
| - | | |
| 250,000 | | |
| 2,500 | | |
| - | | |
| 147,500 | | |
| - | | |
| 150,000 | |
Conversion of preferred stock for common stock | |
| (95 | ) | |
| (1 | ) | |
| 949,000 | | |
| 9,490 | | |
| - | | |
| (9,489 | ) | |
| - | | |
| - | |
Issuance of common stock for interest paid-in-kind | |
| - | | |
| - | | |
| 1,949,040 | | |
| 19,490 | | |
| - | | |
| 694,034 | | |
| - | | |
| 713,524 | |
Stock issued with debt | |
| - | | |
| - | | |
| 173,500 | | |
| 1,735 | | |
| - | | |
| 47,110 | | |
| - | | |
| 48,845 | |
Issuance of preferred stock for services | |
| 35 | | |
| - | | |
| - | | |
| - | | |
| - | | |
| 111,500 | | |
| - | | |
| 111,500 | |
Issuance of Preferred stock for debt extension | |
| 556 | | |
| 6 | | |
| - | | |
| - | | |
| - | | |
| 1,286,594 | | |
| - | | |
| 1,286,600 | |
Net loss | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| (5,629,945 | ) | |
| (5,629,945 | ) |
BALANCE, September 30, 2023 | |
| 9,935 | | |
$ | 100 | | |
| 23,399,945 | | |
$ | 234,000 | | |
$ | 35,684,321 | | |
$ | 93,973,646 | | |
$ | (158,492,770 | ) | |
$ | (28,600,703 | ) |
Pressure BioSciences, Inc. | September 30, 2023 10Q Report | 7 |
| |
Combined Preferred Stock | | |
Common Stock | | |
Stock | | |
Additional Paid In | | |
Accumulated | | |
Total Stockholders’ | |
| |
Shares | | |
Amount | | |
Shares | | |
Amount | | |
Warrants | | |
Capital | | |
Deficit | | |
Deficit | |
BALANCE, December 31, 2021 | |
| 109,878 | | |
$ | 1,099 | | |
| 9,120,526 | | |
$ | 91,206 | | |
$ | 31,715,154 | | |
$ | 64,261,048 | | |
$ | (118,277,468 | ) | |
$ | (22,208,961 | ) |
Balance | |
| 109,878 | | |
$ | 1,099 | | |
| 9,120,526 | | |
$ | 91,206 | | |
$ | 31,715,154 | | |
$ | 64,261,048 | | |
$ | (118,277,468 | ) | |
$ | (22,208,961 | ) |
Early adoption of ASU 2020-06 | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| (2,728,243 | ) | |
| 2,255,216 | | |
| (473,027 | ) |
Stock-based compensation | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| 64,483 | | |
| - | | |
| 64,483 | |
Series AA Preferred Stock dividend | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| (432,149 | ) | |
| (432,149 | ) |
Issuance of common stock for services | |
| - | | |
| - | | |
| 37,000 | | |
| 370 | | |
| - | | |
| 77,330 | | |
| - | | |
| 77,700 | |
Issuance of common stock warrants for services | |
| - | | |
| - | | |
| - | | |
| - | | |
| 39,761 | | |
| - | | |
| - | | |
| 39,761 | |
Warrants issued for debt extension | |
| - | | |
| - | | |
| - | | |
| - | | |
| 132,537 | | |
| - | | |
| - | | |
| 132,537 | |
Common stock issued for debt extension | |
| - | | |
| - | | |
| 214,500 | | |
| 2,145 | | |
| - | | |
| 470,755 | | |
| - | | |
| 472,900 | |
Conversion of debt and interest for common stock | |
| - | | |
| - | | |
| 140,200 | | |
| 1,402 | | |
| - | | |
| 349,098 | | |
| - | | |
| 350,500 | |
Issuance of common stock for dividends paid-in-kind | |
| - | | |
| - | | |
| 31,810 | | |
| 318 | | |
| - | | |
| 63,938 | | |
| - | | |
| 64,256 | |
Issuance of common stock for interest paid-in-kind | |
| - | | |
| - | | |
| 558,100 | | |
| 5,581 | | |
| - | | |
| 1,167,877 | | |
| - | | |
| 1,173,458 | |
Stock issued with debt | |
| - | | |
| - | | |
| 92,000 | | |
| 920 | | |
| - | | |
| 141,560 | | |
| - | | |
| 142,480 | |
Warrants issued with debt | |
| - | | |
| - | | |
| - | | |
| - | | |
| 87,436 | | |
| - | | |
| - | | |
| 87,436 | |
Net loss | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| (4,239,685 | ) | |
| (4,239,685 | ) |
BALANCE, March 31, 2022 | |
| 109,878 | | |
$ | 1,099 | | |
| 10,194,136 | | |
$ | 101,942 | | |
$ | 31,974,888 | | |
$ | 63,867,846 | | |
$ | (120,694,086 | ) | |
$ | (24,748,311 | ) |
Stock-based compensation | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| 32,074 | | |
| - | | |
| 32,074 | |
Stock option exercise | |
| - | | |
| - | | |
| 25,279 | | |
| 253 | | |
| - | | |
| 17,190 | | |
| - | | |
| 17,443 | |
Series AA Preferred Stock dividend | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| (431,708 | ) | |
| (431,708 | ) |
Issuance of common stock for services | |
| - | | |
| - | | |
| 40,000 | | |
| 400 | | |
| - | | |
| 67,400 | | |
| - | | |
| 67,800 | |
Common stock issued for debt extension | |
| - | | |
| - | | |
| 106,400 | | |
| 1,064 | | |
| - | | |
| 190,239 | | |
| - | | |
| 191,303 | |
Conversion of preferred stock for common stock | |
| (4 | ) | |
| (1 | ) | |
| 4,400 | | |
| 44 | | |
| - | | |
| (43 | ) | |
| - | | |
| - | |
Issuance of common stock for dividends paid-in-kind | |
| - | | |
| - | | |
| 86,464 | | |
| 865 | | |
| - | | |
| 150,156 | | |
| - | | |
| 151,021 | |
Issuance of common stock for interest paid-in-kind | |
| - | | |
| - | | |
| 224,500 | | |
| 2,245 | | |
| - | | |
| 386,270 | | |
| - | | |
| 388,515 | |
Stock issued with debt | |
| - | | |
| - | | |
| 22,000 | | |
| 220 | | |
| - | | |
| 35,628 | | |
| - | | |
| 35,848 | |
Net loss | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| (2,916,338 | ) | |
| (2,916,338 | ) |
BALANCE, June 30, 2022 | |
| 109,874 | | |
$ | 1,098 | | |
| 10,703,179 | | |
$ | 107,033 | | |
$ | 31,974,888 | | |
$ | 64,746,760 | | |
$ | (124,042,132 | ) | |
$ | (27,212,353 | ) |
Stock-based compensation | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| 32,427 | | |
| - | | |
| 32,427 | |
Issuance of common stock for interest paid-in-kind | |
| - | | |
| - | | |
| 389,500 | | |
| 3,895 | | |
| - | | |
| 630,410 | | |
| - | | |
| 634,305 | |
Issuance of common stock for dividends paid-in-kind | |
| - | | |
| - | | |
| 52,032 | | |
| 520 | | |
| - | | |
| 90,536 | | |
| - | | |
| 91,056 | |
Issuance of common stock for services | |
| - | | |
| - | | |
| 113,500 | | |
| 1,135 | | |
| - | | |
| 166,240 | | |
| | | |
| 167,375 | |
Series AA Preferred Stock dividend | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| (431,709 | ) | |
| (431,709 | ) |
Common stock issued for debt extension | |
| - | | |
| - | | |
| 707,900 | | |
| 7,079 | | |
| - | | |
| 1,043,396 | | |
| - | | |
| 1,050,475 | |
Warrants issued for services | |
| - | | |
| - | | |
| - | | |
| - | | |
| 14,734 | | |
| - | | |
| - | | |
| 14,734 | |
Stock issued with debt | |
| - | | |
| - | | |
| 254,500 | | |
| 2,545 | | |
| - | | |
| 331,720 | | |
| - | | |
| 334,265 | |
Stock warrants issued | |
| - | | |
| - | | |
| - | | |
| - | | |
| 6,140 | | |
| - | | |
| - | | |
| 6,140 | |
Net loss | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| (4,462,237 | ) | |
| (4,462,237 | ) |
BALANCE, September 30, 2022 | |
| 109,874 | | |
$ | 1,098 | | |
| 12,220,611 | | |
$ | 122,207 | | |
$ | 31,995,762 | | |
$ | 67,041,489 | | |
$ | (128,936,078 | ) | |
$ | (29,775,522 | ) |
Balance | |
| 109,874 | | |
$ | 1,098 | | |
| 12,220,611 | | |
$ | 122,207 | | |
$ | 31,995,762 | | |
$ | 67,041,489 | | |
$ | (128,936,078 | ) | |
$ | (29,775,522 | ) |
The
accompanying notes are an integral part of these unaudited consolidated financial statements.
Pressure BioSciences, Inc. | September 30, 2023 10Q Report | 8 |
PRESSURE
BIOSCIENCES, INC. AND SUBSIDIARIES
NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS
September
30, 2023
(UNAUDITED)
1)
Business Overview, Liquidity and Management Plans
Pressure
BioSciences, Inc. (OTCQB: PBIO) (the “Company”) is a leader in the development & sale of innovative, enabling, high
pressure technology-based instruments, consumables, and services for the life sciences and other industries worldwide. Our products/services
are based on three patented, high-pressure platforms: (i) Ultra Shear Technology™ (“UltraShear™” or “UST™”),
(ii) BaroFold Technology™ (“BaroFold™”), and (iii) Pressure Cycling Technology™ (“PCT™”)
The
Company was founded on the belief that its PCT platform had the potential to significantly increase the quality of sample preparation
in both research and clinical settings. This premise has been well proven and PBI has been successful in installing its PCT platform
in the laboratories of key opinion leaders worldwide. Although developed subsequently, the Company now assesses that the commercial potential
for its UST platform across diverse multi-billion-dollar markets far exceeds the potential of the PCT platform. Consequently, in January
2022, PBI made the critical strategy decision to immediately shift its primary business focus from PCT to its innovative UST Platform.
The
UST Platform (8 issued patents) is based on the use of intense shear forces from ultra-high-pressure discharge (greater than
20,000 psi) through a dynamically controlled nano-gap valve under precisely controlled temperatures. UST has been shown to turn
hydrophobic (water-repelling) oil-based supplements (e.g., CBD, curcumin, astaxanthin), therapeutics (e.g., prednisone), and other
active ingredients (e.g., retinol) into long-term stable, effectively water-soluble, highly bioavailable, oil-in-water nanoemulsion
formulations. The Company first introduced the UST Platform in May 2022 through participation in several cannabis/health &
wellness meetings combined with a free-sample program. Executed agreements were subsequently announced with six CBD companies and
one cosmeceutical/skincare company for full commercialization in Q3 202 3.
The Company began shipping Nano CBD topical spray on October 2, 2023.
The
BaroFold Platform (14 issued patents) can be used to significantly improve the quality and production costs of protein biotherapeutics.
It employs high pressure manipulations for the disaggregation, unfolding and controlled refolding of proteins to their desired native
structures at yields and efficiencies not achievable using existing technologies. The BaroFold Platform has been shown to remove protein
aggregates in biotherapeutic drug manufacturing, thereby improving product efficacy, safety, and cost for both new-drug entities and
biosimilar (follow-on biologic) products. It is scalable and practical for standard manufacturing processes.
The
PCT Platform (17 issued patents) uses alternating cycles of hydrostatic pressure between ambient and ultra-high pressures to
control bio-molecular interactions safely and reproducibly in sample preparation (e.g., the critical steps performed by tens of thousands
of scientists worldwide prior to analytical measurements, such as cell lysis and biomolecule extraction from tissue samples). Our focus
for PCT is on making, GMP-compliant, next generation PCT-based Barocycler EXTREME system available globally to
biopharmaceutical drug manufacturers for use in the design, development, characterization, and quality control of biotherapeutic drugs.
We currently have over 350 PCT Systems placed in approximately 250 academic, government, pharmaceutical, and biotech research laboratories
worldwide. There are currently over 200 independent publications highlighting the advantages of using the PCT Platform in scientific
research & clinical laboratories.
2)
Going Concern
The
accompanying financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the
realization of assets and the liquidation of liabilities in the normal course of business. However, we have experienced losses from operations and negative cash flows
from operationing business since our inception. As of September 30, 2023, we do not have adequate working capital resources to satisfy
our current liabilities and as a result, there is substantial doubt regarding our ability to continue as a going concern. We have been
successful in raising debt and equity capital in the past as described in Notes 5 and 6. In addition, we raised debt and equity capital
after September 30, 2023, as described in Note 7. We have financing efforts in place to continue to raise cash through debt and equity
offerings. Although we have successfully completed financings and reduced expenses in the past, we cannot assure you that our plans to
address these matters in the future will be successful. These financial statements do not include any adjustments that might result from
this uncertainty.
Pressure BioSciences, Inc. | September 30, 2023 10Q Report | 9 |
3)
Summary of Significant Accounting Policies
Basis
of Presentation
The
unaudited interim financial statements of Pressure BioSciences, Inc. and its consolidated subsidiaries (collectively, the “Company”)
included herein have been prepared by the Company in accordance with the instructions to Form 10-Q and the rules and regulations of the
U.S. Securities and Exchange Commission. Under these rules and regulations, some information and footnote disclosures normally included
in financial statements prepared under accounting principles generally accepted in the United States of America have been shortened or
omitted. Management believes that all adjustments necessary for a fair statement of the financial position and the results of operations
for the periods shown have been made. All adjustments are normal and recurring. These financial statements should be read together with
the Company’s audited financial statements included in its Form 10-K for the fiscal year ended December 31, 2022. Operating results
for the nine months ended September 30, 2023 are not necessarily indicative of the final results that may be expected for the year ending
December 31, 2023.
Use
of Estimates
The
Company’s consolidated financial statements and accompanying notes are prepared in accordance with accounting principles generally
accepted in the United States of America, which require the use of estimates, judgements and assumptions that affect the reported amounts
of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the periods
presented. Global concerns about the COVID-19 pandemic have adversely affected, and we expect will continue to adversely affect, our
business, financial condition and results of operations including the estimates and assumptions made by management. Significant estimates
and assumptions include valuations of share-based awards, investments in equity securities and intangible asset impairment. Actual results
could differ from the estimates, and such differences may be material to the Company’s consolidated financial statements.
Recent
Accounting Pronouncements
In
August 2020, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2020-06, Accounting for Convertible
Instruments and Contracts in an Entity’s Own Equity, as part of its overall simplification initiative to reduce costs and complexity
of applying accounting standards while maintaining or improving the usefulness of the information provided to users of financial statements.
Among other changes, the new guidance removes the beneficial conversion separation model for convertible debt. As a result, after adopting
the guidance, entities will no longer account for beneficial conversion features in equity. The guidance is effective for public business
entities, other than small reporting company’s financial statements starting January 1, 2022, with early adoption permitted. The
Company is a small reporting company and early adopted the new guidance on January 1, 2022 using the modified retrospective approach
and recorded a cumulative effect of adoption equal to a $2,728,243 decrease in additional paid in capital and a $2,255,216 decrease in
accumulated deficit. There is no material impact to the Company’s statements of operations or cash flows as the result of the adoption
of ASU 2020-06.
In
June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses, which requires measurement and recognition of expected
credit losses for financial assets held. We adopted this new accounting guidance effective January 1, 2023. The adoption did not have
a material impact on our consolidated financial statements and disclosures and did not significantly impact the Company’s accounting
policies or estimation methods related to the allowance for doubtful accounts. The Company does not have any reserve for doubtful accounts
due to its customers being distributors, universities, research organizations and government agencies. In the past several years, all
its customers have paid in full without any need for a write-down.
Principles
of Consolidation
The
consolidated financial statements include the accounts of Pressure BioSciences, Inc., and its wholly owned subsidiaries PBI BioSeq, Inc.
and PBI Agrochem, Inc. All intercompany accounts and transactions have been eliminated in consolidation.
Pressure BioSciences, Inc. | September 30, 2023 10Q Report | 10 |
Revenue
Recognition
We
recognize revenue in accordance with FASB ASC 606, Revenue from Contracts with Customers, and ASC 340-40, Other Assets and
Deferred Costs—Contracts with Customers. Revenue is measured based on a consideration specified in a contract with a customer,
and excludes any sales incentives and amounts collected on behalf of third parties. We enter sales contracts that may consist of multiple
distinct performance obligations where certain performance obligations of the sales contract are not delivered in one reporting period.
We measure and allocate revenue according to ASC 606-10.
We
identify a performance obligation as distinct if both the following criteria are true: the customer can benefit from the good or service
either on its own or together with other resources that are readily available to the customer and the entity’s promise to transfer
the good or service to the customer is separately identifiable from other promises in the contract. Determining the standalone selling
price (“SSP”) and allocation of consideration from a contract to the individual performance obligations, and the appropriate
timing of revenue recognition, is the result of significant qualitative and quantitative judgments. Management considers a variety of
factors such as historical sales, usage rates, costs, and expected margin, which may vary over time depending upon the unique facts and
circumstances related to each performance obligation in making these estimates. While changes in the allocation of the SSP between performance
obligations will not affect the amount of total revenue recognized for a particular contract, any material changes could impact the timing
of revenue recognition, which would have a material effect on our financial position and result of operations. This is because the contract
consideration is allocated to each performance obligation, delivered or undelivered, at the inception of the contract based on the SSP
of each distinct performance obligation.
Taxes
assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction, that are
collected by the Company from a customer, are excluded from revenue.
Shipping
and handling costs associated with outbound freight after control over a product has transferred to a customer are accounted for as a
fulfillment cost and are included in cost of revenues as consistent with treatment in prior periods.
Our
current Barocycler® instruments require a basic level of instrumentation expertise to set-up for initial operation. To support a
favorable first experience for our customers, upon customer request, and for an additional fee, we will send a highly trained technical
representative to the customer site to install Barocyclers® that we sell, lease, or rent through our domestic sales force. The installation
process includes uncrating and setting up the instrument, followed by introductory user training. Our sales arrangements do not provide
our customers with a right of return. Any shipping costs billed to customers are recognized as revenue.
Most
of our instrument and consumable contracts contain pricing that is based on the market price for the product at the time of delivery.
Our obligations to deliver product volumes are typically satisfied and revenue is recognized when control of the product transfers to
our customers. Concurrent with the transfer of control, we typically receive the right to payment for the shipped product and the customer
takes on the significant risks and rewards of ownership of the product. Payment terms require customers to pay shortly after delivery
and do not contain significant financing components.
Revenue
from scientific services customers is recognized upon completion of each stage of service as defined in service agreements.
We
apply ASC 845, “Accounting for Non-Monetary Transactions”, to account for products and services sold through non-cash transactions
based on the fair values of the products and services involved, where such values can be determined. Non-cash exchanges would require
revenue to be recognized at recorded cost or carrying value of the assets or services sold if any of the following conditions apply:
|
a) |
The
fair value of the asset or service involved is not determinable. |
|
|
|
|
b) |
The
transaction is an exchange of a product or property held for sale in the ordinary course of business for a product or property to
be sold in the same line of business to facilitate sales to customers other than the parties to the exchange. |
|
|
|
|
c) |
The
transaction lacks commercial substance. |
We
recognize revenue for non-cash transactions at recorded cost or carrying value of the assets or services sold.
Pressure BioSciences, Inc. | September 30, 2023 10Q Report | 11 |
We
account for lease agreements of our instruments in accordance with ASC 842, Leases. We record revenue over the life of the lease term,
and we record depreciation expense on a straight-line basis over the thirty-six-month estimated useful life of the Barocycler® instrument.
The depreciation expense associated with assets under lease agreement is included in the “Cost of PCT products and services”
line item in our accompanying consolidated statements of operations. Many of our lease and rental agreements allow the lessee to purchase
the instrument at any point during the term of the agreement with partial or full credit for payments previously made. We pay all maintenance
costs associated with the instrument during the term of the leases.
Deferred
revenue represents amounts received from service contracts for which the related revenues have not been recognized because one or more
of the revenue recognition criteria have not been met. Revenue from service contracts is recorded ratably over the length of the contract.
Disaggregation
of revenue
In
the following table, revenue is disaggregated by primary geographical market, major product line, and timing of revenue recognition.
Schedule
of Disaggregation of Revenue
In thousands of US dollars ($) | |
Three Months Ended September 30, | | |
Nine Months Ended September 30, | |
Primary geographical markets | |
2023 | | |
2022 | | |
2023 | | |
2022 | |
North America | |
$ | 251 | | |
$ | 138 | | |
$ | 1,067 | | |
$ | 709 | |
Europe | |
| 76 | | |
| 13 | | |
| 130 | | |
| 61 | |
Asia | |
| 86 | | |
| (7 | ) | |
| 468 | | |
| 352 | |
| |
$ | 413 | | |
$ | 144 | | |
$ | 1,665 | | |
$ | 1,122 | |
| |
Three Months Ended September 30, | | |
Nine Months Ended September 30, | |
Major products/services lines | |
2023 | | |
2022 | | |
2023 | | |
2022 | |
Hardware | |
$ | 273 | | |
$ | 1 | | |
$ | 994 | | |
$ | 532 | |
Consumables | |
| 50 | | |
| 49 | | |
| 173 | | |
| 165 | |
Contract research services | |
| -1 | | |
| - | | |
| 35 | | |
| 125 | |
Sample preparation accessories | |
| 31 | | |
| 41 | | |
| 113 | | |
| 93 | |
Technical support/extended service contracts | |
| 34 | | |
| 41 | | |
| 123 | | |
| 94 | |
| |
| | | |
| | | |
| | | |
| | |
Agrochem Products | |
| 15 | | |
| 10 | | |
| 181 | | |
| 93 | |
Shipping and handling | |
| 11 | | |
| 2 | | |
| 38 | | |
| 20 | |
Other | |
| - | | |
| - | | |
| 8 | | |
| - | |
| |
$ | 413 | | |
$ | 144 | | |
$ | 1,665 | | |
$ | 1,122 | |
| |
Three Months Ended September 30, | | |
Nine Months Ended September 30, | |
Timing of revenue recognition | |
2023 | | |
2022 | | |
2023 | | |
2022 | |
Products transferred at a point in time | |
$ | 379 | | |
$ | 103 | | |
$ | 1,506 | | |
$ | 903 | |
Services transferred over time | |
| 34 | | |
| 41 | | |
| 159 | | |
| 219 | |
| |
$ | 413 | | |
$ | 144 | | |
$ | 1,665 | | |
$ | 1,122 | |
Contract
balances
Schedule
of Contract Balances
In thousands of US dollars ($) | |
September 30, 2023 | | |
December 31, 2022 | |
Receivables, which are included in ‘Accounts Receivable’ | |
$ | 329 | | |
$ | 295 | |
Contract liabilities (deferred revenue) | |
| 59 | | |
| 60 | |
Pressure BioSciences, Inc. | September 30, 2023 10Q Report | 12 |
Transaction
price allocated to the remaining performance obligations
The
following table includes estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied
(or partially unsatisfied) at the end of the reporting period.
Schedule
of Future Related to Performance Obligations
In thousands of US dollars ($) | |
2023 | | |
2024 | | |
Total | |
Extended warranty service | |
$ | 48 | | |
$ | 11 | | |
$ | 59 | |
All
consideration from contracts with customers is included in the amounts presented above.
Contract
Costs
The
Company recognizes the incremental costs of obtaining contracts as an expense when incurred if the amortization period of the assets
that the Company otherwise would have recognized is one year or less. These costs are included in selling, general, and administrative
expenses. The costs to obtain a contract are recorded immediately in the period when the revenue is recognized either upon shipment or
installation. The costs to obtain a service contract are considered immaterial when spread over the life of the contract so the Company
records the costs immediately upon billing.
Concentrations
Credit
Risk
Our
financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash, cash equivalents, and trade
receivables. We have cash investment policies which, among other things, limit investments to investment-grade securities. We perform
ongoing credit evaluations of our customers, and the risk with respect to trade receivables is further mitigated by the fact that many
of our customers are government institutions, large pharmaceutical and biotechnology companies, and academic laboratories.
The
following table illustrates the level of concentration as a percentage of total revenues during the three and nine months ended September
30, 2023 and 2022.
Schedule
of Customer Concentration Risk Percentage
| |
Three Months Ended September 30, | | |
Nine months Ended September 30, | |
| |
2023 | | |
2022 | | |
2023 | | |
2022 | |
Top five customers | |
| 80 | % | |
| 42 | % | |
| 49 | % | |
| 31 | % |
Federal agencies | |
| 18 | % | |
| 4 | % | |
| 5 | % | |
| 1 | % |
The
following table illustrates the level of concentration as a percentage of net accounts receivable balance as of September 30, 2023 and
December 31, 2022. The Top Five Customers category may include federal agency receivable balances if applicable.
| |
September 30, 2023 | | |
December 31, 2022 | |
Top five customers | |
| 80 | % | |
| 93 | % |
Federal agencies | |
| 22 | % | |
| 0 | % |
Product
Supply
In
recent years we utilized a contract assembler for our Barocycler® 2320EXT. They provided us with precision manufacturing services
that included management support services to meet our specific application and operational requirements. Among the services provided
to us were:
|
● |
CNC
Machining |
|
● |
Contract
Assembly & Kitting |
|
● |
Component
and Subassembly Design |
|
● |
Inventory
Management |
|
● |
ISO
certification |
Pressure BioSciences, Inc. | September 30, 2023 10Q Report | 13 |
Beginning
in July 2021, we brought the assembly of our Barocycler 2320EXT instruments in-house. This became necessary when our independent contract
assembler (CBM Industries) informed us that they were about to need 100% of their assembly space for one of their customers (one of the
largest life science instrument manufacturers in the U.S.). We worked with our notified body to gain approval to use both the CE and
CSA marks on the instrument, which we received during Q3 2021. Until further notice, we expect to continue to assemble our Barocycler
2320EXT instrument at our South Easton, MA location.
We
currently manufacture and assemble the Barocycler®, HUB440, HUB880, the SHREDDER SG3, and most of our consumables at our South Easton,
MA facility. We will regularly reassess the tradeoffs between in-house assembly versus the benefits of outsourced relationships for of
the entire Barocycler® product line, and future instruments.
Investment
in Equity Securities
As
of September 30, 2023, we held 100,250 shares of common stock of Nexity Global SA, (a Polish publicly traded company).
We
account for this investment in accordance with ASC 320 “Investments — Debt and Equity Securities.” ASC 320 requires
equity investments with readily determinable fair values to be measured at fair value with changes in fair value recognized in net income.
As
of September 30, 2023, our consolidated balance sheet reflected the fair value, determined on a recurring basis based on Level 1 inputs
of our investment in Nexity, to be $77,918. We recorded $14,280 as an unrealized gain during the nine months ended September 30, 2023
for changes in market value.
Computation
of Loss per Share
Basic
loss per share is computed by dividing loss available to common shareholders by the weighted average number of common shares outstanding.
Diluted loss per share is computed by dividing loss available to common shareholders by the weighted average number of common shares
outstanding plus additional common shares that would have been outstanding if dilutive potential common shares had been issued. For purposes
of this calculation, convertible preferred stock, common stock dividends, and warrants and options to acquire common stock, are all considered
common stock equivalents in periods in which they have a dilutive effect and are excluded from this calculation in periods in which these
are anti-dilutive to our net loss.
The
following table illustrates our computation of loss per share for the three and nine months ended September 30, 2023 and 2022:
Schedule
of Computation of Loss Per Share
| |
2023 | | |
2022 | | |
2023 | | |
2022 | |
| |
For the Three Months Ended September 30, | | |
For the Nine months Ended September 30, | |
| |
2023 | | |
2022 | | |
2023 | | |
2022 | |
Numerator: | |
| | | |
| | | |
| | | |
| | |
Net loss attributable to common shareholders | |
$ | (6,261,999 | ) | |
$ | (4,893,946 | ) | |
$ | (24,666,565 | ) | |
$ | (12,913,826 | ) |
Denominator for basic and diluted loss per share: | |
| | | |
| | | |
| | | |
| | |
Weighted average common stock shares outstanding | |
| 21,716,950 | | |
| 11,131,742 | | |
| 20,337,229 | | |
| 10,429,817 | |
Loss per common share - basic and diluted | |
$ | (0.29 | ) | |
$ | (0.44 | ) | |
$ | (1.21 | ) | |
$ | (1.24 | ) |
Pressure BioSciences, Inc. | September 30, 2023 10Q Report | 14 |
The
following table presents securities that could potentially dilute basic loss per share in the future. For all periods presented, the
potentially dilutive securities were not included in the computation of diluted loss per share because these securities would have been
anti-dilutive to our net loss. The Series D Convertible Preferred Stock, Series G Convertible Preferred Stock, Series H and H2 Convertible
Preferred Stock, Series J Convertible Preferred Stock, Series K Convertible Preferred Stock, Series AA Convertible Preferred Stock, Series
BB Convertible Stock and Series CC Convertible Preferred Stock are presented below as if they were converted into common shares according
to the conversion terms.
Schedule
of Anti-Dilutive Securities Excluded from Computation of Earnings Per Share
| |
As of September 30, | |
| |
2023 | | |
2022 | |
Stock options | |
| 3,420,754 | | |
| 1,307,822 | |
Convertible debt | |
| 7,417,906 | | |
| 6,471,034 | |
Common stock warrants | |
| 15,732,940 | | |
| 16,293,768 | |
Convertible preferred stock: | |
| | | |
| | |
Series D Convertible Preferred Stock | |
| 6,250 | | |
| 25,000 | |
Series G Convertible Preferred Stock | |
| - | | |
| 26,857 | |
Series H Convertible Preferred Stock | |
| - | | |
| 33,334 | |
Series H2 Convertible Preferred Stock | |
| - | | |
| 70,000 | |
Series J Convertible Preferred Stock | |
| - | | |
| 115,267 | |
Series K Convertible Preferred Stock | |
| - | | |
| 229,334 | |
Series AA Convertible Preferred Stock | |
| 8,601,000 | | |
| 8,645,000 | |
Series BB Convertible Preferred Stock | |
| 8,580,000 | | |
| - | |
Series CC Convertible Preferred Stock | |
| 4,010,000 | | |
| - | |
| |
| 47,768,850 | | |
| 33,217,416 | |
Accounting
for Stock-Based Compensation Expense
We
maintain equity compensation plans under which incentive stock options and non-qualified stock options are granted to employees, independent
members of our Board of Directors and outside consultants. We recognize stock-based compensation expense over the requisite service period
using the Black-Scholes formula to estimate the fair value of the stock options on the date of grant.
Determining
Fair Value of Stock Option Grants
The
following table summarizes the assumptions we utilized for grants of stock options to the three sub-groups of our stock option recipients
during the nine months ended September 30, 2023:
Summary of Assumptions for Grants of Stock Options
Assumptions | |
CEO, other Officers and Employees | |
Expected life | |
| 6.0 (yrs) | |
Expected volatility | |
| 130.5 | % |
Risk-free interest rate | |
| 3.90 | % |
Forfeiture rate | |
| 0 to 5.00 | % |
Expected dividend yield | |
| 0.0 | % |
Valuation
and Amortization Method - The fair value of each option award is estimated on the date of the grant using the Black-Scholes pricing
model based on certain assumptions. The estimated fair value of employee stock options is amortized to expense using the
straight-line method over the vesting period.
Expected
Term - The Company uses the simplified calculation of expected life, as the Company does not currently have sufficient historical
exercise data on which to base an estimate of the expected term. Using this method, the expected term is determined using the
average of the vesting period and the contractual life of the stock options granted.
Expected
Volatility - Expected volatility is based on the Company’s historical stock volatility data over the expected term of the award.
Pressure BioSciences, Inc. | September 30, 2023 10Q Report | 15 |
Risk-Free
Interest Rate - The Company bases the risk-free interest rate used in the Black-Scholes valuation method on the implied yield currently
available on U.S. Treasury zero-coupon issues with an equivalent remaining term.
Forfeitures
- The Company records stock-based compensation expense only for those awards that are expected to vest. The Company estimated a forfeiture
rate of 0% to 5% for awards granted based on historical experience and future expectations of options vesting. The Company used this
historical rate as our assumption in calculating future stock-based compensation expense.
All
of the outstanding non-qualified options had an exercise price that was at or above the Company’s common stock share price at time
of issuance.
The
Company recognized stock-based compensation expense of $140,622 and $32,427 for the three months ended September 30, 2023 and 2022, respectively.
The company recognized stock-based compensation expense of $1,706,420 and $128,984 for the nine months ended September 30, 2023 and 2022,
respectfully. The following table summarizes the effect of this stock-based compensation expense within each of the line items of our
costs and expenses within our Consolidated Statements of Operations:
Schedule
of Stock Based Compensation Expense
| |
For the Three Months Ended | | |
For the Nine Months Ended | |
| |
September 30, | | |
September 30, | |
| |
2023 | | |
2022 | | |
2023 | | |
2022 | |
Cost of sales | |
$ | 11,183 | | |
$ | 2,184 | | |
$ | 75,724 | | |
$ | 8,694 | |
Research and development | |
| 35,676 | | |
| 9,499 | | |
| 241,585 | | |
| 37,803 | |
Selling and marketing | |
| 17,150 | | |
| 4,583 | | |
| 102,675 | | |
| 18,166 | |
General and administrative | |
| 76,613 | | |
| 16,161 | | |
| 1,286,436 | | |
| 64,321 | |
Total stock-based compensation expense | |
$ | 140,622 | | |
$ | 32,427 | | |
$ | 1,706,420 | | |
$ | 128,984 | |
Due
to their short maturities, the carrying amounts for cash and cash equivalents, accounts receivable, accounts payable, accrued expenses
and debt approximate their fair value. The carrying amount of long-term debt approximates fair value due to interest rates that approximate
prevailing market rates.
Fair
Value Measurements
The
Company follows the guidance of FASB ASC Topic 820, “Fair Value Measurements and Disclosures” (“ASC 820”)
as it related to all financial assets and financial liabilities that are recognized or disclosed at fair value in the financial statements
on a recurring basis.
The
Company generally defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly
transaction between market participants at the measurement date (exit price). The Company uses a three-tier fair value hierarchy, which
classifies the inputs used in measuring fair values. These tiers include Level 1, defined as observable inputs such as quoted prices
for identical instruments in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly
or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring the
Company to develop its own assumptions. A slight change in an unobservable input like volatility could have a significant impact on fair
value measurement.
Financial
assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement.
The Company has determined that its financial assets are classified within Level 1 in the fair value hierarchy. The development of the
unobservable inputs for Level 3 fair value measurements and fair value calculations are the responsibility of the Company’s management.
The
following tables set forth the Company’s financial assets and liabilities that were accounted for at fair value on a recurring
basis as of September 30, 2023:
Schedule
of Assets and Liabilities Measured at Fair Value on Recurring Basis
| |
| | |
Fair value measurements at September 30, 2023 using: | |
| |
September 30, 2023 | | |
Quoted prices in active markets (Level 1) | | |
Significant other observable inputs (Level 2) | | |
Significant unobservable inputs (Level 3) | |
Equity Securities | |
$ | 77,918 | | |
$ | 77,918 | | |
| - | | |
| - | |
Total Financial Assets | |
$ | 77,918 | | |
$ | 77,918 | | |
$ | - | | |
$ | - | |
The
following tables set forth the Company’s financial assets and liabilities that were accounted for at fair value on a recurring
basis as of December 31, 2022:
| |
| | |
Fair value measurements at December 31, 2022 using: | |
| |
December 31, 2022 | | |
Quoted prices in active markets (Level 1) | | |
Significant other observable inputs (Level 2) | | |
Significant unobservable inputs (Level 3) | |
Equity Securities | |
| 63,638 | | |
| 63,638 | | |
| - | | |
| - | |
Total Financial Assets | |
$ | 63,638 | | |
$ | 63,638 | | |
$ | - | | |
$ | - | |
4)
Commitments and Contingencies
Operating
Leases
The
Company accounts for its leases under ASC 842. The Company has elected to apply the short-term lease exception to leases of one year
or less. Our corporate office is currently located at 14 Norfolk Avenue, South Easton, Massachusetts 02375. We are currently paying $7,650
per month, on a lease extension, signed on December 5, 2022, that expires December 31, 2023, for our corporate office. We expanded our
space to include offices, warehouse and a loading dock on the first floor starting May 1, 2017 with a monthly rent increase already reflected
in the current payments.
We
extended our lease for our space in Medford, MA (the “Medford Lease”) from December 30, 2020 to December 30, 2023. The lease
required monthly payments of $7,282 subject to annual cost of living increases. The lease shall be automatically extended for additional
three years unless either party terminates at least nine months prior to the expiration of the current lease term.
The
Company accounted for the lease extension of our Medford Lease as a lease modification under ASC 842. At the effective date of modification,
the Company recorded an adjustment to the right-of-use asset and lease liability in the amount of $221,432 based on the net present value
of lease payments discounted using an estimated borrowing rate of 12%.
On
August 9, 2021, we entered into an operating lease agreement for our warehouse space in Sparks, NV (the “Sparks Lease”) for
the period from September 1, 2021 through September 30, 2026. The lease contains escalating payments during the lease period. The lease
can be extended for an additional three years if the Company provides notice at least six months prior to the expiration of the current
lease term.
The
Company accounted for the Sparks Lease as an operating lease under ASC 842. Upon the commencement of the lease, the Company recorded
a right-of-use asset and lease liability in the amount of $239,327 based on the net present value of lease payments discounted using
an estimated borrowing rate of 12%.
Following
is a schedule by years of future minimum rental payments required under operating leases with initial or remaining non-cancelable lease
terms in excess of one year as of September 30, 2023:
Schedule
of Future Minimum Rental Payments Required Under Operating Leases
Year | |
Total | |
October 1 – December 31, 2023 | |
$ | 15,887 | |
2024 | |
| 64,393 | |
2025 | |
| 66,969 | |
2026 | |
| 51,778 | |
Total future undiscounted lease payments | |
| 199,027 | |
Less imputed interest | |
| (61,481 | ) |
Present value of lease liabilities | |
$ | 137,546 | |
Pressure BioSciences, Inc. | September 30, 2023 10Q Report | 16 |
The
operating cash flows from the operating leases were $122,671 for the nine months ended September 30, 2023 and $82,001 for the nine months
ended September 30, 2022. The weighted-average remaining lease term (years) of the above leases is 2.59 year as of September 30, 2023.
Below
is a table for the right of use asset and the corresponding lease liability in the consolidated balance sheets:
Schedule
of Right of Use Asset and the Corresponding Lease Liability
Operating Leases | |
September 30, 2023 | | |
December 31, 2022 | |
Right of use asset | |
$ | 159,424 | | |
$ | 282,095 | |
Right of use liability, current | |
$ | 66,259 | | |
$ | 142,171 | |
Right of use liability, long term | |
$ | 71,287 | | |
$ | 139,924 | |
Total lease liability | |
$ | 137,546 | | |
$ | 282,095 | |
The
weighted-average discount rate is 12%.
The
Company had no financing leases during the nine months ended September 30, 2023 and 2022.
The
components of lease cost for operating leases for the nine months ended September 30, 2023 and 2022 are as follows:
Schedule
of Lease Cost for Operating Leases
| |
September 30, 2023 | | |
September 30, 2022 | |
Operating lease cost | |
$ | 153,290 | | |
$ | 152,193 | |
Short-term lease cost | |
| 110,205 | | |
| 123,514 | |
Total lease cost | |
$ | 263,495 | | |
$ | 275,707 | |
Battelle
Memorial Institute
In
December 2008, we entered into an exclusive patent license agreement with the Battelle Memorial Institute (“Battelle”).
The licensed technology is the subject of a patent application filed by Battelle in 2008 and relates to a method and a system for improving
the analysis of protein samples, including through an automated system utilizing pressure and a pre-selected agent to obtain a digested
sample in a significantly shorter period of time than current methods, while maintaining the integrity of the sample throughout the preparatory
process. In addition to royalty payments on net sales on “licensed products,” we are obligated to make minimum royalty payments
for each year that we retain the rights outlined in the patent license agreement and we are required to have our first commercial sale
of the licensed products within one year following the issuance of the patent covered by the licensed technology. After re-negotiating
the terms of the contract in 2013, the minimum annual royalty was $1,200 in 2014 and $2,000 in 2015; the minimum royalties were $3,000
in 2016, $4,000 in 2017 and $5,000 in 2018 and each calendar year thereafter during the term of the agreement.
Target
Discovery Inc.
In
March 2010, we signed a strategic product licensing, manufacturing, co-marketing, and collaborative research and development agreement
with Target Discovery Inc. (“TDI”), a related party. Under the terms of the agreement, we have been licensed by TDI
to manufacture and sell an innovative line of chemicals used in the preparation of tissues for scientific analysis (“TDI reagents”).
The TDI reagents were designed for use in combination with our pressure cycling technology. The companies believe that the combination
of PCT and the TDI reagents can fill an existing need in life science research for an automated method for rapid extraction and recovery
of intact, functional proteins associated with cell membranes in tissue samples. We did not incur any royalty obligation under this agreement
in 2023 or 2022.
In
April 2012, we signed a non-exclusive license agreement with TDI to grant the non-exclusive use of our pressure cycling technology. We
executed an amendment to this agreement on October 1, 2016 wherein we agreed to pay a monthly fee of $1,400 for the use of a lab bench,
shared space, and other utilities, and $2,000 per day for technical support services as needed. The agreement requires TDI to pay the
Company a minimum royalty fee of $60,000 in 2022 and $60,000 in 2023. For the nine months ended September 30, 2023 and September 30,
2022, the Company reported $55,400 and $65,100, respectively in TDI fees.
Pressure BioSciences, Inc. | September 30, 2023 10Q Report | 17 |
Severance
and Change of Control Agreements
Each
of Mr. Schumacher, and Drs. Ting, and Lazarev, executive officers of the Company, are entitled to receive a severance payment if terminated
by the Company without cause. The severance benefits would include a payment in an amount equal to one year of such executive officer’s
annualized base salary compensation plus accrued paid time off. Additionally, the officer will be entitled to receive medical and dental
insurance coverage for one year following the date of termination.
Each
of these executive officers, other than Mr. Schumacher, is entitled to receive a change of control payment in an amount equal to one
year of such executive officer’s annualized base salary compensation, accrued paid time off, and medical and dental coverage, in
the event of their termination upon a change of control of the Company. In the case of Mr. Schumacher, this payment would be equal to
two years of annualized base salary compensation, accrued paid time off, and two years of medical and dental coverage. The severance
payment is meant to induce the aforementioned executives to remain in the employ of the Company, in general, and particularly in the
occurrence of a change in control, as a disincentive to the control change.
5)
Debt
Convertible
Debt
On
various dates during the nine months ended September 30, 2023, the Company issued convertible notes for net proceeds of approximate total
of $4.3 million which contained varied terms and conditions as follows: a) 1-12 month maturity date; b) interest rates of 0-120%; c)
convertible to the Company’s common stock at issuance at a fixed rate of $2.50 or at variable conversion rates upon the Company’s
up-listing to NASDAQ or NYSE or an event of default. These notes were issued with shares of common stock that were fair valued at issuance
date. The aggregate relative fair value of the shares of common stock and preferred stock issued with the notes of $1,832,757 was
recorded as a debt discount to be amortized over the term of the notes. We also evaluated the convertible notes for derivative liability
treatment and determined that the notes did not qualify for derivative accounting treatment on September 30, 2023.
For
the nine months ended September 30, 2023, deferred financing costs and OID issued with the debt are $648,470 and the Company repaid
$2,462,269.
The
summary of specific terms of the convertible notes and outstanding balances as of September 30, 2023, and December 31, 2022, are listed
in the tables below. The convertible notes are from numerous parties and with original issue dates from July 2019 to September 2023
and maturity dates from July 2020 to September 2024. There are approximately $12.3 million of notes that are past due as of September
30, 2023.
Schedule
of Convertible Debts and Outstanding Balances
| |
September
30, 2023 | | |
December
31, 2022 | |
Holders | |
Interest
Rate | | |
Conversion
Price | | |
Principal | | |
Interest
Rate | | |
Conversion
Price | | |
Principal | |
Main Investor | |
| 10 | % | |
$ | 2.50
(1) | | |
$ | 8,586,750 | | |
| 10 | % | |
$ | 2.50
(1 | ) | |
$ | 9,393,150 | |
Others | |
| 0
to 24 | % | |
$ | 2.50
(2) or $7.50 | | |
| 10,379,763 | | |
| 0
to 24 | % | |
$ | 2.50
(2) or $7.50 |
| |
| 8,886,036 | |
Totals | |
| | | |
| | | |
| - | | |
| | | |
| | | |
| 18,279,186 | |
Discount | |
| | | |
| | | |
| 744,393 | | |
| | | |
| | | |
| 455,517 | |
Net | |
| | | |
| | | |
$ | 18,222,120 | | |
| | | |
| | | |
$ | 17,823,669 | |
Notes:
| a. | Notes
are convertible before maturity at $2.50 per share or mandatorily convertible when the Company
up-lists to the NASDAQ at the lower of $2.50 or the up-list price. |
Pressure BioSciences, Inc. | September 30, 2023 10Q Report | 18 |
| b. | Notes
are convertible upon an Event of Default at 75% multiplied by the lowest trading price for
the common stock during the five days prior to the conversion. |
| c. | Notes
are convertible at $2.50 per share except that following an Event of Default the conversion
price will be adjusted to 75% multiplied by the lowest trading price for the common stock
during the five days prior to the conversion. |
| d. | Notes
can be voluntary converted at lower of 1) $2.50/share; or 2) purchase price of stock sold
by PBI at a price lower than $2.50/share. In the event of default, these notes can be converted
at lower of 1) $2.50/share; 2) 30% discount to 5-day VWAP prior to date of default. |
| e. | Notes
can be voluntary converted at lower of 1) $2.50/share; or 2) purchase price of stock sold
by PBI at a price lower than $2.50/share. In the event of default, these notes can be converted
at lower of 1) $2.50/share; 2) 25% discount to 5-day VWAP prior to date of default. |
| f. | Conversion
price is lower of (i) $2.50 or (ii) the price per share that the Company last sold Common
Stock after the execution of an anti-dilution protection agreement. |
| g. | Note
can be converted at a Voluntary Conversion Price which is the lower of 1) $2.50/share; or
2) purchase price of stock sold by the Company at a price lower than $2.50 except that following
an Event of Default, the Holder shall have the right, with no further consent from the Borrower,
to convert notes which can be the lower of 1) the Voluntary Conversion Price, or 2) 70% of
the 5-day VWAP prior to conversion. |
| h. | Conversion
price is $2.50. If note is in default, it is $1. |
| i. | Notes
can be voluntarily converted before maturity at $2.50 per share. Lender retains the option
upon an Up-list to convert at the lower of $2.50 or 10% off Up-list price. |
| j. | Notes
can be converted at the lesser of $2.5 per share or 25% discount to the opening price of
the Company’s first day of trading on either Nasdaq or NYSE. In addition, if the Company
fails to pay the Note in cash on maturity date, the conversion price will be adjusted to
the lesser of (i) original conversion price or (ii) a 35% discount to the VWAP prior to each
conversion date. |
| k. | Some
notes are not convertible until 180 days from the date of issuance of the Note and following
an Event of Default will be convertible at the lowest trading price of the 20 days prior
to conversion. The loan with a principal balance of $950,000 as of September 30, 2023 is
guaranteed by the Company’s Chief Executive Officer, but the lender may only enforce
this guarantee after certain conditions have been met, specifically after (i) the occurrence
of an Event of Default (as defined in the Note), (ii) the failure of the Company to cure
the Default in 10 business days, and (iii) a failure by the Company to issue, or cause to
be issued, shares of its common stock upon submission by the lender of a notice of conversion. |
| l. | Some
notes can be converted at the lesser of $2.50 per share or 25% discount to the opening price
of the Company’s first day of trading on either Nasdaq or NYSE. In addition, if the
Company fails to pay the Note in cash on maturity date, the conversion price will be adjusted
to the lesser of original conversion price or the product of the VWAP of the common stock
for the 5 trading dates immediately prior to the maturity date multiplied by 0.75. |
For
the nine months ended September 30, 2023, the Company recognized amortization expense related to the debt discounts indicated above of
$2,621,523. The unamortized debt discounts as of September 30, 2023 related to the convertible notes amounted to $744,393.
As
of September 30, 2023, the principal balance that is secured by the assets of the Company’s subsidiary, PBI Agrochem, Inc. is $352,188.
Standstill
and Forbearance Agreements
In
recent years, the Company entered into Standstill and Forbearance Agreements with lenders who hold variable-rate convertible notes. Pursuant
to these agreements the lenders agreed to not convert any portion of their notes into shares of common stock at a variable rate. During
the nine months ended September 30, 2023, the Company settled one note with total principal of $302,484, leaving one final lender (three
notes) with total principal of $272,500 outstanding and incurred interest, penalties and fees of approximately $253,425 in connection
with the Standstill and Forbearance Agreements.
Convertible
Loan Modifications and Extinguishments
We
refinanced certain convertible loans during the nine months ended September 30, 2023 at substantially the same terms for extensions ranging
over a period of two to nine months. We amortized any remaining unamortized debt discount as of the modification date over the remaining,
extended term of the new loans. We applied ASC 470 of modification accounting to the debt instruments which were modified during the
quarter or those settled with new notes issued concurrently for the same amounts but different maturity dates. The terms such as the
interest rate, prepayment penalties, and default rates will be the same over the new extensions. According to ASC 470, an exchange of
debt instruments between or a modification of a debt instrument by a debtor and a creditor in a nontroubled debt situation is deemed
to have been accomplished with debt instruments that are substantially different if the present value of the cash flows under the terms
of the new debt instrument is at least 10 percent different from the present value of the remaining cash flows under the terms of the
original instrument. If the terms of a debt instrument are changed or modified and the cash flow effect on a present value basis is less
than 10 percent, the debt instruments are not considered to be substantially different and will be accounted for as modifications.
Pressure BioSciences, Inc. | September 30, 2023 10Q Report | 19 |
The
cash flows of new debt exceeded 10% of the remaining cash flows of the original debt on several loans. During the nine months ended September
30, 2023 we recorded gains on extinguishment of liabilities of approximately $0.7 million by calculating the difference of the
fair value of the new debt and the carrying value of the old debt. During the nine months ended September 30, 2023, the Company extended
17 loans totaling $3,917,898 and increased the principal to $4,067,898. The Company issued 1,346,800 shares of common stock and 741
shares of preferred stock for these extensions and increased principal.
Other
Debt
No
notes in Other Debt are past due as of September 30, 2023.
Schedule
of Other Debt
| |
September
30, 2023 | | |
December
31, 2022 | |
Holders | |
Interest
Rate | | |
Principal | | |
Interest
Rate | | |
Principal | |
Non-Convertible | |
| -(1 | ) | |
$ | 1,016,500 | | |
| -(1 | ) | |
$ | 878,809 | |
Merchant
debt (3) | |
| | | |
| 1,014,010 | | |
| | | |
| 760,160 | |
SBA
(2) | |
| 3.75 | % | |
| 162,522 | | |
| 3.75 | % | |
| 150,000 | |
Totals | |
| | | |
| 2,193,032 | | |
| | | |
$ | 1,788,969 | |
Discount | |
| | | |
| - | | |
| | | |
| - | |
Long
Term | |
| | | |
| 162,522 | | |
| | | |
| 150,000 | |
Short
Term | |
| | | |
$ | 2,030,510 | | |
| | | |
$ | 1,638,969 | |
Notes:
Related
Party Notes
Schedule
of Related Party Debt
| |
September 30, 2023 | | |
December 31, 2022 | |
Holders | |
Interest Rate | | |
Principal | | |
Interest Rate | | |
Principal | | |
Security | |
Officers & Directors | |
| -(1 | ) | |
$ | 522,450 | | |
| -(1 | ) | |
$ | 521,950 | | |
| Unsecured | |
Other Related Parties | |
| 12 | % | |
| 126,050 | | |
| 12 | % | |
| 120,850 | | |
| Unsecured | |
Totals | |
| | | |
| 648,500 | | |
| | | |
| 642,800 | | |
| | |
Discount | |
| | | |
| 514 | | |
| | | |
| 7,915 | | |
| | |
Net | |
| | | |
$ | 647,986 | | |
| | | |
$ | 634,885 | | |
| | |
Notes:
Pressure BioSciences, Inc. | September 30, 2023 10Q Report | 20 |
During
the nine months ended September 30, 2023, we received short-term convertible loans of $164,700 with $5,514 OID from related parties
and repaid $159,000 of related party loans. These notes bear interest of 12% to 120% and are due upon demand. All related party notes
are convertible at $2.50/share.
We
amortized $592,099
of debt discounts during the nine months ended September 30, 2023 for all non-convertible and related party notes. The total unamortized
discount for all non-convertible and related party convertible notes as of September 30, 2023, and December 31, 2022 was $514
and $7,915,
respectively.
6)
Stockholders’ Deficit
Preferred
Stock
We
are authorized to issue 1,000,000 shares of preferred stock with a par value of $0.01. Of the 1,000,000 shares of preferred stock, the
following is outstanding:
Schedule
of Preferred Stock Outstanding
| |
September 30, 2023 | | |
December 31, 2022 | |
Series D Convertible Preferred Stock, $.01 par value; 850 shares authorized; 75 shares issued and outstanding on September 30, 2023, and 300 shares issued and outstanding on December 31, 2022 (Liquidation value of $300,000) | |
$ | - | | |
$ | 3 | |
Series G Convertible Preferred Stock, $.01 par value; 240,000 shares authorized; no shares issued and outstanding on September 30, 2023 and 80,570 shares issued and outstanding on December 31, 2022 | |
| - | | |
| 806 | |
Series H Convertible Preferred Stock, $.01 par value; 10,000 shares authorized; no shares issued and outstanding on September 30, 2023 and 10,000 shares issued and outstanding on December 31, 2022 | |
| - | | |
| 100 | |
Series J Convertible Preferred Stock, $.01 par value; 6,250 shares authorized; no shares issued and outstanding on September 30, 2023 and 3,458 shares issued and outstanding on December 31, 2022 | |
| - | | |
| 35 | |
Series K Convertible Preferred Stock, $.01 par value; 15,000 shares authorized; no shares issued and outstanding on September 30, 2023 and 6,880 shares issued and outstanding on December 31, 2022 | |
| - | | |
| 68 | |
Series AA Convertible Preferred Stock, $.01 par value; 10,000 shares authorized; 8,601 shares issued and outstanding on September 30, 2023 and December 31, 2022, respectively | |
| 86 | | |
| 86 | |
Series BB Convertible Preferred Stock, $.01 par value; 1,000 shares authorized; 858 shares issued and outstanding on September 30, 2023 and no shares outstanding at December 31, 2022 | |
| 10 | | |
| - | |
Series CC Convertible Preferred Stock, $.01 par value; 2,000 shares authorized; 401 shares issued and outstanding on September 30, 2023 and no shares outstanding at December 31, 2022 | |
| 4 | | |
| - | |
Series H2 Convertible Preferred Stock, $.01 par value; 21 shares authorized; no shares issued and outstanding on September 30, 2023 and 21 shares issued and outstanding on December 31, 2022 | |
| - | | |
| - | |
Series A Junior Participating Preferred Stock, $.01 par value, 20,000 shares authorized, no shares outstanding | |
| - | | |
| - | |
Series A Convertible Preferred Stock, $.01 par value, 313,960 shares authorized, no shares outstanding | |
| - | | |
| - | |
Series B Convertible Preferred Stock, $.01 par value, 279,256 shares authorized, no shares outstanding | |
| - | | |
| - | |
Series C Convertible Preferred Stock, $.01 par value, 88,098 shares authorized, no shares outstanding | |
| - | | |
| - | |
Series E Convertible Preferred Stock, $.01 par value, 500 shares authorized, no shares outstanding | |
| - | | |
| - | |
Total Convertible Preferred Shares | |
$ | 100 | | |
$ | 1,098 | |
Pressure BioSciences, Inc. | September 30, 2023 10Q Report | 21 |
On
May 1, 2023, Pressure Biosciences, Inc. (the “Company”) filed Articles of Amendment to Restated Articles of Organization
(the “Amendment”) with the Secretary of the Commonwealth of Massachusetts to designate 1,000 shares of its Preferred Stock
as Series BB Convertible Preferred Stock, par value $0.01 per share (the “Series BB Preferred Stock”) and 2,000 shares of
Preferred Stock as Series CC Convertible Preferred Stock, par value $0.01 per share (the “Series CC Preferred Stock”). Each
of the Certificate of Designation of Series BB Convertible Preferred Stock (the “Series BB COD”) and Certificate of Designation
of Series CC Convertible Preferred Stock (the “Series CC COD”) filed with the Amendment set forth the terms and provisions
of the Series BB Preferred Stock and Series CC Preferred Stock, respectively.
Series
BB Preferred Stock
Rank.
The Series BB Preferred Stock ranks prior to the Company’s common stock, par value $0.01 per share (the “Common Stock”),
and subordinate to the Series AA and Series CC Preferred Stock, and to all other classes of classes and series of equity securities of
the Company, which by its terms does not rank on a parity with or senior to the Series BB Preferred, and all indebtedness of the Company.
Dividends.
The holders of shares of the Series BB Preferred Stock are not entitled to receive dividends.
Voting
Rights. The Series BB Preferred Stock has all of the same voting rights as the Common Stock. Each share of Series BB Preferred Stock.
The holders of Series BB Preferred Stock shall have the right to vote along with the holders of Common Stock in an amount equal to 10,000
votes for each share of Series BB Preferred Stock held.
Voluntary
Conversion. The holders of Series BB Preferred Stock have the right to convert its Series BB Preferred Stock into Common Stock at
a ratio of 10,000 shares of Common Stock for each share of Series BB Preferred Stock held, subject to adjustment as set forth in Section
4(e) of the Series BB COD.
Company
Forced Conversion. The Company has the right to cause the conversion of all shares of Series BB Preferred Stock into Common Stock
(“Forced Conversion”). Following the effectiveness of a registration statement permitting the resale of the Conversion Shares
held by holders of the Series BB Preferred Stock, the Company may effectuate a Forced Conversion if either of the following conditions
are satisfied: (i) the VWAP of the Common Stock shall equal or exceed 300% of $2.50 (with such dollar figure to be appropriately adjusted
for any stock dividend, stock split, stock combination or other similar transaction that affects the share price of the Common Stock)
for either 10 consecutive trading days, or 15 of 25 consecutive trading days immediately preceding the date of the Forced Conversion
Notice; or (ii) listing of the Common Stock on any national securities exchange (NYSE, NYSE American or Nasdaq). The Company shall not
have an obligation to register the Conversion Shares of the shares of Series BB Preferred Stock that are issued pursuant to any exchange
of previously issued securities.
Series
CC Preferred Stock
Rank.
The Series CC Preferred Stock ranks prior to the Common Stock, pari passu to the Series AA Preferred Stock, and prior to all other classes
and series of equity securities of the Company which by its terms does not rank on a parity with or senior to the Series CC Preferred
Stock (the “Junior Stock”). The Series CC Preferred Stock is subordinate to and ranks junior to all indebtedness of the Company.
Quarterly
Dividends. The holders of shares of the Series CC Preferred Stock are entitled to receive, out of funds legally available therefor,
dividends at an annual rate equal to 8% of the Liquidation Preference Amount (as defined below), calculated on the basis of a 360-day
year, consisting of twelve 30-day months, and shall accrue on a daily basis from April 24, 2023. Accrued and unpaid dividends shall compound
on a quarterly basis, and shall be, except as set forth in Section 2(b) of the Series CC COD, payable in cash. The first such dividend
payment shall be due and payable on April 30, 2023, with subsequent dividend payments due and payable on June 30, September 30, and December
31, 2023. Each year thereafter, dividend payments shall be due and payable on March 31, June 30, September 30, and December 31.
Pressure BioSciences, Inc. | September 30, 2023 10Q Report | 22 |
Junior
Stock Dividends. The Company shall not declare or pay any cash dividends on or make any other distributions with respect to or redeem,
purchase, or otherwise acquire for consideration, any shares of Junior Stock unless and until all accrued and unpaid dividends on the
Series CC Preferred Stock have been paid in full, subject to restrictions as set forth in Section 3(a) of the Series CC COD.
Class
Voting Rights. So long as more than ten percent (10%) of the Series CC Preferred Stock remain outstanding, the Company shall not,
and shall not permit any subsidiary to, without the affirmative vote or consent of the holders of at least 75% of the shares of the Series
CC Preferred Stock outstanding at the time, given in person or by proxy, either in writing or at a meeting, in which the holders of the
Series CC Preferred Stock vote separately as a class: (i) authorize, create, issue or increase the authorized or issued amount of any
class or series of stock, including but not limited to the issuance of any more shares of previously authorized Preferred Stock, ranking
prior to the Series CC Preferred Stock, with respect to the distribution of assets on liquidation, dissolution or winding up; (ii) amend,
alter or repeal the provisions of the Series CC Preferred Stock, whether by merger, consolidation or otherwise, so as to adversely affect
any right, preference, privilege or voting power of the Series CC Preferred Stock; (iii) repurchase, redeem or pay dividends on (whether
in cash, in kind, or otherwise), shares of Junior Stock; (iv) amend the Articles of Incorporation or By-Laws of the Company so as to
affect materially and adversely any right, preference, privilege or voting power of the Series CC Preferred Stock; (v) effect any distribution
with respect to Junior Stock or parity stock; (vi) reclassify the Company’s outstanding securities; or (vii) effect a transaction
with one or more persons or entities whereby such other persons or entities will own more than the 50% of the outstanding shares of Common
Stock following such transaction.
General
Voting Rights. Except with respect to transactions upon which the Series CC Preferred Stock shall be entitled to vote separately
as a class as set forth in “Class Voting Rights” above and except as otherwise required by Massachusetts law, the Series
CC Preferred Stock shall have no voting rights. The Common Stock into which the Series CC Preferred Stock is convertible shall, upon
issuance, have all of the same voting rights as the Common Stock.
Liquidation
Preference. In the event of the liquidation, dissolution or winding up of the affairs of the Company, whether voluntary or involuntary,
the holders of shares of the Series CC Preferred Stock then outstanding shall be entitled to receive, out of the assets of the Company
whether such assets are capital or surplus of any nature, an amount equal to $25,000.00 per share (the “Liquidation Preference
Amount”) of the Series CC Preferred Stock, on a pro rata and pari passu basis with any parity stock (the “Pari Passu Preferred
Stock”), together with all accrued but unpaid dividends, before any payment shall be made or any assets distributed to the holders
of the Common Stock or any other Junior Stock. If the assets of the Company are not sufficient to pay in full the Liquidation Preference
Amount payable to the holders of outstanding shares of the Series CC Preferred Stock and any series of preferred stock or any other class
of stock on a parity as to rights on liquidation, dissolution or winding up, with the Series CC Preferred Stock, then all of said assets
will be distributed among the holders of the Series CC Preferred Stock, the Pari Passu Preferred Stock and the other classes of stock
on a parity with the Series CC Preferred Stock, if any, ratably in accordance with the respective amounts that would be payable on such
shares if all amounts payable thereon were paid in full.
Voluntary
Conversion. The holders of Series CC Preferred Stock have the right to convert its Series CC Preferred Stock into a number of fully
paid and nonassessable shares of Common Stock (the “Conversion Shares”) equal to the quotient of (i) the Liquidation Preference
Amount of the shares of Series CC Preferred Stock being converted thereon divided by (ii) the Conversion Price then in effect as of the
date of the delivery by such holder of its notice of election to convert. The “Conversion Price” shall mean $2.50 per share,
subject to adjustment under Section 5(e) of the Series CC COD.
Company
Forced Conversion. The Company has the right to cause the conversion of all shares of Series CC Preferred Stock into Common Stock
(“Forced Conversion”). Following the effectiveness of a registration statement permitting the resale of the Conversion Shares
held by holders of the Series CC Preferred Stock the Company may effectuate a Forced Conversion if either of the following conditions
are satisfied as of the Forced Conversion Effective Date: (i) the VWAP of the Common Stock shall equal or exceed 300% of the Conversion
Price for either 10 consecutive trading days, or 15 of 25 consecutive trading days immediately preceding the date of the Forced Conversion
Notice; or (ii) listing of the Common Stock on any national securities exchange (NYSE, NYSE American or Nasdaq). The Company shall not
have an obligation to register the Conversion Shares of the shares of Series CC Preferred Stock that are issued pursuant to any exchange
of previously issued securities.
Pressure BioSciences, Inc. | September 30, 2023 10Q Report | 23 |
Conversion
Restriction. At no time may a holder of shares of Series CC Preferred Stock convert shares of the Series CC Preferred Stock if the
number of shares of Common Stock to be issued pursuant to such conversion would exceed, when aggregated with all other shares of Common
Stock owned by such holder at such time, the number of shares of Common Stock which would result in such holder beneficially owning (as
determined in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended, and the rules thereunder) in excess of
4.99% of all of the Common Stock outstanding at such time (the “Conversion Restriction”); provided, however, that a holder
may waive the Conversion Restriction by providing the Company with sixty-one (61) days’ notice that such holder is waiving the
Conversion Restriction.
During
the nine months ended September 30, 2023 the Company issued a total of 953 shares of Series BB restricted preferred stock and 401 shares
of Series CC restricted preferred stock to accredited investors and consultants, with the following detail:
| ● | 92
shares of Series BB preferred stock with a fair value of $617,200, for services rendered; |
| ● | 741
shares of Series BB preferred stock with a fair value of $2,683,600 for convertible debt
extensions; |
| ● | 58
shares of Series BB preferred stock with a fair value of $539,487 and issued with convertible
debt; |
| ● | 62
shares of Series BB preferred stock from the conversion of common stock to preferred stock; |
| ● | 95
shares of Series BB preferred stock was converted into common stock; |
| ● | 401
shares of Series CC preferred stock with a fair value of $10,017,212 for the conversion of
debt/accrued interest and dividends. |
Stock
Options and Warrants
At
the Company’s December 30, 2021 Special Meeting, the shareholder’s approved the 2021 Equity Incentive Plan (the “2021
Plan”) pursuant to which 3,000,000 shares of our common stock were reserved for issuance upon exercise of stock options or other
equity awards. Consistent with the Company’s existing 2013 Equity Incentive plan (the “2013 plan”), under the 2021
plan, we may award stock options, shares of common stock, and other equity interests in the Company to employees, officers, directors,
consultants, and advisors, and to any other persons the Board of Directors deems appropriate. As of September 30, 2023, options to acquire
3,420,754 shares were outstanding under these Plans.
As
of September 30, 2023, total unrecognized compensation cost related to the unvested stock-based awards was $963,322 , which is expected
to be recognized over weighted average period of 2.2 years. The aggregate intrinsic value associated with the options outstanding and
exercisable as of September 30, 2023, based on the September 30, 2023, closing stock price of $0.20, was $0.00.
The
following table summarizes information concerning options and warrants outstanding and exercisable:
Schedule
of Concerning Options and Warrants Outstanding and Exercisable
| |
Stock Options | | |
Warrants | | |
| | |
| |
| |
Weighted Average | | |
Weighted Average | | |
Total | |
| |
Shares | | |
price per share | | |
Shares | | |
price per share | | |
Shares | | |
Exercisable | |
Balance outstanding, December 31, 2022 | |
| 1,307,822 | | |
$ | 0.72 | | |
| 16,278,769 | | |
$ | 3.50 | | |
| 17,586,591 | | |
| 17,570,591 | |
Granted | |
| 2,230,484 | | |
| 1.50 | | |
| 100,000 | | |
| 3.50 | | |
| 2,330,484 | | |
| | |
Exercised | |
| (117,552 | ) | |
| 0.69 | | |
| - | | |
| - | | |
| (117,552 | ) | |
| | |
Expired | |
| - | | |
| - | | |
| (645,829 | ) | |
| 3.50 | | |
| (645,829 | ) | |
| | |
Forfeited | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| | |
Balance outstanding, September 30, 2023 | |
| 3,420,754 | | |
$ | 1.23 | | |
| 15,732,940 | | |
$ | 3.50 | | |
| 19,153,694 | | |
| 18,289,721 | |
As
of September 30, 2023, the 3,420,754 options outstanding have a $1.23 weighted average exercise price and 8.14 years of weighted average
remaining life for outstanding options and 7.75 years of weighted average remaining life for exercisable options. Of these options, 2,556,781
are currently exercisable.
On
April 13, 2023, the Board authorized a 3-year extension of common stock warrants held by Series AA preferred shares holders. Therefore,
8,897,603 warrants were extended with new expiration dates between May 2, 2026 to September 14, 2029. Based on a fair value computation,
this extension resulted in net incremental expense of $3,626,950, which was booked as an increase in the value of warrants and an increase
of the retained deficit.
Pressure BioSciences, Inc. | September 30, 2023 10Q Report | 24 |
As
of September 30, 2023, the warrants outstanding have a $3.50 weighted average exercise price and a 2.42 year weighted average remaining
life.
Common
Stock and Warrant Issuances
During
the nine months ended September 30, 2023, the Company accrued approximately $3,715,204 in interest expense for these obligations
to issue common stock. During the nine months ended September 30, 2022, the Company accrued $634,305 in interest expense for these
obligations to issue common stock.
During
the nine months ended September 30, 2023 the Company issued a total of 9,717,035 shares of restricted common stock and to accredited
investors and consultants, with the following detail:
|
● |
4,094,121
shares of common stock with a fair value of $3,715,204 to lenders for interest paid-in-kind; |
|
● |
1,630,500
shares with a fair value of $1,917,036 for services rendered; |
|
● |
203,613
shares with a fair value of $509,033 for conversions of debt principal and interest; |
|
● |
117,552
shares for stock option exercises (at an exercise price of $0.69 per share); |
|
● |
142,767
shares with a fair value of $162,528 for dividends paid-in-kind; |
|
● |
1,258,742
shares with a fair value of $1,293,270 for common stock issued with convertible debt; |
|
● |
1,346,800
shares with a fair value of $1,671,573 for convertible debt extensions; |
|
● |
60,000
shares with a fair value of $150,000 for sale of common, and |
|
● |
1,486,940
shares for the conversion of preferred stock to common stock. |
During
the nine months ended September 30, 2023, the Company issued 100,000 warrants (four-year term at a $3.50 exercise price) to acquire common
stock at a fair value of $61,609 to a consultant for professional services.
During
the nine months ended September 30, 2022, we issued 3,100,085
shares of restricted common stock to accredited
investors and consultants, 140,200
shares with a fair value of $350,500
for conversions of debt principal and interest
for common stock, 1,172,100
of the shares with a fair value of $2,196,278
were issued for interest paid-in-kind, 190,500
of the shares with a fair value of $312,875
were issued for services rendered,170,306
shares with a fair value of $306,333
for dividends paid-in-kind, 368,500
shares with a fair value $512,593
for new convertible debt issuances, 25,279
shares with a fair value of $17,433
from a stock option exercise, 1,028,800
shares with a fair value of $1,714,678
for debt extension and shareholders converted
shares of series AA convertible preferred stock into 4,400
shares of common stock
During
the nine months ended September 30, 2022, we issued 277,500
warrants (three-year to five-year terms at a $3.50
exercise price) to acquire common stock at a total fair value of $280,608
to a lender in conjunction with the signing of new convertible loans, a vendor for services rendered and for debt
extension.
7)
Subsequent Events
From
October 1, 2023, through November 10, 2023, the Company issued seven (7) convertible loan with a principal balance of $439,000.
The terms of the convertible notes were 15 days to 12 months with interest rates of 10-120%
and convertible into the Company’s common stock at a fixed rate of $2.50 per
share. In this time the Company also issued 278,500 shares
of common stock for new convertible debt loans in the third quarter, 455,350 shares
of common stock for accrued interest paid-in-kind, 310,000 shares of common stock for debt extensions, 505,000 shares
of common stock from the conversion of Series BB preferred stock, 145,809 shares
of common stock for Series AA preferred dividends and 40 Series
BB preferred stock for professional services.
On
October 18, 2023, the Board of Directors (the “Board”) of Pressure BioSciences, Inc. (the “Company”) approved
an amendment (the “Amendment”) to the Pressure BioSciences, Inc. 2021 Equity Incentive Plan (the “Plan”). The
Plan originally provided that no one person could be granted awards pursuant to the Plan during any one fiscal year to purchase more
than 300,000 shares of the Company’s common stock, par value $0.01 per share (the “Common Stock”). Pursuant to the
amendment, the yearly limit for any one person was raised to 500,000 shares of Common Stock.
On
the same date, the Board granted a total of 1,500,000 stock options to a number of employees, consultants and the four members of the
Board with each option having an exercise price of $0.25 per share. Each award of options expires on October 18, 2033. The options for
the members of the Board vest in equal amounts over twelve (12) months. The options for Mr. Schumacher and Drs. Ting and Lazarev were
each vested 25% on the date of issuance and 25% of the options vest each year for the next three (3) years.
In
addition, on the same date, the Board approved the repricing of all outstanding options (including those held by the Board members and
the named executive officers) to $0.25. The previous exercise prices of the outstanding stock options held by the Board members and the
named executive officers ranged from $0.69 to $1.50.
Pressure BioSciences, Inc. | September 30, 2023 10Q Report | 25 |
ITEM
2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
CAUTIONARY
NOTE REGARDING FORWARD-LOOKING STATEMENTS
This
Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as
amended (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”).
In some cases, forward-looking statements are identified by terms such as “may,” “will,” “should,”
“could,” “would,” “expects,” “plans,” “anticipates,” “believes,”
“estimates,” “projects,” “predicts,” “potential” and similar expressions intended to
identify forward-looking statements. Such statements include, without limitation, statements regarding:
|
● |
our
need for, and our ability to raise, additional equity or debt financing on acceptable terms, if at all; |
|
● |
our
need to take additional cost reduction measures, cease operations or sell our operating assets, if we are unable to obtain sufficient
additional financing; |
|
● |
our
belief that we will have sufficient liquidity to finance normal operations for the foreseeable future; |
|
● |
the
options we may pursue in light of our financial condition; |
|
● |
the
potential applications for Ultra Shear Technology (UST); |
|
● |
the
potential applications of the BaroFold high-pressure protein refolding and disaggregation technology |
|
● |
the
amount of cash necessary to operate our business; |
|
● |
the
anticipated uses of grant revenue and the potential for increased grant revenue in future periods; |
|
● |
our
plans and expectations with respect to our continued operations; |
|
● |
the
expected number of Pressure Cycling Technology (“PCT”) and Constant Pressure (“CP”) based units that we believe
will be installed and the expected revenues from the sale of consumable products, extended service contracts, and biopharma contract
services; |
|
● |
our
belief that PCT has achieved initial market acceptance in the mass spectrometry and other markets; |
|
● |
the
expected development and success of new instrument and consumables product offerings; |
|
● |
the
potential applications for our instrument and consumables product offerings; |
|
● |
the
expected expenses of, and benefits and results from, our research and development efforts; |
|
● |
the
expected benefits and results from our collaboration programs, strategic alliances and joint ventures; |
|
● |
our
expectations of the results of our development activities funded by government research grants; |
|
● |
the
potential size of the market for biological sample preparation, biopharma contract services and Ultra Shear Technology; |
|
● |
general
economic conditions; |
|
● |
the
anticipated future financial performance and business operations of our company; |
|
● |
our
reasons for resources expended in the market for genomic, proteomic, lipidomic and small molecule sample preparation; |
|
● |
the
importance of mass spectrometry as a laboratory tool; |
|
● |
the
advantages of PCT over other current technologies as a method of biological sample preparation and protein characterization in biomarker
discovery, forensics, and histology, as well as for other applications; |
|
● |
the
capabilities and benefits of our PCT Sample Preparation System, consumables and other products; |
|
● |
our
belief that laboratory scientists will achieve results comparable with those reported to date by certain research scientists who
have published or presented publicly on PCT and our other products and services; |
|
● |
our
ability to retain our core group of scientific, administrative and sales personnel; and |
|
● |
our
ability to expand our customer base in sample preparation and for other applications of PCT, as well as for our other products and
services in both the BaroFold and Ultra Shear Technology areas. |
These
forward-looking statements are only predictions and involve known and unknown risks, uncertainties and other factors that may cause our
actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity,
performance or achievements, expressed or implied, by such forward-looking statements. Also, these forward-looking statements represent
our estimates and assumptions only as of the date of this Quarterly Report on Form 10-Q. Except as otherwise required by law, we expressly
disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statement contained in this
Quarterly Report on Form 10-Q to reflect any change in our expectations or any change in events, conditions or circumstances on which
any of our forward-looking statements are based. Factors that could cause or contribute to differences in our future financial and other
results include those discussed in the risk factors set forth in Part I, Item 1A of our Annual Report on Form 10-K for the year ended
December 31, 2022 and in this Report. We qualify all of our forward-looking statements by these cautionary statements.
Pressure BioSciences, Inc. | September 30, 2023 10Q Report | 26 |
Pressure
BioSciences, Inc. (OTCQB: PBIO) (the “Company”) is a leader in the development & sale of innovative, enabling, high
pressure technology-based instruments, consumables, and services for the life sciences and other industries worldwide. Our products/services
are based on three patented, high-pressure platforms: (i) Ultra Shear Technology™ (“UltraShear™” or “UST™”),
(ii) BaroFold Technology™ (“BaroFold™”), and (iii) Pressure Cycling Technology™ (“PCT™”)
The
Company was founded on the belief that its PCT platform had the potential to significantly increase the quality of sample preparation
in both research and clinical settings. This premise has been well proven and PBI has been successful in installing its PCT platform
in the laboratories of key opinion leaders worldwide. Although developed subsequently, the Company now assesses that the commercial potential
for its UST platform across diverse multi-billion dollar markets far exceeds the potential of the PCT platform. Consequently, in January
2022, PBI made the critical strategy decision to immediately shift its primary business focus from PCT to its innovative UST Platform.
The
UST Platform (8 issued patents) is based on the use of intense shear forces from ultra-high pressure discharge (greater than
20,000 psi) through a dynamically-controlled nano-gap valve under precisely controlled temperatures. UST has been shown to turn hydrophobic
(water-repelling) oil-based supplements (e.g., CBD, curcumin, astaxanthin), therapeutics (e.g., prednisone), and other active ingredients
(e.g., retinol) into long-term stable, effectively water-soluble, highly bioavailable, oil-in-water nanoemulsion formulations. The Company
began early commercial introduction of the UST Platform in May 2022, and executed agreements were subsequently announced with three CBD
companies and one cosmeceutical/skincare company for commercialization in Q4 2022.
The
BaroFold Platform (14 issued patents) can be used to significantly improve the quality and production costs of protein biotherapeutics.
It employs high-pressure manipulations for the disaggregation, unfolding and controlled refolding of proteins to their desired native
structures at yields and efficiencies not achievable using existing technologies. The BaroFold Platform has been shown to remove protein
aggregates in biotherapeutic drug manufacturing, thereby improving product efficacy, safety, and cost for both new-drug entities and
biosimilar (follow-on biologic) products. It is scalable and practical for standard manufacturing processes.
The
PCT Platform (17 issued patents) uses alternating cycles of hydrostatic pressure between ambient and ultra-high pressures to
control bio-molecular interactions safely and reproducibly in sample preparation (e.g., the critical steps performed by tens of thousands
of scientists worldwide prior to analytical measurements, such as cell lysis and biomolecule extraction from tissue samples). Our focus
for PCT is on making our, GMP-compliant, next generation PCT-based Barocycler EXTREME system available globally to
biopharmaceutical drug manufacturers for use in the design, development, characterization, and quality control of biotherapeutic drugs.
We currently have over 350 PCT Systems placed in approximately 225 academic, government, pharmaceutical, and biotech research laboratories
worldwide. There are currently over 200 independent publications highlighting the advantages of using the PCT Platform in scientific
research & clinical laboratories.
2023
Key Accomplishments
From
January 1, 2023 to September 30, 2023, we announced the following key accomplishments:
| ● | September
22: PBIO’s partner Veterans Service Team increases existing purchase order by 10X
for bottles of UltraShear Nano-CBD topical spray, effective immediately. |
| ● | September
21: PBIO’s fulfillment of UltraShear Nano-CBD orders is underway; customer shipments
begin first week of October |
| ● | September
8: PBIO’s Barofold technology achieves pivotal equipment sale and begins scale-up
in service to leading global contract development and manufacturing organization. |
| ● | August
30: PBIO provides second progress report on UltraShear Nano-CBD Launch: “Drive
to 420”. |
| ● | August
22: PBIO reports Q22023 financial results, provides business update, and offers guidance. |
| ● | August
9: PBIO reports strongly accelerating UltraShear Nano-CBD orders. |
| ● | July
26: PBIO and master distributor Canopy CBD Farms announce major increase in sales pipeline. |
| ● | July
25: PBIO to evaluate Company’s patented UltraShear process to extend shelf-life
of fresh produce. |
| ● | July
17: Company’s UltraShear Nano-CBD commercial roll-out program enters rapid expansion
phase 2. |
| ● | July
10: Company announces Nano-CBD topical spray distribution agreement with Crème
de Canna. |
| ● | July
6: Key academic publication further validates PBIO’s UltraShear platforms’
impact in clean-label foods. |
Pressure BioSciences, Inc. | September 30, 2023 10Q Report | 27 |
| ● | July
5: PBIO partners with Somalab Int’l for development & distribution of UltraShear-enabled
health products. |
| ● | June
13: PBIO partners with Veterans Service Team to offer exclusive access for VST members
to Nano-CBD. |
| ● | June
1: PBIO expands on six key goals for June 2023 with expected multi-million-dollar growth
potential. |
| ● | May
22: Commercial availability of Best-in-Class Nano-CBD topical spray with lightning-fast
action announced. |
| ● | May
16: PBIO announces Q1 2023 financial results: all-time quarterly record revenue. |
| ● | May
9: Extended consumer testing strongly validates market transforming speed and dosing
efficiency of PBIO’s UltraShear processed nano-THC oral spray. |
| ● | April
26: PBIO updates rapid progress on potential sales of exclusive THC licenses. |
| ● | April
21, 2023: PBIO unveils powerful THC market leapfrog opportunity with exclusive licensing
of UltraShear nanoemulsion processing platform. |
| ● | April
18: PBIO announces expansion into strategic manufacturing facilities with premier process
tech company. |
| ● | April
14: PBIO reports Q4 and FY 2022 financial results – offers guidance for a strong
2023. |
| ● | April
6, 2023: PBIO and NutraLife Biosciences renew partnership for development and distribution
of next generation nutraceuticals. |
| ● | March
28: Company reports fresh sales momentum for PBI Agrochem. |
| ● | March
22: PBIO receives $1.5 million contract for UltraShear nanoemulsified CBD. |
| ● | March
1: Company announces the exchange of over $10 million of debt into equity. |
| ● | February
1: Company receives record order (nearly $600,000) for 16 PCT instruments. |
| ● | January
27: PBIO and One World Products partner to develop CBD-Nano sports performance/recovery
drink. |
| ● | January
19: Dramatic consumer testing results confirm UltraShear nanoemulsion oral spray delivers
first effects and maximization in lightning speed – simple, reliable dosing delivers
profoundly improved results. |
Results
of Operations
The
following disclosure compares the results of operations for the quarter ended September 30, 2023 (“Q2 2023”) with September
30, 2022 (“Q2 2022”) and compares the nine months ended September 30, 2023 with September 30, 2022.
Products
and Services Revenue
We
recognized total revenue of $413,009 for Q3 2023 compared to $144,032 for Q3 2022, a 187% increase. For the year-to-date periods ending
September 30, 2023 and September 30, 2022, we recognized revenue of $1,665,412 and $1,122,169 respectively, a 48% increase.
This
increase in revenue was primarily attributable to a $506,828 increase in PCT instrumentation and consumable sales, a $30,295 increase
in technical support services and an $87,378 increase in Agrochem products, offset by a decrease of $89,350 in scientific services.
Cost
of Products and Services
The
cost of products and services was $229,457 for Q3 2023 compared to $126,203 for Q3 2022. For the year-to-date periods ending September
30, 2023 and September 30, 2022 our cost of products and services were $844,684 and $742,707, respectively. Gross profit margin on products
and services increased to 49% in the year-to-date period ended September 30, 2023 from 34% in the same period ended September 30, 2022.
The increase in gross profit margin was attributable to $180,670 of Agrochem products sold in 2023 at no cost due to 2022 inventory write-off
and a $79,901 instrument non-monetary exchange sale in 2022 was recorded at no profit.
Research
and Development
Research
and development expenses were $288,345 for Q3 2023 compared to $262,370 for Q3 2022. For the year-to-date periods ending September 30,
2023 and September 30, 2022, these expenses were $1,004,437 and $716,685, respectively, a 40% increase. The reported increase was due
to a $71,777 reclass of salaries to COGS for a non-monetary instrument exchange in 2022 and $241,585 of stock-based compensation expense
for employee stock options issued in 2023.
Pressure BioSciences, Inc. | September 30, 2023 10Q Report | 28 |
Selling
and Marketing
Selling
and marketing expenses were $157,773 for Q3 2023 compared to $226,526 for Q3 2022. For the year-to-date periods ending September 30,
2023 and September 30, 2022, these expenses were $537,802 and $422,422, respectively a 27% increase The reported increase was primarily
attributable to the hiring of a Marketing FTE in Q2 2023 and $102,675 of stock-based compensation expense for employee stock options
issued in 2023.
General
and Administrative
General
and administrative expenses were $1,030,244 for Q3 2023 compared to $892,293 for Q3 2022. For the year-to-date periods ending September
30, 2023 and September 30, 2022, these expenses were $5,290,564 and $2,591,644, respectively, a 104% increase. The increase was primarily
due to approximately $2.0 million common stock and warrants issued for services, approximately $1.3 million of stock-based compensation
expense for employee, BOD and financial consultant stock options issued in 2023, and approximately $132,000 of financial consulting expenses
in 2023, offset by an approximately $423,000 decrease in IR expenses.
Operating
Loss
Operating
loss was $1,292,809 for Q3 2023 compared to $1,363,360 for Q3 2022. For the year-to-date periods ending September 30, 2023 and
September 30, 2022, the operating loss was $6,012,075 and $3,551,289 respectively, a 79% increase. This increase was primarily due
to $2.0 millions in common stock and warrants issued for services and $1.7 million of stock-based compensation expense for employee, BOD financial consultant stock options issued in 2023, offset by an approximate $423,000 decrease in IR expenses.
Interest
Expense, net
Interest
expense was $4,338,759 for Q3 2023 compared to $2,034,021 for Q3 2022. For the year-to-date periods ending September 30, 2023 and September
30, 2022, these expenses were $14,112,098 and $6,448,771, respectively, a 119% increase. This increase was attributable to an increase
in convertible debt and merchant cash loans, in addition to stock issuances for interest paid in kind and stock issued for debt extensions.
Unrealized
gain on investment in equity securities
Unrealized
loss on investments in equity securities was $5,965 for Q3 2023 compared to an unrealized loss of $8,675 for Q3 2022. For the nine months
ended September 30, 2023, the unrealized gain on investment in equity securities was $14,280 as compared to an unrealized loss of $8,047
for the nine months ended September 30, 2022. The reported change was attributable to movement in the market price of the Company’s
investment in Nexity.
Loss
on extinguishment of liabilities
In
connection with debt extensions and forgiveness, we recognized a net gain of $0 for Q3 2023 compared to $1,054,122 of losses for Q3 2022.
For the nine months ended September 30, 2023 the recognized net gain of $687,591 as compared to a net loss of $1,809,249 for the nine
months ended September 30, 2022. The increase/decline in gains/losses was attributable to decreased extension and forgiveness activity.
Net
loss attributable to common stockholders
Net
loss attributable to common stockholders was $6,261,999 ($0.29 per share) for Q3 2023 compared to $4,893,946 ($0.44 per share) for Q3
2022. For the nine months ended September 30, 2023, the net loss attributable to common stock was $24,666,565 ($1.21 per share) as compared
to $12,913,826 ($1.24 per share).
Liquidity
and Financial Condition
We
have experienced negative cash flows from operations since our inception. As
of September 30, 2023, we did not have adequate working capital resources to satisfy our current liabilities and as a result, we have
substantial doubt regarding our ability to continue as a going concern. As described in Notes 5 and 6 of the accompanying consolidated
financial statements, we have been successful in raising debt and equity capital. We received approximately $6.5 million in net
proceeds from loans in the nine months ended September 30, 2023. We have efforts in place to continue to raise cash through debt and
equity offerings. (See Note 7 to the financial statements)
Pressure BioSciences, Inc. | September 30, 2023 10Q Report | 29 |
We
will need substantial additional capital to fund our operations in future periods. If we are unable to obtain financing on acceptable
terms, or at all, we will likely be required to cease our operations, pursue a plan to sell our operating assets, or otherwise modify
our business strategy, which could materially harm our future business prospects.
Net
cash used in operations for the nine months ended September 30, 2023 was $2,053,823 as compared to $3,051,257 for the nine months
ended September 30, 2022.
Net
cash used in investing activities for the nine months ended September 30, 2023 was $7,495 compared to $20,754 in the nine months ended
September 30, 2022.
Net
cash provided by financing activities for the nine months ended September 30, 2023 was $2,062,716 as compared to $3,170,580 for the nine
months ended September 30, 2022.
ITEM
3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
This
Item 3 is not applicable to us as a smaller reporting company and has been omitted.
ITEM
4. CONTROLS AND PROCEDURES
We
maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our Securities Exchange
Act of 1934 filings are recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms,
and that such information is accumulated and communicated to our management, including our President and Chief Executive Officer (Principal
Executive Officer) and Chief Financial Officer (Principal Financial Officer), as appropriate, to allow timely decisions regarding required
disclosure. In designing and evaluating the disclosure controls and procedures, management recognized that controls and procedures, no
matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, as ours are
designed to do, and management was necessarily required to apply its judgment in evaluating the cost-benefit relationship of possible
controls and procedures.
As
of September 30, 2023, we carried out an evaluation, under the supervision and with the participation of our management, including our
Principal Executive Officer and Principal Financial Officer, of the effectiveness of the design and operation of our disclosure controls
and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934. Based upon that evaluation, our
Principal Executive Officer and Principal Financial Officer concluded that our disclosure controls and procedures were not effective.
Our
conclusion that our disclosure controls and procedures were not effective as of September 30, 2023 is due to the continued presence of
the material weaknesses in our internal control over financial reporting identified in our Annual Report on Form 10-K for the year ended
December 31, 2022. These material weaknesses are the following:
|
● |
We
identified a lack of sufficient segregation of duties. Specifically, this material weakness is such that the design over these areas
relies primarily on detective controls and could be strengthened by adding preventative controls to properly safeguard Company assets. |
|
|
|
|
● |
Management
has identified a lack of sufficient personnel in the accounting function due to our limited resources with appropriate skills, training,
and experience to perform the review processes to ensure the complete and proper application of generally accepted accounting principles,
particularly as it relates to valuation of warrants and other complex debt /equity transactions. Specifically, this material weakness
resulted in audit adjustments to the annual consolidated financial statements and revisions to related disclosures, valuation of
warrants and other equity transactions. |
|
|
|
|
● |
Limited
policies and procedures that cover recording and reporting of financial transactions. |
|
|
|
|
● |
Lack
of multiple levels of review over the financial reporting process |
Pressure BioSciences, Inc. | September 30, 2023 10Q Report | 30 |
We
continue to plan to remediate those material weaknesses as follows:
|
● |
Improve
the effectiveness of the accounting group by augmenting our existing resources with additional consultants or employees to assist
in the analysis and recording of complex accounting transactions, and to simultaneously achieve desired organizational structuring
for improved segregation of duties. We plan to mitigate this identified deficiency by hiring an independent consultant once we generate
significantly more revenue or raise significant additional working capital. |
|
|
|
|
● |
Improve
expert review and achieve desired segregation procedures by strengthening cross approval of various functions including quarterly
internal audit procedures where appropriate once we generate significantly more revenue or raise significantly more working capital. |
During
the period covered by this Report, we implemented and performed additional substantive procedures, such as supervisory review of work
papers and consistent use of financial models used in equity valuations, to ensure our consolidated financial statements as of and for
the six-month period ended September 30, 2023, are fairly stated in all material respects in accordance with GAAP. We have not, however,
been able to fully remediate the material weaknesses due to our limited financial resources. Our remediation efforts are largely dependent
upon our securing additional financing to cover the costs of implementing the changes required. If we are unsuccessful in securing such
funds, remediation efforts may be adversely affected in a material manner.
Except
as described above, there have been no changes in our internal controls over financial reporting that occurred during the period ended
September 30, 2023 that have materially affected, or are reasonably likely to materially affect, our internal controls over financial
reporting.
PART
II. OTHER INFORMATION
Item
1. Legal Proceedings
We
are not currently involved in any litigation that we believe could have a material adverse effect on our financial condition or results
of operations. There is no action, suit, proceeding, inquiry or investigation before or by any court, public board, government agency,
self-regulatory organization or body pending or, to the knowledge of the executive officers of our company or any of our subsidiaries,
threatened against or affecting our company, our common stock, any of our subsidiaries or of our companies or our subsidiaries’
officers or directors in their capacities as such, in which an adverse decision could have a material adverse effect.
Item
1A. Risk Factors
Factors
that could cause or contribute to differences in our future financial and operating results include those discussed in the risk factors
set forth in Item 1 of our Annual Report on Form 10-K for the year ended December 31, 2022 and, in this Item, 1A. The risks described
in our Form 10-K and this Report are not the only risks that we face. Additional risks not presently known to us or that we do not currently
consider significant may also have an adverse effect on the Company. If any of the risks occur, our business, results of operations,
cash flows or financial condition could suffer.
There
have been no material changes to the risk factors set forth in Item 1A of our 10-K for the year ended December 31, 2022.
Item
2. Unregistered Sales of Equity Securities and Use of Proceeds
Except
where noted, all the securities discussed in this Part II, Item 2 were issued in reliance on the exemption under Section 4(a)(2) of the
Securities Act.
On
various dates in the nine months ended September 30, 2023 the Company issued a total of 9,917,035 of its common shares, 953 shares
of Series BB preferred stock and 401 shares of Series CC preferred stock as follows:
| ● | 117,552
shares from option exercises; |
| ● | 1,630,500
shares for professional services; |
| ● | 1,346,800
shares for debt extensions; |
| ● | 203,613
shares for conversion of debt and interest; |
Pressure BioSciences, Inc. | September 30, 2023 10Q Report | 31 |
| ● | 142,767
shares for dividends paid-in-kind; |
| ● | 4,094,121
shares for interest paid-in-kind; |
| ● | 1,258,742
shares for shares issued with debt; |
| ● | 60,000
shares from sale of common shares; |
| ● | 95
shares of Series BB preferred stock was converted to common stock; |
| ● | 92
shares of Series BB preferred stock for professional services; |
| ● | 741
shares of Series BB preferred stock for debt extensions; |
| ● | 58
shares of Series BB preferred stock issued with debt; |
| ● | 401
shares of Series CC preferred stock for conversion of debt/accrued interest and dividends,
and |
| ● | 62
shares of Series BB preferred stock for the conversion of common stock. |
Item
3. Defaults upon Senior Securities
None.
Item
4. Mine Safety Disclosures
Not
applicable.
Item
5. Other Information
None.
Item
6. Exhibits
*
Filed herewith.
**
In accordance with SEC Release 33-8238, Exhibits 32.1 and 32.2 are furnished and not filed.
Pressure BioSciences, Inc. | September 30, 2023 10Q Report | 32 |
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant caused this report to be signed on its behalf by the undersigned
thereunto duly authorized.
|
PRESSURE
BIOSCIENCES, INC. |
|
|
|
Date:
November 20, 2023 |
By:
|
/s/
Richard T. Schumacher |
|
|
Richard
T. Schumacher |
|
|
President
& Chief Executive Officer |
|
|
(Principal
Executive Officer and Principal Financial Officer) |
Pressure BioSciences, Inc. | September 30, 2023 10Q Report | 33 |
Exhibit
21.1
SECURITIES
Issuance AND EXCHANGE AGREEMENT
This
Securities Issuance and Exchange Agreement (this “Agreement”) is dated as of February 28, 2023, between Pressure
BioSciences, Inc., a Massachusetts corporation (the “Company”), and Clayton A. Struve (the “Purchaser”).
WHEREAS,
the Company has determined that it is in its best interests to issue shares of a newly created series of Preferred Stock (as defined
below) to the Purchaser in exchange for (i) all unpaid accrued interest owed to the Purchaser up to February 22, 2023 from his purchase
of $9,393,150 of a series of secured convertible promissory notes issued to the Purchaser by the Company from November 15, 2019 up to
August 31, 2021; (ii) unpaid accrued Series AA dividends owed to the Purchaser from the purchase issued by the Company from a series
of Series AA Preferred Stock from May 2, 2018 up to February 22, 2023; and (iii) the conversion of $1,535,500 of certain secured convertible
promissory notes purchased by the Purchaser from the Company, all totaling $10,017,212 (collectively the “Debt”)
and decided by the Purchaser to include in this Agreement on Schedule A, subject to the terms and conditions set forth in this Agreement
and pursuant to Section 4(2) of the Securities Act of 1933, as amended (the “Securities Act”), and Rule 506
promulgated thereunder; and
WHEREAS,
the Purchaser desires to receive Shares of Preferred Stock (as defined below) in exchange for all Debt, subject to the terms and conditions
set forth in this Agreement and pursuant to Section 4(2) of the Securities Act and Rule 506 promulgated thereunder.
NOW,
THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration the receipt
and adequacy of which are hereby acknowledged, the Company and the Purchaser agree as follows:
ARTICLE
I.
DEFINITIONS
1.1
Definitions. In addition to the terms defined elsewhere in this Agreement, for all purposes of this Agreement, the following terms
have the meanings set forth in this Section 1.1:
“Affiliate”
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control
with a Person as such terms are used in and construed under Rule 144 under the Securities Act.
“Articles
of Amendment” means the Articles of Amendment to the Company’s Restated Articles of Organization, as amended, in
the form of Exhibit A attached hereto, that includes a Certificate of Designation setting forth the rights, preferences, powers,
privileges, restrictions, qualifications and limitations of the Preferred Stock.
“Business
Day” means any day except Saturday, Sunday, any day which shall be a federal legal holiday in the United States, or any
day on which banking institutions in the State of New York are authorized or required by law or other governmental action to close.
“Closing”
means the approval and issuance of the Shares of Preferred Stock in exchange for the Debt pursuant to Section 2.1.
“Closing
Date” means the date on which the Company completes the issuance of the Shares of Preferred Stock in exchange for the Debt.
“Common
Stock” means the common stock of the Company, par value $.01 per share, and any other class of securities into which such
securities may hereafter be reclassified or changed into.
“Conversion
Shares” means such shares of Common Stock which, from time to time, have been issued, or may be issuable, upon conversion
of the Preferred Stock.
“Debt”
means unpaid accrued interest, unpaid Series AA dividends, and those certain convertible promissory notes owned by the Purchaser and
listed on Schedule A.
“Exchange
Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.
“Liens”
means a lien, liability, charge, security interest, encumbrance, pledge, right of first refusal, preemptive right or other restriction
of any kind, nature or description.
“Material
Adverse Effect” shall have the meaning assigned to such term in Section 3.1(a).
“Person”
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability
company, joint stock company, government (or an agency or subdivision thereof), or other entity of any kind.
“Preferred
Stock” means the Series CC Convertible Preferred Stock of the Company, $.01 par value, issued or issuable to the Purchaser
pursuant to this Agreement with such rights, preferences, powers, privileges, restrictions, qualifications and limitations as are set
forth in the Certificate of Designation included in the Articles of Amendment and attached on Schedule B.
“Proceeding”
means an action, claim, suit, investigation or proceeding (including, without limitation, an investigation or partial proceeding, such
as a deposition), whether commenced or threatened.
“Required
Approvals” shall have the meaning ascribed to such term in Section 3.1(d).
“Rule
144” means Rule 144 promulgated by the Commission pursuant to the Securities Act, as such rule may be amended from time
to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same effect as such rule.
“SEC
Reports” shall have the meaning ascribed to such term in Section 3.1(f).
“Securities
Act” means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.
“Shares
of Common Stock” shall have the meaning ascribed to such term in Section 2.2(a).
“Shares
of Preferred Stock” shall have the meaning ascribed to such term in Section 2.2(a).
“Unpaid
Accrued Interest” shall mean all earned and unpaid accrued interest owed to the Purchaser from all outstanding convertible
loans and Series AA Preferred Stock currently held by the Purchase up until the Closing of this Agreement, see Section 2.2(a).
ARTICLE
II.
ISSUANCE AND EXCHANGE
2.1
Articles of Amendment. On or before the Closing, the Company shall adopt and file with the Secretary of the Commonwealth of Massachusetts
the Articles of Amendment.
2.2
Purchase, Exchange and Sale.
(a)
Effective upon the Closing and subject to the terms and conditions set forth herein, (i) the Company hereby issues to the Purchaser that
number of shares of Preferred Stock Series CC that represents a number of Common Stock Equivalents (“CSE”) that is the result
of the total debt being exchanged (Schedule A) divided by $2.50 (the “Shares of Preferred Stock”), and (ii)
the Purchaser hereby assigns, transfers and delivers to the Company all of the Purchaser’s right, title and interest in and to
the amount of the Debt, free and clear of all Liens, in exchange for the Shares of Preferred Stock.
(b)
The Closing and issuance of the Shares of Preferred Stock in exchange for the debt shall take place on February 28, 2023, at the
offices of the Company, remotely via the exchange of documents and signatures, or on such other date or at such other location or by
such other means as the parties shall mutually agree.
2.3
Closing Deliveries.
(a)
On or prior to the Closing (except as otherwise required below, or agreed to between Company and Purchaser), the Company shall deliver
or cause to be delivered to the Purchaser a certificate or certificates registered in the name of the Purchaser representing the Shares
of Preferred Stock.
(b)
On or prior to the Closing (or following the closing, if agreed to between Company and Purchaser), the Purchaser shall deliver or cause
to be delivered to the Company an IRS Form W-9 completed with respect to the Purchaser in accordance with the instructions accompanying
such form.
2.4 Closing
Conditions.
(a)
The obligations of the Company hereunder in connection with the exchange of the Debt and issuance of the Shares of Preferred Stock to
the Purchaser at the Closing are subject to the following conditions being met:
(i)
the accuracy in all material respects when made and on the Closing Date of the representations and warranties of the Purchaser contained
herein;
(ii)
all obligations, covenants and agreements of the Purchaser required to be performed at or prior to the Closing Date shall have been performed;
and
(iii)
the delivery by the Purchaser of the items set forth in Section 2.3(b) of this Agreement.
(b)
The obligations of the Purchaser hereunder in connection with the Closing are subject to the following conditions being met:
(i)
the accuracy in all material respects when made and on the Closing Date of the representations and warranties of the Company contained
herein (except that the representations and warranties of the Company contained herein that are qualified by materiality or Material
Adverse Effect shall be true and correct in all respects when made and on the Closing Date);
(ii)
all obligations, covenants and agreements of the Company required to be performed at or prior to the Closing Date shall have been performed;
and
(iii)
the delivery by the Company of the items set forth in Section 2.3(a) of this Agreement.
ARTICLE
III.REPRESENTATIONS AND WARRANTIES
3.1
Representations and Warranties of the Company. The Company hereby makes the following representations and warranties to the Purchaser:
(a)
Organization and Qualification. The Company is a corporation duly incorporated, validly existing and in good standing under the
laws of The Commonwealth of Massachusetts, with the requisite power and authority to own and use its properties and assets and to carry
on its business as currently conducted. The Company is not in violation or default of any of the provisions of its Restated Articles
of Organization, as amended, and bylaws. The Company is duly qualified to conduct business and is in good standing as a foreign corporation
or other entity in each jurisdiction in which the nature of the business conducted or property owned by it makes such qualification necessary,
except where the failure to be so qualified or in good standing, as the case may be, would
not, individually or in the aggregate, have or reasonably be expected to
result in (i) a material adverse effect on the legality, validity or enforceability of this Agreement, (ii) a material adverse effect
on the results of operations, assets, business or condition (financial or otherwise) of the Company, or (iii) a material adverse effect
on the Company’s ability to perform in any material respect on a timely basis its obligations under this Agreement (any of (i),
(ii) or (iii), a “Material Adverse Effect”).
(b)
Authorization; Enforcement. The Company has the requisite corporate power and authority to enter into and to consummate the transactions
contemplated by this Agreement and otherwise to carry out its obligations hereunder. The execution and delivery of each of this Agreement
by the Company and the consummation by it of the transactions contemplated hereby have been duly authorized by all necessary corporate
action on the part of the Company and no further action is required by the Company, its board of directors or its stockholders in connection
therewith other than the Required Approvals. This Agreement has been duly executed and delivered by the Company and constitutes the valid
and binding obligation of the Company enforceable against the Company in accordance with its terms except (i) as limited by general equitable
principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application affecting enforcement
of creditors’ rights generally, (ii) as limited by laws relating to the availability of specific performance, injunctive relief
or other equitable remedies and (iii) insofar as indemnification and contribution provisions may be limited by applicable law.
(c)
No Conflicts. The execution, delivery, and performance of this Agreement by the Company and the sale and issuance of the Shares
of Preferred Stock do not and will not (i) conflict with or violate any provision of the Company’s Restated Articles of Organization,
as amended, or bylaws, or (ii) conflict with, or constitute a default (or an event that with notice or lapse of time or both would become
a default) under, result in the creation of any Lien upon any of the properties or assets of the Company, or give to others any rights
of termination, amendment, acceleration or cancellation (with or without notice, lapse of time or both) of, any agreement, credit facility,
debt or other instrument (evidencing a Company debt or otherwise) or other understanding to which the Company is a party or by which
any property or asset of the Company is bound or affected, or (iii) subject to the Required Approvals, conflict with or result in a violation
of any law, rule, regulation, order, judgment, injunction, decree or other restriction of any court or governmental authority to which
the Company is subject (including federal and state securities laws and regulations), or by which any property or asset of the Company
is bound or affected, except in the case of each of clauses (ii) and (iii), such as would
not, individually or in the aggregate, have or reasonably be expected to
result in a Material Adverse Effect.
(d)
Filings, Consents and Approvals. The Company is not required to obtain any consent, waiver, authorization, or order of, give any
notice to, or make any filing or registration with, any court or other federal, state, local or other governmental authority or other
Person in connection with the execution, delivery, and performance by the Company of this Agreement, other than (i) the filing of the
Articles of Amendment with, and the acceptance of such filing by, the Secretary of the Commonwealth of Massachusetts, (ii) if determined
necessary by the Company, the filing of Form D with the Commission and such filings, if any, as are required to be made under applicable
state securities laws and (iii) any approvals required under the Company’s Restated Articles of Organization, as amended, as determined
by the Company (collectively, the “Required Approvals”).
(e)
Issuance of Shares of Preferred Stock. The Shares of Preferred Stock are duly authorized and, when issued in accordance with this
Agreement, will be duly and validly issued, non-assessable, free and clear of all Liens imposed by the Company other than restrictions
on transfer provided for in this Agreement, applicable federal and state securities laws and Liens created by or imposed by the Purchaser.
The Conversion Shares have been duly reserved for issuance, and upon issuance in accordance with the terms of the Company’s Restated
Articles of Organization, as amended, will be validly issued, non-assessable and free of restrictions on transfer other than restrictions
on transfer under this Agreement, applicable federal and state securities laws and Liens created by or imposed by a Purchaser.
(f)
SEC Reports; Financial Statements. The Company has filed all reports, schedules, forms, statements and other documents required
to be filed by the Company under the Securities Act and the Exchange Act, including pursuant to Section 13(a) or 15(d) thereof, for the
two years preceding the date hereof (the foregoing materials, including the exhibits thereto and documents incorporated by reference
therein, being collectively referred to herein as the “SEC Reports”) on a timely basis or has received a valid
extension of such time of filing and has filed any such SEC Reports prior to the expiration of any such extension. As of their respective
dates, the SEC Reports complied in all material respects with the requirements of the Securities Act and the Exchange Act, as applicable,
and none of the SEC Reports, when filed, contained any untrue statement of a material fact or omitted to state a material fact required
to be stated therein or necessary in order to make the statements therein, in the light of the circumstances under which they were made,
not misleading.
(g)
Exchange Act Registration. No Registration has been filed.
(h)
Private Placement. Assuming the accuracy of the Purchaser’s representations and warranties set forth in Section 3.2, no
registration under the Securities Act is required for the exchange and issuance of the Shares of Preferred Stock by the Company to the
Purchaser as contemplated hereby.
3.2
Representations and Warranties of the Purchaser. The Purchaser hereby represents and warrants as follows:
(a)
Organization; Authority. The Purchaser has full legal capacity to execute and deliver this Agreement and the documents representing
the Debt and to consummate the transactions contemplated by this Agreement and otherwise to carry out his obligations hereunder. This
Agreement has been, and the documents the Debt will be, duly executed by the Purchaser, and when delivered by the Purchaser in accordance
with the terms hereof, will constitute the valid and legally binding obligation of the Purchaser, enforceable against the Purchaser in
accordance with its terms, except (i) as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization,
moratorium and other laws of general application affecting enforcement of creditors’ rights generally, (ii) as limited by laws
relating to the availability of specific performance, injunctive relief or other equitable remedies and (iii) insofar as indemnification
and contribution provisions may be limited by applicable law.
(b)
Own Account. The Purchaser understands that the Shares of Preferred Stock are “restricted securities” and have not
been registered under the Securities Act or any applicable state or other securities law and is acquiring the Shares of Preferred Stock
as principal for his own account and not with a view to or for distributing or reselling such Shares of Preferred Stock or any part thereof
in violation of the Securities Act or any applicable state or other securities law, has no present intention of distributing any of such
Shares of Preferred Stock in violation of the Securities Act or any applicable state or other securities law, and has no direct or indirect
arrangement or understandings with any other persons to distribute or regarding the distribution of such Shares of Preferred Stock (this
representation and warranty not limiting the Purchaser’s right to sell the Shares of Preferred Stock or the Conversion Shares in
compliance with the Securities Act and any applicable state or other securities laws) in violation of the Securities Act or any applicable
state or other securities law.
(c)
Purchaser Status. At the time the Purchaser was offered the Shares of Preferred Stock, the Purchaser was, on the date hereof he
is, and on the Closing Date he will be, an “accredited investor” as defined in Rule 501(a) under the Securities Act.
(d)
Experience of Such Purchaser. The Purchaser has such knowledge, sophistication and experience in business and financial matters
so as to be capable of evaluating the merits and risks of the prospective investment in the Shares of Preferred Stock and has so evaluated
the merits and risks of such investment. The Purchaser understands that the purchase of the Shares of Preferred Stock involves substantial
risk. The Purchaser is able to bear the economic risk of an investment in the Shares of Preferred Stock and, at the present time, is
able to afford a complete loss of such investment.
(e)
General Solicitation. The Purchaser is not purchasing the Shares of Preferred Stock as a result of any advertisement, article,
notice or other communication regarding the Shares of Preferred Stock published in any newspaper, magazine or similar media or broadcast
over television or radio or presented at any seminar or any other general solicitation or general advertisement.
(f)
Provision of Information. The Purchaser has been afforded (i) the opportunity to ask such questions as he has deemed necessary
of, and to receive answers from, representatives of the Company concerning the terms and conditions of the Shares of Preferred Stock,
the Debt and the finances, operations and business of the Company; and (ii) the opportunity to request such additional information which
the Company possesses or can acquire without unreasonable effort or expense. All of the Purchaser’s questions have been answered
to his satisfaction and such Purchaser has received all of such requested additional information.
(g)
Certain Fees. No brokerage or finder’s fees or commissions are or will be payable by the Purchaser to any broker, financial
advisor or consultant, finder, placement agent, investment banker, bank, or other Person with respect to the transactions contemplated
by this Agreement.
(h)
Residency. The residence or principal place of business of the Purchaser is set forth below the Purchaser’s signature on
the signature page to this Agreement, and all communications between the Purchaser and the Company regarding the transactions contemplated
by this Agreement took place within or from the state of such residence or principal place of business.
(i)
Ownership of Shares of Common Stock. Not Applicable.
(j)
Acknowledgement. Such Purchaser acknowledges that the Company has relied upon the representations and warranties of the Purchaser
set forth in this Section 3.2 in its determination that no registration under the Securities Act is required for the sale and
issuance of the Shares of Preferred Stock by the Company to the Purchaser as contemplated by this Agreement.
ARTICLE
IV.
OTHER AGREEMENTS OF THE PARTIES
4.1
Transfer Restrictions.
(a)
The Shares of Preferred Stock and the Conversion Shares may only be disposed of in compliance with state and federal securities laws.
In connection with any transfer of the Shares of Preferred Stock and the Conversion Shares other than pursuant to an effective registration
statement under the Securities Act or Rule 144, or to the Company, the Company may require the transferor thereof to provide to the Company
an opinion of counsel selected by the transferor and reasonably acceptable to the Company, the form and substance of which opinion shall
be reasonably satisfactory to the Company, to the effect that such transfer does not require registration of such transferred securities
under the Securities Act. As a condition of transfer, any such transferee shall agree in writing to be bound by the terms of this Agreement.
(b)
Certificates evidencing the Shares of Preferred Stock and the Conversion Shares will contain the following legend or such other legend
as may be reasonably appropriate under the Securities Act so long as is required by this Section 4.1:
THE
OFFER AND SALE OF THIS SECURITY HAVE NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF
ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”),
AND, ACCORDINGLY, SUCH SECURITY MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES
ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT
AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS AS EVIDENCED BY A LEGAL OPINION OF COUNSEL TO THE TRANSFEROR TO SUCH EFFECT,
THE SUBSTANCE OF WHICH SHALL BE REASONABLY ACCEPTABLE TO THE COMPANY.
If
the Purchaser or other holder of the Shares of Preferred Stock or the Conversion Shares is not an Affiliate of the Company, certificates
evidencing the Shares of Preferred Stock or the Conversion Shares shall not contain any legend (including the legend set forth in Section
4.1(b), (i) while a registration statement covering the resale of such security is effective under the Securities Act, (ii) following
any sale of such securities pursuant to Rule 144, (iii) if such securities are eligible for sale under Rule 144 without limitations,
or (iv) if such legend is not required under applicable requirements of the Securities Act (including judicial interpretations and pronouncements
issued by the staff of the Securities Exchange Commission). The Company agrees that at such time as such legend is no longer required
with respect to such securities under this Section 4.1(b), promptly following the delivery by the Purchaser to the Company or its transfer
agent of a certificate representing such securities, it will deliver or cause to be delivered to the Purchaser a certificate representing
such securities that is free from all restrictive and other legends.
4.2
Reservation of Common Stock. The Company has reserved and the Company shall continue to reserve and keep available at all times,
free of preemptive rights, a sufficient number of shares of Common Stock for the purpose of enabling the Company to issue the Conversion
Shares pursuant to the conversion of the Shares of Preferred Stock.
ARTICLE
V.
MISCELLANEOUS
5.1
Fees and Expenses. Each party shall pay the fees and expenses of its advisers, counsel, accountants and other experts, if any,
and all other expenses incurred by such party incident to the negotiation, preparation, execution, delivery and performance of this Agreement.
5.2
Entire Agreement. This Agreement contains the entire understanding of the parties with respect to the subject matter hereof and
thereof and supersede all prior agreements and understandings, oral or written, with respect to such matters, which the parties acknowledge
have been merged into such documents, exhibits and schedules.
5.3
Notices. Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be in
writing and shall be deemed given and effective on the earliest of (a) the date of transmission, if such notice or communication is delivered
via facsimile or e-mail at the facsimile number or e-mail address set forth on the signature pages attached hereto prior to 5:30 p.m.
(New York City time) on a Business Day, (b) the next Business Day after the date of transmission, if such notice or communication is
delivered via facsimile or e-mail at the facsimile number or e-mail address set forth on the signature pages attached hereto on a day
that is not a Business Day or later than 5:30 p.m. (New York City time) on any Business Day, (c) the second Business Day following the
date of mailing, if sent by internationally recognized overnight courier service for next business day delivery, or (d) upon actual receipt
by the party to whom such notice is required to be given. The address for such notices and communications shall be as set forth on the
signature pages attached hereto.
5.4
Amendments; Waivers. No provision of this Agreement may be waived, amended, modified or terminated except in a written instrument
signed, by the Company and by the Purchaser. No waiver of any default with respect to any provision, condition or requirement of this
Agreement shall be deemed to be a continuing waiver in the future or a waiver of any subsequent default or a waiver of any other provision,
condition or requirement hereof, nor shall any delay or omission of any party to exercise any right hereunder in any manner impair the
exercise of any such right.
5.5
Headings. The headings herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed to
limit or affect any of the provisions hereof.
5.6
Successors and Assigns. This Agreement shall be binding upon and inure to the benefit of the parties and their successors and
permitted assigns. The Purchaser may not assign any or all of his rights under this Agreement to any Person without the prior written
consent of the Company.
5.7
No Third-Party Beneficiaries. This Agreement is intended for the benefit of the parties hereto and their respective successors
and permitted assigns and is not for the benefit of, nor may any provision hereof be enforced by, any other Person.
5.8
Governing Law. All questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be
governed by and construed and enforced in accordance with the internal laws of The Commonwealth of Massachusetts, without regard to the
principles of conflicts of law thereof. Each party agrees that all Proceedings concerning the interpretations, enforcement, and defense
of the transactions contemplated by this Agreement (whether brought against a party hereto or its respective affiliates, directors, officers,
shareholders, employees, or agents) shall be commenced exclusively in the state and federal courts sitting in The Commonwealth of Massachusetts.
Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the City of Boston for
the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein (including
with respect to the enforcement of this Agreement), and hereby irrevocably waives, and agrees not to assert in any Proceeding, any claim
that it is not personally subject to the jurisdiction of any such court, that such Proceeding is improper or is an inconvenient venue
for such Proceeding. The parties hereby waive all rights to a trial by jury.
5.9
Execution. This Agreement may be executed in two counterparts, each of which when taken together shall be considered one and the
same agreement and shall become effective against the Company and the Purchaser when counterparts have been signed by the Company and
the Purchaser and delivered to each other, it being understood that the Company and the Purchaser need not sign the same counterpart.
In the event that any signature is delivered by facsimile transmission or by e-mail delivery of a “.pdf” format data file,
such signature shall create a valid and binding obligation of the party executing (or on whose behalf such signature is executed) with
the same force and effect as if such facsimile or “.pdf” signature page were an original thereof.
5.10
Severability. If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction to
be invalid, illegal, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall
remain in full force and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use their commercially
reasonable efforts to find and employ an alternative means to achieve the same or substantially the same result as that contemplated
by such term, provision, covenant or restriction. It is hereby stipulated and declared to be the intention of the parties that they would
have executed the remaining terms, provisions, covenants and restrictions without including any of such that may be hereafter declared
invalid, illegal, void or unenforceable.
5.11
Construction. The parties agree that each of them and/or their respective counsel has reviewed and had an opportunity to revise
this Agreement and, therefore, the normal rule of construction to the effect that any ambiguities are to be resolved against the drafting
party shall not be employed in the interpretation of this Agreement or any amendments hereto.
IN
WITNESS WHEREOF, the parties hereto have caused this Securities Purchase and Exchange Agreement to be duly executed by their respective
authorized signatories as of the date first indicated above.
Pressure
BioSciences Inc.
|
|
Address
for Notice: |
By:
![](https://www.sec.gov/Archives/edgar/data/830656/000149315223042131/ex21-1_001.jpg)
Name:
Richard T. Schumacher
Title:
President and Chief Executive Officer
|
|
14
Norfolk Avenue
South
Easton, MA 02375
Facsimile:
(508) 580-1829
E-Mail:
rschumacher@pressurebiosciences.com
Attention:
Richard T. Schumacher |
|
|
|
Purchaser:
|
|
Address
for Notice: |
|
|
|
|
|
[_____________________] |
Name:
Accredited Investor
|
|
[_____________________]
Facsimile:
E-Mail:
|
Taxpayer
Identification Number: On File at the Company
Schedule
A
Series AA – dividend (8%) |
|
|
|
|
|
|
|
|
|
● Accrued Dividend (May 2, 2018 – Dec 31, 2022) |
|
$ |
6,028,158 |
|
● Accrued Dividend (Jan 1, 2023 – Feb 22, 2023) |
|
$ |
197,967 |
|
|
|
$ |
6,226,125¹ |
|
Promissory Notes – interest (10%) |
|
|
|
|
|
|
|
|
|
● Accrued Interest (Nov 15, 2019 – Dec 31, 2022) |
|
$ |
2,120,306 |
|
● Accrued Interest (Jan 1, 2023 – Feb 22, 2023) |
|
$ |
135,281 |
|
|
|
$ |
2,255,587² |
|
Promissory Notes (“PN”) |
|
|
|
|
|
|
|
|
|
● November 15, 2019 |
|
$ |
320,000 |
|
● January 2, 2020 |
|
$ |
330,000 |
|
● January 23, 2020 |
|
$ |
247,500 |
|
● January 29, 2020 |
|
$ |
363,000 |
|
● February 12, 2020 |
|
$ |
275,000 |
|
|
|
$ |
1,535,500³ |
|
|
|
|
|
|
Total Debt to be Exchanged into Series CC Equity: |
|
$ |
10,017,212 |
|
Purchase Price for each share of Preferred Stock Series CC: |
|
$ |
25,000.00 |
|
Number of Shares of Series CC Preferred Stock Purchased: |
|
|
400.6885 |
|
|
|
|
|
|
No. of Common Stock Equivalents (CSE) from the Series CC: |
|
|
4,006,885 |
|
¹Accrued
Series AA Dividends as of February 22, 2023 = $0.00
²Accrued
Promissory Note (“PN”) Interest as of February 22, 2023 = $0.00
³PN
Principal as of February 22, 2023 = $9,393,150 - $1,535,500 = $7,857,650
Schedule
B
1.
Series CC Preferred Stock Designation and Rank.
(a)
Designation. The designation of such series of the Preferred Stock shall be the Series CC Convertible Preferred Stock, par value $0.01
per share (the “Series CC Preferred Stock”). The maximum number of shares of Series CC Preferred Stock shall be Two Thousand
(2,000) shares.
(b)
Rank. The Series CC Preferred Stock shall rank prior to the common stock, par value $0.01 per share (the “Common Stock”),
and to all other classes and series of equity securities of the Company which by its terms does not rank on a parity with or senior to
the Series CC Preferred Stock (“Junior Stock”). The Series CC Preferred Stock shall be subordinate to and rank junior to
all indebtedness of the Company now or hereafter outstanding.
2.
Dividends.
(a)
Quarterly Dividends. The holders of shares of the Series CC Preferred Stock shall be entitled to receive, out of funds legally
available therefor, dividends at an annual rate equal to 8% of the Liquidation Preference Amount (as defined below), calculated on the
basis of a 360-day year, consisting of twelve 30-day months, and shall accrue on a daily basis from February 22, 2023. Accrued and unpaid
dividends shall compound on a quarterly basis, and shall be, except as set forth in Section 2(b) below, payable in cash. The first such
dividend payment shall be due and payable on March 31, 2023, with subsequent dividend payments due and payable on June 30, September
30, and December 31, 2023. Each year thereafter, dividend payments shall be due and payable on March 31, June 30, September 30, and December
31 (each a “Dividend Payment Date”). All accrued and unpaid dividends, if any, shall be mandatorily paid immediately prior
to the earlier to occur of (i) a liquidation, dissolution or winding up (or deemed liquidation, dissolution or winding up under Section
4(b) hereof) of the Company (a “Liquidation”), or (ii) a Voluntary Conversion pursuant to Section 5 hereof (the “Mandatory
Dividend Payment Date”).
(b)
Payment of Dividends. At the option of the Company in compliance with this Section 2(b), the Company may pay dividends on the
Series CC Preferred Stock in shares of Common Stock, with each share of Common Stock being valued for this purpose as the VWAP (as hereafter
defined) of the Common Stock for the five trading days immediately prior to the Dividend Payment date. In order to pay the dividends
in Common Stock, the Company must provide the holders of the Series CC Preferred Stock with at least 10 days’ notice, prior to
the Dividend Payment Date, of its election to pay a regularly scheduled dividend in shares of Common Stock (the Company may indicate
in such notice that the election contained in such notice shall continue for later periods until revised by a subsequent notice). In
the event the Company fails to provide such notice, the dividend shall be payable in cash. Notwithstanding the above, no dividend shall
be paid in Common Stock (i) in connection with a Liquidation, (ii) if such payment would cause the limitations on beneficial ownership
set forth in Section 7 hereof to be exceeded or (iii) unless the shares of Common Stock received upon such payment shall be freely salable
by the recipient pursuant to a then effective registration statement.
(c)
Junior Stock Dividends. The Company shall not declare or pay any cash dividends on or make any other distributions with respect
to or redeem, purchase, or otherwise acquire for consideration, any shares of Junior Stock unless and until all accrued and unpaid dividends
on the Series CC Preferred Stock have been paid in full. In all events, Junior Stock dividends shall be subject to the restrictions set
forth in Section 3(a) below.
3.
Voting Rights.
(a)
Class Voting Rights. The Series CC Preferred Stock shall have the following class voting rights (in addition to the voting rights
set forth in Section 3(b) hereof). So long as more than ten percent (10%) of the Series CC Preferred Stock remain outstanding, the Company
shall not, and shall not permit any subsidiary to, without the affirmative vote or consent of the holders of at least 75% of the shares
of the Series CC Preferred Stock outstanding at the time, given in person or by proxy, either in writing or at a meeting, in which the
holders of the Series CC Preferred Stock vote separately as a class: (i) authorize, create, issue or increase the authorized or issued
amount of any class or series of stock, including but not limited to the issuance of any more shares of previously authorized Preferred
Stock, ranking prior to the Series CC Preferred Stock, with respect to the distribution of assets on liquidation, dissolution or winding
up; (ii) amend, alter or repeal the provisions of the Series CC Preferred Stock, whether by merger, consolidation or otherwise, so as
to adversely affect any right, preference, privilege or voting power of the Series CC Preferred Stock; (iii) repurchase, redeem or pay
dividends on (whether in cash, in kind, or otherwise), shares of the Company’s Junior Stock; (iv) amend the Articles of Incorporation
or By-Laws of the Company so as to affect materially and adversely any right, preference, privilege or voting power of the Series CC
Preferred Stock; (v) effect any distribution with respect to Junior Stock or parity stock; (vi) reclassify the Company’s outstanding
securities; or (vii) effect a transaction with one or more persons or entities whereby such other persons or entities will own more than
the 50% of the outstanding shares of Common Stock following such transaction (“Change in Control Transaction”).
(b)
General Voting Rights. Except with respect to transactions upon which the Series CC Preferred Stock shall be entitled to vote
separately as a class pursuant to Section 3(a) above and except as otherwise required by Massachusetts law, the Series CC Preferred Stock
shall have no voting rights. The Common Stock into which the Series CC Preferred Stock is convertible shall, upon issuance, have all
of the same voting rights as other issued and outstanding Common Stock of the Company.
4.
Liquidation Preference.
(a)
In the event of the liquidation, dissolution or winding up of the affairs of the Company, whether voluntary or involuntary, the holders
of shares of the Series CC Preferred Stock then outstanding shall be entitled to receive, out of the assets of the Company whether such
assets are capital or surplus of any nature, an amount equal to $25,000.00 per share (the “Liquidation Preference Amount”)
of the Series CC Preferred Stock, on a pro rata and pari passu basis with any parity stock (the “Pari Passu Preferred Stock”),
together with all accrued but unpaid dividends, before any payment shall be made or any assets distributed to the holders of the Common
Stock or any other Junior Stock. If the assets of the Company are not sufficient to pay in full the Liquidation Preference Amount payable
to the holders of outstanding shares of the Series CC Preferred Stock and any series of preferred stock or any other class of stock on
a parity as to rights on liquidation, dissolution or winding up, with the Series CC Preferred Stock, then all of said assets will be
distributed among the holders of the Series CC Preferred Stock, the Pari Passu Preferred Stock and the other classes of stock on a parity
with the Series CC Preferred Stock, if any, ratably in accordance with the respective amounts that would be payable on such shares if
all amounts payable thereon were paid in full. The liquidation payment with respect to each outstanding fractional share of Series CC
Preferred Stock shall be equal to a ratably proportionate amount of the liquidation payment with respect to each outstanding share of
Series CC Preferred Stock. All payments for which this Section 4(a) provides shall be in cash, property (valued at its fair market value
as determined by an independent appraiser reasonably acceptable to the holders of a majority of the Series CC Preferred Stock) or a combination
thereof; provided, however, that no cash shall be paid to holders of Junior Stock unless each holder of the outstanding shares of Series
CC Preferred Stock has been paid in cash the full Liquidation Preference Amount to which such holder is entitled as provided herein.
After payment of the full Liquidation Preference Amount to which each holder is entitled, such holders of shares of Series CC Preferred
Stock will not be entitled to any further participation as such in any distribution of the assets of the Company.
Notwithstanding
the foregoing, at the option of the holder of Series CC Preferred Shares, such holder may elect to convert the entire Liquidation Preference
Amount into shares of Common Stock pursuant to a Voluntary Conversion as set forth in Section 5(a), effective immediately prior to liquidation
event.
(b)
A consolidation or merger of the Company with or into any other corporation or corporations, or a sale or transfer of more than 50% of
the assets of the Company, or the effectuation by the Company of a transaction or series of transactions in which more than 50% of the
voting shares of the Company is disposed of or conveyed, shall be, at the election of the holders of 75% of the Series CC Preferred Stock,
deemed to be a liquidation, dissolution, or winding up within the meaning of this Section 4. In the event of the merger or consolidation
of the Company with or into another corporation that is not treated as a liquidation pursuant to this Section 4(b), the Series CC Preferred
Stock shall maintain its relative powers, designations and preferences provided for herein and no merger shall result inconsistent therewith.
(c)
Written notice of any voluntary or involuntary liquidation, dissolution or winding up of the affairs of the Company, stating a payment
date and the place where the distributable amounts shall be payable, shall be given by mail, postage prepaid, no less than thirty (30)
days prior to the payment date stated therein, to the holders of record of the Series CC Preferred Stock at their respective addresses
as the same shall appear on the books of the Company.
5.
Conversion. The holder of Series CC Preferred Stock shall have the following conversion rights (the “Conversion Rights”):
(a)
Right to Convert. At any time on or after the Issuance Date, the holder of any such shares of Series CC Preferred Stock may, at
such holder’s option, subject to the limitations set forth in Section 7 herein, elect to convert (a “Voluntary Conversion”)
all or any portion of the shares of Series CC Preferred Stock held by such person, together with accrued but unpaid dividends thereon,
into a number of fully paid and nonassessable shares of Common Stock (the “Conversion Shares”) equal to the quotient of (i)
the Liquidation Preference Amount of the shares of Series CC Preferred Stock being converted thereon divided by (ii) the Conversion Price
(as defined in Section 5(d) below) then in effect as of the date of the delivery by such holder of its notice of election to convert.
The Company shall keep written records of the conversion of the shares of Series CC Preferred Stock converted by each holder. A holder
shall be required to deliver the original certificates representing the shares of Series CC Preferred Stock upon complete conversion
of the Series CC Preferred Stock.
(b)
Mechanics of Conversion. The Voluntary Conversion of Series CC Preferred Stock shall be conducted in the following manner:
(i)
Holder’s Delivery Requirements. To convert Series CC Preferred Stock into full shares of Common Stock on any date (the “Voluntary
Conversion Date”), the holder thereof shall (A) transmit by facsimile (or otherwise deliver), for receipt on or prior to 5:00 p.m.,
New York time on such date, a copy of a fully executed notice of conversion in the form attached hereto as Exhibit I (the “Conversion
Notice”), to the Company, and (B) with respect to the final conversion of shares of Series CC Preferred Stock held by any holder,
such holder shall surrender to a common carrier for delivery to the Company as soon as practicable following such Conversion Date but
in no event later than five (5) business days after such date the original certificates representing the shares of Series CC Preferred
Stock being converted (or an indemnification undertaking with respect to such shares in the case of their loss, theft or destruction)
(the “Preferred Stock Certificates”).
(ii)
Company’s Response. Within two (2) business days following the Conversion Notice delivery date (the “Registered Share
Delivery Date”), the Company shall transmit the shares of Common Stock to the holder by crediting the account of the holder’s
prime broker with The Depository Trust Company through its Deposit or Withdrawal at Custodian system (“DWAC”) if the Company
is then a participant in such system and there is an effective registration statement permitting the issuance of the shares to or resale
of the shares by the holder. Within three (3) business days following the Conversion Notice delivery date (the “144 Share Delivery
Date”), the Company shall transmit the shares of Common Stock to the holder by crediting the account of the holder’s prime
broker with The Depository Trust Company through the DWAC system if the Company is then a participant in such system and the shares are
eligible for resale by the holders without volume or manner-of-sale limitations pursuant to Rule 144, and otherwise by physical delivery
to the holder. In case of conversion under this Section 5 of only a part of the shares of Series CC Preferred Stock represented by a
certificate surrendered to the Company, the Company shall issue and deliver a new certificate for the number of shares of Series CC Preferred
Stock which have not been converted, upon receipt of the original certificate or certificates representing shares of Series CC Preferred
Stock so converted. Until such time as the certificate or certificates representing shares of Series CC Preferred Stock which have been
converted are surrendered to the Company and a certificate or certificates representing the Common Stock into which such shares of Series
CC Preferred Stock have been converted have been issued and delivered, the certificate or certificates representing the shares of Series
CC Preferred Stock which have been converted shall represent the shares of Common Stock into which such shares of Series CC Preferred
Stock have been converted. The Company shall pay all documentary, stamp or similar issue or transfer tax due on the issue of shares of
Common Stock issuable upon conversion of the Series CC Preferred Stock.
(iii)
Dispute Resolution. In the case of a dispute as to the arithmetic calculation of the number of shares of Common Stock to be issued
upon conversion, the Company shall promptly issue to the holder the number of shares of Common Stock that is not disputed and shall submit
the arithmetic calculations to the holder via facsimile as soon as possible, but in no event later than three (3) business days after
receipt of such holder’s Conversion Notice. If such holder and the Company are unable to agree upon the arithmetic calculation
of the number of shares of Common Stock to be issued upon such conversion within three (3) business day of such disputed arithmetic calculation
being submitted to the holder, then the Company shall within three (3) business day submit via facsimile the disputed arithmetic calculation
of the number of shares of Common Stock to be issued upon such conversion to the Company’s independent, outside accountant. The
Company shall cause the accountant to perform the calculations and notify the Company and the holder of the results no later than seventy-two
(72) hours from the time it receives the disputed calculations. Such accountant’s calculation shall be binding upon all parties
absent manifest error. The reasonable expenses of such accountant in making such determination shall be paid by the Company, in the event
the holder’s calculation was correct, or by the holder, in the event the Company’s calculation was correct, or equally by
the Company and the holder in the event that neither the Company’s or the holder’s calculation was correct. The period of
time in which the Company is required to effect conversions or redemptions under this Certificate of Designation shall be tolled with
respect to the subject conversion or redemption pending resolution of any dispute by the Company made in good faith and in accordance
with this Section 5(b)(iii).
(iv)
Record Holder. The person or persons entitled to receive the shares of Common Stock issuable upon a conversion of the Series CC
Preferred Stock shall be treated for all purposes as the record holder or holders of such shares of Common Stock on the Conversion Date.
(v)
Company’s Failure to Timely Convert. If within three (3) business days of the Company’s receipt of the Conversion
Notice (the “Share Delivery Period”) the Company shall fail to issue and deliver to a holder the undisputed number of shares
of Common Stock to which such holder is entitled upon such holder’s conversion of the Series CC Preferred Stock (a “Conversion
Failure”), in addition to all other available remedies which such holder may pursue, the Company shall pay additional damages to
such holder on each business day after such third (3rd) business day that such conversion is not timely effected in an amount
equal 0.5% of the product of (A) the sum of the number of shares of Common Stock not issued to the holder on a timely basis pursuant
to Section 5(b)(ii) and to which such holder is entitled and (B) the VWAP (as defined below) of the Common Stock on the last possible
date which the Company could have issued such Common Stock to such holder without violating Section 5(b)(ii). If the Company fails to
pay the additional damages set forth in this Section 5(b)(v) within five (5) business days of the date incurred, then such payment shall
bear interest at the rate of 2% per month (prorated for partial months) until such payments are made. “VWAP” means, for any
security as of any date, the dollar volume-weighted average price for such security on the principal market or exchange during the period
beginning at 9:30:01 a.m., New York time, and ending at 4:00:00 p.m., New York time, as reported by Bloomberg through its “Volume
at Price” function or, if the foregoing does not apply, the dollar volume-weighted average price of such security in the over-the-counter
market on the electronic bulletin board for such security during the period beginning at 9:30:01 a.m., New York time, and ending at 4:00:00
p.m., New York time, as reported by Bloomberg, or, if no dollar volume-weighted average price is reported for such security by Bloomberg
for such hours, the average of the highest closing bid price and the lowest closing ask price of any of the market makers for such security
as reported in the “pink sheets” by OTC Markets Group Inc. (formerly Pink Sheets LLC). If VWAP cannot be calculated for such
security on such date on any of the foregoing bases, the VWAP of such security on such date shall be the fair market value as mutually
determined by the Company and the holder. If the Company and the holder are unable to agree upon the fair market value of such security,
then such dispute shall be resolved in accordance with the procedures in Section 5(b)(iii) above. All such determinations shall be appropriately
adjusted for any stock dividend, stock split, stock combination or other similar transaction during such period.
(c)
Company Forced Conversion. The Company shall have the right, subject to satisfaction of the conditions in this Section 5(c), to
cause the conversion of all shares of Series CC Preferred Stock into Common Stock (“Forced Conversion”). The Company shall
deliver prior written notice to the Holder at least ten (10) business days (“Forced Conversion Notice”) prior to the effective
date (the “Forced Conversion Effective Date”) of such Forced Conversion. Following the effectiveness of a registration statement
permitting the resale of the Conversion Shares held by holders of the Series CC Preferred Stock the Company may effectuate a Forced Conversion
if either of the following conditions are satisfied as of the Forced Conversion Effective Date: (i) the VWAP of the Common Stock shall
equal or exceed 300% of the Conversion Price for either 10 consecutive trading days, or 15 of 25 consecutive trading days immediately
preceding the date of the Forced Conversion Notice; or (ii) listing of the Common Stock on any national securities exchange (NYSE, NYSE
American or Nasdaq). The Company shall not have an obligation to register the Conversion Shares of the shares of Series CC Preferred
Stock that are issued pursuant to any exchange of previously issued securities.
Upon
any Forced Conversion, all accrued but unpaid dividends shall be paid and the Company shall transmit the shares of Common Stock to the
holder by crediting the account of the holder’s prime broker with The Depository Trust Company through DWAC if the Company is then
a participant in such system, and otherwise by physical delivery to the holder. If within three (3) business days of the Forced Conversion
Effective Date, the Company shall fail to issue and deliver to a holder the number of shares of Common Stock to which such holder is
entitled upon such Forced Conversion, in addition to all other available remedies which such holder may pursue, the Company shall pay
additional damages to such holder on each business day after such third (3rd) business day that such conversion is not timely
effected in an amount equal 0.5% of the product of (A) the sum of the number of shares of Common Stock not issued to the holder on a
timely basis pursuant to Section 5(c) and to which such holder is entitled, and (B) the VWAP of the Common Stock on the last possible
date which the Company could have issued such Common Stock to such holder without violating Section 5(c). If the Company fails to pay
the additional damages set forth in this Section 5(c) within five (5) business days of the date incurred, then such payment shall bear
interest at the rate of 2% per month (prorated for partial months) until such payments are made.
If
any shares of Series CC Preferred Stock cannot be fully converted into Common Stock of the Company upon a Forced Conversion due to the
Conversion Restriction, such shares of Series CC Preferred Stock shall remain unconverted. However, upon such Forced Conversion until
such time as the shares of Series CC Preferred Stock are in fact converted into Common Stock, the following rights, preferences, and
privileges of the Series CC Preferred Stock shall be of no further force or effect: dividend rights pursuant to Section 2; anti-dilution
rights pursuant to Section 5(e)(vi); liquidation preference pursuant to Section 4; and the additional covenants set forth in Section
8.
(d)
Conversion Price. The term “Conversion Price” shall mean $2.50 per share, subject to adjustment under Section 5(e)
hereof.
(e)
Adjustments of Conversion Price.
(i)
Adjustments for Stock Splits and Combinations. If the Company shall at any time or from time to time after the Issuance Date,
effect a stock split of the outstanding Common Stock, the Conversion Price shall be proportionately decreased. If the Company shall at
any time or from time to time after the Issuance Date, combine the outstanding shares of Common Stock, the Conversion Price shall be
proportionately increased. Any adjustments under this Section 5(e)(i) shall be effective at the close of business on the date the stock
split or combination occurs.
(ii)
Adjustments for Certain Dividends and Distributions. If the Company shall at any time or from time to time after the Issuance
Date, make or issue or set a record date for the determination of holders of Common Stock entitled to receive a dividend or other distribution
payable in shares of Common Stock, then, and in each event, the Conversion Price shall be decreased as of the time of such issuance or,
in the event such record date shall have been fixed, as of the close of business on such record date, by multiplying, as applicable,
the Conversion Price then in effect by a fraction:
(1)
the numerator of which shall be the total number of shares of Common Stock issued and outstanding immediately prior to the time of such
issuance or the close of business on such record date; and
(2)
the denominator of which shall be the total number of shares of Common Stock issued and outstanding immediately prior to the time of
such issuance or the close of business on such record date plus the number of shares of Common Stock issuable in payment of such dividend
or distribution.
(iii)
Adjustment for Other Dividends and Distributions. If the Company shall at any time or from time to time after the Issuance Date,
make or issue or set a record date for the determination of holders of Common Stock entitled to receive a dividend or other distribution
payable in securities of the Company other than shares of Common Stock, then, and in each event, an appropriate revision to the applicable
Conversion Price shall be made and provision shall be made (by adjustments of the Conversion Price or otherwise) so that the holders
of Series CC Preferred Stock shall receive upon conversions thereof, in addition to the number of shares of Common Stock receivable thereon,
the number of securities of the Company which they would have received had their Series CC Preferred Stock been converted into Common
Stock immediately prior to such event (or the record date for such event, if applicable) and had thereafter, during the period from the
date of such event to and including the Conversion Date, retained such securities (together with any distributions payable thereon during
such period), giving application to all adjustments called for during such period under this Section 5(e)(iii) with respect to the rights
of the holders of the Series CC Preferred Stock.
(iv)
Adjustments for Reclassification, Exchange or Substitution. If the Common Stock issuable upon conversion of the Series CC Preferred
Stock at any time or from time to time after the Issuance Date shall be changed to the same or different number of shares of any class
or classes of stock, whether by reclassification, exchange, substitution or otherwise (other than by way of a stock split or combination
of shares or stock dividends provided for in Sections 5(e)(i), (ii) and (iii), or a reorganization, merger, consolidation, or sale of
assets provided for in Section 5(e)(v)), then, and in each event, an appropriate revision to the Conversion Price shall be made and provisions
shall be made (by adjustments of the Conversion Price or otherwise) so that the holder of each share of Series CC Preferred Stock shall
have the right thereafter to convert such share of Series CC Preferred Stock into the kind and amount of shares of stock and other securities
receivable upon reclassification, exchange, substitution or other change, by holders of the number of shares of Common Stock into which
such share of Series CC Preferred Stock might have been converted immediately prior to such reclassification, exchange, substitution
or other change, all subject to further adjustment as provided herein.
(v)
Adjustments for Reorganization, Merger, Consolidation or Sales of Assets. If at any time or from time to time after the Issuance
Date there shall be a capital reorganization of the Company (other than by way of a stock split or combination of shares or stock dividends
or distributions provided for in Section 5(e)(i), (ii) and (iii), or a reclassification, exchange or substitution of shares provided
for in Section 5(e)(iv)), or a merger or consolidation of the Company with or into another corporation, or the sale of all or substantially
all of the Company’s properties or assets to any other person that is not deemed a liquidation pursuant to Section 4(b) (an “Organic
Change”), then as a part of such Organic Change an appropriate revision to the Conversion Price shall be made and provision shall
be made (by adjustments of the Conversion Price or otherwise) so that the holder of each share of Series CC Preferred Stock shall have
the right thereafter to convert such share of Series CC Preferred Stock into the kind and amount of shares of stock and other securities
or property of the Company or any successor corporation resulting from the Organic Change as the holder would have received as a result
of the Organic Change and if the holder had converted its Series CC Preferred Stock into the Company’s Common Stock prior to the
Organic Change. In any such case, appropriate adjustment shall be made in the application of the provisions of this Section 5(e)(v) with
respect to the rights of the holders of the Series CC Preferred Stock after the Organic Change to the end that the provisions of this
Section 5(e)(v) (including any adjustment in the Conversion Price then in effect and the number of shares of stock or other securities
deliverable upon conversion of the Series CC Preferred Stock) shall be applied after that event in as nearly an equivalent manner as
may be practicable.
(vi)
Subsequent Equity Sales. If, at any time while shares of Series CC Preferred Stock are outstanding, the Company or any subsidiary,
as applicable, sells or grants any option to purchase or sells or grants any right to reprice outstanding securities, or otherwise disposes
of or issues (or announces any sale, grant or any option to purchase or other disposition), any Common Stock or any security convertible
or exchangeable into Common Stock (a “Common Stock Equivalent”), entitling any Person to acquire shares of Common Stock at
an effective price per share that is lower than the then Conversion Price (such lower price, the “Base Conversion Price”
and such issuances, collectively, a “Dilutive Issuance”) (if the holder of the Common Stock or Common Stock Equivalents
so issued shall at any time, whether by operation of purchase price adjustments, reset provisions, floating conversion, exercise or exchange
prices or otherwise, or due to warrants, options or rights per share which are issued in connection with such issuance, be entitled to
receive shares of Common Stock at an effective price per share that is lower than the Conversion Price, such issuance shall be deemed
to have occurred for less than the Conversion Price on such date of the Dilutive Issuance), then the Conversion Price shall be reduced
to equal the Base Conversion Price. Such adjustment shall be made whenever such Common Stock or Common Stock Equivalents are issued.
Notwithstanding the foregoing, no adjustment will be made under this Section in respect of an Exempt Issuance (as hereafter defined).
The Company shall notify the Holder in writing, no later than the Trading Day following the issuance of any Common Stock or Common Stock
Equivalents subject to this Section, indicating therein the applicable issuance price, or applicable reset price, exchange price, conversion
price and other pricing terms (such notice, the “Dilutive Issuance Notice”). For purposes of clarification, whether
or not the Company provides a Dilutive Issuance Notice, upon the occurrence of any Dilutive Issuance, the Holder is entitled to receive
a number of Conversion Shares based upon the Base Conversion Price on or after the date of such Dilutive Issuance, regardless of whether
the Holder accurately refers to the Base Conversion Price in the Notice of Conversion. Notwithstanding the foregoing, if any shares of
Series CC Preferred Stock cannot be fully converted into Common Stock of the Company upon a Forced Conversion due to the Conversion Restriction,
such shares of Series CC Preferred Stock shall remain unconverted. However, upon such Forced Conversion this Section 5(e)(vi); shall
be of no further force or effect in accordance with Section 5(c).
(a)
For the purposes hereof, an Exempt Issuance shall mean: the issuance of (a) shares of Common Stock or options or other stock based awards
to employees, officers or directors and consultants of the Company pursuant to the Company’s stock or option plans existing as
of the date hereof, to employees, officers or directors and consultants of the Company pursuant to a written agreement, provided that
such shares of Common Stock are not registered and carry no registration rights other than on Form S-8, (b) securities upon the exercise
or exchange of or conversion of any Securities issued hereunder and/or other securities exercisable or exchangeable for or convertible
into shares of Common Stock issued and outstanding on the original Issue Date of this Series CC Preferred Stock, provided that such securities
have not been amended or has a provision, since the date of this Agreement, to increase the number of such securities or to decrease
the exercise price, exchange price or conversion price of such securities, and (c) securities issued pursuant to acquisitions or strategic
transactions approved by a majority of the disinterested directors of the Company, provided that any such issuance shall only be to a
Person (or to the equity holders of a Person) which is, itself or through its subsidiaries, an operating company or an owner of an asset
in a business synergistic with the business of the Company and shall provide to the Company additional benefits in addition to the investment
of funds, but shall not include a transaction in which the Company is issuing securities primarily for the purpose of raising capital
or to an entity whose primary business is investing in securities. An Exempt Issuance shall not include any Change in Control Transaction.
(vii)
Consideration for Stock. In case any shares of Common Stock or convertible securities other than the Series CC Preferred Stock,
or any rights or warrants or options to purchase any such Common Stock or Convertible securities, shall be issued or sold in connection
with any merger or consolidation in which the Company is the surviving corporation (other than any consolidation or merger in which the
previously outstanding shares of Common Stock of the Company shall be changed to or exchanged for the stock or other securities of another
corporation), the amount of consideration therefor shall be deemed to be the fair value, as determined reasonably and in good faith by
the Board of Directors of the Company, of such portion of the assets and business of the non-surviving corporation as such Board may
determine to be attributable to such shares of Common Stock, Convertible securities , rights or warrants or options, as the case may
be.
(viii)
Record Date. In case the Company shall take record of the holders of its Common Stock or any other Preferred Stock for the purpose
of entitling them to subscribe for or purchase Common Stock or Convertible securities, then the date of the issue or sale of the shares
of Common Stock shall be deemed to be such record date.
(f)
No Impairment. The Company shall not, by amendment of its Articles of Incorporation or through any reorganization, transfer of
assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance
or performance of any of the terms to be observed or performed hereunder by the Company, but will at all times in good faith, assist
in the carrying out of all the provisions of this Section 5 and in the taking of all such action as may be necessary or appropriate in
order to protect the Conversion Rights of the holders of the Series CC Preferred Stock against impairment. In the event a holder shall
elect to convert any shares of Series CC Preferred Stock as provided herein, the Company cannot refuse conversion based on any claim
that such holder or any one associated or affiliated with such holder has been engaged in any violation of law, unless, an injunction
from a court, on notice, restraining and/or enjoining conversion of all or of said shares of Series CC Preferred Stock shall have been
issued and the Company posts a surety bond for the benefit of such holder in an amount equal to 130% of the Liquidation Preference Amount
of the Series CC Preferred Stock such holder has elected to convert, which bond shall remain in effect until the completion of arbitration/litigation
of the dispute and the proceeds of which shall be payable to such holder in the event it obtains judgment.
(g)
Certificates as to Adjustments. Upon occurrence of each adjustment or readjustment of the Conversion Price or number of shares
of Common Stock issuable upon conversion of the Series CC Preferred Stock pursuant to this Section 5, the Company at its expense shall
promptly compute such adjustment or readjustment in accordance with the terms hereof and furnish to each holder of such Series CC Preferred
Stock a certificate setting forth such adjustment and readjustment, showing in detail the facts upon which such adjustment or readjustment
is based. The Company shall, upon written request of the holder of such affected Series CC Preferred Stock, at any time, furnish or cause
to be furnished to such holder a like certificate setting forth such adjustments and readjustments, the Conversion Price in effect at
the time, and the number of shares of Common Stock and the amount, if any, of other securities or property which at the time would be
received upon the conversion of a share of such Series CC Preferred Stock. Notwithstanding the foregoing, the Company shall not be obligated
to deliver a certificate unless such certificate would reflect an increase or decrease of at least one percent of such adjusted amount.
(h)
Issue Taxes. The Company shall pay any and all issue and other taxes, excluding federal, state or local income taxes, that may
be payable in respect of any issue or delivery of shares of Common Stock on conversion of shares of Series CC Preferred Stock pursuant
thereto; provided, however, that the Company shall not be obligated to pay any transfer taxes resulting from any transfer requested by
any holder in connection with any such conversion.
(i)
Notices. All notices and other communications hereunder shall be in writing and shall be deemed given if delivered personally
or by facsimile or three (3) business days following being mailed by certified or registered mail, postage prepaid, return-receipt requested,
addressed to the holder of record at its address appearing on the books of the Company. The Company will give written notice to each
holder of Series CC Preferred Stock at least twenty (20) days prior to the date on which the Company closes its books or takes a record
(I) with respect to any dividend or distribution upon the Common Stock, (II) with respect to any pro rata subscription offer to holders
of Common Stock or (III) for determining rights to vote with respect to any Organic Change, dissolution, liquidation or winding-up and
in no event shall such notice be provided to such holder prior to such information being made known to the public. The Company will also
give written notice to each holder of Series CC Preferred Stock at least twenty (20) days prior to the date on which any Organic Change,
dissolution, liquidation or winding-up will take place and in no event shall such notice be provided to such holder prior to such information
being made known to the public.
(j)
Fractional Shares. No fractional shares of Common Stock shall be issued upon conversion of the Series CC Preferred Stock. In lieu
of any fractional shares to which the holder would otherwise be entitled, the Company shall at its option either (i) pay cash equal to
the product of such fraction multiplied by the average of the VWAP of the Common Stock for the five (5) consecutive trading days immediately
preceding the Voluntary Conversion Date, or (ii) in lieu of issuing such fractional shares issue one additional whole share to the holder.
(k)
Reservation of Common Stock. The Company shall, so long as any shares of Series CC Preferred Stock are outstanding, reserve and
keep available out of its authorized and unissued Common Stock, solely for the purpose of effecting the conversion of the Series CC Preferred
Stock, such number of shares of Common Stock as shall from time to time be sufficient to effect the conversion of all of the Series CC
Preferred Stock then outstanding; provided that the number of shares of Common Stock so reserved shall at no time be less than 120% of
the number of shares of Common Stock for which the shares of Series CC Preferred Stock are at any time convertible (without regard to
the limitations on conversion set forth in Section 7 hereof). The initial number of shares of Common Stock reserved for conversions of
the Series CC Preferred Stock and each increase in the number of shares so reserved shall be allocated pro rata among the holders of
the Series CC Preferred Stock based on the number of shares of Series CC Preferred Stock held by each holder at the time of issuance
of the Series CC Preferred Stock or increase in the number of reserved shares, as the case may be. In the event a holder shall sell or
otherwise transfer any of such holder’s shares of Series CC Preferred Stock, each transferee shall be allocated a pro rata portion
of the number of reserved shares of Common Stock reserved for such transferor. Any shares of Common Stock reserved, and which remain
allocated to any person or entity which does not hold any shares of Series CC Preferred Stock, shall be allocated to the remaining holders
of Series CC Preferred Stock, pro rata based on the number of shares of Series CC Preferred Stock then held by such holder.
(l)
Retirement of Series CC Preferred Stock. Conversion of Series CC Preferred Stock shall be deemed to have been effected on the
applicable Voluntary Conversion Date or upon the Forced Conversion Effective Date. The Company shall keep written records of the conversion
of the shares of Series CC Preferred Stock converted by each holder. A holder shall be required to deliver the original certificates
representing the shares of Series CC Preferred Stock upon complete conversion of the Series CC Preferred Stock.
(m)
Regulatory Compliance. If any shares of Common Stock to be reserved for the purpose of conversion of Series CC Preferred Stock
require registration or listing with or approval of any governmental authority, stock exchange or other regulatory body under any federal
or state law or regulation or otherwise before such shares may be validly issued or delivered upon conversion, the Company shall, at
its sole cost and expense, in good faith and as expeditiously as possible, endeavor to secure such registration, listing or approval,
as the case may be.
6.
No Preemptive Rights. No holder of the Series CC Preferred Stock shall be entitled to rights to subscribe for, purchase or receive
any part of any new or additional shares of any class, whether now or hereinafter authorized, or of bonds or debentures, or other evidences
of indebtedness convertible into or exchangeable for shares of any class, but all such new or additional shares of any class, or any
bond, debentures or other evidences of indebtedness convertible into or exchangeable for shares, may be issued and disposed of by the
Board of Directors on such terms and for such consideration (to the extent permitted by law), and to such person or persons as the Board
of Directors in their absolute discretion may deem advisable.
7.
Conversion Restriction.
Notwithstanding
anything to the contrary set forth in Section 5 of this Certificate of Designation, at no time may a holder of shares of Series CC Preferred
Stock convert shares of the Series CC Preferred Stock if the number of shares of Common Stock to be issued pursuant to such conversion
would exceed, when aggregated with all other shares of Common Stock owned by such holder at such time, the number of shares of Common
Stock which would result in such holder beneficially owning (as determined in accordance with Section 13(d) of the Securities Exchange
Act of 1934, as amended, and the rules thereunder) in excess of 4.99% of all of the Common Stock outstanding at such time (the “Conversion
Restriction”); provided, however, that upon a holder of Series CC Preferred Stock providing the Company with sixty-one (61) days’
notice (pursuant to Section 5(i) hereof) (the “Waiver Notice”) that such holder would like to waive Section 7 of this Certificate
of Designation with regard to any or all shares of Common Stock issuable upon conversion of Series CC Preferred Stock, this Section 7
shall be of no force or effect with regard to those shares of Series CC Preferred Stock referenced in the Waiver Notice.
8.
Additional Covenants. For as long as there has not been a Forced Conversion, the Company shall not: (i) issue any variable priced
equity or variable priced equity linked securities; or (ii) issue any additional shares of preferred or convertible debt that rank in
terms of liquidation preference or any other priority senior to the Series CC Preferred Stock, without prior written permission of holder
of 75% of the then outstanding shares of Series CC Preferred Stock. In addition, the Company agrees that upon listing of the Common Stock
on any national securities exchange (NYSE, NYSE American or Nasdaq), the Company will not issue any Common Stock or Common Stock equivalents
at a price below the initial listing price on any such exchange for a period of 12 months from the date of listing.
9.
Inability to Fully Convert.
(a)
Holder’s Option if Company Cannot Fully Convert. If, upon the Company’s receipt of a Conversion Notice, the Company
cannot issue shares of Common Stock registered for resale or such shares cannot be sold pursuant to Rule 144 for any reason, including,
without limitation, because the Company (x) does not have a sufficient number of shares of Common Stock authorized and available, (y)
is otherwise prohibited by applicable law or by the rules or regulations of any stock exchange, interdealer quotation system or other
self-regulatory organization with jurisdiction over the Company or its securities from issuing all of the Common Stock which is to be
issued to a holder of Series CC Preferred Stock pursuant to a Conversion Notice or (z) fails to have a sufficient number of shares of
Common Stock registered for resale in such holder’s name, then the Company shall issue as many shares of Common Stock as it is
able to issue in accordance with such holder’s Conversion Notice and pursuant to Section 5(b)(ii) above and, with respect to the
unconverted Series CC Preferred Stock, the holder, solely at such holder’s option, can elect, in addition to other remedies available
to such holder, within five (5) business days after receipt of notice from the Company thereof to:
(i)
require the Company to redeem from such holder those shares of Series CC Preferred Stock for which the Company is unable to issue Common
Stock in accordance with such holder’s Conversion Notice (“Mandatory Redemption”) at a price per share equal to 120%
of the Liquidation Preference Amount as of such Conversion Date (the “Mandatory Redemption Price”);
(ii)
if the Company’s inability to fully convert Series CC Preferred Stock pursuant to Section 9(a)(z) above, require the Company to
issue restricted shares of Common Stock in accordance with such holder’s Conversion Notice and pursuant to Section 5(b)(ii) above;
(iii)
void its Conversion Notice and retain or have returned, as the case may be, the shares of Series CC Preferred Stock that were to be converted
pursuant to such holder’s Conversion Notice (provided that a holder’s voiding its Conversion Notice shall not affect the
Company’s obligations to make any payments which have accrued prior to the date of such notice).
In
the event a Holder shall elect to convert any shares of Series CC Preferred Stock as provided herein, the Company cannot refuse conversion
based on any claim that such Holder or any one associated or affiliated with such Holder has been engaged in any violation of law, violation
of an agreement to which such Holder is a party or for any reason whatsoever, unless, an injunction from a court, on notice, restraining
and or enjoining conversion of all or of said shares of Series CC Preferred Stock shall have issued and the Company posts a surety bond
for the benefit of such Holder in an amount equal to 130% of the amount of shares of Series CC Preferred Stock the Holder has elected
to convert, which bond shall remain in effect until the completion of arbitration/litigation of the dispute and the proceeds of which
shall be payable to such Holder in the event it obtains judgment.
(b)
Mechanics of Fulfilling Holder’s Election. The Company shall immediately send via facsimile to a holder of Series CC Preferred
Stock, upon receipt of a facsimile copy of a Conversion Notice from such holder which cannot be fully satisfied as described in Section
9(a) above, a notice of the Company’s inability to fully satisfy such holder’s Conversion Notice (the “Inability to
Fully Convert Notice”). Such Inability to Fully Convert Notice shall indicate (i) the reason why the Company is unable to fully
satisfy such holder’s Conversion Notice, (ii) the number of Series CC Preferred Stock which cannot be converted and (iii) the applicable
Mandatory Redemption Price. Such holder shall notify the Company of its election pursuant to Section 9(a) above by delivering written
notice via facsimile to the Company (“Notice in Response to Inability to Convert”).
(c)
Payment of Redemption Price. If such holder shall elect to have its shares redeemed pursuant to Section 9(a)(i) above, the Company
shall pay the Mandatory Redemption Price to such holder within thirty (30) days of the Company’s receipt of the holder’s
Notice in Response to Inability to Convert, provided that prior to the Company’s receipt of the holder’s Notice in Response
to Inability to Convert the Company has not delivered a notice to such holder stating, to the satisfaction of the holder, that the event
or condition resulting in the Mandatory Redemption has been cured and all shares of Common Stock issuable to such holder can and will
be delivered to the holder in accordance with the terms of Section 2(c). If the Company shall fail to pay the applicable Mandatory Redemption
Price to such holder on a timely basis as described in this Section 9(c) (other than pursuant to a dispute as to the determination of
the arithmetic calculation of the Redemption Price), in addition to any remedy such holder of Series CC Preferred Stock may have, such
unpaid amount shall bear interest at the rate of 1.5% per month (prorated for partial months) until paid in full. Until the full Mandatory
Redemption Price is paid in full to such holder, such holder may (i) void the Mandatory Redemption with respect to those Series CC Preferred
Stock for which the full Mandatory Redemption Price has not been paid, (ii) receive back such Series CC Preferred Stock, and (iii) require
that the Conversion Price of such returned Series CC Preferred Stock be adjusted to the lesser of (A) the Conversion Price and (B) the
lowest VWAP of the Common Stock during the period beginning on the Conversion Date and ending on the date the holder voided the Mandatory
Redemption.
(d)
Pro-rata Conversion and Redemption. In the event the Company receives a Conversion Notice from more than one holder of Series
CC Preferred Stock on the same day and the Company can convert and redeem some, but not all, of the Series CC Preferred Stock pursuant
to this Section 9, the Company shall convert and redeem from each holder of Series CC Preferred Stock electing to have Series CC Preferred
Stock converted and redeemed at such time an amount equal to such holder’s pro-rata amount (based on the number shares of Series
CC Preferred Stock held by such holder relative to the number shares of Series CC Preferred Stock outstanding) of all shares of Series
CC Preferred Stock being converted and redeemed at such time.
10.
Vote to Change the Terms of or Issue Preferred Stock. The affirmative vote at a meeting duly called for such purpose or the written
consent without a meeting, of the holders of not less than 75% of the then outstanding shares of Series CC Preferred Stock, shall be
required (a) for any change to this Certificate of Designation or the Company’s Articles of Incorporation which would amend, alter,
change or repeal any of the powers, designations, preferences and rights of the Series CC Preferred Stock or (b) for the issuance of
shares of Series CC Preferred Stock.
11.
Lost or Stolen Certificates. Upon receipt by the Company of evidence satisfactory to the Company of the loss, theft, destruction
or mutilation of any Preferred Stock Certificates representing the shares of Series CC Preferred Stock, and, in the case of loss, theft
or destruction, of any indemnification undertaking by the holder to the Company and, in the case of mutilation, upon surrender and cancellation
of the Preferred Stock Certificate(s), the Company shall execute and deliver new preferred stock certificate(s) of like tenor and date.
12.
Remedies, Characterizations, Other Obligations, Breaches and Injunctive Relief. The remedies provided in this Certificate of Designation
shall be cumulative and in addition to all other remedies available under this Certificate of Designation, at law or in equity (including
a decree of specific performance and/or other injunctive relief), no remedy contained herein shall be deemed a waiver of compliance with
the provisions giving rise to such remedy and nothing herein shall limit a holder’s right to pursue actual damages for any failure
by the Company to comply with the terms of this Certificate of Designation. Amounts set forth or provided for herein with respect to
payments, conversion, and the like (and the computation thereof) shall be the amounts to be received by the holder thereof and shall
not, except as expressly provided herein, be subject to any other obligation of the Company (or the performance thereof). The Company
acknowledges that a breach by it of its obligations hereunder will cause irreparable harm to the holders of the Series CC Preferred Stock
and that the remedy at law for any such breach may be inadequate. The Company therefore agrees that, in the event of any such breach
or threatened breach, the holders of the Series CC Preferred Stock shall be entitled, in addition to all other available remedies, to
an injunction restraining any breach, without the necessity of showing economic loss and without any bond or other security being required.
13.
Specific Shall Not Limit General; Construction. No specific provision contained in this Certificate of Designation shall limit
or modify any more general provision contained herein. This Certificate of Designation shall be deemed to be jointly drafted by the Company
and all initial purchasers of the Series CC Preferred Stock and shall not be construed against any person as the drafter hereof.
14.
Failure or Indulgence Not Waiver. No failure or delay on the part of a holder of Series CC Preferred Stock in the exercise of
any power, right or privilege hereunder shall operate as a waiver thereof, nor shall any single or partial exercise of any such power,
right or privilege preclude other or further exercise thereof or of any other right, power, or privilege.
IN
WITNESS WHEREOF, the undersigned has executed and subscribed this Certificate and does affirm the foregoing as true this 28th day of
February 2023.
EXHIBIT
I
PRESSURE
BIOSCIENCES, INC.
CONVERSION
NOTICE
Reference
is made to the Certificate of Designation of the Relative Rights and Preferences of the Series CC Preferred Stock of Pressure BioSciences,
Inc. (the “Certificate of Designation”). In accordance with and pursuant to the Certificate of Designation, the undersigned
hereby elects to convert the number of shares of Series CC Preferred Stock, par value $0.01 per share (the “Preferred Shares”),
of Pressure BioSciences, Inc., a Massachusetts corporation (the “Company”), indicated below into shares of Common Stock,
par value $0.01 per share (the “Common Stock”), of the Company, by tendering the stock certificate(s) representing the share(s)
of Preferred Shares specified below as of the date specified below.
Number
of Preferred Shares to be converted: _______
Stock
certificate no(s). of Preferred Shares to be converted: ________
The
Common Stock have been sold pursuant to the Registration Statement (as defined in the Registration Rights Agreement): YES ____ NO____
The
holder wishes to exercise on a cashless basis: YES _____ NO_____
Please
confirm the following information:
Conversion
Price: |
|
|
|
Number
of shares of Common Stock |
|
to
be issued: |
|
Number
of shares of Common Stock beneficially owned or deemed beneficially owned by the Holder on the Date of Conversion determined in accordance
with Section 16 of the Securities Exchange Act of 1934, as amended: _________________________
Please
issue the Common Stock into which the Preferred Shares are being converted and, if applicable, any check drawn on an account of the Company
in the following name and to the following address:
Issue
to: |
|
|
|
|
|
Facsimile
Number: |
|
|
|
Authorization: |
|
![](https://www.sec.gov/Archives/edgar/data/830656/000149315223042131/ex21-1_002.jpg)
![](https://www.sec.gov/Archives/edgar/data/830656/000149315223042131/ex21-1_003.jpg)
EXHIBIT
31.1
CERTIFICATION
PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I,
Richard T. Schumacher, certify that:
1.
I have reviewed this Quarterly Report on Form 10-Q of Pressure BioSciences, Inc.;
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the
period covered by this report;
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this
report;
4.
The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures
(as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act
Rule 13a-15(f) and 15d-15(f)) for the registrant and have:
a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
to ensure that material information relating to the registrant, including its consolidated subsidiary, is made known to us by others
within those entities, particularly during the period in which this report is being prepared;
b)
Designed such internal controls over financial reporting, or caused such internal controls over financial reporting to be designed under
our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
for external purposes in accordance with generally accepted accounting principles;
c)
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions
about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;
and
d)
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s
most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected,
or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.
The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial
reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing
the equivalent functions):
a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information;
and
b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s
internal control over financial reporting.
Dated:
November 20, 2023
/s/
Richard T. Schumacher |
|
Richard
T. Schumacher |
|
President
and Chief Executive Officer |
|
Principal
Executive Officer |
|
EXHIBIT
31.2
CERTIFICATION
PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I,
Richard T. Schumacher, certify that:
1.
I have reviewed this Quarterly Report on Form 10-Q of Pressure BioSciences, Inc.;
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the
period covered by this report;
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this
report;
4.
The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures
(as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act
Rule 13a-15(f) and 15d-15(f)) for the registrant and have:
a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
to ensure that material information relating to the registrant, including its consolidated subsidiary, is made known to us by others
within those entities, particularly during the period in which this report is being prepared;
b)
Designed such internal controls over financial reporting, or caused such internal controls over financial reporting to be designed under
our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
for external purposes in accordance with generally accepted accounting principles;
c)
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions
about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;
and
d)
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s
most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected,
or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.
The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial
reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing
the equivalent functions):
a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information;
and
b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s
internal control over financial reporting.
Dated:
November 20, 2023
/s/
Richard T. Schumacher |
|
Richard
T. Schumacher |
|
Principal
Financial Officer |
|
EXHIBIT
32.1
Certification
Pursuant
to Section 906 of the Sarbanes-Oxley Act of 2002
(Subsections
(a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code)
In
connection with the Quarterly Report on Form 10-Q of Pressure BioSciences, Inc., a Massachusetts corporation (the “Company”)
for the period ended September 30, 2023 as filed with the Securities and Exchange Commission on the date hereof (the “Report”),
I, Richard T. Schumacher, President and Chief Executive Officer of the Company, do hereby certify, pursuant to Section 906 of the Sarbanes-Oxley
Act of 2002 (subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code) that:
|
(1) |
The
Report of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended;
and |
|
|
|
|
(2) |
The
information contained in the Report fairly presents, in all material respects, the financial condition and results of operations
of the Company. |
Date:
November 20, 2023 |
By: |
/s/
Richard T. Schumacher |
|
|
Richard
T. Schumacher |
|
|
President
& Chief Executive Officer |
|
|
(Principal
Executive Officer) |
A
signed original of this written statement required by Section 906 has been provided to Pressure BioSciences, Inc. and will be retained
by Pressure BioSciences, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.
EXHIBIT
32.2
Certification
Pursuant
to Section 906 of the Sarbanes-Oxley Act of 2002
(Subsections
(a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code)
In
connection with the Quarterly Report on Form 10-Q of Pressure BioSciences, Inc., a Massachusetts corporation (the “Company”)
for the period ended September 30, 2023 as filed with the Securities and Exchange Commission on the date hereof (the “Report”),
I, Richard T. Schumacher, Principal Financial Officer of the Company, do hereby certify, pursuant to Section 906 of the Sarbanes-Oxley
Act of 2002 (subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code) that:
|
(1) |
The
Report of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended;
and |
|
|
|
|
(2) |
The
information contained in the Report fairly presents, in all material respects, the financial condition and results of operations
of the Company. |
Date:
November 20, 2023 |
By: |
/s/
Richard T. Schumacher |
|
|
Richard
T. Schumacher |
|
|
President
& Chief Executive Officer |
|
|
(Principal
Financial Officer) |
A
signed original of this written statement required by Section 906 has been provided to Pressure BioSciences, Inc. and will be retained
by Pressure BioSciences, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.
v3.23.3
Cover - shares
|
9 Months Ended |
|
Sep. 30, 2023 |
Nov. 10, 2023 |
Cover [Abstract] |
|
|
Document Type |
10-Q
|
|
Amendment Flag |
false
|
|
Document Quarterly Report |
true
|
|
Document Transition Report |
false
|
|
Document Period End Date |
Sep. 30, 2023
|
|
Document Fiscal Period Focus |
Q3
|
|
Document Fiscal Year Focus |
2023
|
|
Current Fiscal Year End Date |
--12-31
|
|
Entity File Number |
001-38185
|
|
Entity Registrant Name |
PRESSURE
BIOSCIENCES, INC.
|
|
Entity Central Index Key |
0000830656
|
|
Entity Tax Identification Number |
04-2652826
|
|
Entity Incorporation, State or Country Code |
MA
|
|
Entity Address, Address Line One |
14
Norfolk Avenue
|
|
Entity Address, City or Town |
South
Easton
|
|
Entity Address, State or Province |
MA
|
|
Entity Address, Postal Zip Code |
02375
|
|
City Area Code |
(508)
|
|
Local Phone Number |
230-1828
|
|
Entity Current Reporting Status |
Yes
|
|
Entity Interactive Data Current |
Yes
|
|
Entity Filer Category |
Non-accelerated Filer
|
|
Entity Small Business |
true
|
|
Entity Emerging Growth Company |
false
|
|
Entity Shell Company |
false
|
|
Entity Common Stock, Shares Outstanding |
|
21,726,433
|
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionEnd date of current fiscal year in the format --MM-DD.
+ References
+ Details
Name: |
dei_CurrentFiscalYearEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:gMonthDayItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.
+ References
+ Details
Name: |
dei_DocumentFiscalPeriodFocus |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fiscalPeriodItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThis is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.
+ References
+ Details
Name: |
dei_DocumentFiscalYearFocus |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:gYearItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true only for a form used as an quarterly report.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 10-Q -Number 240 -Section 308 -Subsection a
+ Details
Name: |
dei_DocumentQuarterlyReport |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true only for a form used as a transition report.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Forms 10-K, 10-Q, 20-F -Number 240 -Section 13 -Subsection a-1
+ Details
Name: |
dei_DocumentTransitionReport |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.
+ References
+ Details
Name: |
dei_EntityCommonStockSharesOutstanding |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionIndicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ References
+ Details
Name: |
dei_EntityCurrentReportingStatus |
Namespace Prefix: |
dei_ |
Data Type: |
dei:yesNoItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityFilerCategory |
Namespace Prefix: |
dei_ |
Data Type: |
dei:filerCategoryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-T -Number 232 -Section 405
+ Details
Name: |
dei_EntityInteractiveDataCurrent |
Namespace Prefix: |
dei_ |
Data Type: |
dei:yesNoItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityShellCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicates that the company is a Smaller Reporting Company (SRC).
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntitySmallBusiness |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.3
Consolidated Balance Sheets (Unaudited) - USD ($)
|
Sep. 30, 2023 |
Dec. 31, 2022 |
CURRENT ASSETS |
|
|
Cash and cash equivalents |
$ 5,263
|
$ 3,865
|
Accounts receivable |
329,263
|
295,374
|
Inventories, net of $905,759 and $982,973 reserve, respectively |
467,155
|
686,383
|
Prepaid expenses and other current assets |
219,283
|
257,527
|
Total current assets |
1,020,964
|
1,243,149
|
Investment in equity securities |
77,918
|
63,638
|
Property and equipment, net |
91,409
|
103,351
|
Right of use asset operating leases |
159,424
|
282,095
|
Intangible assets, net |
252,404
|
317,308
|
TOTAL ASSETS |
1,602,119
|
2,009,541
|
CURRENT LIABILITIES |
|
|
Accounts payable |
1,062,565
|
637,238
|
Accrued employee compensation |
376,760
|
167,247
|
Accrued professional fees and other |
2,722,666
|
2,497,762
|
Accrued interest and dividends payable |
4,576,350
|
10,803,983
|
Deferred revenue |
253,152
|
58,242
|
Convertible debt, net of unamortized debt discounts of $744,393 and $455,517, respectively |
18,222,120
|
17,823,669
|
Other debt, net of unamortized discounts of $0 and $0, respectively |
2,030,510
|
1,638,969
|
Related party, net of unamortized debt discount of $514 and $7,915, respectively |
647,986
|
634,885
|
Right of use operating lease liability |
66,259
|
142,171
|
Total current liabilities |
29,958,368
|
34,404,166
|
LONG TERM LIABILITIES |
|
|
Long term debt |
162,522
|
150,000
|
Right of use operating lease liability long term |
71,287
|
139,924
|
Deferred revenue |
10,645
|
1,822
|
TOTAL LONG TERM LIABILITIES |
244,454
|
291,746
|
TOTAL LIABILITIES |
30,202,822
|
34,695,912
|
COMMITMENTS AND CONTINGENCIES (Note 4) |
|
|
STOCKHOLDERS’ DEFICIT |
|
|
Preferred stock, value |
100
|
1,098
|
Common stock, $.01 par value; 100,000,000 shares authorized; 23,399,945 and 13,682,910 shares issued and outstanding on September 30, 2023 and December 31, 2022, respectively |
234,000
|
136,829
|
Warrants to acquire common stock |
35,684,321
|
31,995,762
|
Additional paid-in capital |
93,973,646
|
69,006,145
|
Accumulated deficit |
(158,492,770)
|
(133,826,205)
|
TOTAL STOCKHOLDERS’ DEFICIT |
(28,600,703)
|
(32,686,371)
|
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT |
$ 1,602,119
|
$ 2,009,541
|
X |
- DefinitionWarrants to acquire common stock.
+ References
+ Details
Name: |
PBIO_WarrantsToAcquireCommonStock |
Namespace Prefix: |
PBIO_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionCarrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.19(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_AccountsPayableCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481990/310-10-45-2
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481990/310-10-45-9
+ Details
Name: |
us-gaap_AccountsReceivableNetCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionCarrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.20) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_AccruedProfessionalFeesCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(18)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_AdditionalPaidInCapital |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionSum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28
Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(12)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(8)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(18)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7
Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30
Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(11)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1
+ Details
Name: |
us-gaap_Assets |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionSum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28
Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7
+ Details
Name: |
us-gaap_AssetsCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- References
+ Details
Name: |
us-gaap_AssetsCurrentAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4
+ Details
Name: |
us-gaap_CashAndCashEquivalentsAtCarryingValue |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionRepresents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(19)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(15)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 942 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03.17) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1
Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.25) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_CommitmentsAndContingencies |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(22)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_CommonStockValue |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionThe portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_ConvertibleDebtCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_DeferredRevenueCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(26)(c)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_DeferredRevenueNoncurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionThis item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481664/323-10-45-1
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3
Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(10)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-25
+ Details
Name: |
us-gaap_EquityMethodInvestments |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionSum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph ((a)(1),(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482686/350-30-45-1
+ Details
Name: |
us-gaap_IntangibleAssetsNetExcludingGoodwill |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionSum of the carrying values as of the balance sheet date of (a) interest payable on all forms of debt, including trade payables, that has been incurred, and (b) dividends declared but unpaid on equity securities issued by the entity and outstanding (also includes dividends collected on behalf of another owner of securities that are being held by the entity). Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.20) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_InterestAndDividendsPayableCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_InventoryNet |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionSum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28
Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(14)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7
Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7
Reference 21: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30
Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.19-26) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_Liabilities |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(25)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1
Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3
Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28
Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(23)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1
Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(32)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_LiabilitiesAndStockholdersEquity |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionTotal obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28
Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7
Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7
Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.21) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_LiabilitiesCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- References
+ Details
Name: |
us-gaap_LiabilitiesCurrentAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of obligation due after one year or beyond the normal operating cycle, if longer.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7
Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7
Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(23)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 201.5-02(24)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 201.5-02(25)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 23: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 201.5-02(26)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_LiabilitiesNoncurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- References
+ Details
Name: |
us-gaap_LiabilitiesNoncurrentAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B
Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D
Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1
Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4
+ Details
Name: |
us-gaap_LongTermDebt |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as current.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1
+ Details
Name: |
us-gaap_OperatingLeaseLiabilityCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1
+ Details
Name: |
us-gaap_OperatingLeaseLiabilityNoncurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of lessee's right to use underlying asset under operating lease.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1
+ Details
Name: |
us-gaap_OperatingLeaseRightOfUseAsset |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount of liabilities classified as other, due within one year or the normal operating cycle, if longer.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.20) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_OtherLiabilitiesCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of long-term debt classified as other, payable within one year or the operating cycle, if longer.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(13)(a)(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_OtherLongTermDebtCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(21)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_PreferredStockValue |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_PrepaidExpenseAndOtherAssetsCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1
Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1
+ Details
Name: |
us-gaap_PropertyPlantAndEquipmentNet |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount of accumulated undistributed earnings (deficit).
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1
Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1
Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_RetainedEarningsAccumulatedDeficit |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2
Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3
Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28
Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2
+ Details
Name: |
us-gaap_StockholdersEquity |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- References
+ Details
Name: |
us-gaap_StockholdersEquityAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.3
Consolidated Balance Sheets (Unaudited) (Parenthetical) - USD ($)
|
Sep. 30, 2023 |
Dec. 31, 2022 |
Inventory valuation reserves |
$ 905,759
|
$ 982,973
|
Debt instrument, unamortized discount |
744,393
|
455,517
|
Other debt, unamortized discounts net. |
$ 0
|
$ 0
|
Common stock, par value |
$ 0.01
|
$ 0.01
|
Common stock, shares authorized |
100,000,000
|
100,000,000
|
Common stock, share,issued |
23,399,945
|
13,682,910
|
Common stock, shares, outstanding |
23,399,945
|
13,682,910
|
Series D Convertible Preferred Stock [Member] |
|
|
Preferred stock, par value |
$ 0.01
|
$ 0.01
|
Series G Convertible Preferred Stock [Member] |
|
|
Preferred stock, par value |
0.01
|
0.01
|
Series H Convertible Preferred Stock [Member] |
|
|
Preferred stock, par value |
0.01
|
0.01
|
Series H2 Convertible Preferred Stock [Member] |
|
|
Preferred stock, par value |
0.01
|
0.01
|
Series J Convertible Preferred Stock [Member] |
|
|
Preferred stock, par value |
0.01
|
0.01
|
Series K Convertible Preferred Stock [Member] |
|
|
Preferred stock, par value |
0.01
|
0.01
|
Series AA Convertible Preferred Stock [Member] |
|
|
Preferred stock, par value |
0.01
|
0.01
|
Series BB Convertible Preferred Stock [Member] |
|
|
Preferred stock, par value |
0.01
|
0.01
|
Series CC Convertible Preferred Stock [Member] |
|
|
Preferred stock, par value |
$ 0.01
|
$ 0.01
|
Convertible Debt [Member] |
|
|
Debt instrument, unamortized discount |
$ 744,393
|
$ 455,517
|
Related Party [Member] |
|
|
Debt instrument, unamortized discount |
$ 514
|
$ 7,915
|
X |
- DefinitionOther debt, unamortized discounts net.
+ References
+ Details
Name: |
PBIO_OtherDebtUnamortizedDiscountsNet |
Namespace Prefix: |
PBIO_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionFace amount or stated value per share of common stock.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_CommonStockParOrStatedValuePerShare |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_CommonStockSharesAuthorized |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_CommonStockSharesIssued |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2
Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1
Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_CommonStockSharesOutstanding |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionAmount, after accumulated amortization, of debt discount.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 45 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org//1943274/2147482925/835-30-45-1A
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8
Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D
+ Details
Name: |
us-gaap_DebtInstrumentUnamortizedDiscount |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount of valuation reserve for inventory.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 330 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SAB TOPIC 5.BB) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480581/330-10-S99-2
+ Details
Name: |
us-gaap_InventoryValuationReserves |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionFace amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_PreferredStockParOrStatedValuePerShare |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=PBIO_SeriesDConvertiblePreferredStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=PBIO_SeriesGConvertiblePreferredStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=PBIO_SeriesHConvertiblePreferredStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=PBIO_SeriesH2ConvertiblePreferredStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=PBIO_SeriesJConvertiblePreferredStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=PBIO_SeriesKConvertiblePreferredStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=PBIO_SeriesAAConvertiblePreferredStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=PBIO_SeriesBBConvertiblePreferredStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=PBIO_SeriesCCConvertiblePreferredStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleDebtMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.23.3
Consolidated Statements of Operations (Unaudited) - USD ($)
|
3 Months Ended |
9 Months Ended |
Sep. 30, 2023 |
Sep. 30, 2022 |
Sep. 30, 2023 |
Sep. 30, 2022 |
Revenue: |
|
|
|
|
Products, services, other |
$ 413,009
|
$ 144,032
|
$ 1,665,412
|
$ 1,122,169
|
Total revenue |
413,009
|
144,032
|
1,665,412
|
1,122,169
|
Costs and expenses: |
|
|
|
|
Cost of products and services |
229,457
|
126,203
|
844,684
|
742,707
|
Research and development |
288,345
|
262,370
|
1,004,437
|
716,685
|
Selling and marketing |
157,773
|
226,526
|
537,802
|
422,422
|
General and administrative |
1,030,243
|
892,293
|
5,290,564
|
2,591,644
|
Total operating costs |
1,705,818
|
1,507,392
|
7,677,487
|
4,473,458
|
Operating loss |
(1,292,809)
|
(1,363,360)
|
(6,012,075)
|
(3,351,289)
|
Other (expense) income: |
|
|
|
|
Interest expense, net |
(4,338,759)
|
(2,034,021)
|
(14,112,098)
|
(6,448,771)
|
Unrealized gain (loss) on investment in equity securities |
(5,965)
|
(8,675)
|
14,280
|
(8,047)
|
Gain (loss) on extinguishment of liabilities |
|
(1,054,122)
|
687,591
|
(1,809,249)
|
Other income (expense) |
7,588
|
(2,059)
|
11,820
|
(904)
|
Total other expense |
(4,337,136)
|
(3,098,877)
|
(13,398,407)
|
(8,266,971)
|
Net loss |
(5,629,945)
|
(4,462,237)
|
(19,410,482)
|
(11,618,260)
|
Deemed dividends on extension of warrants |
|
|
(3,626,950)
|
|
Preferred stock dividends |
(632,054)
|
(431,709)
|
(1,629,133)
|
(1,295,566)
|
Net loss attributable to common shareholders |
$ (6,261,999)
|
$ (4,893,946)
|
$ (24,666,565)
|
$ (12,913,826)
|
Basic net loss per share attributable to common shareholders |
$ (0.29)
|
$ (0.44)
|
$ (1.21)
|
$ (1.24)
|
Diluted net loss per share attributable to common shareholders |
$ (0.29)
|
$ (0.44)
|
$ (1.21)
|
$ (1.24)
|
Weighted average number of shares of common stock outstanding, basic |
21,716,950
|
11,131,742
|
20,337,229
|
10,429,817
|
Weighted average number of shares of common stock outstanding, diluted |
21,716,950
|
11,131,742
|
20,337,229
|
10,429,817
|
X |
- DefinitionDeemed dividends on extension of warrants.
+ References
+ Details
Name: |
PBIO_DeemedDividendsOnExtensionOfWarrants |
Namespace Prefix: |
PBIO_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionLoss On Extinguishment Of Liabilities.
+ References
+ Details
Name: |
PBIO_LossOnExtinguishmentOfLiabilities |
Namespace Prefix: |
PBIO_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.2(a),(d)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
+ Details
Name: |
us-gaap_CostOfGoodsAndServicesSold |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionTotal costs of sales and operating expenses for the period.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
+ Details
Name: |
us-gaap_CostsAndExpenses |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_CostsAndExpensesAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of unrealized gain (loss) on investment in debt and equity securities.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column D)(Footnote 4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column D)(Footnote 6)(f)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column D)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6
Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)(c)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(9)(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(7)(c)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(7)(c)(2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1
+ Details
Name: |
us-gaap_DebtAndEquitySecuritiesUnrealizedGainLoss |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1
Reference 16: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7
+ Details
Name: |
us-gaap_EarningsPerShareBasic |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1
Reference 15: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7
+ Details
Name: |
us-gaap_EarningsPerShareDiluted |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.4) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
+ Details
Name: |
us-gaap_GeneralAndAdministrativeExpense |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount of the cost of borrowed funds accounted for as interest expense.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483581/946-220-45-3
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(3)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3
Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04.9) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (210.5-03(11)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483013/835-20-50-1
+ Details
Name: |
us-gaap_InterestExpense |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4
Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30
Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B
Reference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31
Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7
Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A
Reference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B
Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1
+ Details
Name: |
us-gaap_NetIncomeLoss |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 5 -Subparagraph (SAB Topic 6.B) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-5
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10
Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-11
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B
+ Details
Name: |
us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.7) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
+ Details
Name: |
us-gaap_NonoperatingIncomeExpense |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_NonoperatingIncomeExpenseAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe net result for the period of deducting operating expenses from operating revenues.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
+ Details
Name: |
us-gaap_OperatingIncomeLoss |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount of income (expense) related to nonoperating activities, classified as other.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.9) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
+ Details
Name: |
us-gaap_OtherNonoperatingIncomeExpense |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe aggregate value of preferred stock dividends and other adjustments necessary to derive net income apportioned to common stockholders.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/recommendedDisclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 5 -Subparagraph (SAB Topic 6.B) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-5
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-11
Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1
+ Details
Name: |
us-gaap_PreferredStockDividendsAndOtherAdjustments |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 985 -SubTopic 20 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1
+ Details
Name: |
us-gaap_ResearchAndDevelopmentExpense |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4
+ Details
Name: |
us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_RevenuesAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe aggregate total amount of expenses directly related to the marketing or selling of products or services.
+ References
+ Details
Name: |
us-gaap_SellingAndMarketingExpense |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16
+ Details
Name: |
us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10
+ Details
Name: |
us-gaap_WeightedAverageNumberOfSharesOutstandingBasic |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.3
X |
- References
+ Details
Name: |
us-gaap_IncomeStatementAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicates product and service for revenue from satisfaction of performance obligation by transferring promised product and service to customer.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91
+ Details
Name: |
us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList |
Namespace Prefix: |
us-gaap_ |
Data Type: |
enum2:enumerationSetItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.3
Consolidated Statements of Cash Flows (Unaudited) - USD ($)
|
9 Months Ended |
Sep. 30, 2023 |
Sep. 30, 2022 |
CASH FLOWS FROM OPERATING ACTIVITIES: |
|
|
Net loss |
$ (19,410,482)
|
$ (11,618,260)
|
Adjustments to reconcile net loss to net cash used in operating activities: |
|
|
(Gain) on extinguishment of debt |
(687,591)
|
(10,000)
|
Non-cash lease expense |
122,671
|
82,001
|
Common stock and warrants issued for interest |
3,715,204
|
2,196,278
|
Depreciation and amortization |
84,341
|
67,985
|
Accretion of interest and amortization of debt discount |
3,213,622
|
1,777,863
|
Loss on extinguishment of accrued liabilities and debt |
|
1,809,249
|
Common stock and warrants issued for debt extension |
1,671,573
|
|
Preferred stock issued for debt extension |
2,683,600
|
|
Stock-based compensation expense |
1,706,420
|
128,984
|
(Gain)/Loss on investment in equity securities |
(14,280)
|
8,047
|
Common stock and warrants issued for services |
1,978,645
|
367,370
|
Preferred stock issued for services |
617,200
|
|
Changes in operating assets and liabilities: |
|
|
Accounts receivable |
(33,889)
|
(11,568)
|
Inventories |
219,228
|
(238,973)
|
Prepaid expenses and other assets |
38,244
|
204,141
|
Accounts payable |
425,327
|
80,130
|
Accrued employee compensation |
209,513
|
104,258
|
Operating lease liability |
(144,549)
|
(82,001)
|
Deferred revenue and other accrued expenses |
1,551,380
|
2,083,239
|
Net cash used in operating activities |
(2,053,823)
|
(3,051,257)
|
CASH FLOWS FROM INVESTING ACTIVITIES: |
|
|
Purchases of property plant and equipment |
(7,495)
|
(20,754)
|
Net cash used in investing activities |
(7,495)
|
(20,754)
|
CASH FLOWS FROM FINANCING ACTIVITIES: |
|
|
Sale of common stock for cash |
150,000
|
|
Proceeds from stock option exercises |
81,111
|
17,443
|
Net proceeds from convertible debt |
4,336,665
|
3,428,249
|
Net proceeds from non-convertible debt - third party |
2,043,681
|
1,815,000
|
Net proceeds from debt - related party |
159,186
|
762,500
|
Payments on convertible debt |
(2,462,269)
|
(1,086,946)
|
Payments on debt - related party |
(159,000)
|
(259,600)
|
Payments on non-convertible debt |
(2,086,658)
|
(1,506,066)
|
Net cash provided by financing activities |
2,062,716
|
3,170,580
|
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS |
1,398
|
98,569
|
CASH AND CASH EQUIVALENTS AT BEGINNING OF YEAR |
3,865
|
132,311
|
CASH AND CASH EQUIVALENTS AT END OF PERIOD |
5,263
|
230,880
|
CASH FLOWS SUPPLEMENTAL INFORMATION |
|
|
Interest paid in cash |
1,219,038
|
938,451
|
NON CASH TRANSACTIONS: |
|
|
Early adoption of ASU 2020-06 |
|
473,027
|
Common stock issued with debt |
1,293,270
|
512,593
|
Discount from warrants issued with debt |
|
93,576
|
Common stock issued in lieu of cash for dividend |
162,528
|
306,333
|
Preferred stock issued with debt |
539,487
|
|
Preferred stock dividends |
1,629,133
|
1,295,566
|
Conversion of preferred stock for common stock |
14,869
|
44
|
Conversion of debt, interest, preferred stock dividend for preferred stock |
10,017,212
|
|
Conversion of debt and interest into common stock |
509,033
|
350,500
|
Conversion of common stock for preferred stock |
6,240
|
|
Extension of warrants for Series AA preferred stock |
$ 3,626,950
|
|
X |
- DefinitionCommon stock and warrants issued for debt extension.
+ References
+ Details
Name: |
PBIO_CommonStockAndWarrantsIssuedForDebtExtension |
Namespace Prefix: |
PBIO_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionCommon stock and warrants issued for interest.
+ References
+ Details
Name: |
PBIO_CommonStockAndWarrantsIssuedForInterest |
Namespace Prefix: |
PBIO_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionCommon stock issued in lieu of cash for dividend
+ References
+ Details
Name: |
PBIO_CommonStockIssuedInLieuOfCashForDividend |
Namespace Prefix: |
PBIO_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionConversion of common stock for preferred stock.
+ References
+ Details
Name: |
PBIO_ConversionOfCommonStockForPreferredStock |
Namespace Prefix: |
PBIO_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionConversion of debt accrued interest and accrued dividend for preferred stock.
+ References
+ Details
Name: |
PBIO_ConversionOfDebtAccruedInterestAndAccruedDividendForPreferredStock |
Namespace Prefix: |
PBIO_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionConversion of debt into common stock.
+ References
+ Details
Name: |
PBIO_ConversionOfDebtIntoCommonStock |
Namespace Prefix: |
PBIO_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionConversion of preferred stock for common stock.
+ References
+ Details
Name: |
PBIO_ConversionOfPreferredStockForCommonStock |
Namespace Prefix: |
PBIO_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionDiscount from warrants issued with debt.
+ References
+ Details
Name: |
PBIO_DiscountFromWarrantsIssuedWithDebt |
Namespace Prefix: |
PBIO_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionEarly Asu 202006 Adoption.
+ References
+ Details
Name: |
PBIO_EarlyAsu202006Adoption |
Namespace Prefix: |
PBIO_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionExtension of warrants for series AA preferred stock.
+ References
+ Details
Name: |
PBIO_ExtensionOfWarrantsForSeriesAaPreferredStock |
Namespace Prefix: |
PBIO_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionLoss on extinguishment of accrued liabilities and debt.
+ References
+ Details
Name: |
PBIO_LossOnExtinguishmentOfAccruedLiabilitiesAndDebt |
Namespace Prefix: |
PBIO_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionNoncash preferred stock dividends.
+ References
+ Details
Name: |
PBIO_NoncashPreferredStockDividends |
Namespace Prefix: |
PBIO_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionPreferred stock issued for debt extension.
+ References
+ Details
Name: |
PBIO_PreferredStockIssuedForDebtExtension |
Namespace Prefix: |
PBIO_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionPreferred stock issued for services.
+ References
+ Details
Name: |
PBIO_PreferredStockIssuedForServices |
Namespace Prefix: |
PBIO_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionPreferred stock issued with debt.
+ References
+ Details
Name: |
PBIO_PreferredStockIssuedWithDebt |
Namespace Prefix: |
PBIO_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
+ Details
Name: |
us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4
+ Details
Name: |
us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 1 -SubTopic 230 -Topic 830 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1
+ Details
Name: |
us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount of realized gain (loss) on investment in debt and equity securities.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column C)(Footnote 4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column C)(Footnote 6)(e)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column C)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6
Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)(c)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(9)(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(7)(a)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(7)(a)(2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1
+ Details
Name: |
us-gaap_DebtAndEquitySecuritiesRealizedGainLoss |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1
+ Details
Name: |
us-gaap_DepreciationAndAmortization |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionDifference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 470 -SubTopic 50 -Section 40 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481303/470-50-40-2
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 470 -SubTopic 50 -Section 40 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481303/470-50-40-4
+ Details
Name: |
us-gaap_GainsLossesOnExtinguishmentOfDebt |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
+ Details
Name: |
us-gaap_IncreaseDecreaseInAccountsPayable |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
+ Details
Name: |
us-gaap_IncreaseDecreaseInAccountsReceivable |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount of increase (decrease) in accrued expenses, and obligations classified as other.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
+ Details
Name: |
us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
+ Details
Name: |
us-gaap_IncreaseDecreaseInInventories |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_IncreaseDecreaseInOperatingCapitalAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of increase (decrease) in obligation for operating lease.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(1) -SubTopic 20 -Topic 842 -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4
+ Details
Name: |
us-gaap_IncreaseDecreaseInOperatingLeaseLiability |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount of increase (decrease) in prepaid expenses, and assets classified as other.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
+ Details
Name: |
us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-17
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2
+ Details
Name: |
us-gaap_InterestPaidNet |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionFair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
+ Details
Name: |
us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24
+ Details
Name: |
us-gaap_NetCashProvidedByUsedInFinancingActivities |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24
+ Details
Name: |
us-gaap_NetCashProvidedByUsedInInvestingActivities |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25
+ Details
Name: |
us-gaap_NetCashProvidedByUsedInOperatingActivities |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4
Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30
Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B
Reference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31
Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7
Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A
Reference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B
Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1
+ Details
Name: |
us-gaap_NetIncomeLoss |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_NoncashInvestingAndFinancingItemsAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13
+ Details
Name: |
us-gaap_PaymentsToAcquirePropertyPlantAndEquipment |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14
+ Details
Name: |
us-gaap_ProceedsFromConvertibleDebt |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe cash inflow from the additional capital contribution to the entity.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14
+ Details
Name: |
us-gaap_ProceedsFromIssuanceOfCommonStock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount of cash inflow from issuance of long-term debt classified as other.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14
+ Details
Name: |
us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount of cash inflow from exercise of option under share-based payment arrangement.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2A -Subparagraph (a) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2A
+ Details
Name: |
us-gaap_ProceedsFromStockOptionsExercised |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15
+ Details
Name: |
us-gaap_RepaymentsOfConvertibleDebt |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount of cash outflow for the payment of debt classified as other, maturing after one year or the operating cycle, if longer.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15
+ Details
Name: |
us-gaap_RepaymentsOfOtherLongTermDebt |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount of noncash expense for share-based payment arrangement.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
+ Details
Name: |
us-gaap_ShareBasedCompensation |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe fair value of stock issued in noncash financing activities.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5
+ Details
Name: |
us-gaap_StockIssued1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
v3.23.3
Consolidated Statements of Changes in Stockholders' Deficit (Unaudited) - USD ($)
|
Preferred Stock [Member] |
Common Stock [Member] |
Warrant [Member] |
Additional Paid-in Capital [Member] |
Retained Earnings [Member] |
Total |
Beginning balance, value at Dec. 31, 2021 |
$ 1,099
|
$ 91,206
|
$ 31,715,154
|
$ 64,261,048
|
$ (118,277,468)
|
$ (22,208,961)
|
Balance, shares at Dec. 31, 2021 |
109,878
|
9,120,526
|
|
|
|
|
Stock-based compensation |
|
|
|
64,483
|
|
64,483
|
Series AA Preferred Stock dividend |
|
|
|
|
(432,149)
|
(432,149)
|
Issuance of common stock for services |
|
$ 370
|
|
77,330
|
|
77,700
|
Issuance of common stock for services, shares |
|
37,000
|
|
|
|
|
Stock warrants issued |
|
|
39,761
|
|
|
39,761
|
Conversion of debt and interest for common stock |
|
$ 1,402
|
|
349,098
|
|
350,500
|
Conversion of debt and interest for common stock, shares |
|
140,200
|
|
|
|
|
Issuance of common stock for dividends paid-in-kind |
|
$ 318
|
|
63,938
|
|
64,256
|
Issuance of common stock for dividends paid-in-kind, shares |
|
31,810
|
|
|
|
|
Issuance of common stock for interest paid-in-kind |
|
$ 5,581
|
|
1,167,877
|
|
1,173,458
|
Issuance of common stock for interest paid-in-kind, shares |
|
558,100
|
|
|
|
|
Common stock issued for debt extension |
|
$ 2,145
|
|
470,755
|
|
472,900
|
Common stock issued for debt extension, shares |
|
214,500
|
|
|
|
|
Stock issued with debt |
|
$ 920
|
|
141,560
|
|
142,480
|
Stock issued with debt, shares |
|
92,000
|
|
|
|
|
Net loss |
|
|
|
|
(4,239,685)
|
(4,239,685)
|
Early adoption of ASU 2020-06 |
|
|
|
(2,728,243)
|
2,255,216
|
(473,027)
|
Warrants issued for debt extension |
|
|
132,537
|
|
|
132,537
|
Warrants issued with debt |
|
|
87,436
|
|
|
87,436
|
Balance at Mar. 31, 2022 |
$ 1,099
|
$ 101,942
|
31,974,888
|
63,867,846
|
(120,694,086)
|
(24,748,311)
|
Balance, shares at Mar. 31, 2022 |
109,878
|
10,194,136
|
|
|
|
|
Beginning balance, value at Dec. 31, 2021 |
$ 1,099
|
$ 91,206
|
31,715,154
|
64,261,048
|
(118,277,468)
|
(22,208,961)
|
Balance, shares at Dec. 31, 2021 |
109,878
|
9,120,526
|
|
|
|
|
Net loss |
|
|
|
|
|
(11,618,260)
|
Extension of warrants for Series AA Preferred stock |
|
|
|
|
|
|
Balance at Sep. 30, 2022 |
$ 1,098
|
$ 122,207
|
31,995,762
|
67,041,489
|
(128,936,078)
|
(29,775,522)
|
Balance, shares at Sep. 30, 2022 |
109,874
|
12,220,611
|
|
|
|
|
Beginning balance, value at Mar. 31, 2022 |
$ 1,099
|
$ 101,942
|
31,974,888
|
63,867,846
|
(120,694,086)
|
(24,748,311)
|
Balance, shares at Mar. 31, 2022 |
109,878
|
10,194,136
|
|
|
|
|
Stock option exercise |
|
$ 253
|
|
17,190
|
|
17,443
|
Stock option exercise, shares |
|
25,279
|
|
|
|
|
Stock-based compensation |
|
|
|
32,074
|
|
32,074
|
Series AA Preferred Stock dividend |
|
|
|
|
(431,708)
|
(431,708)
|
Issuance of common stock for services |
|
$ 400
|
|
67,400
|
|
67,800
|
Issuance of common stock for services, shares |
|
40,000
|
|
|
|
|
Issuance of common stock for dividends paid-in-kind |
|
$ 865
|
|
150,156
|
|
151,021
|
Issuance of common stock for dividends paid-in-kind, shares |
|
86,464
|
|
|
|
|
Issuance of common stock for interest paid-in-kind |
|
$ 2,245
|
|
386,270
|
|
388,515
|
Issuance of common stock for interest paid-in-kind, shares |
|
224,500
|
|
|
|
|
Common stock issued for debt extension |
|
$ 1,064
|
|
190,239
|
|
191,303
|
Common stock issued for debt extension, shares |
|
106,400
|
|
|
|
|
Stock issued with debt |
|
$ 220
|
|
35,628
|
|
35,848
|
Stock issued with debt, shares |
|
22,000
|
|
|
|
|
Conversion of preferred stock for common stock |
$ (1)
|
$ 44
|
|
(43)
|
|
|
Conversion of preferred stock for common stock, shares |
(4)
|
4,400
|
|
|
|
|
Net loss |
|
|
|
|
(2,916,338)
|
(2,916,338)
|
Balance at Jun. 30, 2022 |
$ 1,098
|
$ 107,033
|
31,974,888
|
64,746,760
|
(124,042,132)
|
(27,212,353)
|
Balance, shares at Jun. 30, 2022 |
109,874
|
10,703,179
|
|
|
|
|
Stock-based compensation |
|
|
|
32,427
|
|
32,427
|
Series AA Preferred Stock dividend |
|
|
|
|
(431,709)
|
(431,709)
|
Issuance of common stock for services |
|
$ 1,135
|
|
166,240
|
|
167,375
|
Issuance of common stock for services, shares |
|
113,500
|
|
|
|
|
Stock warrants issued |
|
|
6,140
|
|
|
6,140
|
Issuance of common stock for dividends paid-in-kind |
|
$ 520
|
|
90,536
|
|
91,056
|
Issuance of common stock for dividends paid-in-kind, shares |
|
52,032
|
|
|
|
|
Issuance of common stock for interest paid-in-kind |
|
$ 3,895
|
|
630,410
|
|
634,305
|
Issuance of common stock for interest paid-in-kind, shares |
|
389,500
|
|
|
|
|
Common stock issued for debt extension |
|
$ 7,079
|
|
1,043,396
|
|
1,050,475
|
Common stock issued for debt extension, shares |
|
707,900
|
|
|
|
|
Stock issued with debt |
|
$ 2,545
|
|
331,720
|
|
334,265
|
Stock issued with debt, shares |
|
254,500
|
|
|
|
|
Net loss |
|
|
|
|
(4,462,237)
|
(4,462,237)
|
Warrants issued for services |
|
|
14,734
|
|
|
14,734
|
Balance at Sep. 30, 2022 |
$ 1,098
|
$ 122,207
|
31,995,762
|
67,041,489
|
(128,936,078)
|
(29,775,522)
|
Balance, shares at Sep. 30, 2022 |
109,874
|
12,220,611
|
|
|
|
|
Beginning balance, value at Dec. 31, 2022 |
$ 1,098
|
$ 136,829
|
31,995,762
|
69,006,145
|
(133,826,205)
|
(32,686,371)
|
Balance, shares at Dec. 31, 2022 |
109,874
|
13,682,910
|
|
|
|
|
Stock option exercise |
|
$ 1,176
|
|
79,935
|
|
81,111
|
Stock option exercise, shares |
|
117,552
|
|
|
|
|
Stock-based compensation |
|
|
|
1,430,244
|
|
1,430,244
|
Series AA Preferred Stock dividend |
|
|
|
|
(431,807)
|
(431,807)
|
Issuance of common stock for services |
|
$ 9,905
|
|
1,409,430
|
|
1,419,335
|
Issuance of common stock for services, shares |
|
990,500
|
|
|
|
|
Stock warrants issued |
|
|
61,609
|
|
|
61,609
|
Conversion of debt and interest for common stock |
|
$ 2,036
|
|
506,997
|
|
509,033
|
Conversion of debt and interest for common stock, shares |
|
203,613
|
|
|
|
|
Issuance of common stock for dividends paid-in-kind |
|
$ 737
|
|
101,698
|
|
102,435
|
Issuance of common stock for dividends paid-in-kind, shares |
|
73,694
|
|
|
|
|
Issuance of common stock for interest paid-in-kind |
|
$ 11,111
|
|
1,694,123
|
|
1,705,234
|
Issuance of common stock for interest paid-in-kind, shares |
|
1,111,081
|
|
|
|
|
Common stock issued for debt extension |
|
$ 5,682
|
|
1,024,257
|
|
1,029,939
|
Common stock issued for debt extension, shares |
|
568,200
|
|
|
|
|
Stock issued with debt |
|
$ 7,832
|
|
1,079,919
|
|
1,087,751
|
Stock issued with debt, shares |
|
783,150
|
|
|
|
|
Conversion of preferred stock for common stock |
$ (1,012)
|
$ 4,935
|
|
(3,923)
|
|
|
Conversion of preferred stock for common stock, shares |
(101,154)
|
493,540
|
|
|
|
|
Sale of Common Stock |
|
$ 400
|
|
99,600
|
|
100,000
|
Stock issued with debt, shares |
|
40,000
|
|
|
|
|
Net loss |
|
|
|
|
(6,857,834)
|
(6,857,834)
|
Balance at Mar. 31, 2023 |
$ 86
|
$ 180,643
|
32,057,371
|
76,428,425
|
(141,115,846)
|
(32,449,321)
|
Balance, shares at Mar. 31, 2023 |
8,720
|
18,064,240
|
|
|
|
|
Beginning balance, value at Dec. 31, 2022 |
$ 1,098
|
$ 136,829
|
$ 31,995,762
|
69,006,145
|
(133,826,205)
|
$ (32,686,371)
|
Balance, shares at Dec. 31, 2022 |
109,874
|
13,682,910
|
|
|
|
|
Stock option exercise, shares |
|
|
|
|
|
117,552
|
Net loss |
|
|
|
|
|
$ (19,410,482)
|
Extension of warrants for Series AA Preferred stock |
|
|
|
|
|
3,626,950
|
Balance at Sep. 30, 2023 |
$ 100
|
$ 234,000
|
$ 35,684,321
|
93,973,646
|
(158,492,770)
|
(28,600,703)
|
Balance, shares at Sep. 30, 2023 |
9,935
|
23,399,945
|
|
|
|
|
Beginning balance, value at Mar. 31, 2023 |
$ 86
|
$ 180,643
|
32,057,371
|
76,428,425
|
(141,115,846)
|
(32,449,321)
|
Balance, shares at Mar. 31, 2023 |
8,720
|
18,064,240
|
|
|
|
|
Stock-based compensation |
|
|
|
135,554
|
|
135,554
|
Series AA Preferred Stock dividend |
|
|
|
|
(565,272)
|
(565,272)
|
Issuance of common stock for services |
|
$ 1,475
|
|
170,925
|
|
172,400
|
Issuance of common stock for services, shares |
|
147,500
|
|
|
|
|
Conversion of debt and interest for common stock |
$ 4
|
|
|
10,017,208
|
|
10,017,212
|
Conversion of debt and interest for common stock, shares |
401
|
|
|
|
|
|
Issuance of common stock for dividends paid-in-kind |
|
$ 690
|
|
59,403
|
|
60,093
|
Issuance of common stock for dividends paid-in-kind, shares |
|
69,073
|
|
|
|
|
Issuance of common stock for interest paid-in-kind |
|
$ 10,340
|
|
1,286,106
|
|
1,296,446
|
Issuance of common stock for interest paid-in-kind, shares |
|
1,034,000
|
|
|
|
|
Common stock issued for debt extension |
|
$ 5,286
|
|
486,348
|
|
491,634
|
Common stock issued for debt extension, shares |
|
528,600
|
|
|
|
|
Stock issued with debt |
|
$ 3,021
|
|
153,653
|
|
156,674
|
Stock issued with debt, shares |
|
302,092
|
|
|
|
|
Conversion of preferred stock for common stock |
|
$ 444
|
|
(444)
|
|
|
Conversion of preferred stock for common stock, shares |
(44)
|
44,400
|
|
|
|
|
Sale of Common Stock |
|
$ 200
|
|
49,800
|
|
50,000
|
Stock issued with debt, shares |
|
20,000
|
|
|
|
|
Net loss |
|
|
|
|
(6,922,703)
|
(6,922,703)
|
Extension of warrants for Series AA Preferred stock |
|
|
3,626,950
|
|
(3,626,950)
|
|
Conversion of common stock to preferred stock |
$ 1
|
$ (6,240)
|
|
6,239
|
|
|
Conversion of common stock to preferred stock, shares |
62
|
(624,000)
|
|
|
|
|
Issuance of preferred stock for services |
$ 1
|
|
|
505,699
|
|
505,700
|
Issuance of preferred stock for services, shares |
57
|
|
|
|
|
|
Issuance of Preferred stock for debt extension |
$ 2
|
|
|
1,396,998
|
|
1,397,000
|
Preferred stock for debt extension |
185
|
|
|
|
|
|
Preferred stock issued with debt |
$ 1
|
|
|
539,486
|
|
539,487
|
Preferred stock issued for debt, share |
58
|
|
|
|
|
|
Balance at Jun. 30, 2023 |
$ 95
|
$ 195,859
|
35,684,321
|
91,235,400
|
(152,230,771)
|
(25,115,096)
|
Balance, shares at Jun. 30, 2023 |
9,439
|
19,585,905
|
|
|
|
|
Stock-based compensation |
|
|
|
140,622
|
|
140,622
|
Series AA Preferred Stock dividend |
|
|
|
|
(632,054)
|
(632,054)
|
Issuance of common stock for services |
|
$ 4,926
|
|
320,375
|
|
325,301
|
Issuance of common stock for services, shares |
|
492,500
|
|
|
|
|
Issuance of common stock for interest paid-in-kind |
|
$ 19,490
|
|
694,034
|
|
713,524
|
Issuance of common stock for interest paid-in-kind, shares |
|
1,949,040
|
|
|
|
|
Common stock issued for debt extension |
|
$ 2,500
|
|
147,500
|
|
150,000
|
Common stock issued for debt extension, shares |
|
250,000
|
|
|
|
|
Stock issued with debt |
|
$ 1,735
|
|
47,110
|
|
48,845
|
Stock issued with debt, shares |
|
173,500
|
|
|
|
|
Conversion of preferred stock for common stock |
$ (1)
|
$ 9,490
|
|
(9,489)
|
|
|
Conversion of preferred stock for common stock, shares |
(95)
|
949,000
|
|
|
|
|
Net loss |
|
|
|
|
(5,629,945)
|
(5,629,945)
|
Issuance of preferred stock for services |
|
|
|
111,500
|
|
111,500
|
Issuance of preferred stock for services, shares |
35
|
|
|
|
|
|
Issuance of Preferred stock for debt extension |
$ 6
|
|
|
1,286,594
|
|
1,286,600
|
Preferred stock for debt extension |
556
|
|
|
|
|
|
Balance at Sep. 30, 2023 |
$ 100
|
$ 234,000
|
$ 35,684,321
|
$ 93,973,646
|
$ (158,492,770)
|
$ (28,600,703)
|
Balance, shares at Sep. 30, 2023 |
9,935
|
23,399,945
|
|
|
|
|
X |
- DefinitionCumulative effect, period of adoption, adjustment.
+ References
+ Details
Name: |
PBIO_CumulativeEffectPeriodOfAdoptionAdjustment |
Namespace Prefix: |
PBIO_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionExtension of warrants for series AA preferred stock.
+ References
+ Details
Name: |
PBIO_ExtensionOfWarrantsForSeriesAaPreferredStock |
Namespace Prefix: |
PBIO_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionIssuance of common stock for dividends paid in kind.
+ References
+ Details
Name: |
PBIO_IssuanceOfCommonStockForDividendsPaidinkind |
Namespace Prefix: |
PBIO_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionIssuance of common stock for interest paid in kind.
+ References
+ Details
Name: |
PBIO_IssuanceOfCommonStockForInterestPaidinkind |
Namespace Prefix: |
PBIO_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionIssuance of common stock shares for dividends paid in kind.
+ References
+ Details
Name: |
PBIO_IssuanceOfCommonStockSharesForDividendsPaidinkind |
Namespace Prefix: |
PBIO_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIssuance of common stock shares for interest paid in kind.
+ References
+ Details
Name: |
PBIO_IssuanceOfCommonStockSharesForInterestPaidinkind |
Namespace Prefix: |
PBIO_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionPreferred stock issued for debt settlement.
+ References
+ Details
Name: |
PBIO_PreferredStockIssuedForDebtSettlement |
Namespace Prefix: |
PBIO_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionPreferred stock issued for debt shares.
+ References
+ Details
Name: |
PBIO_PreferredStockIssuedForDebtShares |
Namespace Prefix: |
PBIO_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionSale of common stock for cash.
+ References
+ Details
Name: |
PBIO_SaleOfCommonStockForCash |
Namespace Prefix: |
PBIO_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionSale of common stock for cash shares.
+ References
+ Details
Name: |
PBIO_SaleOfCommonStockForCashShares |
Namespace Prefix: |
PBIO_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionStock issued during period shares conversion of common stock to preferred stock.
+ References
+ Details
Name: |
PBIO_StockIssuedDuringPeriodSharesConversionOfCommonStockToPreferredStock |
Namespace Prefix: |
PBIO_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionStock issued during period shares conversion of convertible securities conversion of preferred stock for common stock.
+ References
+ Details
Name: |
PBIO_StockIssuedDuringPeriodSharesConversionOfConvertibleSecuritiesConversionOfPreferredStockForCommonStock |
Namespace Prefix: |
PBIO_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionStock issued during period shares issuance of preferred stock for debt extension.
+ References
+ Details
Name: |
PBIO_StockIssuedDuringPeriodSharesIssuanceOfPreferredStockForDebtExtension |
Namespace Prefix: |
PBIO_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionStock issued during period value conversion of common stock to preferred stock.
+ References
+ Details
Name: |
PBIO_StockIssuedDuringPeriodValueConversionOfCommonStockToPreferredStock |
Namespace Prefix: |
PBIO_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionConversion of preferred stock for common stock.
+ References
+ Details
Name: |
PBIO_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesConversionOfPreferredStockForCommonStock |
Namespace Prefix: |
PBIO_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionStock issued during period value issuance of preferred stock for debt extension.
+ References
+ Details
Name: |
PBIO_StockIssuedDuringPeriodValueIssuanceOfPreferredStockForDebtExtension |
Namespace Prefix: |
PBIO_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionStock issued during period value issued preferred stock for services.
+ References
+ Details
Name: |
PBIO_StockIssuedDuringPeriodValueIssuedPreferredStockForServices |
Namespace Prefix: |
PBIO_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionStock issued during period value shares preferred stock for services.
+ References
+ Details
Name: |
PBIO_StockIssuedDuringPeriodValueSharesPreferredStockForServices |
Namespace Prefix: |
PBIO_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionStock issued during period value warrants issued for services.
+ References
+ Details
Name: |
PBIO_StockIssuedDuringPeriodValueWarrantsIssuedForServices |
Namespace Prefix: |
PBIO_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionStock issued with debt shares.
+ References
+ Details
Name: |
PBIO_StockIssuedWithDebtShares |
Namespace Prefix: |
PBIO_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionWarrants issued for debt extension.
+ References
+ Details
Name: |
PBIO_WarrantsIssuedForDebtExtension |
Namespace Prefix: |
PBIO_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480483/718-10-35-2
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 20 -Section 55 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481089/718-20-55-13
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 20 -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481089/718-20-55-12
+ Details
Name: |
us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 470 -SubTopic 20 -Section 25 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481284/470-20-25-2
+ Details
Name: |
us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4
Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30
Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B
Reference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31
Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7
Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A
Reference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B
Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1
+ Details
Name: |
us-gaap_NetIncomeLoss |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionNumber of shares issued which are neither cancelled nor held in the treasury.
+ References
+ Details
Name: |
us-gaap_SharesOutstanding |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionValue of preferred stock and warrants for common stock issued.
+ References
+ Details
Name: |
us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionNumber of shares issued during the period as a result of the conversion of convertible securities.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1
Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29-30) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNumber of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.
+ References
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodSharesIssuedForServices |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNumber of new stock issued during the period.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1
Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodSharesNewIssues |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNumber of share options (or share units) exercised during the current period.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe gross value of stock issued during the period upon the conversion of convertible securities.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29-31) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionValue of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.
+ References
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodValueIssuedForServices |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionEquity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2
Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1
Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodValueNewIssues |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionValue of stock issued to shareholders as a dividend during the period.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29-31) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodValueStockDividend |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionValue of stock issued as a result of the exercise of stock options.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29-31) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2
Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3
Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28
Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2
+ Details
Name: |
us-gaap_StockholdersEquity |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
v3.23.3
Business Overview, Liquidity and Management Plans
|
9 Months Ended |
Sep. 30, 2023 |
Organization, Consolidation and Presentation of Financial Statements [Abstract] |
|
Business Overview, Liquidity and Management Plans |
1)
Business Overview, Liquidity and Management Plans
Pressure
BioSciences, Inc. (OTCQB: PBIO) (the “Company”) is a leader in the development & sale of innovative, enabling, high
pressure technology-based instruments, consumables, and services for the life sciences and other industries worldwide. Our products/services
are based on three patented, high-pressure platforms: (i) Ultra Shear Technology™ (“UltraShear™” or “UST™”),
(ii) BaroFold Technology™ (“BaroFold™”), and (iii) Pressure Cycling Technology™ (“PCT™”)
The
Company was founded on the belief that its PCT platform had the potential to significantly increase the quality of sample preparation
in both research and clinical settings. This premise has been well proven and PBI has been successful in installing its PCT platform
in the laboratories of key opinion leaders worldwide. Although developed subsequently, the Company now assesses that the commercial potential
for its UST platform across diverse multi-billion-dollar markets far exceeds the potential of the PCT platform. Consequently, in January
2022, PBI made the critical strategy decision to immediately shift its primary business focus from PCT to its innovative UST Platform.
The
UST Platform (8 issued patents) is based on the use of intense shear forces from ultra-high-pressure discharge (greater than
20,000 psi) through a dynamically controlled nano-gap valve under precisely controlled temperatures. UST has been shown to turn
hydrophobic (water-repelling) oil-based supplements (e.g., CBD, curcumin, astaxanthin), therapeutics (e.g., prednisone), and other
active ingredients (e.g., retinol) into long-term stable, effectively water-soluble, highly bioavailable, oil-in-water nanoemulsion
formulations. The Company first introduced the UST Platform in May 2022 through participation in several cannabis/health &
wellness meetings combined with a free-sample program. Executed agreements were subsequently announced with six CBD companies and
one cosmeceutical/skincare company for full commercialization in Q3 202 3.
The Company began shipping Nano CBD topical spray on October 2, 2023.
The
BaroFold Platform (14 issued patents) can be used to significantly improve the quality and production costs of protein biotherapeutics.
It employs high pressure manipulations for the disaggregation, unfolding and controlled refolding of proteins to their desired native
structures at yields and efficiencies not achievable using existing technologies. The BaroFold Platform has been shown to remove protein
aggregates in biotherapeutic drug manufacturing, thereby improving product efficacy, safety, and cost for both new-drug entities and
biosimilar (follow-on biologic) products. It is scalable and practical for standard manufacturing processes.
The
PCT Platform (17 issued patents) uses alternating cycles of hydrostatic pressure between ambient and ultra-high pressures to
control bio-molecular interactions safely and reproducibly in sample preparation (e.g., the critical steps performed by tens of thousands
of scientists worldwide prior to analytical measurements, such as cell lysis and biomolecule extraction from tissue samples). Our focus
for PCT is on making, GMP-compliant, next generation PCT-based Barocycler EXTREME system available globally to
biopharmaceutical drug manufacturers for use in the design, development, characterization, and quality control of biotherapeutic drugs.
We currently have over 350 PCT Systems placed in approximately 250 academic, government, pharmaceutical, and biotech research laboratories
worldwide. There are currently over 200 independent publications highlighting the advantages of using the PCT Platform in scientific
research & clinical laboratories.
|
X |
- References
+ Details
Name: |
us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480424/946-10-50-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480424/946-10-50-2
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//810/tableOfContent
Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//205/tableOfContent
+ Details
Name: |
us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.3
Going Concern
|
9 Months Ended |
Sep. 30, 2023 |
Organization, Consolidation and Presentation of Financial Statements [Abstract] |
|
Going Concern |
2)
Going Concern
The
accompanying financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the
realization of assets and the liquidation of liabilities in the normal course of business. However, we have experienced losses from operations and negative cash flows
from operationing business since our inception. As of September 30, 2023, we do not have adequate working capital resources to satisfy
our current liabilities and as a result, there is substantial doubt regarding our ability to continue as a going concern. We have been
successful in raising debt and equity capital in the past as described in Notes 5 and 6. In addition, we raised debt and equity capital
after September 30, 2023, as described in Note 7. We have financing efforts in place to continue to raise cash through debt and equity
offerings. Although we have successfully completed financings and reduced expenses in the past, we cannot assure you that our plans to
address these matters in the future will be successful. These financial statements do not include any adjustments that might result from
this uncertainty.
|
X |
- References
+ Details
Name: |
us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 40 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//205-40/tableOfContent
+ Details
Name: |
us-gaap_SubstantialDoubtAboutGoingConcernTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.3
Summary of Significant Accounting Policies
|
9 Months Ended |
Sep. 30, 2023 |
Accounting Policies [Abstract] |
|
Summary of Significant Accounting Policies |
3)
Summary of Significant Accounting Policies
Basis
of Presentation
The
unaudited interim financial statements of Pressure BioSciences, Inc. and its consolidated subsidiaries (collectively, the “Company”)
included herein have been prepared by the Company in accordance with the instructions to Form 10-Q and the rules and regulations of the
U.S. Securities and Exchange Commission. Under these rules and regulations, some information and footnote disclosures normally included
in financial statements prepared under accounting principles generally accepted in the United States of America have been shortened or
omitted. Management believes that all adjustments necessary for a fair statement of the financial position and the results of operations
for the periods shown have been made. All adjustments are normal and recurring. These financial statements should be read together with
the Company’s audited financial statements included in its Form 10-K for the fiscal year ended December 31, 2022. Operating results
for the nine months ended September 30, 2023 are not necessarily indicative of the final results that may be expected for the year ending
December 31, 2023.
Use
of Estimates
The
Company’s consolidated financial statements and accompanying notes are prepared in accordance with accounting principles generally
accepted in the United States of America, which require the use of estimates, judgements and assumptions that affect the reported amounts
of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the periods
presented. Global concerns about the COVID-19 pandemic have adversely affected, and we expect will continue to adversely affect, our
business, financial condition and results of operations including the estimates and assumptions made by management. Significant estimates
and assumptions include valuations of share-based awards, investments in equity securities and intangible asset impairment. Actual results
could differ from the estimates, and such differences may be material to the Company’s consolidated financial statements.
Recent
Accounting Pronouncements
In
August 2020, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2020-06, Accounting for Convertible
Instruments and Contracts in an Entity’s Own Equity, as part of its overall simplification initiative to reduce costs and complexity
of applying accounting standards while maintaining or improving the usefulness of the information provided to users of financial statements.
Among other changes, the new guidance removes the beneficial conversion separation model for convertible debt. As a result, after adopting
the guidance, entities will no longer account for beneficial conversion features in equity. The guidance is effective for public business
entities, other than small reporting company’s financial statements starting January 1, 2022, with early adoption permitted. The
Company is a small reporting company and early adopted the new guidance on January 1, 2022 using the modified retrospective approach
and recorded a cumulative effect of adoption equal to a $2,728,243 decrease in additional paid in capital and a $2,255,216 decrease in
accumulated deficit. There is no material impact to the Company’s statements of operations or cash flows as the result of the adoption
of ASU 2020-06.
In
June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses, which requires measurement and recognition of expected
credit losses for financial assets held. We adopted this new accounting guidance effective January 1, 2023. The adoption did not have
a material impact on our consolidated financial statements and disclosures and did not significantly impact the Company’s accounting
policies or estimation methods related to the allowance for doubtful accounts. The Company does not have any reserve for doubtful accounts
due to its customers being distributors, universities, research organizations and government agencies. In the past several years, all
its customers have paid in full without any need for a write-down.
Principles
of Consolidation
The
consolidated financial statements include the accounts of Pressure BioSciences, Inc., and its wholly owned subsidiaries PBI BioSeq, Inc.
and PBI Agrochem, Inc. All intercompany accounts and transactions have been eliminated in consolidation.
Revenue
Recognition
We
recognize revenue in accordance with FASB ASC 606, Revenue from Contracts with Customers, and ASC 340-40, Other Assets and
Deferred Costs—Contracts with Customers. Revenue is measured based on a consideration specified in a contract with a customer,
and excludes any sales incentives and amounts collected on behalf of third parties. We enter sales contracts that may consist of multiple
distinct performance obligations where certain performance obligations of the sales contract are not delivered in one reporting period.
We measure and allocate revenue according to ASC 606-10.
We
identify a performance obligation as distinct if both the following criteria are true: the customer can benefit from the good or service
either on its own or together with other resources that are readily available to the customer and the entity’s promise to transfer
the good or service to the customer is separately identifiable from other promises in the contract. Determining the standalone selling
price (“SSP”) and allocation of consideration from a contract to the individual performance obligations, and the appropriate
timing of revenue recognition, is the result of significant qualitative and quantitative judgments. Management considers a variety of
factors such as historical sales, usage rates, costs, and expected margin, which may vary over time depending upon the unique facts and
circumstances related to each performance obligation in making these estimates. While changes in the allocation of the SSP between performance
obligations will not affect the amount of total revenue recognized for a particular contract, any material changes could impact the timing
of revenue recognition, which would have a material effect on our financial position and result of operations. This is because the contract
consideration is allocated to each performance obligation, delivered or undelivered, at the inception of the contract based on the SSP
of each distinct performance obligation.
Taxes
assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction, that are
collected by the Company from a customer, are excluded from revenue.
Shipping
and handling costs associated with outbound freight after control over a product has transferred to a customer are accounted for as a
fulfillment cost and are included in cost of revenues as consistent with treatment in prior periods.
Our
current Barocycler® instruments require a basic level of instrumentation expertise to set-up for initial operation. To support a
favorable first experience for our customers, upon customer request, and for an additional fee, we will send a highly trained technical
representative to the customer site to install Barocyclers® that we sell, lease, or rent through our domestic sales force. The installation
process includes uncrating and setting up the instrument, followed by introductory user training. Our sales arrangements do not provide
our customers with a right of return. Any shipping costs billed to customers are recognized as revenue.
Most
of our instrument and consumable contracts contain pricing that is based on the market price for the product at the time of delivery.
Our obligations to deliver product volumes are typically satisfied and revenue is recognized when control of the product transfers to
our customers. Concurrent with the transfer of control, we typically receive the right to payment for the shipped product and the customer
takes on the significant risks and rewards of ownership of the product. Payment terms require customers to pay shortly after delivery
and do not contain significant financing components.
Revenue
from scientific services customers is recognized upon completion of each stage of service as defined in service agreements.
We
apply ASC 845, “Accounting for Non-Monetary Transactions”, to account for products and services sold through non-cash transactions
based on the fair values of the products and services involved, where such values can be determined. Non-cash exchanges would require
revenue to be recognized at recorded cost or carrying value of the assets or services sold if any of the following conditions apply:
|
a) |
The
fair value of the asset or service involved is not determinable. |
|
|
|
|
b) |
The
transaction is an exchange of a product or property held for sale in the ordinary course of business for a product or property to
be sold in the same line of business to facilitate sales to customers other than the parties to the exchange. |
|
|
|
|
c) |
The
transaction lacks commercial substance. |
We
recognize revenue for non-cash transactions at recorded cost or carrying value of the assets or services sold.
We
account for lease agreements of our instruments in accordance with ASC 842, Leases. We record revenue over the life of the lease term,
and we record depreciation expense on a straight-line basis over the thirty-six-month estimated useful life of the Barocycler® instrument.
The depreciation expense associated with assets under lease agreement is included in the “Cost of PCT products and services”
line item in our accompanying consolidated statements of operations. Many of our lease and rental agreements allow the lessee to purchase
the instrument at any point during the term of the agreement with partial or full credit for payments previously made. We pay all maintenance
costs associated with the instrument during the term of the leases.
Deferred
revenue represents amounts received from service contracts for which the related revenues have not been recognized because one or more
of the revenue recognition criteria have not been met. Revenue from service contracts is recorded ratably over the length of the contract.
Disaggregation
of revenue
In
the following table, revenue is disaggregated by primary geographical market, major product line, and timing of revenue recognition.
Schedule
of Disaggregation of Revenue
In thousands of US dollars ($) | |
Three Months Ended September 30, | | |
Nine Months Ended September 30, | |
Primary geographical markets | |
2023 | | |
2022 | | |
2023 | | |
2022 | |
North America | |
$ | 251 | | |
$ | 138 | | |
$ | 1,067 | | |
$ | 709 | |
Europe | |
| 76 | | |
| 13 | | |
| 130 | | |
| 61 | |
Asia | |
| 86 | | |
| (7 | ) | |
| 468 | | |
| 352 | |
| |
$ | 413 | | |
$ | 144 | | |
$ | 1,665 | | |
$ | 1,122 | |
| |
Three Months Ended September 30, | | |
Nine Months Ended September 30, | |
Major products/services lines | |
2023 | | |
2022 | | |
2023 | | |
2022 | |
Hardware | |
$ | 273 | | |
$ | 1 | | |
$ | 994 | | |
$ | 532 | |
Consumables | |
| 50 | | |
| 49 | | |
| 173 | | |
| 165 | |
Contract research services | |
| -1 | | |
| - | | |
| 35 | | |
| 125 | |
Sample preparation accessories | |
| 31 | | |
| 41 | | |
| 113 | | |
| 93 | |
Technical support/extended service contracts | |
| 34 | | |
| 41 | | |
| 123 | | |
| 94 | |
| |
| | | |
| | | |
| | | |
| | |
Agrochem Products | |
| 15 | | |
| 10 | | |
| 181 | | |
| 93 | |
Shipping and handling | |
| 11 | | |
| 2 | | |
| 38 | | |
| 20 | |
Other | |
| - | | |
| - | | |
| 8 | | |
| - | |
| |
$ | 413 | | |
$ | 144 | | |
$ | 1,665 | | |
$ | 1,122 | |
| |
Three Months Ended September 30, | | |
Nine Months Ended September 30, | |
Timing of revenue recognition | |
2023 | | |
2022 | | |
2023 | | |
2022 | |
Products transferred at a point in time | |
$ | 379 | | |
$ | 103 | | |
$ | 1,506 | | |
$ | 903 | |
Services transferred over time | |
| 34 | | |
| 41 | | |
| 159 | | |
| 219 | |
| |
$ | 413 | | |
$ | 144 | | |
$ | 1,665 | | |
$ | 1,122 | |
Contract
balances
Schedule
of Contract Balances
In thousands of US dollars ($) | |
September 30, 2023 | | |
December 31, 2022 | |
Receivables, which are included in ‘Accounts Receivable’ | |
$ | 329 | | |
$ | 295 | |
Contract liabilities (deferred revenue) | |
| 59 | | |
| 60 | |
Transaction
price allocated to the remaining performance obligations
The
following table includes estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied
(or partially unsatisfied) at the end of the reporting period.
Schedule
of Future Related to Performance Obligations
In thousands of US dollars ($) | |
2023 | | |
2024 | | |
Total | |
Extended warranty service | |
$ | 48 | | |
$ | 11 | | |
$ | 59 | |
All
consideration from contracts with customers is included in the amounts presented above.
Contract
Costs
The
Company recognizes the incremental costs of obtaining contracts as an expense when incurred if the amortization period of the assets
that the Company otherwise would have recognized is one year or less. These costs are included in selling, general, and administrative
expenses. The costs to obtain a contract are recorded immediately in the period when the revenue is recognized either upon shipment or
installation. The costs to obtain a service contract are considered immaterial when spread over the life of the contract so the Company
records the costs immediately upon billing.
Concentrations
Credit
Risk
Our
financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash, cash equivalents, and trade
receivables. We have cash investment policies which, among other things, limit investments to investment-grade securities. We perform
ongoing credit evaluations of our customers, and the risk with respect to trade receivables is further mitigated by the fact that many
of our customers are government institutions, large pharmaceutical and biotechnology companies, and academic laboratories.
The
following table illustrates the level of concentration as a percentage of total revenues during the three and nine months ended September
30, 2023 and 2022.
Schedule
of Customer Concentration Risk Percentage
| |
Three Months Ended September 30, | | |
Nine months Ended September 30, | |
| |
2023 | | |
2022 | | |
2023 | | |
2022 | |
Top five customers | |
| 80 | % | |
| 42 | % | |
| 49 | % | |
| 31 | % |
Federal agencies | |
| 18 | % | |
| 4 | % | |
| 5 | % | |
| 1 | % |
The
following table illustrates the level of concentration as a percentage of net accounts receivable balance as of September 30, 2023 and
December 31, 2022. The Top Five Customers category may include federal agency receivable balances if applicable.
| |
September 30, 2023 | | |
December 31, 2022 | |
Top five customers | |
| 80 | % | |
| 93 | % |
Federal agencies | |
| 22 | % | |
| 0 | % |
Product
Supply
In
recent years we utilized a contract assembler for our Barocycler® 2320EXT. They provided us with precision manufacturing services
that included management support services to meet our specific application and operational requirements. Among the services provided
to us were:
|
● |
CNC
Machining |
|
● |
Contract
Assembly & Kitting |
|
● |
Component
and Subassembly Design |
|
● |
Inventory
Management |
|
● |
ISO
certification |
Beginning
in July 2021, we brought the assembly of our Barocycler 2320EXT instruments in-house. This became necessary when our independent contract
assembler (CBM Industries) informed us that they were about to need 100% of their assembly space for one of their customers (one of the
largest life science instrument manufacturers in the U.S.). We worked with our notified body to gain approval to use both the CE and
CSA marks on the instrument, which we received during Q3 2021. Until further notice, we expect to continue to assemble our Barocycler
2320EXT instrument at our South Easton, MA location.
We
currently manufacture and assemble the Barocycler®, HUB440, HUB880, the SHREDDER SG3, and most of our consumables at our South Easton,
MA facility. We will regularly reassess the tradeoffs between in-house assembly versus the benefits of outsourced relationships for of
the entire Barocycler® product line, and future instruments.
Investment
in Equity Securities
As
of September 30, 2023, we held 100,250 shares of common stock of Nexity Global SA, (a Polish publicly traded company).
We
account for this investment in accordance with ASC 320 “Investments — Debt and Equity Securities.” ASC 320 requires
equity investments with readily determinable fair values to be measured at fair value with changes in fair value recognized in net income.
As
of September 30, 2023, our consolidated balance sheet reflected the fair value, determined on a recurring basis based on Level 1 inputs
of our investment in Nexity, to be $77,918. We recorded $14,280 as an unrealized gain during the nine months ended September 30, 2023
for changes in market value.
Computation
of Loss per Share
Basic
loss per share is computed by dividing loss available to common shareholders by the weighted average number of common shares outstanding.
Diluted loss per share is computed by dividing loss available to common shareholders by the weighted average number of common shares
outstanding plus additional common shares that would have been outstanding if dilutive potential common shares had been issued. For purposes
of this calculation, convertible preferred stock, common stock dividends, and warrants and options to acquire common stock, are all considered
common stock equivalents in periods in which they have a dilutive effect and are excluded from this calculation in periods in which these
are anti-dilutive to our net loss.
The
following table illustrates our computation of loss per share for the three and nine months ended September 30, 2023 and 2022:
Schedule
of Computation of Loss Per Share
| |
2023 | | |
2022 | | |
2023 | | |
2022 | |
| |
For the Three Months Ended September 30, | | |
For the Nine months Ended September 30, | |
| |
2023 | | |
2022 | | |
2023 | | |
2022 | |
Numerator: | |
| | | |
| | | |
| | | |
| | |
Net loss attributable to common shareholders | |
$ | (6,261,999 | ) | |
$ | (4,893,946 | ) | |
$ | (24,666,565 | ) | |
$ | (12,913,826 | ) |
Denominator for basic and diluted loss per share: | |
| | | |
| | | |
| | | |
| | |
Weighted average common stock shares outstanding | |
| 21,716,950 | | |
| 11,131,742 | | |
| 20,337,229 | | |
| 10,429,817 | |
Loss per common share - basic and diluted | |
$ | (0.29 | ) | |
$ | (0.44 | ) | |
$ | (1.21 | ) | |
$ | (1.24 | ) |
The
following table presents securities that could potentially dilute basic loss per share in the future. For all periods presented, the
potentially dilutive securities were not included in the computation of diluted loss per share because these securities would have been
anti-dilutive to our net loss. The Series D Convertible Preferred Stock, Series G Convertible Preferred Stock, Series H and H2 Convertible
Preferred Stock, Series J Convertible Preferred Stock, Series K Convertible Preferred Stock, Series AA Convertible Preferred Stock, Series
BB Convertible Stock and Series CC Convertible Preferred Stock are presented below as if they were converted into common shares according
to the conversion terms.
Schedule
of Anti-Dilutive Securities Excluded from Computation of Earnings Per Share
| |
As of September 30, | |
| |
2023 | | |
2022 | |
Stock options | |
| 3,420,754 | | |
| 1,307,822 | |
Convertible debt | |
| 7,417,906 | | |
| 6,471,034 | |
Common stock warrants | |
| 15,732,940 | | |
| 16,293,768 | |
Convertible preferred stock: | |
| | | |
| | |
Series D Convertible Preferred Stock | |
| 6,250 | | |
| 25,000 | |
Series G Convertible Preferred Stock | |
| - | | |
| 26,857 | |
Series H Convertible Preferred Stock | |
| - | | |
| 33,334 | |
Series H2 Convertible Preferred Stock | |
| - | | |
| 70,000 | |
Series J Convertible Preferred Stock | |
| - | | |
| 115,267 | |
Series K Convertible Preferred Stock | |
| - | | |
| 229,334 | |
Series AA Convertible Preferred Stock | |
| 8,601,000 | | |
| 8,645,000 | |
Series BB Convertible Preferred Stock | |
| 8,580,000 | | |
| - | |
Series CC Convertible Preferred Stock | |
| 4,010,000 | | |
| - | |
| |
| 47,768,850 | | |
| 33,217,416 | |
Accounting
for Stock-Based Compensation Expense
We
maintain equity compensation plans under which incentive stock options and non-qualified stock options are granted to employees, independent
members of our Board of Directors and outside consultants. We recognize stock-based compensation expense over the requisite service period
using the Black-Scholes formula to estimate the fair value of the stock options on the date of grant.
Determining
Fair Value of Stock Option Grants
The
following table summarizes the assumptions we utilized for grants of stock options to the three sub-groups of our stock option recipients
during the nine months ended September 30, 2023:
Summary of Assumptions for Grants of Stock Options
Assumptions | |
CEO, other Officers and Employees | |
Expected life | |
| 6.0 (yrs) | |
Expected volatility | |
| 130.5 | % |
Risk-free interest rate | |
| 3.90 | % |
Forfeiture rate | |
| 0 to 5.00 | % |
Expected dividend yield | |
| 0.0 | % |
Valuation
and Amortization Method - The fair value of each option award is estimated on the date of the grant using the Black-Scholes pricing
model based on certain assumptions. The estimated fair value of employee stock options is amortized to expense using the
straight-line method over the vesting period.
Expected
Term - The Company uses the simplified calculation of expected life, as the Company does not currently have sufficient historical
exercise data on which to base an estimate of the expected term. Using this method, the expected term is determined using the
average of the vesting period and the contractual life of the stock options granted.
Expected
Volatility - Expected volatility is based on the Company’s historical stock volatility data over the expected term of the award.
Risk-Free
Interest Rate - The Company bases the risk-free interest rate used in the Black-Scholes valuation method on the implied yield currently
available on U.S. Treasury zero-coupon issues with an equivalent remaining term.
Forfeitures
- The Company records stock-based compensation expense only for those awards that are expected to vest. The Company estimated a forfeiture
rate of 0% to 5% for awards granted based on historical experience and future expectations of options vesting. The Company used this
historical rate as our assumption in calculating future stock-based compensation expense.
All
of the outstanding non-qualified options had an exercise price that was at or above the Company’s common stock share price at time
of issuance.
The
Company recognized stock-based compensation expense of $140,622 and $32,427 for the three months ended September 30, 2023 and 2022, respectively.
The company recognized stock-based compensation expense of $1,706,420 and $128,984 for the nine months ended September 30, 2023 and 2022,
respectfully. The following table summarizes the effect of this stock-based compensation expense within each of the line items of our
costs and expenses within our Consolidated Statements of Operations:
Schedule
of Stock Based Compensation Expense
| |
For the Three Months Ended | | |
For the Nine Months Ended | |
| |
September 30, | | |
September 30, | |
| |
2023 | | |
2022 | | |
2023 | | |
2022 | |
Cost of sales | |
$ | 11,183 | | |
$ | 2,184 | | |
$ | 75,724 | | |
$ | 8,694 | |
Research and development | |
| 35,676 | | |
| 9,499 | | |
| 241,585 | | |
| 37,803 | |
Selling and marketing | |
| 17,150 | | |
| 4,583 | | |
| 102,675 | | |
| 18,166 | |
General and administrative | |
| 76,613 | | |
| 16,161 | | |
| 1,286,436 | | |
| 64,321 | |
Total stock-based compensation expense | |
$ | 140,622 | | |
$ | 32,427 | | |
$ | 1,706,420 | | |
$ | 128,984 | |
Due
to their short maturities, the carrying amounts for cash and cash equivalents, accounts receivable, accounts payable, accrued expenses
and debt approximate their fair value. The carrying amount of long-term debt approximates fair value due to interest rates that approximate
prevailing market rates.
Fair
Value Measurements
The
Company follows the guidance of FASB ASC Topic 820, “Fair Value Measurements and Disclosures” (“ASC 820”)
as it related to all financial assets and financial liabilities that are recognized or disclosed at fair value in the financial statements
on a recurring basis.
The
Company generally defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly
transaction between market participants at the measurement date (exit price). The Company uses a three-tier fair value hierarchy, which
classifies the inputs used in measuring fair values. These tiers include Level 1, defined as observable inputs such as quoted prices
for identical instruments in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly
or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring the
Company to develop its own assumptions. A slight change in an unobservable input like volatility could have a significant impact on fair
value measurement.
Financial
assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement.
The Company has determined that its financial assets are classified within Level 1 in the fair value hierarchy. The development of the
unobservable inputs for Level 3 fair value measurements and fair value calculations are the responsibility of the Company’s management.
The
following tables set forth the Company’s financial assets and liabilities that were accounted for at fair value on a recurring
basis as of September 30, 2023:
Schedule
of Assets and Liabilities Measured at Fair Value on Recurring Basis
| |
| | |
Fair value measurements at September 30, 2023 using: | |
| |
September 30, 2023 | | |
Quoted prices in active markets (Level 1) | | |
Significant other observable inputs (Level 2) | | |
Significant unobservable inputs (Level 3) | |
Equity Securities | |
$ | 77,918 | | |
$ | 77,918 | | |
| - | | |
| - | |
Total Financial Assets | |
$ | 77,918 | | |
$ | 77,918 | | |
$ | - | | |
$ | - | |
The
following tables set forth the Company’s financial assets and liabilities that were accounted for at fair value on a recurring
basis as of December 31, 2022:
| |
| | |
Fair value measurements at December 31, 2022 using: | |
| |
December 31, 2022 | | |
Quoted prices in active markets (Level 1) | | |
Significant other observable inputs (Level 2) | | |
Significant unobservable inputs (Level 3) | |
Equity Securities | |
| 63,638 | | |
| 63,638 | | |
| - | | |
| - | |
Total Financial Assets | |
$ | 63,638 | | |
$ | 63,638 | | |
$ | - | | |
$ | - | |
|
X |
- References
+ Details
Name: |
us-gaap_AccountingPoliciesAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for all significant accounting policies of the reporting entity.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483426/235-10-50-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 235 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//235/tableOfContent
+ Details
Name: |
us-gaap_SignificantAccountingPoliciesTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.3
Commitments and Contingencies
|
9 Months Ended |
Sep. 30, 2023 |
Commitments and Contingencies Disclosure [Abstract] |
|
Commitments and Contingencies |
4)
Commitments and Contingencies
Operating
Leases
The
Company accounts for its leases under ASC 842. The Company has elected to apply the short-term lease exception to leases of one year
or less. Our corporate office is currently located at 14 Norfolk Avenue, South Easton, Massachusetts 02375. We are currently paying $7,650
per month, on a lease extension, signed on December 5, 2022, that expires December 31, 2023, for our corporate office. We expanded our
space to include offices, warehouse and a loading dock on the first floor starting May 1, 2017 with a monthly rent increase already reflected
in the current payments.
We
extended our lease for our space in Medford, MA (the “Medford Lease”) from December 30, 2020 to December 30, 2023. The lease
required monthly payments of $7,282 subject to annual cost of living increases. The lease shall be automatically extended for additional
three years unless either party terminates at least nine months prior to the expiration of the current lease term.
The
Company accounted for the lease extension of our Medford Lease as a lease modification under ASC 842. At the effective date of modification,
the Company recorded an adjustment to the right-of-use asset and lease liability in the amount of $221,432 based on the net present value
of lease payments discounted using an estimated borrowing rate of 12%.
On
August 9, 2021, we entered into an operating lease agreement for our warehouse space in Sparks, NV (the “Sparks Lease”) for
the period from September 1, 2021 through September 30, 2026. The lease contains escalating payments during the lease period. The lease
can be extended for an additional three years if the Company provides notice at least six months prior to the expiration of the current
lease term.
The
Company accounted for the Sparks Lease as an operating lease under ASC 842. Upon the commencement of the lease, the Company recorded
a right-of-use asset and lease liability in the amount of $239,327 based on the net present value of lease payments discounted using
an estimated borrowing rate of 12%.
Following
is a schedule by years of future minimum rental payments required under operating leases with initial or remaining non-cancelable lease
terms in excess of one year as of September 30, 2023:
Schedule
of Future Minimum Rental Payments Required Under Operating Leases
Year | |
Total | |
October 1 – December 31, 2023 | |
$ | 15,887 | |
2024 | |
| 64,393 | |
2025 | |
| 66,969 | |
2026 | |
| 51,778 | |
Total future undiscounted lease payments | |
| 199,027 | |
Less imputed interest | |
| (61,481 | ) |
Present value of lease liabilities | |
$ | 137,546 | |
The
operating cash flows from the operating leases were $122,671 for the nine months ended September 30, 2023 and $82,001 for the nine months
ended September 30, 2022. The weighted-average remaining lease term (years) of the above leases is 2.59 year as of September 30, 2023.
Below
is a table for the right of use asset and the corresponding lease liability in the consolidated balance sheets:
Schedule
of Right of Use Asset and the Corresponding Lease Liability
Operating Leases | |
September 30, 2023 | | |
December 31, 2022 | |
Right of use asset | |
$ | 159,424 | | |
$ | 282,095 | |
Right of use liability, current | |
$ | 66,259 | | |
$ | 142,171 | |
Right of use liability, long term | |
$ | 71,287 | | |
$ | 139,924 | |
Total lease liability | |
$ | 137,546 | | |
$ | 282,095 | |
The
weighted-average discount rate is 12%.
The
Company had no financing leases during the nine months ended September 30, 2023 and 2022.
The
components of lease cost for operating leases for the nine months ended September 30, 2023 and 2022 are as follows:
Schedule
of Lease Cost for Operating Leases
| |
September 30, 2023 | | |
September 30, 2022 | |
Operating lease cost | |
$ | 153,290 | | |
$ | 152,193 | |
Short-term lease cost | |
| 110,205 | | |
| 123,514 | |
Total lease cost | |
$ | 263,495 | | |
$ | 275,707 | |
Battelle
Memorial Institute
In
December 2008, we entered into an exclusive patent license agreement with the Battelle Memorial Institute (“Battelle”).
The licensed technology is the subject of a patent application filed by Battelle in 2008 and relates to a method and a system for improving
the analysis of protein samples, including through an automated system utilizing pressure and a pre-selected agent to obtain a digested
sample in a significantly shorter period of time than current methods, while maintaining the integrity of the sample throughout the preparatory
process. In addition to royalty payments on net sales on “licensed products,” we are obligated to make minimum royalty payments
for each year that we retain the rights outlined in the patent license agreement and we are required to have our first commercial sale
of the licensed products within one year following the issuance of the patent covered by the licensed technology. After re-negotiating
the terms of the contract in 2013, the minimum annual royalty was $1,200 in 2014 and $2,000 in 2015; the minimum royalties were $3,000
in 2016, $4,000 in 2017 and $5,000 in 2018 and each calendar year thereafter during the term of the agreement.
Target
Discovery Inc.
In
March 2010, we signed a strategic product licensing, manufacturing, co-marketing, and collaborative research and development agreement
with Target Discovery Inc. (“TDI”), a related party. Under the terms of the agreement, we have been licensed by TDI
to manufacture and sell an innovative line of chemicals used in the preparation of tissues for scientific analysis (“TDI reagents”).
The TDI reagents were designed for use in combination with our pressure cycling technology. The companies believe that the combination
of PCT and the TDI reagents can fill an existing need in life science research for an automated method for rapid extraction and recovery
of intact, functional proteins associated with cell membranes in tissue samples. We did not incur any royalty obligation under this agreement
in 2023 or 2022.
In
April 2012, we signed a non-exclusive license agreement with TDI to grant the non-exclusive use of our pressure cycling technology. We
executed an amendment to this agreement on October 1, 2016 wherein we agreed to pay a monthly fee of $1,400 for the use of a lab bench,
shared space, and other utilities, and $2,000 per day for technical support services as needed. The agreement requires TDI to pay the
Company a minimum royalty fee of $60,000 in 2022 and $60,000 in 2023. For the nine months ended September 30, 2023 and September 30,
2022, the Company reported $55,400 and $65,100, respectively in TDI fees.
Severance
and Change of Control Agreements
Each
of Mr. Schumacher, and Drs. Ting, and Lazarev, executive officers of the Company, are entitled to receive a severance payment if terminated
by the Company without cause. The severance benefits would include a payment in an amount equal to one year of such executive officer’s
annualized base salary compensation plus accrued paid time off. Additionally, the officer will be entitled to receive medical and dental
insurance coverage for one year following the date of termination.
Each
of these executive officers, other than Mr. Schumacher, is entitled to receive a change of control payment in an amount equal to one
year of such executive officer’s annualized base salary compensation, accrued paid time off, and medical and dental coverage, in
the event of their termination upon a change of control of the Company. In the case of Mr. Schumacher, this payment would be equal to
two years of annualized base salary compensation, accrued paid time off, and two years of medical and dental coverage. The severance
payment is meant to induce the aforementioned executives to remain in the employ of the Company, in general, and particularly in the
occurrence of a change in control, as a disincentive to the control change.
|
X |
- References
+ Details
Name: |
us-gaap_CommitmentsAndContingenciesDisclosureAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for commitments and contingencies.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//450/tableOfContent
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 440 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 440 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//440/tableOfContent
+ Details
Name: |
us-gaap_CommitmentsAndContingenciesDisclosureTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.3
Debt
|
9 Months Ended |
Sep. 30, 2023 |
Debt Disclosure [Abstract] |
|
Debt |
5)
Debt
Convertible
Debt
On
various dates during the nine months ended September 30, 2023, the Company issued convertible notes for net proceeds of approximate total
of $4.3 million which contained varied terms and conditions as follows: a) 1-12 month maturity date; b) interest rates of 0-120%; c)
convertible to the Company’s common stock at issuance at a fixed rate of $2.50 or at variable conversion rates upon the Company’s
up-listing to NASDAQ or NYSE or an event of default. These notes were issued with shares of common stock that were fair valued at issuance
date. The aggregate relative fair value of the shares of common stock and preferred stock issued with the notes of $1,832,757 was
recorded as a debt discount to be amortized over the term of the notes. We also evaluated the convertible notes for derivative liability
treatment and determined that the notes did not qualify for derivative accounting treatment on September 30, 2023.
For
the nine months ended September 30, 2023, deferred financing costs and OID issued with the debt are $648,470 and the Company repaid
$2,462,269.
The
summary of specific terms of the convertible notes and outstanding balances as of September 30, 2023, and December 31, 2022, are listed
in the tables below. The convertible notes are from numerous parties and with original issue dates from July 2019 to September 2023
and maturity dates from July 2020 to September 2024. There are approximately $12.3 million of notes that are past due as of September
30, 2023.
Schedule
of Convertible Debts and Outstanding Balances
| |
September
30, 2023 | | |
December
31, 2022 | |
Holders | |
Interest
Rate | | |
Conversion
Price | | |
Principal | | |
Interest
Rate | | |
Conversion
Price | | |
Principal | |
Main Investor | |
| 10 | % | |
$ | 2.50
(1) | | |
$ | 8,586,750 | | |
| 10 | % | |
$ | 2.50
(1 | ) | |
$ | 9,393,150 | |
Others | |
| 0
to 24 | % | |
$ | 2.50
(2) or $7.50 | | |
| 10,379,763 | | |
| 0
to 24 | % | |
$ | 2.50
(2) or $7.50 |
| |
| 8,886,036 | |
Totals | |
| | | |
| | | |
| - | | |
| | | |
| | | |
| 18,279,186 | |
Discount | |
| | | |
| | | |
| 744,393 | | |
| | | |
| | | |
| 455,517 | |
Net | |
| | | |
| | | |
$ | 18,222,120 | | |
| | | |
| | | |
$ | 17,823,669 | |
Notes:
| (1) | Conversion
price of these note is $2.50
except for a note for $189,750,
which will be adjusted to, upon an Event of Default, the lower of (i) the conversion price or (ii) a 25%
discount to the 5-day average VWAP of the stock prior to default and $729,100 lower of (i) $2.50 or (ii) the conversion price of the
Series AA Preferred Stock as adjusted. These notes are secured by all assets of the company. |
| | |
| (2) | Conversion
price of these notes is $2.50 but also varies with one or more of these notes having the
following conversion adjustment: |
| a. | Notes
are convertible before maturity at $2.50 per share or mandatorily convertible when the Company
up-lists to the NASDAQ at the lower of $2.50 or the up-list price. |
| b. | Notes
are convertible upon an Event of Default at 75% multiplied by the lowest trading price for
the common stock during the five days prior to the conversion. |
| c. | Notes
are convertible at $2.50 per share except that following an Event of Default the conversion
price will be adjusted to 75% multiplied by the lowest trading price for the common stock
during the five days prior to the conversion. |
| d. | Notes
can be voluntary converted at lower of 1) $2.50/share; or 2) purchase price of stock sold
by PBI at a price lower than $2.50/share. In the event of default, these notes can be converted
at lower of 1) $2.50/share; 2) 30% discount to 5-day VWAP prior to date of default. |
| e. | Notes
can be voluntary converted at lower of 1) $2.50/share; or 2) purchase price of stock sold
by PBI at a price lower than $2.50/share. In the event of default, these notes can be converted
at lower of 1) $2.50/share; 2) 25% discount to 5-day VWAP prior to date of default. |
| f. | Conversion
price is lower of (i) $2.50 or (ii) the price per share that the Company last sold Common
Stock after the execution of an anti-dilution protection agreement. |
| g. | Note
can be converted at a Voluntary Conversion Price which is the lower of 1) $2.50/share; or
2) purchase price of stock sold by the Company at a price lower than $2.50 except that following
an Event of Default, the Holder shall have the right, with no further consent from the Borrower,
to convert notes which can be the lower of 1) the Voluntary Conversion Price, or 2) 70% of
the 5-day VWAP prior to conversion. |
| h. | Conversion
price is $2.50. If note is in default, it is $1. |
| i. | Notes
can be voluntarily converted before maturity at $2.50 per share. Lender retains the option
upon an Up-list to convert at the lower of $2.50 or 10% off Up-list price. |
| j. | Notes
can be converted at the lesser of $2.5 per share or 25% discount to the opening price of
the Company’s first day of trading on either Nasdaq or NYSE. In addition, if the Company
fails to pay the Note in cash on maturity date, the conversion price will be adjusted to
the lesser of (i) original conversion price or (ii) a 35% discount to the VWAP prior to each
conversion date. |
| k. | Some
notes are not convertible until 180 days from the date of issuance of the Note and following
an Event of Default will be convertible at the lowest trading price of the 20 days prior
to conversion. The loan with a principal balance of $950,000 as of September 30, 2023 is
guaranteed by the Company’s Chief Executive Officer, but the lender may only enforce
this guarantee after certain conditions have been met, specifically after (i) the occurrence
of an Event of Default (as defined in the Note), (ii) the failure of the Company to cure
the Default in 10 business days, and (iii) a failure by the Company to issue, or cause to
be issued, shares of its common stock upon submission by the lender of a notice of conversion. |
| l. | Some
notes can be converted at the lesser of $2.50 per share or 25% discount to the opening price
of the Company’s first day of trading on either Nasdaq or NYSE. In addition, if the
Company fails to pay the Note in cash on maturity date, the conversion price will be adjusted
to the lesser of original conversion price or the product of the VWAP of the common stock
for the 5 trading dates immediately prior to the maturity date multiplied by 0.75. |
For
the nine months ended September 30, 2023, the Company recognized amortization expense related to the debt discounts indicated above of
$2,621,523. The unamortized debt discounts as of September 30, 2023 related to the convertible notes amounted to $744,393.
As
of September 30, 2023, the principal balance that is secured by the assets of the Company’s subsidiary, PBI Agrochem, Inc. is $352,188.
Standstill
and Forbearance Agreements
In
recent years, the Company entered into Standstill and Forbearance Agreements with lenders who hold variable-rate convertible notes. Pursuant
to these agreements the lenders agreed to not convert any portion of their notes into shares of common stock at a variable rate. During
the nine months ended September 30, 2023, the Company settled one note with total principal of $302,484, leaving one final lender (three
notes) with total principal of $272,500 outstanding and incurred interest, penalties and fees of approximately $253,425 in connection
with the Standstill and Forbearance Agreements.
Convertible
Loan Modifications and Extinguishments
We
refinanced certain convertible loans during the nine months ended September 30, 2023 at substantially the same terms for extensions ranging
over a period of two to nine months. We amortized any remaining unamortized debt discount as of the modification date over the remaining,
extended term of the new loans. We applied ASC 470 of modification accounting to the debt instruments which were modified during the
quarter or those settled with new notes issued concurrently for the same amounts but different maturity dates. The terms such as the
interest rate, prepayment penalties, and default rates will be the same over the new extensions. According to ASC 470, an exchange of
debt instruments between or a modification of a debt instrument by a debtor and a creditor in a nontroubled debt situation is deemed
to have been accomplished with debt instruments that are substantially different if the present value of the cash flows under the terms
of the new debt instrument is at least 10 percent different from the present value of the remaining cash flows under the terms of the
original instrument. If the terms of a debt instrument are changed or modified and the cash flow effect on a present value basis is less
than 10 percent, the debt instruments are not considered to be substantially different and will be accounted for as modifications.
The
cash flows of new debt exceeded 10% of the remaining cash flows of the original debt on several loans. During the nine months ended September
30, 2023 we recorded gains on extinguishment of liabilities of approximately $0.7 million by calculating the difference of the
fair value of the new debt and the carrying value of the old debt. During the nine months ended September 30, 2023, the Company extended
17 loans totaling $3,917,898 and increased the principal to $4,067,898. The Company issued 1,346,800 shares of common stock and 741
shares of preferred stock for these extensions and increased principal.
Other
Debt
No
notes in Other Debt are past due as of September 30, 2023.
Schedule
of Other Debt
| |
September
30, 2023 | | |
December
31, 2022 | |
Holders | |
Interest
Rate | | |
Principal | | |
Interest
Rate | | |
Principal | |
Non-Convertible | |
| -(1 | ) | |
$ | 1,016,500 | | |
| -(1 | ) | |
$ | 878,809 | |
Merchant
debt (3) | |
| | | |
| 1,014,010 | | |
| | | |
| 760,160 | |
SBA
(2) | |
| 3.75 | % | |
| 162,522 | | |
| 3.75 | % | |
| 150,000 | |
Totals | |
| | | |
| 2,193,032 | | |
| | | |
$ | 1,788,969 | |
Discount | |
| | | |
| - | | |
| | | |
| - | |
Long
Term | |
| | | |
| 162,522 | | |
| | | |
| 150,000 | |
Short
Term | |
| | | |
$ | 2,030,510 | | |
| | | |
$ | 1,638,969 | |
Notes:
| (1) | Interest
varies from 1% to 10%. The maturity is between being past due and May 2, 2023. As of September
30, 2023, $861,500 of the non-convertible debt is past due. |
| (2) | The
Company entered a COVID-19 government loan in 2020, the Economic Injury Disaster Loan (or
“EIDL”). The Company’s EIDL loan, $150,000, accrues interest at 3.75% and
requires monthly payments of $731 for principal and interest beginning in December 2022.
The balance of the principal will be due in 30 years. In connection with the EIDL loan the
Company entered into a security agreement with the SBA, whereby the Company granted the SBA
a security interest in all of the Company’s right, title and interest in all of the
Company’s assets. During the nine months ended September 30, 2023, $14,719 interest
was deferred and added to principal on EIDL loan and the Company repaid $2,197 principal
on this loan. During the year ended December 31, 2020, the Company borrowed $367,039 (two-year
term and 1% interest rate per annum) under the Payroll Protection program (or “2020
PPP”). During the year ended December 31, 2021, the Company borrowed $367,039 through
a second Payroll Protection program (or “2021 PPP”) and extended the monthly
payment date on the EIDL to December 2022. In year 2021, both 2020 PPP and 2021 PPP was forgiven
by the United States and SBA. |
| (3) | During
the nine months ended September 30, 2023 and the year ended December 31, 2022 we signed various
Merchant Agreements which are secured by second position rights to all customer receipts
until the loan has been repaid in full and subject to interest rates of 4.1% - 100.9% per
month. Under the terms of these agreements, we received the disclosed Purchase Price and
agreed to repay the disclosed Purchase Amount, which is collected by the Merchant lenders
at the Daily Payment Rate. We accounted for the Merchant Agreements as loans under ASC 860
because while we provided rights to current and future receipts, we still had control over
the receipts. The difference between the Purchase Amount and the Purchase Price is imputed
interest that is recorded as interest expense when paid each day. The Company’s Chief
Executive Officer guarantees the Company’s performance of all representations, warranties,
and covenants made by the Company in the Agreement. For loans outstanding on September 30,
2023, the maturity dates ranged from June 26, 2023 to October 15, 2023. For loan outstanding
on December 31, 2022, the maturity dates ranged from April 4 to June 6, 2023. |
Related
Party Notes
Schedule
of Related Party Debt
| |
September 30, 2023 | | |
December 31, 2022 | |
Holders | |
Interest Rate | | |
Principal | | |
Interest Rate | | |
Principal | | |
Security | |
Officers & Directors | |
| -(1 | ) | |
$ | 522,450 | | |
| -(1 | ) | |
$ | 521,950 | | |
| Unsecured | |
Other Related Parties | |
| 12 | % | |
| 126,050 | | |
| 12 | % | |
| 120,850 | | |
| Unsecured | |
Totals | |
| | | |
| 648,500 | | |
| | | |
| 642,800 | | |
| | |
Discount | |
| | | |
| 514 | | |
| | | |
| 7,915 | | |
| | |
Net | |
| | | |
$ | 647,986 | | |
| | | |
$ | 634,885 | | |
| | |
Notes:
| (1) | Interest
varies from 12% to 120%. |
During
the nine months ended September 30, 2023, we received short-term convertible loans of $164,700 with $5,514 OID from related parties
and repaid $159,000 of related party loans. These notes bear interest of 12% to 120% and are due upon demand. All related party notes
are convertible at $2.50/share.
We
amortized $592,099
of debt discounts during the nine months ended September 30, 2023 for all non-convertible and related party notes. The total unamortized
discount for all non-convertible and related party convertible notes as of September 30, 2023, and December 31, 2022 was $514
and $7,915,
respectively.
|
X |
- References
+ Details
Name: |
us-gaap_DebtDisclosureAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(c)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 470 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//470/tableOfContent
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I
+ Details
Name: |
us-gaap_DebtDisclosureTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.3
Stockholders’ Deficit
|
9 Months Ended |
Sep. 30, 2023 |
Equity [Abstract] |
|
Stockholders’ Deficit |
6)
Stockholders’ Deficit
Preferred
Stock
We
are authorized to issue 1,000,000 shares of preferred stock with a par value of $0.01. Of the 1,000,000 shares of preferred stock, the
following is outstanding:
Schedule
of Preferred Stock Outstanding
| |
September 30, 2023 | | |
December 31, 2022 | |
Series D Convertible Preferred Stock, $.01 par value; 850 shares authorized; 75 shares issued and outstanding on September 30, 2023, and 300 shares issued and outstanding on December 31, 2022 (Liquidation value of $300,000) | |
$ | - | | |
$ | 3 | |
Series G Convertible Preferred Stock, $.01 par value; 240,000 shares authorized; no shares issued and outstanding on September 30, 2023 and 80,570 shares issued and outstanding on December 31, 2022 | |
| - | | |
| 806 | |
Series H Convertible Preferred Stock, $.01 par value; 10,000 shares authorized; no shares issued and outstanding on September 30, 2023 and 10,000 shares issued and outstanding on December 31, 2022 | |
| - | | |
| 100 | |
Series J Convertible Preferred Stock, $.01 par value; 6,250 shares authorized; no shares issued and outstanding on September 30, 2023 and 3,458 shares issued and outstanding on December 31, 2022 | |
| - | | |
| 35 | |
Series K Convertible Preferred Stock, $.01 par value; 15,000 shares authorized; no shares issued and outstanding on September 30, 2023 and 6,880 shares issued and outstanding on December 31, 2022 | |
| - | | |
| 68 | |
Series AA Convertible Preferred Stock, $.01 par value; 10,000 shares authorized; 8,601 shares issued and outstanding on September 30, 2023 and December 31, 2022, respectively | |
| 86 | | |
| 86 | |
Series BB Convertible Preferred Stock, $.01 par value; 1,000 shares authorized; 858 shares issued and outstanding on September 30, 2023 and no shares outstanding at December 31, 2022 | |
| 10 | | |
| - | |
Series CC Convertible Preferred Stock, $.01 par value; 2,000 shares authorized; 401 shares issued and outstanding on September 30, 2023 and no shares outstanding at December 31, 2022 | |
| 4 | | |
| - | |
Series H2 Convertible Preferred Stock, $.01 par value; 21 shares authorized; no shares issued and outstanding on September 30, 2023 and 21 shares issued and outstanding on December 31, 2022 | |
| - | | |
| - | |
Series A Junior Participating Preferred Stock, $.01 par value, 20,000 shares authorized, no shares outstanding | |
| - | | |
| - | |
Series A Convertible Preferred Stock, $.01 par value, 313,960 shares authorized, no shares outstanding | |
| - | | |
| - | |
Series B Convertible Preferred Stock, $.01 par value, 279,256 shares authorized, no shares outstanding | |
| - | | |
| - | |
Series C Convertible Preferred Stock, $.01 par value, 88,098 shares authorized, no shares outstanding | |
| - | | |
| - | |
Series E Convertible Preferred Stock, $.01 par value, 500 shares authorized, no shares outstanding | |
| - | | |
| - | |
Total Convertible Preferred Shares | |
$ | 100 | | |
$ | 1,098 | |
On
May 1, 2023, Pressure Biosciences, Inc. (the “Company”) filed Articles of Amendment to Restated Articles of Organization
(the “Amendment”) with the Secretary of the Commonwealth of Massachusetts to designate 1,000 shares of its Preferred Stock
as Series BB Convertible Preferred Stock, par value $0.01 per share (the “Series BB Preferred Stock”) and 2,000 shares of
Preferred Stock as Series CC Convertible Preferred Stock, par value $0.01 per share (the “Series CC Preferred Stock”). Each
of the Certificate of Designation of Series BB Convertible Preferred Stock (the “Series BB COD”) and Certificate of Designation
of Series CC Convertible Preferred Stock (the “Series CC COD”) filed with the Amendment set forth the terms and provisions
of the Series BB Preferred Stock and Series CC Preferred Stock, respectively.
Series
BB Preferred Stock
Rank.
The Series BB Preferred Stock ranks prior to the Company’s common stock, par value $0.01 per share (the “Common Stock”),
and subordinate to the Series AA and Series CC Preferred Stock, and to all other classes of classes and series of equity securities of
the Company, which by its terms does not rank on a parity with or senior to the Series BB Preferred, and all indebtedness of the Company.
Dividends.
The holders of shares of the Series BB Preferred Stock are not entitled to receive dividends.
Voting
Rights. The Series BB Preferred Stock has all of the same voting rights as the Common Stock. Each share of Series BB Preferred Stock.
The holders of Series BB Preferred Stock shall have the right to vote along with the holders of Common Stock in an amount equal to 10,000
votes for each share of Series BB Preferred Stock held.
Voluntary
Conversion. The holders of Series BB Preferred Stock have the right to convert its Series BB Preferred Stock into Common Stock at
a ratio of 10,000 shares of Common Stock for each share of Series BB Preferred Stock held, subject to adjustment as set forth in Section
4(e) of the Series BB COD.
Company
Forced Conversion. The Company has the right to cause the conversion of all shares of Series BB Preferred Stock into Common Stock
(“Forced Conversion”). Following the effectiveness of a registration statement permitting the resale of the Conversion Shares
held by holders of the Series BB Preferred Stock, the Company may effectuate a Forced Conversion if either of the following conditions
are satisfied: (i) the VWAP of the Common Stock shall equal or exceed 300% of $2.50 (with such dollar figure to be appropriately adjusted
for any stock dividend, stock split, stock combination or other similar transaction that affects the share price of the Common Stock)
for either 10 consecutive trading days, or 15 of 25 consecutive trading days immediately preceding the date of the Forced Conversion
Notice; or (ii) listing of the Common Stock on any national securities exchange (NYSE, NYSE American or Nasdaq). The Company shall not
have an obligation to register the Conversion Shares of the shares of Series BB Preferred Stock that are issued pursuant to any exchange
of previously issued securities.
Series
CC Preferred Stock
Rank.
The Series CC Preferred Stock ranks prior to the Common Stock, pari passu to the Series AA Preferred Stock, and prior to all other classes
and series of equity securities of the Company which by its terms does not rank on a parity with or senior to the Series CC Preferred
Stock (the “Junior Stock”). The Series CC Preferred Stock is subordinate to and ranks junior to all indebtedness of the Company.
Quarterly
Dividends. The holders of shares of the Series CC Preferred Stock are entitled to receive, out of funds legally available therefor,
dividends at an annual rate equal to 8% of the Liquidation Preference Amount (as defined below), calculated on the basis of a 360-day
year, consisting of twelve 30-day months, and shall accrue on a daily basis from April 24, 2023. Accrued and unpaid dividends shall compound
on a quarterly basis, and shall be, except as set forth in Section 2(b) of the Series CC COD, payable in cash. The first such dividend
payment shall be due and payable on April 30, 2023, with subsequent dividend payments due and payable on June 30, September 30, and December
31, 2023. Each year thereafter, dividend payments shall be due and payable on March 31, June 30, September 30, and December 31.
Junior
Stock Dividends. The Company shall not declare or pay any cash dividends on or make any other distributions with respect to or redeem,
purchase, or otherwise acquire for consideration, any shares of Junior Stock unless and until all accrued and unpaid dividends on the
Series CC Preferred Stock have been paid in full, subject to restrictions as set forth in Section 3(a) of the Series CC COD.
Class
Voting Rights. So long as more than ten percent (10%) of the Series CC Preferred Stock remain outstanding, the Company shall not,
and shall not permit any subsidiary to, without the affirmative vote or consent of the holders of at least 75% of the shares of the Series
CC Preferred Stock outstanding at the time, given in person or by proxy, either in writing or at a meeting, in which the holders of the
Series CC Preferred Stock vote separately as a class: (i) authorize, create, issue or increase the authorized or issued amount of any
class or series of stock, including but not limited to the issuance of any more shares of previously authorized Preferred Stock, ranking
prior to the Series CC Preferred Stock, with respect to the distribution of assets on liquidation, dissolution or winding up; (ii) amend,
alter or repeal the provisions of the Series CC Preferred Stock, whether by merger, consolidation or otherwise, so as to adversely affect
any right, preference, privilege or voting power of the Series CC Preferred Stock; (iii) repurchase, redeem or pay dividends on (whether
in cash, in kind, or otherwise), shares of Junior Stock; (iv) amend the Articles of Incorporation or By-Laws of the Company so as to
affect materially and adversely any right, preference, privilege or voting power of the Series CC Preferred Stock; (v) effect any distribution
with respect to Junior Stock or parity stock; (vi) reclassify the Company’s outstanding securities; or (vii) effect a transaction
with one or more persons or entities whereby such other persons or entities will own more than the 50% of the outstanding shares of Common
Stock following such transaction.
General
Voting Rights. Except with respect to transactions upon which the Series CC Preferred Stock shall be entitled to vote separately
as a class as set forth in “Class Voting Rights” above and except as otherwise required by Massachusetts law, the Series
CC Preferred Stock shall have no voting rights. The Common Stock into which the Series CC Preferred Stock is convertible shall, upon
issuance, have all of the same voting rights as the Common Stock.
Liquidation
Preference. In the event of the liquidation, dissolution or winding up of the affairs of the Company, whether voluntary or involuntary,
the holders of shares of the Series CC Preferred Stock then outstanding shall be entitled to receive, out of the assets of the Company
whether such assets are capital or surplus of any nature, an amount equal to $25,000.00 per share (the “Liquidation Preference
Amount”) of the Series CC Preferred Stock, on a pro rata and pari passu basis with any parity stock (the “Pari Passu Preferred
Stock”), together with all accrued but unpaid dividends, before any payment shall be made or any assets distributed to the holders
of the Common Stock or any other Junior Stock. If the assets of the Company are not sufficient to pay in full the Liquidation Preference
Amount payable to the holders of outstanding shares of the Series CC Preferred Stock and any series of preferred stock or any other class
of stock on a parity as to rights on liquidation, dissolution or winding up, with the Series CC Preferred Stock, then all of said assets
will be distributed among the holders of the Series CC Preferred Stock, the Pari Passu Preferred Stock and the other classes of stock
on a parity with the Series CC Preferred Stock, if any, ratably in accordance with the respective amounts that would be payable on such
shares if all amounts payable thereon were paid in full.
Voluntary
Conversion. The holders of Series CC Preferred Stock have the right to convert its Series CC Preferred Stock into a number of fully
paid and nonassessable shares of Common Stock (the “Conversion Shares”) equal to the quotient of (i) the Liquidation Preference
Amount of the shares of Series CC Preferred Stock being converted thereon divided by (ii) the Conversion Price then in effect as of the
date of the delivery by such holder of its notice of election to convert. The “Conversion Price” shall mean $2.50 per share,
subject to adjustment under Section 5(e) of the Series CC COD.
Company
Forced Conversion. The Company has the right to cause the conversion of all shares of Series CC Preferred Stock into Common Stock
(“Forced Conversion”). Following the effectiveness of a registration statement permitting the resale of the Conversion Shares
held by holders of the Series CC Preferred Stock the Company may effectuate a Forced Conversion if either of the following conditions
are satisfied as of the Forced Conversion Effective Date: (i) the VWAP of the Common Stock shall equal or exceed 300% of the Conversion
Price for either 10 consecutive trading days, or 15 of 25 consecutive trading days immediately preceding the date of the Forced Conversion
Notice; or (ii) listing of the Common Stock on any national securities exchange (NYSE, NYSE American or Nasdaq). The Company shall not
have an obligation to register the Conversion Shares of the shares of Series CC Preferred Stock that are issued pursuant to any exchange
of previously issued securities.
Conversion
Restriction. At no time may a holder of shares of Series CC Preferred Stock convert shares of the Series CC Preferred Stock if the
number of shares of Common Stock to be issued pursuant to such conversion would exceed, when aggregated with all other shares of Common
Stock owned by such holder at such time, the number of shares of Common Stock which would result in such holder beneficially owning (as
determined in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended, and the rules thereunder) in excess of
4.99% of all of the Common Stock outstanding at such time (the “Conversion Restriction”); provided, however, that a holder
may waive the Conversion Restriction by providing the Company with sixty-one (61) days’ notice that such holder is waiving the
Conversion Restriction.
During
the nine months ended September 30, 2023 the Company issued a total of 953 shares of Series BB restricted preferred stock and 401 shares
of Series CC restricted preferred stock to accredited investors and consultants, with the following detail:
| ● | 92
shares of Series BB preferred stock with a fair value of $617,200, for services rendered; |
| ● | 741
shares of Series BB preferred stock with a fair value of $2,683,600 for convertible debt
extensions; |
| ● | 58
shares of Series BB preferred stock with a fair value of $539,487 and issued with convertible
debt; |
| ● | 62
shares of Series BB preferred stock from the conversion of common stock to preferred stock; |
| ● | 95
shares of Series BB preferred stock was converted into common stock; |
| ● | 401
shares of Series CC preferred stock with a fair value of $10,017,212 for the conversion of
debt/accrued interest and dividends. |
Stock
Options and Warrants
At
the Company’s December 30, 2021 Special Meeting, the shareholder’s approved the 2021 Equity Incentive Plan (the “2021
Plan”) pursuant to which 3,000,000 shares of our common stock were reserved for issuance upon exercise of stock options or other
equity awards. Consistent with the Company’s existing 2013 Equity Incentive plan (the “2013 plan”), under the 2021
plan, we may award stock options, shares of common stock, and other equity interests in the Company to employees, officers, directors,
consultants, and advisors, and to any other persons the Board of Directors deems appropriate. As of September 30, 2023, options to acquire
3,420,754 shares were outstanding under these Plans.
As
of September 30, 2023, total unrecognized compensation cost related to the unvested stock-based awards was $963,322 , which is expected
to be recognized over weighted average period of 2.2 years. The aggregate intrinsic value associated with the options outstanding and
exercisable as of September 30, 2023, based on the September 30, 2023, closing stock price of $0.20, was $0.00.
The
following table summarizes information concerning options and warrants outstanding and exercisable:
Schedule
of Concerning Options and Warrants Outstanding and Exercisable
| |
Stock Options | | |
Warrants | | |
| | |
| |
| |
Weighted Average | | |
Weighted Average | | |
Total | |
| |
Shares | | |
price per share | | |
Shares | | |
price per share | | |
Shares | | |
Exercisable | |
Balance outstanding, December 31, 2022 | |
| 1,307,822 | | |
$ | 0.72 | | |
| 16,278,769 | | |
$ | 3.50 | | |
| 17,586,591 | | |
| 17,570,591 | |
Granted | |
| 2,230,484 | | |
| 1.50 | | |
| 100,000 | | |
| 3.50 | | |
| 2,330,484 | | |
| | |
Exercised | |
| (117,552 | ) | |
| 0.69 | | |
| - | | |
| - | | |
| (117,552 | ) | |
| | |
Expired | |
| - | | |
| - | | |
| (645,829 | ) | |
| 3.50 | | |
| (645,829 | ) | |
| | |
Forfeited | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| | |
Balance outstanding, September 30, 2023 | |
| 3,420,754 | | |
$ | 1.23 | | |
| 15,732,940 | | |
$ | 3.50 | | |
| 19,153,694 | | |
| 18,289,721 | |
As
of September 30, 2023, the 3,420,754 options outstanding have a $1.23 weighted average exercise price and 8.14 years of weighted average
remaining life for outstanding options and 7.75 years of weighted average remaining life for exercisable options. Of these options, 2,556,781
are currently exercisable.
On
April 13, 2023, the Board authorized a 3-year extension of common stock warrants held by Series AA preferred shares holders. Therefore,
8,897,603 warrants were extended with new expiration dates between May 2, 2026 to September 14, 2029. Based on a fair value computation,
this extension resulted in net incremental expense of $3,626,950, which was booked as an increase in the value of warrants and an increase
of the retained deficit.
As
of September 30, 2023, the warrants outstanding have a $3.50 weighted average exercise price and a 2.42 year weighted average remaining
life.
Common
Stock and Warrant Issuances
During
the nine months ended September 30, 2023, the Company accrued approximately $3,715,204 in interest expense for these obligations
to issue common stock. During the nine months ended September 30, 2022, the Company accrued $634,305 in interest expense for these
obligations to issue common stock.
During
the nine months ended September 30, 2023 the Company issued a total of 9,717,035 shares of restricted common stock and to accredited
investors and consultants, with the following detail:
|
● |
4,094,121
shares of common stock with a fair value of $3,715,204 to lenders for interest paid-in-kind; |
|
● |
1,630,500
shares with a fair value of $1,917,036 for services rendered; |
|
● |
203,613
shares with a fair value of $509,033 for conversions of debt principal and interest; |
|
● |
117,552
shares for stock option exercises (at an exercise price of $0.69 per share); |
|
● |
142,767
shares with a fair value of $162,528 for dividends paid-in-kind; |
|
● |
1,258,742
shares with a fair value of $1,293,270 for common stock issued with convertible debt; |
|
● |
1,346,800
shares with a fair value of $1,671,573 for convertible debt extensions; |
|
● |
60,000
shares with a fair value of $150,000 for sale of common, and |
|
● |
1,486,940
shares for the conversion of preferred stock to common stock. |
During
the nine months ended September 30, 2023, the Company issued 100,000 warrants (four-year term at a $3.50 exercise price) to acquire common
stock at a fair value of $61,609 to a consultant for professional services.
During
the nine months ended September 30, 2022, we issued 3,100,085
shares of restricted common stock to accredited
investors and consultants, 140,200
shares with a fair value of $350,500
for conversions of debt principal and interest
for common stock, 1,172,100
of the shares with a fair value of $2,196,278
were issued for interest paid-in-kind, 190,500
of the shares with a fair value of $312,875
were issued for services rendered,170,306
shares with a fair value of $306,333
for dividends paid-in-kind, 368,500
shares with a fair value $512,593
for new convertible debt issuances, 25,279
shares with a fair value of $17,433
from a stock option exercise, 1,028,800
shares with a fair value of $1,714,678
for debt extension and shareholders converted
shares of series AA convertible preferred stock into 4,400
shares of common stock
During
the nine months ended September 30, 2022, we issued 277,500
warrants (three-year to five-year terms at a $3.50
exercise price) to acquire common stock at a total fair value of $280,608
to a lender in conjunction with the signing of new convertible loans, a vendor for services rendered and for debt
extension.
|
X |
- References
+ Details
Name: |
us-gaap_EquityAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for equity.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481004/946-505-50-6
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480237/815-40-50-6
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(e)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//505/tableOfContent
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 16 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18
Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18
+ Details
Name: |
us-gaap_StockholdersEquityNoteDisclosureTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.3
Subsequent Events
|
9 Months Ended |
Sep. 30, 2023 |
Subsequent Events [Abstract] |
|
Subsequent Events |
7)
Subsequent Events
From
October 1, 2023, through November 10, 2023, the Company issued seven (7) convertible loan with a principal balance of $439,000.
The terms of the convertible notes were 15 days to 12 months with interest rates of 10-120%
and convertible into the Company’s common stock at a fixed rate of $2.50 per
share. In this time the Company also issued 278,500 shares
of common stock for new convertible debt loans in the third quarter, 455,350 shares
of common stock for accrued interest paid-in-kind, 310,000 shares of common stock for debt extensions, 505,000 shares
of common stock from the conversion of Series BB preferred stock, 145,809 shares
of common stock for Series AA preferred dividends and 40 Series
BB preferred stock for professional services.
On
October 18, 2023, the Board of Directors (the “Board”) of Pressure BioSciences, Inc. (the “Company”) approved
an amendment (the “Amendment”) to the Pressure BioSciences, Inc. 2021 Equity Incentive Plan (the “Plan”). The
Plan originally provided that no one person could be granted awards pursuant to the Plan during any one fiscal year to purchase more
than 300,000 shares of the Company’s common stock, par value $0.01 per share (the “Common Stock”). Pursuant to the
amendment, the yearly limit for any one person was raised to 500,000 shares of Common Stock.
On
the same date, the Board granted a total of 1,500,000 stock options to a number of employees, consultants and the four members of the
Board with each option having an exercise price of $0.25 per share. Each award of options expires on October 18, 2033. The options for
the members of the Board vest in equal amounts over twelve (12) months. The options for Mr. Schumacher and Drs. Ting and Lazarev were
each vested 25% on the date of issuance and 25% of the options vest each year for the next three (3) years.
In
addition, on the same date, the Board approved the repricing of all outstanding options (including those held by the Board members and
the named executive officers) to $0.25. The previous exercise prices of the outstanding stock options held by the Board members and the
named executive officers ranged from $0.69 to $1.50.
ITEM
2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
CAUTIONARY
NOTE REGARDING FORWARD-LOOKING STATEMENTS
This
Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as
amended (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”).
In some cases, forward-looking statements are identified by terms such as “may,” “will,” “should,”
“could,” “would,” “expects,” “plans,” “anticipates,” “believes,”
“estimates,” “projects,” “predicts,” “potential” and similar expressions intended to
identify forward-looking statements. Such statements include, without limitation, statements regarding:
|
● |
our
need for, and our ability to raise, additional equity or debt financing on acceptable terms, if at all; |
|
● |
our
need to take additional cost reduction measures, cease operations or sell our operating assets, if we are unable to obtain sufficient
additional financing; |
|
● |
our
belief that we will have sufficient liquidity to finance normal operations for the foreseeable future; |
|
● |
the
options we may pursue in light of our financial condition; |
|
● |
the
potential applications for Ultra Shear Technology (UST); |
|
● |
the
potential applications of the BaroFold high-pressure protein refolding and disaggregation technology |
|
● |
the
amount of cash necessary to operate our business; |
|
● |
the
anticipated uses of grant revenue and the potential for increased grant revenue in future periods; |
|
● |
our
plans and expectations with respect to our continued operations; |
|
● |
the
expected number of Pressure Cycling Technology (“PCT”) and Constant Pressure (“CP”) based units that we believe
will be installed and the expected revenues from the sale of consumable products, extended service contracts, and biopharma contract
services; |
|
● |
our
belief that PCT has achieved initial market acceptance in the mass spectrometry and other markets; |
|
● |
the
expected development and success of new instrument and consumables product offerings; |
|
● |
the
potential applications for our instrument and consumables product offerings; |
|
● |
the
expected expenses of, and benefits and results from, our research and development efforts; |
|
● |
the
expected benefits and results from our collaboration programs, strategic alliances and joint ventures; |
|
● |
our
expectations of the results of our development activities funded by government research grants; |
|
● |
the
potential size of the market for biological sample preparation, biopharma contract services and Ultra Shear Technology; |
|
● |
general
economic conditions; |
|
● |
the
anticipated future financial performance and business operations of our company; |
|
● |
our
reasons for resources expended in the market for genomic, proteomic, lipidomic and small molecule sample preparation; |
|
● |
the
importance of mass spectrometry as a laboratory tool; |
|
● |
the
advantages of PCT over other current technologies as a method of biological sample preparation and protein characterization in biomarker
discovery, forensics, and histology, as well as for other applications; |
|
● |
the
capabilities and benefits of our PCT Sample Preparation System, consumables and other products; |
|
● |
our
belief that laboratory scientists will achieve results comparable with those reported to date by certain research scientists who
have published or presented publicly on PCT and our other products and services; |
|
● |
our
ability to retain our core group of scientific, administrative and sales personnel; and |
|
● |
our
ability to expand our customer base in sample preparation and for other applications of PCT, as well as for our other products and
services in both the BaroFold and Ultra Shear Technology areas. |
These
forward-looking statements are only predictions and involve known and unknown risks, uncertainties and other factors that may cause our
actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity,
performance or achievements, expressed or implied, by such forward-looking statements. Also, these forward-looking statements represent
our estimates and assumptions only as of the date of this Quarterly Report on Form 10-Q. Except as otherwise required by law, we expressly
disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statement contained in this
Quarterly Report on Form 10-Q to reflect any change in our expectations or any change in events, conditions or circumstances on which
any of our forward-looking statements are based. Factors that could cause or contribute to differences in our future financial and other
results include those discussed in the risk factors set forth in Part I, Item 1A of our Annual Report on Form 10-K for the year ended
December 31, 2022 and in this Report. We qualify all of our forward-looking statements by these cautionary statements.
Pressure
BioSciences, Inc. (OTCQB: PBIO) (the “Company”) is a leader in the development & sale of innovative, enabling, high
pressure technology-based instruments, consumables, and services for the life sciences and other industries worldwide. Our products/services
are based on three patented, high-pressure platforms: (i) Ultra Shear Technology™ (“UltraShear™” or “UST™”),
(ii) BaroFold Technology™ (“BaroFold™”), and (iii) Pressure Cycling Technology™ (“PCT™”)
The
Company was founded on the belief that its PCT platform had the potential to significantly increase the quality of sample preparation
in both research and clinical settings. This premise has been well proven and PBI has been successful in installing its PCT platform
in the laboratories of key opinion leaders worldwide. Although developed subsequently, the Company now assesses that the commercial potential
for its UST platform across diverse multi-billion dollar markets far exceeds the potential of the PCT platform. Consequently, in January
2022, PBI made the critical strategy decision to immediately shift its primary business focus from PCT to its innovative UST Platform.
The
UST Platform (8 issued patents) is based on the use of intense shear forces from ultra-high pressure discharge (greater than
20,000 psi) through a dynamically-controlled nano-gap valve under precisely controlled temperatures. UST has been shown to turn hydrophobic
(water-repelling) oil-based supplements (e.g., CBD, curcumin, astaxanthin), therapeutics (e.g., prednisone), and other active ingredients
(e.g., retinol) into long-term stable, effectively water-soluble, highly bioavailable, oil-in-water nanoemulsion formulations. The Company
began early commercial introduction of the UST Platform in May 2022, and executed agreements were subsequently announced with three CBD
companies and one cosmeceutical/skincare company for commercialization in Q4 2022.
The
BaroFold Platform (14 issued patents) can be used to significantly improve the quality and production costs of protein biotherapeutics.
It employs high-pressure manipulations for the disaggregation, unfolding and controlled refolding of proteins to their desired native
structures at yields and efficiencies not achievable using existing technologies. The BaroFold Platform has been shown to remove protein
aggregates in biotherapeutic drug manufacturing, thereby improving product efficacy, safety, and cost for both new-drug entities and
biosimilar (follow-on biologic) products. It is scalable and practical for standard manufacturing processes.
The
PCT Platform (17 issued patents) uses alternating cycles of hydrostatic pressure between ambient and ultra-high pressures to
control bio-molecular interactions safely and reproducibly in sample preparation (e.g., the critical steps performed by tens of thousands
of scientists worldwide prior to analytical measurements, such as cell lysis and biomolecule extraction from tissue samples). Our focus
for PCT is on making our, GMP-compliant, next generation PCT-based Barocycler EXTREME system available globally to
biopharmaceutical drug manufacturers for use in the design, development, characterization, and quality control of biotherapeutic drugs.
We currently have over 350 PCT Systems placed in approximately 225 academic, government, pharmaceutical, and biotech research laboratories
worldwide. There are currently over 200 independent publications highlighting the advantages of using the PCT Platform in scientific
research & clinical laboratories.
2023
Key Accomplishments
From
January 1, 2023 to September 30, 2023, we announced the following key accomplishments:
| ● | September
22: PBIO’s partner Veterans Service Team increases existing purchase order by 10X
for bottles of UltraShear Nano-CBD topical spray, effective immediately. |
| ● | September
21: PBIO’s fulfillment of UltraShear Nano-CBD orders is underway; customer shipments
begin first week of October |
| ● | September
8: PBIO’s Barofold technology achieves pivotal equipment sale and begins scale-up
in service to leading global contract development and manufacturing organization. |
| ● | August
30: PBIO provides second progress report on UltraShear Nano-CBD Launch: “Drive
to 420”. |
| ● | August
22: PBIO reports Q22023 financial results, provides business update, and offers guidance. |
| ● | August
9: PBIO reports strongly accelerating UltraShear Nano-CBD orders. |
| ● | July
26: PBIO and master distributor Canopy CBD Farms announce major increase in sales pipeline. |
| ● | July
25: PBIO to evaluate Company’s patented UltraShear process to extend shelf-life
of fresh produce. |
| ● | July
17: Company’s UltraShear Nano-CBD commercial roll-out program enters rapid expansion
phase 2. |
| ● | July
10: Company announces Nano-CBD topical spray distribution agreement with Crème
de Canna. |
| ● | July
6: Key academic publication further validates PBIO’s UltraShear platforms’
impact in clean-label foods. |
| ● | July
5: PBIO partners with Somalab Int’l for development & distribution of UltraShear-enabled
health products. |
| ● | June
13: PBIO partners with Veterans Service Team to offer exclusive access for VST members
to Nano-CBD. |
| ● | June
1: PBIO expands on six key goals for June 2023 with expected multi-million-dollar growth
potential. |
| ● | May
22: Commercial availability of Best-in-Class Nano-CBD topical spray with lightning-fast
action announced. |
| ● | May
16: PBIO announces Q1 2023 financial results: all-time quarterly record revenue. |
| ● | May
9: Extended consumer testing strongly validates market transforming speed and dosing
efficiency of PBIO’s UltraShear processed nano-THC oral spray. |
| ● | April
26: PBIO updates rapid progress on potential sales of exclusive THC licenses. |
| ● | April
21, 2023: PBIO unveils powerful THC market leapfrog opportunity with exclusive licensing
of UltraShear nanoemulsion processing platform. |
| ● | April
18: PBIO announces expansion into strategic manufacturing facilities with premier process
tech company. |
| ● | April
14: PBIO reports Q4 and FY 2022 financial results – offers guidance for a strong
2023. |
| ● | April
6, 2023: PBIO and NutraLife Biosciences renew partnership for development and distribution
of next generation nutraceuticals. |
| ● | March
28: Company reports fresh sales momentum for PBI Agrochem. |
| ● | March
22: PBIO receives $1.5 million contract for UltraShear nanoemulsified CBD. |
| ● | March
1: Company announces the exchange of over $10 million of debt into equity. |
| ● | February
1: Company receives record order (nearly $600,000) for 16 PCT instruments. |
| ● | January
27: PBIO and One World Products partner to develop CBD-Nano sports performance/recovery
drink. |
| ● | January
19: Dramatic consumer testing results confirm UltraShear nanoemulsion oral spray delivers
first effects and maximization in lightning speed – simple, reliable dosing delivers
profoundly improved results. |
Results
of Operations
The
following disclosure compares the results of operations for the quarter ended September 30, 2023 (“Q2 2023”) with September
30, 2022 (“Q2 2022”) and compares the nine months ended September 30, 2023 with September 30, 2022.
Products
and Services Revenue
We
recognized total revenue of $413,009 for Q3 2023 compared to $144,032 for Q3 2022, a 187% increase. For the year-to-date periods ending
September 30, 2023 and September 30, 2022, we recognized revenue of $1,665,412 and $1,122,169 respectively, a 48% increase.
This
increase in revenue was primarily attributable to a $506,828 increase in PCT instrumentation and consumable sales, a $30,295 increase
in technical support services and an $87,378 increase in Agrochem products, offset by a decrease of $89,350 in scientific services.
Cost
of Products and Services
The
cost of products and services was $229,457 for Q3 2023 compared to $126,203 for Q3 2022. For the year-to-date periods ending September
30, 2023 and September 30, 2022 our cost of products and services were $844,684 and $742,707, respectively. Gross profit margin on products
and services increased to 49% in the year-to-date period ended September 30, 2023 from 34% in the same period ended September 30, 2022.
The increase in gross profit margin was attributable to $180,670 of Agrochem products sold in 2023 at no cost due to 2022 inventory write-off
and a $79,901 instrument non-monetary exchange sale in 2022 was recorded at no profit.
Research
and Development
Research
and development expenses were $288,345 for Q3 2023 compared to $262,370 for Q3 2022. For the year-to-date periods ending September 30,
2023 and September 30, 2022, these expenses were $1,004,437 and $716,685, respectively, a 40% increase. The reported increase was due
to a $71,777 reclass of salaries to COGS for a non-monetary instrument exchange in 2022 and $241,585 of stock-based compensation expense
for employee stock options issued in 2023.
Selling
and Marketing
Selling
and marketing expenses were $157,773 for Q3 2023 compared to $226,526 for Q3 2022. For the year-to-date periods ending September 30,
2023 and September 30, 2022, these expenses were $537,802 and $422,422, respectively a 27% increase The reported increase was primarily
attributable to the hiring of a Marketing FTE in Q2 2023 and $102,675 of stock-based compensation expense for employee stock options
issued in 2023.
General
and Administrative
General
and administrative expenses were $1,030,244 for Q3 2023 compared to $892,293 for Q3 2022. For the year-to-date periods ending September
30, 2023 and September 30, 2022, these expenses were $5,290,564 and $2,591,644, respectively, a 104% increase. The increase was primarily
due to approximately $2.0 million common stock and warrants issued for services, approximately $1.3 million of stock-based compensation
expense for employee, BOD and financial consultant stock options issued in 2023, and approximately $132,000 of financial consulting expenses
in 2023, offset by an approximately $423,000 decrease in IR expenses.
Operating
Loss
Operating
loss was $1,292,809 for Q3 2023 compared to $1,363,360 for Q3 2022. For the year-to-date periods ending September 30, 2023 and
September 30, 2022, the operating loss was $6,012,075 and $3,551,289 respectively, a 79% increase. This increase was primarily due
to $2.0 millions in common stock and warrants issued for services and $1.7 million of stock-based compensation expense for employee, BOD financial consultant stock options issued in 2023, offset by an approximate $423,000 decrease in IR expenses.
Interest
Expense, net
Interest
expense was $4,338,759 for Q3 2023 compared to $2,034,021 for Q3 2022. For the year-to-date periods ending September 30, 2023 and September
30, 2022, these expenses were $14,112,098 and $6,448,771, respectively, a 119% increase. This increase was attributable to an increase
in convertible debt and merchant cash loans, in addition to stock issuances for interest paid in kind and stock issued for debt extensions.
Unrealized
gain on investment in equity securities
Unrealized
loss on investments in equity securities was $5,965 for Q3 2023 compared to an unrealized loss of $8,675 for Q3 2022. For the nine months
ended September 30, 2023, the unrealized gain on investment in equity securities was $14,280 as compared to an unrealized loss of $8,047
for the nine months ended September 30, 2022. The reported change was attributable to movement in the market price of the Company’s
investment in Nexity.
Loss
on extinguishment of liabilities
In
connection with debt extensions and forgiveness, we recognized a net gain of $0 for Q3 2023 compared to $1,054,122 of losses for Q3 2022.
For the nine months ended September 30, 2023 the recognized net gain of $687,591 as compared to a net loss of $1,809,249 for the nine
months ended September 30, 2022. The increase/decline in gains/losses was attributable to decreased extension and forgiveness activity.
Net
loss attributable to common stockholders
Net
loss attributable to common stockholders was $6,261,999 ($0.29 per share) for Q3 2023 compared to $4,893,946 ($0.44 per share) for Q3
2022. For the nine months ended September 30, 2023, the net loss attributable to common stock was $24,666,565 ($1.21 per share) as compared
to $12,913,826 ($1.24 per share).
Liquidity
and Financial Condition
We
have experienced negative cash flows from operations since our inception. As
of September 30, 2023, we did not have adequate working capital resources to satisfy our current liabilities and as a result, we have
substantial doubt regarding our ability to continue as a going concern. As described in Notes 5 and 6 of the accompanying consolidated
financial statements, we have been successful in raising debt and equity capital. We received approximately $6.5 million in net
proceeds from loans in the nine months ended September 30, 2023. We have efforts in place to continue to raise cash through debt and
equity offerings. (See Note 7 to the financial statements)
We
will need substantial additional capital to fund our operations in future periods. If we are unable to obtain financing on acceptable
terms, or at all, we will likely be required to cease our operations, pursue a plan to sell our operating assets, or otherwise modify
our business strategy, which could materially harm our future business prospects.
Net
cash used in operations for the nine months ended September 30, 2023 was $2,053,823 as compared to $3,051,257 for the nine months
ended September 30, 2022.
Net
cash used in investing activities for the nine months ended September 30, 2023 was $7,495 compared to $20,754 in the nine months ended
September 30, 2022.
Net
cash provided by financing activities for the nine months ended September 30, 2023 was $2,062,716 as compared to $3,170,580 for the nine
months ended September 30, 2022.
ITEM
3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
This
Item 3 is not applicable to us as a smaller reporting company and has been omitted.
ITEM
4. CONTROLS AND PROCEDURES
We
maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our Securities Exchange
Act of 1934 filings are recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms,
and that such information is accumulated and communicated to our management, including our President and Chief Executive Officer (Principal
Executive Officer) and Chief Financial Officer (Principal Financial Officer), as appropriate, to allow timely decisions regarding required
disclosure. In designing and evaluating the disclosure controls and procedures, management recognized that controls and procedures, no
matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, as ours are
designed to do, and management was necessarily required to apply its judgment in evaluating the cost-benefit relationship of possible
controls and procedures.
As
of September 30, 2023, we carried out an evaluation, under the supervision and with the participation of our management, including our
Principal Executive Officer and Principal Financial Officer, of the effectiveness of the design and operation of our disclosure controls
and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934. Based upon that evaluation, our
Principal Executive Officer and Principal Financial Officer concluded that our disclosure controls and procedures were not effective.
Our
conclusion that our disclosure controls and procedures were not effective as of September 30, 2023 is due to the continued presence of
the material weaknesses in our internal control over financial reporting identified in our Annual Report on Form 10-K for the year ended
December 31, 2022. These material weaknesses are the following:
|
● |
We
identified a lack of sufficient segregation of duties. Specifically, this material weakness is such that the design over these areas
relies primarily on detective controls and could be strengthened by adding preventative controls to properly safeguard Company assets. |
|
|
|
|
● |
Management
has identified a lack of sufficient personnel in the accounting function due to our limited resources with appropriate skills, training,
and experience to perform the review processes to ensure the complete and proper application of generally accepted accounting principles,
particularly as it relates to valuation of warrants and other complex debt /equity transactions. Specifically, this material weakness
resulted in audit adjustments to the annual consolidated financial statements and revisions to related disclosures, valuation of
warrants and other equity transactions. |
|
|
|
|
● |
Limited
policies and procedures that cover recording and reporting of financial transactions. |
|
|
|
|
● |
Lack
of multiple levels of review over the financial reporting process |
We
continue to plan to remediate those material weaknesses as follows:
|
● |
Improve
the effectiveness of the accounting group by augmenting our existing resources with additional consultants or employees to assist
in the analysis and recording of complex accounting transactions, and to simultaneously achieve desired organizational structuring
for improved segregation of duties. We plan to mitigate this identified deficiency by hiring an independent consultant once we generate
significantly more revenue or raise significant additional working capital. |
|
|
|
|
● |
Improve
expert review and achieve desired segregation procedures by strengthening cross approval of various functions including quarterly
internal audit procedures where appropriate once we generate significantly more revenue or raise significantly more working capital. |
During
the period covered by this Report, we implemented and performed additional substantive procedures, such as supervisory review of work
papers and consistent use of financial models used in equity valuations, to ensure our consolidated financial statements as of and for
the six-month period ended September 30, 2023, are fairly stated in all material respects in accordance with GAAP. We have not, however,
been able to fully remediate the material weaknesses due to our limited financial resources. Our remediation efforts are largely dependent
upon our securing additional financing to cover the costs of implementing the changes required. If we are unsuccessful in securing such
funds, remediation efforts may be adversely affected in a material manner.
Except
as described above, there have been no changes in our internal controls over financial reporting that occurred during the period ended
September 30, 2023 that have materially affected, or are reasonably likely to materially affect, our internal controls over financial
reporting.
PART
II. OTHER INFORMATION
Item
1. Legal Proceedings
We
are not currently involved in any litigation that we believe could have a material adverse effect on our financial condition or results
of operations. There is no action, suit, proceeding, inquiry or investigation before or by any court, public board, government agency,
self-regulatory organization or body pending or, to the knowledge of the executive officers of our company or any of our subsidiaries,
threatened against or affecting our company, our common stock, any of our subsidiaries or of our companies or our subsidiaries’
officers or directors in their capacities as such, in which an adverse decision could have a material adverse effect.
Item
1A. Risk Factors
Factors
that could cause or contribute to differences in our future financial and operating results include those discussed in the risk factors
set forth in Item 1 of our Annual Report on Form 10-K for the year ended December 31, 2022 and, in this Item, 1A. The risks described
in our Form 10-K and this Report are not the only risks that we face. Additional risks not presently known to us or that we do not currently
consider significant may also have an adverse effect on the Company. If any of the risks occur, our business, results of operations,
cash flows or financial condition could suffer.
There
have been no material changes to the risk factors set forth in Item 1A of our 10-K for the year ended December 31, 2022.
Item
2. Unregistered Sales of Equity Securities and Use of Proceeds
Except
where noted, all the securities discussed in this Part II, Item 2 were issued in reliance on the exemption under Section 4(a)(2) of the
Securities Act.
On
various dates in the nine months ended September 30, 2023 the Company issued a total of 9,917,035 of its common shares, 953 shares
of Series BB preferred stock and 401 shares of Series CC preferred stock as follows:
| ● | 117,552
shares from option exercises; |
| ● | 1,630,500
shares for professional services; |
| ● | 1,346,800
shares for debt extensions; |
| ● | 203,613
shares for conversion of debt and interest; |
| ● | 142,767
shares for dividends paid-in-kind; |
| ● | 4,094,121
shares for interest paid-in-kind; |
| ● | 1,258,742
shares for shares issued with debt; |
| ● | 60,000
shares from sale of common shares; |
| ● | 95
shares of Series BB preferred stock was converted to common stock; |
| ● | 92
shares of Series BB preferred stock for professional services; |
| ● | 741
shares of Series BB preferred stock for debt extensions; |
| ● | 58
shares of Series BB preferred stock issued with debt; |
| ● | 401
shares of Series CC preferred stock for conversion of debt/accrued interest and dividends,
and |
| ● | 62
shares of Series BB preferred stock for the conversion of common stock. |
Item
3. Defaults upon Senior Securities
None.
Item
4. Mine Safety Disclosures
Not
applicable.
Item
5. Other Information
None.
Item
6. Exhibits
*
Filed herewith.
**
In accordance with SEC Release 33-8238, Exhibits 32.1 and 32.2 are furnished and not filed.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant caused this report to be signed on its behalf by the undersigned
thereunto duly authorized.
|
PRESSURE
BIOSCIENCES, INC. |
|
|
|
Date:
November 20, 2023 |
By:
|
/s/
Richard T. Schumacher |
|
|
Richard
T. Schumacher |
|
|
President
& Chief Executive Officer |
|
|
(Principal
Executive Officer and Principal Financial Officer) |
|
X |
- References
+ Details
Name: |
us-gaap_SubsequentEventsAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 855 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//855/tableOfContent
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 855 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2
+ Details
Name: |
us-gaap_SubsequentEventsTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.3
Summary of Significant Accounting Policies (Policies)
|
9 Months Ended |
Sep. 30, 2023 |
Accounting Policies [Abstract] |
|
Basis of Presentation |
Basis
of Presentation
The
unaudited interim financial statements of Pressure BioSciences, Inc. and its consolidated subsidiaries (collectively, the “Company”)
included herein have been prepared by the Company in accordance with the instructions to Form 10-Q and the rules and regulations of the
U.S. Securities and Exchange Commission. Under these rules and regulations, some information and footnote disclosures normally included
in financial statements prepared under accounting principles generally accepted in the United States of America have been shortened or
omitted. Management believes that all adjustments necessary for a fair statement of the financial position and the results of operations
for the periods shown have been made. All adjustments are normal and recurring. These financial statements should be read together with
the Company’s audited financial statements included in its Form 10-K for the fiscal year ended December 31, 2022. Operating results
for the nine months ended September 30, 2023 are not necessarily indicative of the final results that may be expected for the year ending
December 31, 2023.
|
Use of Estimates |
Use
of Estimates
The
Company’s consolidated financial statements and accompanying notes are prepared in accordance with accounting principles generally
accepted in the United States of America, which require the use of estimates, judgements and assumptions that affect the reported amounts
of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the periods
presented. Global concerns about the COVID-19 pandemic have adversely affected, and we expect will continue to adversely affect, our
business, financial condition and results of operations including the estimates and assumptions made by management. Significant estimates
and assumptions include valuations of share-based awards, investments in equity securities and intangible asset impairment. Actual results
could differ from the estimates, and such differences may be material to the Company’s consolidated financial statements.
|
Recent Accounting Pronouncements |
Recent
Accounting Pronouncements
In
August 2020, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2020-06, Accounting for Convertible
Instruments and Contracts in an Entity’s Own Equity, as part of its overall simplification initiative to reduce costs and complexity
of applying accounting standards while maintaining or improving the usefulness of the information provided to users of financial statements.
Among other changes, the new guidance removes the beneficial conversion separation model for convertible debt. As a result, after adopting
the guidance, entities will no longer account for beneficial conversion features in equity. The guidance is effective for public business
entities, other than small reporting company’s financial statements starting January 1, 2022, with early adoption permitted. The
Company is a small reporting company and early adopted the new guidance on January 1, 2022 using the modified retrospective approach
and recorded a cumulative effect of adoption equal to a $2,728,243 decrease in additional paid in capital and a $2,255,216 decrease in
accumulated deficit. There is no material impact to the Company’s statements of operations or cash flows as the result of the adoption
of ASU 2020-06.
In
June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses, which requires measurement and recognition of expected
credit losses for financial assets held. We adopted this new accounting guidance effective January 1, 2023. The adoption did not have
a material impact on our consolidated financial statements and disclosures and did not significantly impact the Company’s accounting
policies or estimation methods related to the allowance for doubtful accounts. The Company does not have any reserve for doubtful accounts
due to its customers being distributors, universities, research organizations and government agencies. In the past several years, all
its customers have paid in full without any need for a write-down.
|
Principles of Consolidation |
Principles
of Consolidation
The
consolidated financial statements include the accounts of Pressure BioSciences, Inc., and its wholly owned subsidiaries PBI BioSeq, Inc.
and PBI Agrochem, Inc. All intercompany accounts and transactions have been eliminated in consolidation.
|
Revenue Recognition |
Revenue
Recognition
We
recognize revenue in accordance with FASB ASC 606, Revenue from Contracts with Customers, and ASC 340-40, Other Assets and
Deferred Costs—Contracts with Customers. Revenue is measured based on a consideration specified in a contract with a customer,
and excludes any sales incentives and amounts collected on behalf of third parties. We enter sales contracts that may consist of multiple
distinct performance obligations where certain performance obligations of the sales contract are not delivered in one reporting period.
We measure and allocate revenue according to ASC 606-10.
We
identify a performance obligation as distinct if both the following criteria are true: the customer can benefit from the good or service
either on its own or together with other resources that are readily available to the customer and the entity’s promise to transfer
the good or service to the customer is separately identifiable from other promises in the contract. Determining the standalone selling
price (“SSP”) and allocation of consideration from a contract to the individual performance obligations, and the appropriate
timing of revenue recognition, is the result of significant qualitative and quantitative judgments. Management considers a variety of
factors such as historical sales, usage rates, costs, and expected margin, which may vary over time depending upon the unique facts and
circumstances related to each performance obligation in making these estimates. While changes in the allocation of the SSP between performance
obligations will not affect the amount of total revenue recognized for a particular contract, any material changes could impact the timing
of revenue recognition, which would have a material effect on our financial position and result of operations. This is because the contract
consideration is allocated to each performance obligation, delivered or undelivered, at the inception of the contract based on the SSP
of each distinct performance obligation.
Taxes
assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction, that are
collected by the Company from a customer, are excluded from revenue.
Shipping
and handling costs associated with outbound freight after control over a product has transferred to a customer are accounted for as a
fulfillment cost and are included in cost of revenues as consistent with treatment in prior periods.
Our
current Barocycler® instruments require a basic level of instrumentation expertise to set-up for initial operation. To support a
favorable first experience for our customers, upon customer request, and for an additional fee, we will send a highly trained technical
representative to the customer site to install Barocyclers® that we sell, lease, or rent through our domestic sales force. The installation
process includes uncrating and setting up the instrument, followed by introductory user training. Our sales arrangements do not provide
our customers with a right of return. Any shipping costs billed to customers are recognized as revenue.
Most
of our instrument and consumable contracts contain pricing that is based on the market price for the product at the time of delivery.
Our obligations to deliver product volumes are typically satisfied and revenue is recognized when control of the product transfers to
our customers. Concurrent with the transfer of control, we typically receive the right to payment for the shipped product and the customer
takes on the significant risks and rewards of ownership of the product. Payment terms require customers to pay shortly after delivery
and do not contain significant financing components.
Revenue
from scientific services customers is recognized upon completion of each stage of service as defined in service agreements.
We
apply ASC 845, “Accounting for Non-Monetary Transactions”, to account for products and services sold through non-cash transactions
based on the fair values of the products and services involved, where such values can be determined. Non-cash exchanges would require
revenue to be recognized at recorded cost or carrying value of the assets or services sold if any of the following conditions apply:
|
a) |
The
fair value of the asset or service involved is not determinable. |
|
|
|
|
b) |
The
transaction is an exchange of a product or property held for sale in the ordinary course of business for a product or property to
be sold in the same line of business to facilitate sales to customers other than the parties to the exchange. |
|
|
|
|
c) |
The
transaction lacks commercial substance. |
We
recognize revenue for non-cash transactions at recorded cost or carrying value of the assets or services sold.
We
account for lease agreements of our instruments in accordance with ASC 842, Leases. We record revenue over the life of the lease term,
and we record depreciation expense on a straight-line basis over the thirty-six-month estimated useful life of the Barocycler® instrument.
The depreciation expense associated with assets under lease agreement is included in the “Cost of PCT products and services”
line item in our accompanying consolidated statements of operations. Many of our lease and rental agreements allow the lessee to purchase
the instrument at any point during the term of the agreement with partial or full credit for payments previously made. We pay all maintenance
costs associated with the instrument during the term of the leases.
Deferred
revenue represents amounts received from service contracts for which the related revenues have not been recognized because one or more
of the revenue recognition criteria have not been met. Revenue from service contracts is recorded ratably over the length of the contract.
Disaggregation
of revenue
In
the following table, revenue is disaggregated by primary geographical market, major product line, and timing of revenue recognition.
Schedule
of Disaggregation of Revenue
In thousands of US dollars ($) | |
Three Months Ended September 30, | | |
Nine Months Ended September 30, | |
Primary geographical markets | |
2023 | | |
2022 | | |
2023 | | |
2022 | |
North America | |
$ | 251 | | |
$ | 138 | | |
$ | 1,067 | | |
$ | 709 | |
Europe | |
| 76 | | |
| 13 | | |
| 130 | | |
| 61 | |
Asia | |
| 86 | | |
| (7 | ) | |
| 468 | | |
| 352 | |
| |
$ | 413 | | |
$ | 144 | | |
$ | 1,665 | | |
$ | 1,122 | |
| |
Three Months Ended September 30, | | |
Nine Months Ended September 30, | |
Major products/services lines | |
2023 | | |
2022 | | |
2023 | | |
2022 | |
Hardware | |
$ | 273 | | |
$ | 1 | | |
$ | 994 | | |
$ | 532 | |
Consumables | |
| 50 | | |
| 49 | | |
| 173 | | |
| 165 | |
Contract research services | |
| -1 | | |
| - | | |
| 35 | | |
| 125 | |
Sample preparation accessories | |
| 31 | | |
| 41 | | |
| 113 | | |
| 93 | |
Technical support/extended service contracts | |
| 34 | | |
| 41 | | |
| 123 | | |
| 94 | |
| |
| | | |
| | | |
| | | |
| | |
Agrochem Products | |
| 15 | | |
| 10 | | |
| 181 | | |
| 93 | |
Shipping and handling | |
| 11 | | |
| 2 | | |
| 38 | | |
| 20 | |
Other | |
| - | | |
| - | | |
| 8 | | |
| - | |
| |
$ | 413 | | |
$ | 144 | | |
$ | 1,665 | | |
$ | 1,122 | |
| |
Three Months Ended September 30, | | |
Nine Months Ended September 30, | |
Timing of revenue recognition | |
2023 | | |
2022 | | |
2023 | | |
2022 | |
Products transferred at a point in time | |
$ | 379 | | |
$ | 103 | | |
$ | 1,506 | | |
$ | 903 | |
Services transferred over time | |
| 34 | | |
| 41 | | |
| 159 | | |
| 219 | |
| |
$ | 413 | | |
$ | 144 | | |
$ | 1,665 | | |
$ | 1,122 | |
Contract
balances
Schedule
of Contract Balances
In thousands of US dollars ($) | |
September 30, 2023 | | |
December 31, 2022 | |
Receivables, which are included in ‘Accounts Receivable’ | |
$ | 329 | | |
$ | 295 | |
Contract liabilities (deferred revenue) | |
| 59 | | |
| 60 | |
Transaction
price allocated to the remaining performance obligations
The
following table includes estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied
(or partially unsatisfied) at the end of the reporting period.
Schedule
of Future Related to Performance Obligations
In thousands of US dollars ($) | |
2023 | | |
2024 | | |
Total | |
Extended warranty service | |
$ | 48 | | |
$ | 11 | | |
$ | 59 | |
All
consideration from contracts with customers is included in the amounts presented above.
Contract
Costs
The
Company recognizes the incremental costs of obtaining contracts as an expense when incurred if the amortization period of the assets
that the Company otherwise would have recognized is one year or less. These costs are included in selling, general, and administrative
expenses. The costs to obtain a contract are recorded immediately in the period when the revenue is recognized either upon shipment or
installation. The costs to obtain a service contract are considered immaterial when spread over the life of the contract so the Company
records the costs immediately upon billing.
|
Concentrations |
Concentrations
Credit
Risk
Our
financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash, cash equivalents, and trade
receivables. We have cash investment policies which, among other things, limit investments to investment-grade securities. We perform
ongoing credit evaluations of our customers, and the risk with respect to trade receivables is further mitigated by the fact that many
of our customers are government institutions, large pharmaceutical and biotechnology companies, and academic laboratories.
The
following table illustrates the level of concentration as a percentage of total revenues during the three and nine months ended September
30, 2023 and 2022.
Schedule
of Customer Concentration Risk Percentage
| |
Three Months Ended September 30, | | |
Nine months Ended September 30, | |
| |
2023 | | |
2022 | | |
2023 | | |
2022 | |
Top five customers | |
| 80 | % | |
| 42 | % | |
| 49 | % | |
| 31 | % |
Federal agencies | |
| 18 | % | |
| 4 | % | |
| 5 | % | |
| 1 | % |
The
following table illustrates the level of concentration as a percentage of net accounts receivable balance as of September 30, 2023 and
December 31, 2022. The Top Five Customers category may include federal agency receivable balances if applicable.
| |
September 30, 2023 | | |
December 31, 2022 | |
Top five customers | |
| 80 | % | |
| 93 | % |
Federal agencies | |
| 22 | % | |
| 0 | % |
|
Product Supply |
Product
Supply
In
recent years we utilized a contract assembler for our Barocycler® 2320EXT. They provided us with precision manufacturing services
that included management support services to meet our specific application and operational requirements. Among the services provided
to us were:
|
● |
CNC
Machining |
|
● |
Contract
Assembly & Kitting |
|
● |
Component
and Subassembly Design |
|
● |
Inventory
Management |
|
● |
ISO
certification |
Beginning
in July 2021, we brought the assembly of our Barocycler 2320EXT instruments in-house. This became necessary when our independent contract
assembler (CBM Industries) informed us that they were about to need 100% of their assembly space for one of their customers (one of the
largest life science instrument manufacturers in the U.S.). We worked with our notified body to gain approval to use both the CE and
CSA marks on the instrument, which we received during Q3 2021. Until further notice, we expect to continue to assemble our Barocycler
2320EXT instrument at our South Easton, MA location.
We
currently manufacture and assemble the Barocycler®, HUB440, HUB880, the SHREDDER SG3, and most of our consumables at our South Easton,
MA facility. We will regularly reassess the tradeoffs between in-house assembly versus the benefits of outsourced relationships for of
the entire Barocycler® product line, and future instruments.
|
Investment in Equity Securities |
Investment
in Equity Securities
As
of September 30, 2023, we held 100,250 shares of common stock of Nexity Global SA, (a Polish publicly traded company).
We
account for this investment in accordance with ASC 320 “Investments — Debt and Equity Securities.” ASC 320 requires
equity investments with readily determinable fair values to be measured at fair value with changes in fair value recognized in net income.
As
of September 30, 2023, our consolidated balance sheet reflected the fair value, determined on a recurring basis based on Level 1 inputs
of our investment in Nexity, to be $77,918. We recorded $14,280 as an unrealized gain during the nine months ended September 30, 2023
for changes in market value.
|
Computation of Loss per Share |
Computation
of Loss per Share
Basic
loss per share is computed by dividing loss available to common shareholders by the weighted average number of common shares outstanding.
Diluted loss per share is computed by dividing loss available to common shareholders by the weighted average number of common shares
outstanding plus additional common shares that would have been outstanding if dilutive potential common shares had been issued. For purposes
of this calculation, convertible preferred stock, common stock dividends, and warrants and options to acquire common stock, are all considered
common stock equivalents in periods in which they have a dilutive effect and are excluded from this calculation in periods in which these
are anti-dilutive to our net loss.
The
following table illustrates our computation of loss per share for the three and nine months ended September 30, 2023 and 2022:
Schedule
of Computation of Loss Per Share
| |
2023 | | |
2022 | | |
2023 | | |
2022 | |
| |
For the Three Months Ended September 30, | | |
For the Nine months Ended September 30, | |
| |
2023 | | |
2022 | | |
2023 | | |
2022 | |
Numerator: | |
| | | |
| | | |
| | | |
| | |
Net loss attributable to common shareholders | |
$ | (6,261,999 | ) | |
$ | (4,893,946 | ) | |
$ | (24,666,565 | ) | |
$ | (12,913,826 | ) |
Denominator for basic and diluted loss per share: | |
| | | |
| | | |
| | | |
| | |
Weighted average common stock shares outstanding | |
| 21,716,950 | | |
| 11,131,742 | | |
| 20,337,229 | | |
| 10,429,817 | |
Loss per common share - basic and diluted | |
$ | (0.29 | ) | |
$ | (0.44 | ) | |
$ | (1.21 | ) | |
$ | (1.24 | ) |
The
following table presents securities that could potentially dilute basic loss per share in the future. For all periods presented, the
potentially dilutive securities were not included in the computation of diluted loss per share because these securities would have been
anti-dilutive to our net loss. The Series D Convertible Preferred Stock, Series G Convertible Preferred Stock, Series H and H2 Convertible
Preferred Stock, Series J Convertible Preferred Stock, Series K Convertible Preferred Stock, Series AA Convertible Preferred Stock, Series
BB Convertible Stock and Series CC Convertible Preferred Stock are presented below as if they were converted into common shares according
to the conversion terms.
Schedule
of Anti-Dilutive Securities Excluded from Computation of Earnings Per Share
| |
As of September 30, | |
| |
2023 | | |
2022 | |
Stock options | |
| 3,420,754 | | |
| 1,307,822 | |
Convertible debt | |
| 7,417,906 | | |
| 6,471,034 | |
Common stock warrants | |
| 15,732,940 | | |
| 16,293,768 | |
Convertible preferred stock: | |
| | | |
| | |
Series D Convertible Preferred Stock | |
| 6,250 | | |
| 25,000 | |
Series G Convertible Preferred Stock | |
| - | | |
| 26,857 | |
Series H Convertible Preferred Stock | |
| - | | |
| 33,334 | |
Series H2 Convertible Preferred Stock | |
| - | | |
| 70,000 | |
Series J Convertible Preferred Stock | |
| - | | |
| 115,267 | |
Series K Convertible Preferred Stock | |
| - | | |
| 229,334 | |
Series AA Convertible Preferred Stock | |
| 8,601,000 | | |
| 8,645,000 | |
Series BB Convertible Preferred Stock | |
| 8,580,000 | | |
| - | |
Series CC Convertible Preferred Stock | |
| 4,010,000 | | |
| - | |
| |
| 47,768,850 | | |
| 33,217,416 | |
|
Accounting for Stock-Based Compensation Expense |
Accounting
for Stock-Based Compensation Expense
We
maintain equity compensation plans under which incentive stock options and non-qualified stock options are granted to employees, independent
members of our Board of Directors and outside consultants. We recognize stock-based compensation expense over the requisite service period
using the Black-Scholes formula to estimate the fair value of the stock options on the date of grant.
Determining
Fair Value of Stock Option Grants
The
following table summarizes the assumptions we utilized for grants of stock options to the three sub-groups of our stock option recipients
during the nine months ended September 30, 2023:
Summary of Assumptions for Grants of Stock Options
Assumptions | |
CEO, other Officers and Employees | |
Expected life | |
| 6.0 (yrs) | |
Expected volatility | |
| 130.5 | % |
Risk-free interest rate | |
| 3.90 | % |
Forfeiture rate | |
| 0 to 5.00 | % |
Expected dividend yield | |
| 0.0 | % |
Valuation
and Amortization Method - The fair value of each option award is estimated on the date of the grant using the Black-Scholes pricing
model based on certain assumptions. The estimated fair value of employee stock options is amortized to expense using the
straight-line method over the vesting period.
Expected
Term - The Company uses the simplified calculation of expected life, as the Company does not currently have sufficient historical
exercise data on which to base an estimate of the expected term. Using this method, the expected term is determined using the
average of the vesting period and the contractual life of the stock options granted.
Expected
Volatility - Expected volatility is based on the Company’s historical stock volatility data over the expected term of the award.
Risk-Free
Interest Rate - The Company bases the risk-free interest rate used in the Black-Scholes valuation method on the implied yield currently
available on U.S. Treasury zero-coupon issues with an equivalent remaining term.
Forfeitures
- The Company records stock-based compensation expense only for those awards that are expected to vest. The Company estimated a forfeiture
rate of 0% to 5% for awards granted based on historical experience and future expectations of options vesting. The Company used this
historical rate as our assumption in calculating future stock-based compensation expense.
All
of the outstanding non-qualified options had an exercise price that was at or above the Company’s common stock share price at time
of issuance.
The
Company recognized stock-based compensation expense of $140,622 and $32,427 for the three months ended September 30, 2023 and 2022, respectively.
The company recognized stock-based compensation expense of $1,706,420 and $128,984 for the nine months ended September 30, 2023 and 2022,
respectfully. The following table summarizes the effect of this stock-based compensation expense within each of the line items of our
costs and expenses within our Consolidated Statements of Operations:
Schedule
of Stock Based Compensation Expense
| |
For the Three Months Ended | | |
For the Nine Months Ended | |
| |
September 30, | | |
September 30, | |
| |
2023 | | |
2022 | | |
2023 | | |
2022 | |
Cost of sales | |
$ | 11,183 | | |
$ | 2,184 | | |
$ | 75,724 | | |
$ | 8,694 | |
Research and development | |
| 35,676 | | |
| 9,499 | | |
| 241,585 | | |
| 37,803 | |
Selling and marketing | |
| 17,150 | | |
| 4,583 | | |
| 102,675 | | |
| 18,166 | |
General and administrative | |
| 76,613 | | |
| 16,161 | | |
| 1,286,436 | | |
| 64,321 | |
Total stock-based compensation expense | |
$ | 140,622 | | |
$ | 32,427 | | |
$ | 1,706,420 | | |
$ | 128,984 | |
Due
to their short maturities, the carrying amounts for cash and cash equivalents, accounts receivable, accounts payable, accrued expenses
and debt approximate their fair value. The carrying amount of long-term debt approximates fair value due to interest rates that approximate
prevailing market rates.
|
Fair Value Measurements |
Fair
Value Measurements
The
Company follows the guidance of FASB ASC Topic 820, “Fair Value Measurements and Disclosures” (“ASC 820”)
as it related to all financial assets and financial liabilities that are recognized or disclosed at fair value in the financial statements
on a recurring basis.
The
Company generally defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly
transaction between market participants at the measurement date (exit price). The Company uses a three-tier fair value hierarchy, which
classifies the inputs used in measuring fair values. These tiers include Level 1, defined as observable inputs such as quoted prices
for identical instruments in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly
or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring the
Company to develop its own assumptions. A slight change in an unobservable input like volatility could have a significant impact on fair
value measurement.
Financial
assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement.
The Company has determined that its financial assets are classified within Level 1 in the fair value hierarchy. The development of the
unobservable inputs for Level 3 fair value measurements and fair value calculations are the responsibility of the Company’s management.
The
following tables set forth the Company’s financial assets and liabilities that were accounted for at fair value on a recurring
basis as of September 30, 2023:
Schedule
of Assets and Liabilities Measured at Fair Value on Recurring Basis
| |
| | |
Fair value measurements at September 30, 2023 using: | |
| |
September 30, 2023 | | |
Quoted prices in active markets (Level 1) | | |
Significant other observable inputs (Level 2) | | |
Significant unobservable inputs (Level 3) | |
Equity Securities | |
$ | 77,918 | | |
$ | 77,918 | | |
| - | | |
| - | |
Total Financial Assets | |
$ | 77,918 | | |
$ | 77,918 | | |
$ | - | | |
$ | - | |
The
following tables set forth the Company’s financial assets and liabilities that were accounted for at fair value on a recurring
basis as of December 31, 2022:
| |
| | |
Fair value measurements at December 31, 2022 using: | |
| |
December 31, 2022 | | |
Quoted prices in active markets (Level 1) | | |
Significant other observable inputs (Level 2) | | |
Significant unobservable inputs (Level 3) | |
Equity Securities | |
| 63,638 | | |
| 63,638 | | |
| - | | |
| - | |
Total Financial Assets | |
$ | 63,638 | | |
$ | 63,638 | | |
$ | - | | |
$ | - | |
|
X |
- DefinitionProduct Supply [Policy Text Block]
+ References
+ Details
Name: |
PBIO_ProductSupplyPolicyTextBlock |
Namespace Prefix: |
PBIO_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionRecent Accounting Pronouncement [Policy Text Block]
+ References
+ Details
Name: |
PBIO_RecentAccountingPronouncementPolicyTextBlock |
Namespace Prefix: |
PBIO_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_AccountingPoliciesAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).
+ References
+ Details
Name: |
us-gaap_BasisOfAccountingPolicyPolicyTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy for credit risk.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 942 -SubTopic 825 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480981/942-825-50-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1
+ Details
Name: |
us-gaap_ConcentrationRiskCreditRisk |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1
+ Details
Name: |
us-gaap_ConsolidationPolicyTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2
+ Details
Name: |
us-gaap_EarningsPerSharePolicyTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.
+ References
+ Details
Name: |
us-gaap_FairValueMeasurementPolicyPolicyTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy for investment in financial asset.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(3)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(d)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(f)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(f)(2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(f)(3)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 12 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-12
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 19 -Subparagraph (2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-19
+ Details
Name: |
us-gaap_InvestmentPolicyTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy for revenue from contract with customer.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-17
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-19
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-18
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-18
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 20 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 20 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 20 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 20 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20
Reference 9: http://www.xbrl.org/2003/role/exampleRef -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (e) -SubTopic 10 -Topic 235 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Topic 606 -Publisher FASB -URI https://asc.fasb.org//606/tableOfContent
+ Details
Name: |
us-gaap_RevenueFromContractWithCustomerPolicyTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.C.Q3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.D.1.Q5) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.D.3.Q2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.D.2.Q6) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//718/tableOfContent
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 11 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 12 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12
Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8
+ Details
Name: |
us-gaap_UseOfEstimates |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.3
Summary of Significant Accounting Policies (Tables)
|
9 Months Ended |
Sep. 30, 2023 |
Accounting Policies [Abstract] |
|
Schedule of Disaggregation of Revenue |
In
the following table, revenue is disaggregated by primary geographical market, major product line, and timing of revenue recognition.
Schedule
of Disaggregation of Revenue
In thousands of US dollars ($) | |
Three Months Ended September 30, | | |
Nine Months Ended September 30, | |
Primary geographical markets | |
2023 | | |
2022 | | |
2023 | | |
2022 | |
North America | |
$ | 251 | | |
$ | 138 | | |
$ | 1,067 | | |
$ | 709 | |
Europe | |
| 76 | | |
| 13 | | |
| 130 | | |
| 61 | |
Asia | |
| 86 | | |
| (7 | ) | |
| 468 | | |
| 352 | |
| |
$ | 413 | | |
$ | 144 | | |
$ | 1,665 | | |
$ | 1,122 | |
| |
Three Months Ended September 30, | | |
Nine Months Ended September 30, | |
Major products/services lines | |
2023 | | |
2022 | | |
2023 | | |
2022 | |
Hardware | |
$ | 273 | | |
$ | 1 | | |
$ | 994 | | |
$ | 532 | |
Consumables | |
| 50 | | |
| 49 | | |
| 173 | | |
| 165 | |
Contract research services | |
| -1 | | |
| - | | |
| 35 | | |
| 125 | |
Sample preparation accessories | |
| 31 | | |
| 41 | | |
| 113 | | |
| 93 | |
Technical support/extended service contracts | |
| 34 | | |
| 41 | | |
| 123 | | |
| 94 | |
| |
| | | |
| | | |
| | | |
| | |
Agrochem Products | |
| 15 | | |
| 10 | | |
| 181 | | |
| 93 | |
Shipping and handling | |
| 11 | | |
| 2 | | |
| 38 | | |
| 20 | |
Other | |
| - | | |
| - | | |
| 8 | | |
| - | |
| |
$ | 413 | | |
$ | 144 | | |
$ | 1,665 | | |
$ | 1,122 | |
| |
Three Months Ended September 30, | | |
Nine Months Ended September 30, | |
Timing of revenue recognition | |
2023 | | |
2022 | | |
2023 | | |
2022 | |
Products transferred at a point in time | |
$ | 379 | | |
$ | 103 | | |
$ | 1,506 | | |
$ | 903 | |
Services transferred over time | |
| 34 | | |
| 41 | | |
| 159 | | |
| 219 | |
| |
$ | 413 | | |
$ | 144 | | |
$ | 1,665 | | |
$ | 1,122 | |
|
Schedule of Contract Balances |
Contract
balances
Schedule
of Contract Balances
In thousands of US dollars ($) | |
September 30, 2023 | | |
December 31, 2022 | |
Receivables, which are included in ‘Accounts Receivable’ | |
$ | 329 | | |
$ | 295 | |
Contract liabilities (deferred revenue) | |
| 59 | | |
| 60 | |
|
Schedule of Future Related to Performance Obligations |
The
following table includes estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied
(or partially unsatisfied) at the end of the reporting period.
Schedule
of Future Related to Performance Obligations
In thousands of US dollars ($) | |
2023 | | |
2024 | | |
Total | |
Extended warranty service | |
$ | 48 | | |
$ | 11 | | |
$ | 59 | |
|
Schedule of Customer Concentration Risk Percentage |
The
following table illustrates the level of concentration as a percentage of total revenues during the three and nine months ended September
30, 2023 and 2022.
Schedule
of Customer Concentration Risk Percentage
| |
Three Months Ended September 30, | | |
Nine months Ended September 30, | |
| |
2023 | | |
2022 | | |
2023 | | |
2022 | |
Top five customers | |
| 80 | % | |
| 42 | % | |
| 49 | % | |
| 31 | % |
Federal agencies | |
| 18 | % | |
| 4 | % | |
| 5 | % | |
| 1 | % |
The
following table illustrates the level of concentration as a percentage of net accounts receivable balance as of September 30, 2023 and
December 31, 2022. The Top Five Customers category may include federal agency receivable balances if applicable.
| |
September 30, 2023 | | |
December 31, 2022 | |
Top five customers | |
| 80 | % | |
| 93 | % |
Federal agencies | |
| 22 | % | |
| 0 | % |
|
Schedule of Computation of Loss Per Share |
The
following table illustrates our computation of loss per share for the three and nine months ended September 30, 2023 and 2022:
Schedule
of Computation of Loss Per Share
| |
2023 | | |
2022 | | |
2023 | | |
2022 | |
| |
For the Three Months Ended September 30, | | |
For the Nine months Ended September 30, | |
| |
2023 | | |
2022 | | |
2023 | | |
2022 | |
Numerator: | |
| | | |
| | | |
| | | |
| | |
Net loss attributable to common shareholders | |
$ | (6,261,999 | ) | |
$ | (4,893,946 | ) | |
$ | (24,666,565 | ) | |
$ | (12,913,826 | ) |
Denominator for basic and diluted loss per share: | |
| | | |
| | | |
| | | |
| | |
Weighted average common stock shares outstanding | |
| 21,716,950 | | |
| 11,131,742 | | |
| 20,337,229 | | |
| 10,429,817 | |
Loss per common share - basic and diluted | |
$ | (0.29 | ) | |
$ | (0.44 | ) | |
$ | (1.21 | ) | |
$ | (1.24 | ) |
|
Schedule of Anti-Dilutive Securities Excluded from Computation of Earnings Per Share |
Schedule
of Anti-Dilutive Securities Excluded from Computation of Earnings Per Share
| |
As of September 30, | |
| |
2023 | | |
2022 | |
Stock options | |
| 3,420,754 | | |
| 1,307,822 | |
Convertible debt | |
| 7,417,906 | | |
| 6,471,034 | |
Common stock warrants | |
| 15,732,940 | | |
| 16,293,768 | |
Convertible preferred stock: | |
| | | |
| | |
Series D Convertible Preferred Stock | |
| 6,250 | | |
| 25,000 | |
Series G Convertible Preferred Stock | |
| - | | |
| 26,857 | |
Series H Convertible Preferred Stock | |
| - | | |
| 33,334 | |
Series H2 Convertible Preferred Stock | |
| - | | |
| 70,000 | |
Series J Convertible Preferred Stock | |
| - | | |
| 115,267 | |
Series K Convertible Preferred Stock | |
| - | | |
| 229,334 | |
Series AA Convertible Preferred Stock | |
| 8,601,000 | | |
| 8,645,000 | |
Series BB Convertible Preferred Stock | |
| 8,580,000 | | |
| - | |
Series CC Convertible Preferred Stock | |
| 4,010,000 | | |
| - | |
| |
| 47,768,850 | | |
| 33,217,416 | |
|
Summary of Assumptions for Grants of Stock Options |
The
following table summarizes the assumptions we utilized for grants of stock options to the three sub-groups of our stock option recipients
during the nine months ended September 30, 2023:
Summary of Assumptions for Grants of Stock Options
Assumptions | |
CEO, other Officers and Employees | |
Expected life | |
| 6.0 (yrs) | |
Expected volatility | |
| 130.5 | % |
Risk-free interest rate | |
| 3.90 | % |
Forfeiture rate | |
| 0 to 5.00 | % |
Expected dividend yield | |
| 0.0 | % |
|
Schedule of Stock Based Compensation Expense |
Schedule
of Stock Based Compensation Expense
| |
For the Three Months Ended | | |
For the Nine Months Ended | |
| |
September 30, | | |
September 30, | |
| |
2023 | | |
2022 | | |
2023 | | |
2022 | |
Cost of sales | |
$ | 11,183 | | |
$ | 2,184 | | |
$ | 75,724 | | |
$ | 8,694 | |
Research and development | |
| 35,676 | | |
| 9,499 | | |
| 241,585 | | |
| 37,803 | |
Selling and marketing | |
| 17,150 | | |
| 4,583 | | |
| 102,675 | | |
| 18,166 | |
General and administrative | |
| 76,613 | | |
| 16,161 | | |
| 1,286,436 | | |
| 64,321 | |
Total stock-based compensation expense | |
$ | 140,622 | | |
$ | 32,427 | | |
$ | 1,706,420 | | |
$ | 128,984 | |
|
Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis |
The
following tables set forth the Company’s financial assets and liabilities that were accounted for at fair value on a recurring
basis as of September 30, 2023:
Schedule
of Assets and Liabilities Measured at Fair Value on Recurring Basis
| |
| | |
Fair value measurements at September 30, 2023 using: | |
| |
September 30, 2023 | | |
Quoted prices in active markets (Level 1) | | |
Significant other observable inputs (Level 2) | | |
Significant unobservable inputs (Level 3) | |
Equity Securities | |
$ | 77,918 | | |
$ | 77,918 | | |
| - | | |
| - | |
Total Financial Assets | |
$ | 77,918 | | |
$ | 77,918 | | |
$ | - | | |
$ | - | |
The
following tables set forth the Company’s financial assets and liabilities that were accounted for at fair value on a recurring
basis as of December 31, 2022:
| |
| | |
Fair value measurements at December 31, 2022 using: | |
| |
December 31, 2022 | | |
Quoted prices in active markets (Level 1) | | |
Significant other observable inputs (Level 2) | | |
Significant unobservable inputs (Level 3) | |
Equity Securities | |
| 63,638 | | |
| 63,638 | | |
| - | | |
| - | |
Total Financial Assets | |
$ | 63,638 | | |
$ | 63,638 | | |
$ | - | | |
$ | - | |
|
X |
- References
+ Details
Name: |
us-gaap_AccountingPoliciesAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-10
+ Details
Name: |
us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5
+ Details
Name: |
us-gaap_DisaggregationOfRevenueTableTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb) -SubTopic 10 -Topic 820 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2
+ Details
Name: |
us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of all significant concentrations of risk, including credit risk and market risk, arising from all financial instruments (as defined), whether from an individual counterparty or groups of counterparties. The disclosure concerning concentrations of risk may consist of the following information: (1) for concentrations of credit risk disclosure may include: (a) information about the (shared) activity, region, or economic characteristic that identifies the concentration, (b) the maximum amount of loss due to credit risk that, based on the gross fair value of the financial instrument, the entity would incur if parties to the financial instruments that make up the concentration failed completely to perform according to the terms of the contracts and the collateral or other security, if any, for the amount due proved to be of no value to the entity, (c) the policy of requiring collateral or other security to support financial instruments subject to credit risk, information about the entity's access to that collateral or other security, and the nature and a brief description of the collateral or other security supporting those financial instruments, and (d) the policy of entering into master netting arrangements to mitigate the credit risk of financial instruments, information about the arrangements for which the entity is a party, and a brief description of the terms of those arrangements, including the extent to which they would reduce the entity's maximum amount of loss due to credit risk and (2) for disclosure of quantitative information about the market risks of financial instruments that is consistent with the way the company manages or adjusts those risks, disclosure may include: (a) more details about current positions and perhaps activity during the period, (b) the hypothetical effects on comprehensive income (or net assets), or annual income, of several possible changes in market prices, (c) a gap analysis of interest rate re-pricing or maturity dates, (d) the duration of the financial instruments, (e) the entity's value at risk from derivatives and from other positions at the end of the reporting period and the average value at risk during the year, or (f) other ways of reporting quantitative information as internally developed.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-21
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 23 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-23
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-20
Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-22
+ Details
Name: |
us-gaap_FairValueConcentrationOfRiskTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of expected timing for satisfying remaining performance obligation.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b)(1) -SubTopic 10 -Topic 606 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-13
+ Details
Name: |
us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1
+ Details
Name: |
us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1
+ Details
Name: |
us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2
+ Details
Name: |
us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.3
Commitments and Contingencies (Tables)
|
9 Months Ended |
Sep. 30, 2023 |
Commitments and Contingencies Disclosure [Abstract] |
|
Schedule of Future Minimum Rental Payments Required Under Operating Leases |
Following
is a schedule by years of future minimum rental payments required under operating leases with initial or remaining non-cancelable lease
terms in excess of one year as of September 30, 2023:
Schedule
of Future Minimum Rental Payments Required Under Operating Leases
Year | |
Total | |
October 1 – December 31, 2023 | |
$ | 15,887 | |
2024 | |
| 64,393 | |
2025 | |
| 66,969 | |
2026 | |
| 51,778 | |
Total future undiscounted lease payments | |
| 199,027 | |
Less imputed interest | |
| (61,481 | ) |
Present value of lease liabilities | |
$ | 137,546 | |
|
Schedule of Right of Use Asset and the Corresponding Lease Liability |
Below
is a table for the right of use asset and the corresponding lease liability in the consolidated balance sheets:
Schedule
of Right of Use Asset and the Corresponding Lease Liability
Operating Leases | |
September 30, 2023 | | |
December 31, 2022 | |
Right of use asset | |
$ | 159,424 | | |
$ | 282,095 | |
Right of use liability, current | |
$ | 66,259 | | |
$ | 142,171 | |
Right of use liability, long term | |
$ | 71,287 | | |
$ | 139,924 | |
Total lease liability | |
$ | 137,546 | | |
$ | 282,095 | |
|
Schedule of Lease Cost for Operating Leases |
The
components of lease cost for operating leases for the nine months ended September 30, 2023 and 2022 are as follows:
Schedule
of Lease Cost for Operating Leases
| |
September 30, 2023 | | |
September 30, 2022 | |
Operating lease cost | |
$ | 153,290 | | |
$ | 152,193 | |
Short-term lease cost | |
| 110,205 | | |
| 123,514 | |
Total lease cost | |
$ | 263,495 | | |
$ | 275,707 | |
|
X |
- DefinitionOperating Leases of Lessee [Table Text Block]
+ References
+ Details
Name: |
PBIO_OperatingLeasesOfLesseeTableTextBlock |
Namespace Prefix: |
PBIO_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of contractual obligation by timing of payment due. Includes, but is not limited to, long-term debt obligation, lease obligation, and purchase obligation.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (S-X 210.12-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3
+ Details
Name: |
srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock |
Namespace Prefix: |
srt_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_CommitmentsAndContingenciesDisclosureAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4
+ Details
Name: |
us-gaap_LeaseCostTableTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.3
Debt (Tables)
|
9 Months Ended |
Sep. 30, 2023 |
Debt Disclosure [Abstract] |
|
Schedule of Convertible Debts and Outstanding Balances |
Schedule
of Convertible Debts and Outstanding Balances
| |
September
30, 2023 | | |
December
31, 2022 | |
Holders | |
Interest
Rate | | |
Conversion
Price | | |
Principal | | |
Interest
Rate | | |
Conversion
Price | | |
Principal | |
Main Investor | |
| 10 | % | |
$ | 2.50
(1) | | |
$ | 8,586,750 | | |
| 10 | % | |
$ | 2.50
(1 | ) | |
$ | 9,393,150 | |
Others | |
| 0
to 24 | % | |
$ | 2.50
(2) or $7.50 | | |
| 10,379,763 | | |
| 0
to 24 | % | |
$ | 2.50
(2) or $7.50 |
| |
| 8,886,036 | |
Totals | |
| | | |
| | | |
| - | | |
| | | |
| | | |
| 18,279,186 | |
Discount | |
| | | |
| | | |
| 744,393 | | |
| | | |
| | | |
| 455,517 | |
Net | |
| | | |
| | | |
$ | 18,222,120 | | |
| | | |
| | | |
$ | 17,823,669 | |
Notes:
| (1) | Conversion
price of these note is $2.50
except for a note for $189,750,
which will be adjusted to, upon an Event of Default, the lower of (i) the conversion price or (ii) a 25%
discount to the 5-day average VWAP of the stock prior to default and $729,100 lower of (i) $2.50 or (ii) the conversion price of the
Series AA Preferred Stock as adjusted. These notes are secured by all assets of the company. |
| | |
| (2) | Conversion
price of these notes is $2.50 but also varies with one or more of these notes having the
following conversion adjustment: |
| a. | Notes
are convertible before maturity at $2.50 per share or mandatorily convertible when the Company
up-lists to the NASDAQ at the lower of $2.50 or the up-list price. |
| b. | Notes
are convertible upon an Event of Default at 75% multiplied by the lowest trading price for
the common stock during the five days prior to the conversion. |
| c. | Notes
are convertible at $2.50 per share except that following an Event of Default the conversion
price will be adjusted to 75% multiplied by the lowest trading price for the common stock
during the five days prior to the conversion. |
| d. | Notes
can be voluntary converted at lower of 1) $2.50/share; or 2) purchase price of stock sold
by PBI at a price lower than $2.50/share. In the event of default, these notes can be converted
at lower of 1) $2.50/share; 2) 30% discount to 5-day VWAP prior to date of default. |
| e. | Notes
can be voluntary converted at lower of 1) $2.50/share; or 2) purchase price of stock sold
by PBI at a price lower than $2.50/share. In the event of default, these notes can be converted
at lower of 1) $2.50/share; 2) 25% discount to 5-day VWAP prior to date of default. |
| f. | Conversion
price is lower of (i) $2.50 or (ii) the price per share that the Company last sold Common
Stock after the execution of an anti-dilution protection agreement. |
| g. | Note
can be converted at a Voluntary Conversion Price which is the lower of 1) $2.50/share; or
2) purchase price of stock sold by the Company at a price lower than $2.50 except that following
an Event of Default, the Holder shall have the right, with no further consent from the Borrower,
to convert notes which can be the lower of 1) the Voluntary Conversion Price, or 2) 70% of
the 5-day VWAP prior to conversion. |
| h. | Conversion
price is $2.50. If note is in default, it is $1. |
| i. | Notes
can be voluntarily converted before maturity at $2.50 per share. Lender retains the option
upon an Up-list to convert at the lower of $2.50 or 10% off Up-list price. |
| j. | Notes
can be converted at the lesser of $2.5 per share or 25% discount to the opening price of
the Company’s first day of trading on either Nasdaq or NYSE. In addition, if the Company
fails to pay the Note in cash on maturity date, the conversion price will be adjusted to
the lesser of (i) original conversion price or (ii) a 35% discount to the VWAP prior to each
conversion date. |
| k. | Some
notes are not convertible until 180 days from the date of issuance of the Note and following
an Event of Default will be convertible at the lowest trading price of the 20 days prior
to conversion. The loan with a principal balance of $950,000 as of September 30, 2023 is
guaranteed by the Company’s Chief Executive Officer, but the lender may only enforce
this guarantee after certain conditions have been met, specifically after (i) the occurrence
of an Event of Default (as defined in the Note), (ii) the failure of the Company to cure
the Default in 10 business days, and (iii) a failure by the Company to issue, or cause to
be issued, shares of its common stock upon submission by the lender of a notice of conversion. |
| l. | Some
notes can be converted at the lesser of $2.50 per share or 25% discount to the opening price
of the Company’s first day of trading on either Nasdaq or NYSE. In addition, if the
Company fails to pay the Note in cash on maturity date, the conversion price will be adjusted
to the lesser of original conversion price or the product of the VWAP of the common stock
for the 5 trading dates immediately prior to the maturity date multiplied by 0.75. |
|
Schedule of Other Debt |
Schedule
of Other Debt
| |
September
30, 2023 | | |
December
31, 2022 | |
Holders | |
Interest
Rate | | |
Principal | | |
Interest
Rate | | |
Principal | |
Non-Convertible | |
| -(1 | ) | |
$ | 1,016,500 | | |
| -(1 | ) | |
$ | 878,809 | |
Merchant
debt (3) | |
| | | |
| 1,014,010 | | |
| | | |
| 760,160 | |
SBA
(2) | |
| 3.75 | % | |
| 162,522 | | |
| 3.75 | % | |
| 150,000 | |
Totals | |
| | | |
| 2,193,032 | | |
| | | |
$ | 1,788,969 | |
Discount | |
| | | |
| - | | |
| | | |
| - | |
Long
Term | |
| | | |
| 162,522 | | |
| | | |
| 150,000 | |
Short
Term | |
| | | |
$ | 2,030,510 | | |
| | | |
$ | 1,638,969 | |
Notes:
| (1) | Interest
varies from 1% to 10%. The maturity is between being past due and May 2, 2023. As of September
30, 2023, $861,500 of the non-convertible debt is past due. |
| (2) | The
Company entered a COVID-19 government loan in 2020, the Economic Injury Disaster Loan (or
“EIDL”). The Company’s EIDL loan, $150,000, accrues interest at 3.75% and
requires monthly payments of $731 for principal and interest beginning in December 2022.
The balance of the principal will be due in 30 years. In connection with the EIDL loan the
Company entered into a security agreement with the SBA, whereby the Company granted the SBA
a security interest in all of the Company’s right, title and interest in all of the
Company’s assets. During the nine months ended September 30, 2023, $14,719 interest
was deferred and added to principal on EIDL loan and the Company repaid $2,197 principal
on this loan. During the year ended December 31, 2020, the Company borrowed $367,039 (two-year
term and 1% interest rate per annum) under the Payroll Protection program (or “2020
PPP”). During the year ended December 31, 2021, the Company borrowed $367,039 through
a second Payroll Protection program (or “2021 PPP”) and extended the monthly
payment date on the EIDL to December 2022. In year 2021, both 2020 PPP and 2021 PPP was forgiven
by the United States and SBA. |
| (3) | During
the nine months ended September 30, 2023 and the year ended December 31, 2022 we signed various
Merchant Agreements which are secured by second position rights to all customer receipts
until the loan has been repaid in full and subject to interest rates of 4.1% - 100.9% per
month. Under the terms of these agreements, we received the disclosed Purchase Price and
agreed to repay the disclosed Purchase Amount, which is collected by the Merchant lenders
at the Daily Payment Rate. We accounted for the Merchant Agreements as loans under ASC 860
because while we provided rights to current and future receipts, we still had control over
the receipts. The difference between the Purchase Amount and the Purchase Price is imputed
interest that is recorded as interest expense when paid each day. The Company’s Chief
Executive Officer guarantees the Company’s performance of all representations, warranties,
and covenants made by the Company in the Agreement. For loans outstanding on September 30,
2023, the maturity dates ranged from June 26, 2023 to October 15, 2023. For loan outstanding
on December 31, 2022, the maturity dates ranged from April 4 to June 6, 2023. |
|
Schedule of Related Party Debt |
Schedule
of Related Party Debt
| |
September 30, 2023 | | |
December 31, 2022 | |
Holders | |
Interest Rate | | |
Principal | | |
Interest Rate | | |
Principal | | |
Security | |
Officers & Directors | |
| -(1 | ) | |
$ | 522,450 | | |
| -(1 | ) | |
$ | 521,950 | | |
| Unsecured | |
Other Related Parties | |
| 12 | % | |
| 126,050 | | |
| 12 | % | |
| 120,850 | | |
| Unsecured | |
Totals | |
| | | |
| 648,500 | | |
| | | |
| 642,800 | | |
| | |
Discount | |
| | | |
| 514 | | |
| | | |
| 7,915 | | |
| | |
Net | |
| | | |
$ | 647,986 | | |
| | | |
$ | 634,885 | | |
| | |
Notes:
| (1) | Interest
varies from 12% to 120%. |
|
X |
- DefinitionSchedule of Other Debt [Table Text Block]
+ References
+ Details
Name: |
PBIO_ScheduleOfOtherDebtTableTextBlock |
Namespace Prefix: |
PBIO_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_DebtDisclosureAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of information on an original debt issue that has been converted in a noncash (or part noncash) transaction during the accounting period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. The information may be presented entirely or partially in this block of text or in the associated elements.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5
+ Details
Name: |
us-gaap_ScheduleOfDebtConversionsTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.
+ References
+ Details
Name: |
us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.3
Stockholders’ Deficit (Tables)
|
9 Months Ended |
Sep. 30, 2023 |
Equity [Abstract] |
|
Schedule of Preferred Stock Outstanding |
Schedule
of Preferred Stock Outstanding
| |
September 30, 2023 | | |
December 31, 2022 | |
Series D Convertible Preferred Stock, $.01 par value; 850 shares authorized; 75 shares issued and outstanding on September 30, 2023, and 300 shares issued and outstanding on December 31, 2022 (Liquidation value of $300,000) | |
$ | - | | |
$ | 3 | |
Series G Convertible Preferred Stock, $.01 par value; 240,000 shares authorized; no shares issued and outstanding on September 30, 2023 and 80,570 shares issued and outstanding on December 31, 2022 | |
| - | | |
| 806 | |
Series H Convertible Preferred Stock, $.01 par value; 10,000 shares authorized; no shares issued and outstanding on September 30, 2023 and 10,000 shares issued and outstanding on December 31, 2022 | |
| - | | |
| 100 | |
Series J Convertible Preferred Stock, $.01 par value; 6,250 shares authorized; no shares issued and outstanding on September 30, 2023 and 3,458 shares issued and outstanding on December 31, 2022 | |
| - | | |
| 35 | |
Series K Convertible Preferred Stock, $.01 par value; 15,000 shares authorized; no shares issued and outstanding on September 30, 2023 and 6,880 shares issued and outstanding on December 31, 2022 | |
| - | | |
| 68 | |
Series AA Convertible Preferred Stock, $.01 par value; 10,000 shares authorized; 8,601 shares issued and outstanding on September 30, 2023 and December 31, 2022, respectively | |
| 86 | | |
| 86 | |
Series BB Convertible Preferred Stock, $.01 par value; 1,000 shares authorized; 858 shares issued and outstanding on September 30, 2023 and no shares outstanding at December 31, 2022 | |
| 10 | | |
| - | |
Series CC Convertible Preferred Stock, $.01 par value; 2,000 shares authorized; 401 shares issued and outstanding on September 30, 2023 and no shares outstanding at December 31, 2022 | |
| 4 | | |
| - | |
Series H2 Convertible Preferred Stock, $.01 par value; 21 shares authorized; no shares issued and outstanding on September 30, 2023 and 21 shares issued and outstanding on December 31, 2022 | |
| - | | |
| - | |
Series A Junior Participating Preferred Stock, $.01 par value, 20,000 shares authorized, no shares outstanding | |
| - | | |
| - | |
Series A Convertible Preferred Stock, $.01 par value, 313,960 shares authorized, no shares outstanding | |
| - | | |
| - | |
Series B Convertible Preferred Stock, $.01 par value, 279,256 shares authorized, no shares outstanding | |
| - | | |
| - | |
Series C Convertible Preferred Stock, $.01 par value, 88,098 shares authorized, no shares outstanding | |
| - | | |
| - | |
Series E Convertible Preferred Stock, $.01 par value, 500 shares authorized, no shares outstanding | |
| - | | |
| - | |
Total Convertible Preferred Shares | |
$ | 100 | | |
$ | 1,098 | |
|
Schedule of Concerning Options and Warrants Outstanding and Exercisable |
The
following table summarizes information concerning options and warrants outstanding and exercisable:
Schedule
of Concerning Options and Warrants Outstanding and Exercisable
| |
Stock Options | | |
Warrants | | |
| | |
| |
| |
Weighted Average | | |
Weighted Average | | |
Total | |
| |
Shares | | |
price per share | | |
Shares | | |
price per share | | |
Shares | | |
Exercisable | |
Balance outstanding, December 31, 2022 | |
| 1,307,822 | | |
$ | 0.72 | | |
| 16,278,769 | | |
$ | 3.50 | | |
| 17,586,591 | | |
| 17,570,591 | |
Granted | |
| 2,230,484 | | |
| 1.50 | | |
| 100,000 | | |
| 3.50 | | |
| 2,330,484 | | |
| | |
Exercised | |
| (117,552 | ) | |
| 0.69 | | |
| - | | |
| - | | |
| (117,552 | ) | |
| | |
Expired | |
| - | | |
| - | | |
| (645,829 | ) | |
| 3.50 | | |
| (645,829 | ) | |
| | |
Forfeited | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| | |
Balance outstanding, September 30, 2023 | |
| 3,420,754 | | |
$ | 1.23 | | |
| 15,732,940 | | |
$ | 3.50 | | |
| 19,153,694 | | |
| 18,289,721 | |
|
X |
- References
+ Details
Name: |
us-gaap_EquityAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-1
+ Details
Name: |
us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of changes in the separate accounts comprising stockholders' equity (in addition to retained earnings) and of the changes in the number of shares of equity securities during at least the most recent annual fiscal period and any subsequent interim period presented is required to make the financial statements sufficiently informative if both financial position and results of operations are presented.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2
+ Details
Name: |
us-gaap_ScheduleOfStockholdersEquityTableTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.3
Schedule of Disaggregation of Revenue (Details) - USD ($)
|
3 Months Ended |
9 Months Ended |
Sep. 30, 2023 |
Sep. 30, 2022 |
Sep. 30, 2023 |
Sep. 30, 2022 |
Product Information [Line Items] |
|
|
|
|
Revenue |
$ 413,009
|
$ 144,032
|
$ 1,665,412
|
$ 1,122,169
|
Hardware [Member] |
|
|
|
|
Product Information [Line Items] |
|
|
|
|
Revenue |
273,000
|
1,000
|
994,000
|
532,000
|
Consumables [Member] |
|
|
|
|
Product Information [Line Items] |
|
|
|
|
Revenue |
50,000
|
49,000
|
173,000
|
165,000
|
Contract Research Services [Member] |
|
|
|
|
Product Information [Line Items] |
|
|
|
|
Revenue |
(1,000)
|
|
35,000
|
125,000
|
Sample Preparation Accessories [Member] |
|
|
|
|
Product Information [Line Items] |
|
|
|
|
Revenue |
31,000
|
41,000
|
113,000
|
93,000
|
Technical Support/Extended Service Contracts [Member] |
|
|
|
|
Product Information [Line Items] |
|
|
|
|
Revenue |
34,000
|
41,000
|
123,000
|
94,000
|
Agrochem Products [Member] |
|
|
|
|
Product Information [Line Items] |
|
|
|
|
Revenue |
15,000
|
10,000
|
181,000
|
93,000
|
Shipping and Handling [Member] |
|
|
|
|
Product Information [Line Items] |
|
|
|
|
Revenue |
11,000
|
2,000
|
38,000
|
20,000
|
Other [Member] |
|
|
|
|
Product Information [Line Items] |
|
|
|
|
Revenue |
|
|
8,000
|
|
Transferred at a Point In Time [Member] |
|
|
|
|
Product Information [Line Items] |
|
|
|
|
Revenue |
379,000
|
103,000
|
1,506,000
|
903,000
|
Transferred Over At Time [Member] |
|
|
|
|
Product Information [Line Items] |
|
|
|
|
Revenue |
34,000
|
41,000
|
159,000
|
219,000
|
North America [Member] |
|
|
|
|
Product Information [Line Items] |
|
|
|
|
Revenue |
251,000
|
138,000
|
1,067,000
|
709,000
|
Europe [Member] |
|
|
|
|
Product Information [Line Items] |
|
|
|
|
Revenue |
76,000
|
13,000
|
130,000
|
61,000
|
Asia [Member] |
|
|
|
|
Product Information [Line Items] |
|
|
|
|
Revenue |
$ 86,000
|
$ (7,000)
|
$ 468,000
|
$ 352,000
|
X |
- DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4
+ Details
Name: |
us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- Details
Name: |
srt_ProductOrServiceAxis=PBIO_HardwareMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_ProductOrServiceAxis=PBIO_ConsumablesMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_ProductOrServiceAxis=PBIO_ContractResearchServicesMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_ProductOrServiceAxis=PBIO_SamplePreparationAccessoriesMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_ProductOrServiceAxis=PBIO_TechnicalSupportExtendedServiceContractsMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_ProductOrServiceAxis=PBIO_AgrochemProductsMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_ProductOrServiceAxis=us-gaap_ShippingAndHandlingMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_ProductOrServiceAxis=PBIO_OtherMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_ProductOrServiceAxis=PBIO_TransferredAtAPointInTimeMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_ProductOrServiceAxis=PBIO_TransferredOverAtTimeMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_StatementGeographicalAxis=srt_NorthAmericaMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_StatementGeographicalAxis=srt_EuropeMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_StatementGeographicalAxis=srt_AsiaMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.23.3
X |
- References
+ Details
Name: |
us-gaap_AccountingPoliciesAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount billed to customers under long-term contracts or programs but not paid. Excludes amounts due that have been withheld because of retainage provisions in a contract.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 910 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482546/910-10-50-6
+ Details
Name: |
us-gaap_AccountsReceivableBilledForLongTermContractsOrPrograms |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(26)(c)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_DeferredRevenue |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
v3.23.3
X |
- DefinitionExtended warranty service.
+ References
+ Details
Name: |
PBIO_ExtendedWarrantyService |
Namespace Prefix: |
PBIO_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_AwardDateAxis=PBIO_TwoThousandAndTwentyThreeMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_AwardDateAxis=PBIO_TwoThousandAndTwentyFourMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.23.3
X |
- DefinitionFor an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-21
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-20
Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482861/275-10-50-18
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482861/275-10-50-20
+ Details
Name: |
us-gaap_ConcentrationRiskPercentage1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:percentItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
srt_MajorCustomersAxis=PBIO_TopFiveCustomersMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_MajorCustomersAxis=PBIO_FederalAgenciesMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.23.3
Schedule of Computation of Loss Per Share (Details) - USD ($)
|
3 Months Ended |
9 Months Ended |
Sep. 30, 2023 |
Sep. 30, 2022 |
Sep. 30, 2023 |
Sep. 30, 2022 |
Accounting Policies [Abstract] |
|
|
|
|
Net loss attributable to common shareholders |
$ (6,261,999)
|
$ (4,893,946)
|
$ (24,666,565)
|
$ (12,913,826)
|
Weighted average common stock shares outstanding basic |
21,716,950
|
11,131,742
|
20,337,229
|
10,429,817
|
Weighted average common stock shares outstanding diluted |
21,716,950
|
11,131,742
|
20,337,229
|
10,429,817
|
Loss per common share - basic |
$ (0.29)
|
$ (0.44)
|
$ (1.21)
|
$ (1.24)
|
Loss per common share - diluted |
$ (0.29)
|
$ (0.44)
|
$ (1.21)
|
$ (1.24)
|
X |
- References
+ Details
Name: |
us-gaap_AccountingPoliciesAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1
Reference 16: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7
+ Details
Name: |
us-gaap_EarningsPerShareBasic |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1
Reference 15: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7
+ Details
Name: |
us-gaap_EarningsPerShareDiluted |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 5 -Subparagraph (SAB Topic 6.B) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-5
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10
Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-11
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B
+ Details
Name: |
us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16
+ Details
Name: |
us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10
+ Details
Name: |
us-gaap_WeightedAverageNumberOfSharesOutstandingBasic |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.3
Schedule of Anti-Dilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares
|
9 Months Ended |
Sep. 30, 2023 |
Sep. 30, 2022 |
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] |
|
|
Total potentially dilutive shares |
47,768,850
|
33,217,416
|
Stock Options [Member] |
|
|
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] |
|
|
Total potentially dilutive shares |
3,420,754
|
1,307,822
|
Convertible Debt Securities [Member] |
|
|
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] |
|
|
Total potentially dilutive shares |
7,417,906
|
6,471,034
|
Common Stock Warrants [Member] |
|
|
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] |
|
|
Total potentially dilutive shares |
15,732,940
|
16,293,768
|
Series D Convertible Preferred Stock [Member] |
|
|
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] |
|
|
Total potentially dilutive shares |
6,250
|
25,000
|
Series G Convertible Preferred Stock [Member] |
|
|
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] |
|
|
Total potentially dilutive shares |
|
26,857
|
Series H Convertible Preferred Stock [Member] |
|
|
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] |
|
|
Total potentially dilutive shares |
|
33,334
|
Series H2 Convertible Preferred Stock [Member] |
|
|
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] |
|
|
Total potentially dilutive shares |
|
70,000
|
Series J Convertible Preferred Stock [Member] |
|
|
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] |
|
|
Total potentially dilutive shares |
|
115,267
|
Series K Convertible Preferred Stock [Member] |
|
|
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] |
|
|
Total potentially dilutive shares |
|
229,334
|
Series AA Convertible Preferred Stock [Member] |
|
|
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] |
|
|
Total potentially dilutive shares |
8,601,000
|
8,645,000
|
Series BB Convertible Preferred Stock [Member] |
|
|
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] |
|
|
Total potentially dilutive shares |
8,580,000
|
|
Series CC Convertible Preferred Stock [Member] |
|
|
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] |
|
|
Total potentially dilutive shares |
4,010,000
|
|
X |
- DefinitionSecurities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1
+ Details
Name: |
us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
+ Details
Name: |
us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=PBIO_EmployeeStockOptionsMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=PBIO_CommonStockWarrantsMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=PBIO_SeriesDConvertiblePreferredStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=PBIO_SeriesGConvertiblePreferredStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=PBIO_SeriesHConvertiblePreferredStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=PBIO_SeriesHTwoConvertiblePreferredStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=PBIO_SeriesJConvertiblePreferredStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=PBIO_SeriesKConvertiblePreferredStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=PBIO_SeriesAAConvertiblePreferredStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=PBIO_SeriesBBConvertiblePreferredStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=PBIO_SeriesCCConvertiblePreferredStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.23.3
X |
- DefinitionShare Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Forfeiture Rate.
+ References
+ Details
Name: |
PBIO_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate |
Namespace Prefix: |
PBIO_ |
Data Type: |
dtr-types:percentItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
+ Details
Name: |
us-gaap_PropertyPlantAndEquipmentLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:percentItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:percentItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe risk-free interest rate assumption that is used in valuing an option on its own shares.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:percentItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionExpected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:durationItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_PlanNameAxis=PBIO_EmployeesOfficersMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_RangeAxis=srt_MinimumMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_RangeAxis=srt_MaximumMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.23.3
Schedule of Stock Based Compensation Expense (Details) - USD ($)
|
3 Months Ended |
9 Months Ended |
Sep. 30, 2023 |
Sep. 30, 2022 |
Sep. 30, 2023 |
Sep. 30, 2022 |
Total stock-based compensation expense |
$ 140,622
|
$ 32,427
|
$ 1,706,420
|
$ 128,984
|
Cost of Sales [Member] |
|
|
|
|
Total stock-based compensation expense |
11,183
|
2,184
|
75,724
|
8,694
|
Research and Development Expense [Member] |
|
|
|
|
Total stock-based compensation expense |
35,676
|
9,499
|
241,585
|
37,803
|
Selling and Marketing Expense [Member] |
|
|
|
|
Total stock-based compensation expense |
17,150
|
4,583
|
102,675
|
18,166
|
General and Administrative Expense [Member] |
|
|
|
|
Total stock-based compensation expense |
$ 76,613
|
$ 16,161
|
$ 1,286,436
|
$ 64,321
|
X |
- DefinitionAmount of noncash expense for share-based payment arrangement.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
+ Details
Name: |
us-gaap_ShareBasedCompensation |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.23.3
Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - USD ($)
|
Sep. 30, 2023 |
Dec. 31, 2022 |
Financing Receivable, Past Due [Line Items] |
|
|
Total Financial Assets |
$ 77,918
|
$ 63,638
|
Fair Value, Inputs, Level 1 [Member] |
|
|
Financing Receivable, Past Due [Line Items] |
|
|
Total Financial Assets |
77,918
|
63,638
|
Fair Value, Inputs, Level 2 [Member] |
|
|
Financing Receivable, Past Due [Line Items] |
|
|
Total Financial Assets |
|
|
Fair Value, Inputs, Level 3 [Member] |
|
|
Financing Receivable, Past Due [Line Items] |
|
|
Total Financial Assets |
|
|
Equity Securities [Member] |
|
|
Financing Receivable, Past Due [Line Items] |
|
|
Total Financial Assets |
77,918
|
63,638
|
Equity Securities [Member] | Fair Value, Inputs, Level 1 [Member] |
|
|
Financing Receivable, Past Due [Line Items] |
|
|
Total Financial Assets |
77,918
|
63,638
|
Equity Securities [Member] | Fair Value, Inputs, Level 2 [Member] |
|
|
Financing Receivable, Past Due [Line Items] |
|
|
Total Financial Assets |
|
|
Equity Securities [Member] | Fair Value, Inputs, Level 3 [Member] |
|
|
Financing Receivable, Past Due [Line Items] |
|
|
Total Financial Assets |
|
|
X |
- DefinitionFair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2
+ Details
Name: |
us-gaap_AssetsFairValueDisclosure |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479319/326-20-50-14
Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 80 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479294/326-20-55-80
+ Details
Name: |
us-gaap_FinancingReceivableRecordedInvestmentPastDueLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_CollateralAxis=us-gaap_EquitySecuritiesMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.23.3
Summary of Significant Accounting Policies (Details Narrative) - USD ($)
|
3 Months Ended |
9 Months Ended |
|
|
Sep. 30, 2023 |
Sep. 30, 2022 |
Sep. 30, 2023 |
Sep. 30, 2022 |
Dec. 31, 2022 |
Aug. 30, 2020 |
Property, Plant and Equipment [Line Items] |
|
|
|
|
|
|
Cumulative effect of adoption, adjustment in additional paid in capital |
$ 93,973,646
|
|
$ 93,973,646
|
|
$ 69,006,145
|
$ 2,728,243
|
Cumulative effect of adoption, adjustment in accumulated deficit |
(158,492,770)
|
|
(158,492,770)
|
|
$ (133,826,205)
|
$ 2,255,216
|
Stock-based compensation expense |
$ 140,622
|
$ 32,427
|
$ 1,706,420
|
$ 128,984
|
|
|
Minimum [Member] |
|
|
|
|
|
|
Property, Plant and Equipment [Line Items] |
|
|
|
|
|
|
Forfeiture rate |
0.00%
|
|
0.00%
|
|
|
|
Maximum [Member] |
|
|
|
|
|
|
Property, Plant and Equipment [Line Items] |
|
|
|
|
|
|
Forfeiture rate |
5.00%
|
|
5.00%
|
|
|
|
Nexity Global SA [Member] |
|
|
|
|
|
|
Property, Plant and Equipment [Line Items] |
|
|
|
|
|
|
Sale of stock number of shares received |
|
|
100,250
|
|
|
|
Investment owned, at fair value |
$ 77,918
|
|
$ 77,918
|
|
|
|
Unrealized gain |
|
|
$ 14,280
|
|
|
|
X |
- DefinitionAmount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(18)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_AdditionalPaidInCapital |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionFair value of investment in security owned.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6
Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 55 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480493/946-210-55-1
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480524/946-210-50-2
Reference 10: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12
Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(11)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(d)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(2)(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(2)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-12(Column C)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-12(Column A)(Footnote 1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1
Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-12(Column C)(Footnote 5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1
Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-12(Column C)(Footnote 6)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1
Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column C)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3
Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column C)(Footnote 2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3
Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column A)(Footnote 6)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3
Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column A)(Footnote 7)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3
Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column C)(Footnote 9)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3
Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column F)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6
Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6
Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6
Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column F)(Footnote 4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6
Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column F)(Footnote 7)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6
+ Details
Name: |
us-gaap_InvestmentOwnedAtFairValue |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount of unrealized gain (loss) on investment in marketable security.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)(c)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
+ Details
Name: |
us-gaap_MarketableSecuritiesUnrealizedGainLoss |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
+ Details
Name: |
us-gaap_PropertyPlantAndEquipmentLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of accumulated undistributed earnings (deficit).
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1
Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1
Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_RetainedEarningsAccumulatedDeficit |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionThe number of shares issued or sold by the subsidiary or equity method investee per stock transaction.
+ References
+ Details
Name: |
us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of noncash expense for share-based payment arrangement.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
+ Details
Name: |
us-gaap_ShareBasedCompensation |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- Details
Name: |
srt_RangeAxis=srt_MinimumMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_RangeAxis=srt_MaximumMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
dei_LegalEntityAxis=PBIO_NexityGlobalSAMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.23.3
Schedule of Future Minimum Rental Payments Required Under Operating Leases (Details) - USD ($)
|
Sep. 30, 2023 |
Dec. 31, 2022 |
Commitments and Contingencies Disclosure [Abstract] |
|
|
October 1 – December 31, 2023 |
$ 15,887
|
|
2024 |
64,393
|
|
2025 |
66,969
|
|
2026 |
51,778
|
|
Total future undiscounted lease payments |
199,027
|
|
Less imputed interest |
(61,481)
|
|
Present value of lease liabilities |
$ 137,546
|
$ 282,095
|
X |
- References
+ Details
Name: |
us-gaap_CommitmentsAndContingenciesDisclosureAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6
+ Details
Name: |
us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6
+ Details
Name: |
us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6
+ Details
Name: |
us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6
+ Details
Name: |
us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6
+ Details
Name: |
us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3
+ Details
Name: |
us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1
+ Details
Name: |
us-gaap_OperatingLeaseLiability |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
v3.23.3
Schedule of Right of Use Asset and the Corresponding Lease Liability (Details) - USD ($)
|
Sep. 30, 2023 |
Dec. 31, 2022 |
Commitments and Contingencies Disclosure [Abstract] |
|
|
Right of use asset |
$ 159,424
|
$ 282,095
|
Right of use liability, current |
66,259
|
142,171
|
Right of use liability, long term |
71,287
|
139,924
|
Total lease liability |
$ 137,546
|
$ 282,095
|
X |
- References
+ Details
Name: |
us-gaap_CommitmentsAndContingenciesDisclosureAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1
+ Details
Name: |
us-gaap_OperatingLeaseLiability |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as current.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1
+ Details
Name: |
us-gaap_OperatingLeaseLiabilityCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1
+ Details
Name: |
us-gaap_OperatingLeaseLiabilityNoncurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of lessee's right to use underlying asset under operating lease.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1
+ Details
Name: |
us-gaap_OperatingLeaseRightOfUseAsset |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
v3.23.3
X |
- References
+ Details
Name: |
us-gaap_CommitmentsAndContingenciesDisclosureAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of lease cost recognized by lessee for lease contract.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4
+ Details
Name: |
us-gaap_LeaseCost |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4
+ Details
Name: |
us-gaap_OperatingLeaseCost |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount of short-term lease cost, excluding expense for lease with term of one month or less.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4
+ Details
Name: |
us-gaap_ShortTermLeaseCost |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
v3.23.3
Commitments and Contingencies (Details Narrative) - USD ($)
|
|
1 Months Ended |
3 Months Ended |
9 Months Ended |
12 Months Ended |
|
Aug. 09, 2021 |
Apr. 30, 2012 |
Sep. 30, 2023 |
Sep. 30, 2022 |
Sep. 30, 2023 |
Sep. 30, 2022 |
Dec. 31, 2018 |
Dec. 31, 2017 |
Dec. 31, 2016 |
Dec. 31, 2015 |
Dec. 31, 2014 |
Dec. 31, 2022 |
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Operating lease liability |
|
|
$ 137,546
|
|
$ 137,546
|
|
|
|
|
|
|
$ 282,095
|
Operating lease |
|
|
|
|
$ 122,671
|
$ 82,001
|
|
|
|
|
|
|
Weighted-average remaining lease term |
|
|
2 years 7 months 2 days
|
|
2 years 7 months 2 days
|
|
|
|
|
|
|
|
Weighted-average discount rate |
|
|
12.00%
|
|
12.00%
|
|
|
|
|
|
|
|
Expenses |
|
|
$ 1,705,818
|
$ 1,507,392
|
$ 7,677,487
|
4,473,458
|
|
|
|
|
|
|
Battelle Memorial Institute [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Mimimum royalty fee |
|
|
|
|
|
|
$ 5,000
|
$ 4,000
|
$ 3,000
|
$ 2,000
|
$ 1,200
|
|
Target Discovery Inc [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Mimimum royalty fee |
|
|
|
|
60,000
|
60,000
|
|
|
|
|
|
|
Payments for fees |
|
$ 1,400
|
|
|
|
|
|
|
|
|
|
|
Professional and contract services expense |
|
$ 2,000
|
|
|
|
|
|
|
|
|
|
|
Expenses |
|
|
|
|
55,400
|
$ 65,100
|
|
|
|
|
|
|
Medford lease [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Annual cost of living payment |
|
|
|
|
$ 7,282
|
|
|
|
|
|
|
|
Lessee operating lease description |
|
|
|
|
The lease shall be automatically extended for additional
three years unless either party terminates at least nine months prior to the expiration of the current lease term
|
|
|
|
|
|
|
|
Operating lease liability |
|
|
$ 221,432
|
|
$ 221,432
|
|
|
|
|
|
|
|
Estimated borrowing rate |
|
|
12.00%
|
|
12.00%
|
|
|
|
|
|
|
|
Sparks lease [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Lessee operating lease description |
On
August 9, 2021, we entered into an operating lease agreement for our warehouse space in Sparks, NV (the “Sparks Lease”) for
the period from September 1, 2021 through September 30, 2026. The lease contains escalating payments during the lease period. The lease
can be extended for an additional three years if the Company provides notice at least six months prior to the expiration of the current
lease term
|
|
|
|
|
|
|
|
|
|
|
|
Operating lease liability |
|
|
$ 239,327
|
|
$ 239,327
|
|
|
|
|
|
|
|
Estimated borrowing rate |
|
|
12.00%
|
|
12.00%
|
|
|
|
|
|
|
|
Corporate Office [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Lease monthly payments |
|
|
|
|
$ 7,650
|
|
|
|
|
|
|
|
Lease expiration date |
|
|
|
|
Dec. 31, 2023
|
|
|
|
|
|
|
|
X |
- DefinitionAnnual cost of living payment.
+ References
+ Details
Name: |
PBIO_AnnualCostOfLivingPayment |
Namespace Prefix: |
PBIO_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionEstimated borrowing rate.
+ References
+ Details
Name: |
PBIO_EstimatedBorrowingRate |
Namespace Prefix: |
PBIO_ |
Data Type: |
dtr-types:percentItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Name Regulation S-X (SX) -Number 210 -Section 12 -Subsection 28 -Paragraph Column B -Publisher SEC
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Regulation S-X (SX) -Number 210 -Section 12 -Subsection 28 -Paragraph Column C -Publisher SEC
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Regulation S-X (SX) -Number 210 -Section 12 -Subsection 28 -Paragraph Column D -Publisher SEC
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Regulation S-X (SX) -Number 210 -Section 12 -Subsection 28 -Paragraph Column E -Publisher SEC
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Name Regulation S-X (SX) -Number 210 -Section 12 -Subsection 28 -Paragraph Column F -Publisher SEC
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Name Regulation S-X (SX) -Number 210 -Section 12 -Subsection 28 -Paragraph Column G -Publisher SEC
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Name Regulation S-X (SX) -Number 210 -Section 12 -Subsection 28 -Paragraph Column H -Publisher SEC
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Name Regulation S-X (SX) -Number 210 -Section 12 -Subsection 28 -Paragraph Column I -Publisher SEC
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Name Regulation S-X (SX) -Number 210 -Section 12 -Subsection 28 -Footnote 2 -Publisher SEC
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 970 -SubTopic 360 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-28(Column F)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479438/970-360-S99-1
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 970 -SubTopic 360 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-28(Column E)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479438/970-360-S99-1
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 970 -SubTopic 360 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-28(Column D)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479438/970-360-S99-1
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 970 -SubTopic 360 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-28(Column C)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479438/970-360-S99-1
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 970 -SubTopic 360 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-28(Column I)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479438/970-360-S99-1
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 970 -SubTopic 360 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-28(Column B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479438/970-360-S99-1
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 970 -SubTopic 360 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-28(Column G)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479438/970-360-S99-1
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 970 -SubTopic 360 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-28(Column H)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479438/970-360-S99-1
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 970 -SubTopic 360 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-28(Footnote 2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479438/970-360-S99-1
+ Details
Name: |
srt_RealEstateAndAccumulatedDepreciationLineItems |
Namespace Prefix: |
srt_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTotal costs of sales and operating expenses for the period.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
+ Details
Name: |
us-gaap_CostsAndExpenses |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionDate which lease or group of leases is set to expire, in YYYY-MM-DD format.
+ References
+ Details
Name: |
us-gaap_LeaseExpirationDate1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDescription of lessee's operating lease.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3
+ Details
Name: |
us-gaap_LesseeOperatingLeaseDescription |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1
+ Details
Name: |
us-gaap_OperatingLeaseLiability |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479041/842-20-45-5
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4
+ Details
Name: |
us-gaap_OperatingLeasePayments |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionWeighted average discount rate for operating lease calculated at point in time.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(4) -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4
+ Details
Name: |
us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:percentItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionWeighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4
+ Details
Name: |
us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:durationItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionAmount of cash outflow for fees classified as other.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (g) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25
+ Details
Name: |
us-gaap_PaymentsForFees |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionCash payments to lessor's for use of assets under operating leases.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (g) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25
+ Details
Name: |
us-gaap_PaymentsForRent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionProfessional and contract service expense includes cost reimbursements for support services related to contracted projects, outsourced management, technical and staff support.
+ References
+ Details
Name: |
us-gaap_ProfessionalAndContractServicesExpense |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_GeographicDistributionAxis=PBIO_MedfordLeaseMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_GeographicDistributionAxis=PBIO_SparksLeaseMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis=PBIO_CorporateOfficeMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.23.3
Schedule of Convertible Debts and Outstanding Balances (Details) - USD ($)
|
9 Months Ended |
12 Months Ended |
Sep. 30, 2023 |
Dec. 31, 2022 |
Debt Instrument [Line Items] |
|
|
|
Conversion price |
|
$ 2.50
|
|
Totals |
|
|
$ 18,279,186
|
Debt unamortized discount |
|
744,393
|
455,517
|
Principal amount |
|
$ 18,222,120
|
$ 17,823,669
|
Investor [Member] |
|
|
|
Debt Instrument [Line Items] |
|
|
|
Interest Rate |
|
10.00%
|
10.00%
|
Conversion price |
[1] |
$ 2.50
|
$ 2.50
|
Totals |
|
$ 8,586,750
|
$ 9,393,150
|
Others [Member] |
|
|
|
Debt Instrument [Line Items] |
|
|
|
Totals |
|
$ 10,379,763
|
$ 8,886,036
|
Others [Member] | Minimum [Member] |
|
|
|
Debt Instrument [Line Items] |
|
|
|
Interest Rate |
|
0.00%
|
0.00%
|
Conversion price |
[2] |
$ 2.50
|
$ 2.50
|
Others [Member] | Maximum [Member] |
|
|
|
Debt Instrument [Line Items] |
|
|
|
Interest Rate |
|
24.00%
|
24.00%
|
Conversion price |
|
$ 7.50
|
$ 7.50
|
|
|
X |
- DefinitionThe portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_ConvertibleDebtCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionDividend or interest rate associated with the financial instrument issued in exchange for the original debt being converted in a noncash or part noncash transaction. Noncash are transactions that affect recognized assets or liabilities but that do not result in cash receipts or cash payments. Part noncash refers to that portion of the transaction not resulting in cash receipts or cash payments.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5
+ Details
Name: |
us-gaap_DebtConversionConvertedInstrumentRate |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:percentItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4
+ Details
Name: |
us-gaap_DebtInstrumentCarryingAmount |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionThe price per share of the conversion feature embedded in the debt instrument.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-5
+ Details
Name: |
us-gaap_DebtInstrumentConvertibleConversionPrice1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B
Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B
Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C
Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E
Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B
Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E
Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E
Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E
Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F
Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F
Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F
Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F
Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I
+ Details
Name: |
us-gaap_DebtInstrumentLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount, after accumulated amortization, of debt discount.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 45 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org//1943274/2147482925/835-30-45-1A
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8
Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D
+ Details
Name: |
us-gaap_DebtInstrumentUnamortizedDiscount |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- Details
Name: |
srt_RangeAxis=srt_MinimumMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_RangeAxis=srt_MaximumMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.23.3
Schedule of Convertible Debts and Outstanding Balances (Details) (Parenthetical)
|
9 Months Ended |
Sep. 30, 2023
USD ($)
Integer
$ / shares
|
Short-Term Debt [Line Items] |
|
Debt instrument, convertible price per shares |
$ 2.50
|
Debt default amount | $ |
$ 1
|
Debt instrument, convertible, conversion price |
$ 2.50
|
Debt default convertible conversion ratio |
75.00%
|
Debt instrument, convertible, conversion price, Increase |
$ 2.50
|
Debt instrument, convertible, conversion price, decrease |
$ 2.50
|
Percentage of price |
10.00%
|
Convertible lesser per share |
$ 2.5
|
Convertible lesser Percent |
25.00%
|
Original debt, interest rate of debt |
35.00%
|
Principal balance | $ |
$ 12,300,000
|
Trading day | Integer |
5
|
Chief Executive Officer [Member] |
|
Short-Term Debt [Line Items] |
|
Principal balance | $ |
$ 950,000
|
Convertible Debt [Member] |
|
Short-Term Debt [Line Items] |
|
Debt instrument, convertible price per shares |
$ 2.50
|
Debt default amount | $ |
$ 189,750
|
Debt instrument lowest trading price |
25.00%
|
Convertible Debt [Member] | Series AA Preferred Stock [Member] |
|
Short-Term Debt [Line Items] |
|
Debt instrument, convertible price per shares |
$ 2.50
|
Convertible Debt [Member] | 5 Day Average VWAP [Member] |
|
Short-Term Debt [Line Items] |
|
Debt default amount | $ |
$ 729,100
|
Convertible Debt One [Member] |
|
Short-Term Debt [Line Items] |
|
Debt instrument, convertible price per shares |
$ 2.50
|
Convertible Debt Two [Member] |
|
Short-Term Debt [Line Items] |
|
Debt instrument lowest trading price |
30.00%
|
Convertible Debt Three [Member] |
|
Short-Term Debt [Line Items] |
|
Debt instrument lowest trading price |
25.00%
|
Convertible Debt Four [Member] |
|
Short-Term Debt [Line Items] |
|
Debt instrument lowest trading price |
70.00%
|
X |
- DefinitionConvertible lesser discount percent.
+ References
+ Details
Name: |
PBIO_ConvertibleLesserDiscountPercent |
Namespace Prefix: |
PBIO_ |
Data Type: |
dtr-types:percentItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionConvertible lesser per share.
+ References
+ Details
Name: |
PBIO_ConvertibleLesserPerShare |
Namespace Prefix: |
PBIO_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionDebt default convertible conversion ratio.
+ References
+ Details
Name: |
PBIO_DebtDefaultConvertibleConversionRatio |
Namespace Prefix: |
PBIO_ |
Data Type: |
dtr-types:percentItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDebt instrument discount percentage of stock price.
+ References
+ Details
Name: |
PBIO_DebtInstrumentDiscountPercentageOfStockPrice |
Namespace Prefix: |
PBIO_ |
Data Type: |
dtr-types:percentItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionPercentage of price rate.
+ References
+ Details
Name: |
PBIO_PercentageOfPriceRate |
Namespace Prefix: |
PBIO_ |
Data Type: |
dtr-types:percentItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionThe rate of interest that was being paid on the original debt issue that is being converted in the noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5
+ Details
Name: |
us-gaap_DebtConversionOriginalDebtInterestRateOfDebt |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:percentItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of outstanding long-term debt or borrowing associated with any securities or credit agreement for which there has been a default in principal, interest, sinking fund, or redemption provisions, or any breach of covenant that existed at the end of the period and subsequently has not been cured.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(c)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
+ Details
Name: |
us-gaap_DebtDefaultLongtermDebtAmount |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionThe price per share of the conversion feature embedded in the debt instrument.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-5
+ Details
Name: |
us-gaap_DebtInstrumentConvertibleConversionPrice1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionPer share decrease in conversion price of debt instrument. Excludes change due to standard antidilution provision.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3
+ Details
Name: |
us-gaap_DebtInstrumentConvertibleConversionPriceDecrease |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionPer share increase in conversion price of debt instrument. Excludes change due to standard antidilution provision.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3
+ Details
Name: |
us-gaap_DebtInstrumentConvertibleConversionPriceIncrease |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionPrice of the entity's common stock which would be required to be attained for the conversion feature embedded in the debt instrument to become effective.
+ References
+ Details
Name: |
us-gaap_DebtInstrumentConvertibleStockPriceTrigger |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThreshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature.
+ References
+ Details
Name: |
us-gaap_DebtInstrumentConvertibleThresholdTradingDays |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:integerItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFace (par) amount of debt instrument at time of issuance.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B
Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B
Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2
Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8
+ Details
Name: |
us-gaap_DebtInstrumentFaceAmount |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
+ Details
Name: |
us-gaap_ShortTermDebtLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleDebtMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=PBIO_SeriesAAPreferredStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_AwardTypeAxis=PBIO_FiveDayAverageVWAPMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_ShortTermDebtTypeAxis=PBIO_ConvertibleDebtOneMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_ShortTermDebtTypeAxis=PBIO_ConvertibleDebtTwoMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_ShortTermDebtTypeAxis=PBIO_ConvertibleDebtThreeMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_ShortTermDebtTypeAxis=PBIO_ConvertibleDebtFourMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.23.3
Schedule of Other Debt (Details) - USD ($)
|
Sep. 30, 2023 |
Dec. 31, 2022 |
Short-Term Debt [Line Items] |
|
|
|
Totals, Principal |
|
$ 2,193,032
|
$ 1,788,969
|
Long Term, discount |
|
|
|
Long Term, Principal |
|
162,522
|
150,000
|
Short Term, Principal |
|
$ 2,030,510
|
$ 1,638,969
|
Non Convertible [Member] |
|
|
|
Short-Term Debt [Line Items] |
|
|
|
Interest Rate |
[1] |
|
|
Totals, Principal |
|
$ 1,016,500
|
$ 878,809
|
Merchant Debt [Member] |
|
|
|
Short-Term Debt [Line Items] |
|
|
|
Totals, Principal |
[2] |
$ 1,014,010
|
$ 760,160
|
SBA [Member] |
|
|
|
Short-Term Debt [Line Items] |
|
|
|
Interest Rate |
[3] |
3.75%
|
3.75%
|
Totals, Principal |
[3] |
$ 162,522
|
$ 150,000
|
|
|
X |
- DefinitionContractual interest rate for funds borrowed, under the debt agreement.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22(a)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_DebtInstrumentInterestRateStatedPercentage |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:percentItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionAmount of debt discount to be amortized after one year or the normal operating cycle, if longer.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 45 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org//1943274/2147482925/835-30-45-1A
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8
+ Details
Name: |
us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B
Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D
Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1
Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4
+ Details
Name: |
us-gaap_LongTermDebt |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of long-term debt classified as other.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1
+ Details
Name: |
us-gaap_OtherLongTermDebt |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of long-term debt classified as other, payable within one year or the operating cycle, if longer.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(13)(a)(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_OtherLongTermDebtCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
+ Details
Name: |
us-gaap_ShortTermDebtLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=PBIO_NonConvertibleLoansMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=PBIO_MerchantDebtMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=PBIO_SBAMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.23.3
Schedule of Other Debt (Details) (Parenthetical) - USD ($)
|
9 Months Ended |
12 Months Ended |
|
|
Sep. 30, 2023 |
Dec. 31, 2022 |
Dec. 31, 2021 |
Dec. 31, 2020 |
Debt Instrument [Line Items] |
|
|
|
|
Debt instrument, maturity date |
May 02, 2023
|
|
|
|
Non- convertible debt amount |
$ 861,500
|
|
|
|
Note payable |
$ 150,000
|
|
|
|
Accrued interest rate percent |
3.75%
|
|
|
|
Debt Instrument periodic payment |
$ 731
|
|
|
|
Deferred interest |
14,719
|
|
|
|
Principal amount paid |
$ 2,197
|
|
|
|
Debt instrument, maturity date description |
July 2020 to September 2024
|
|
|
|
Merchant Agreement [Member] |
|
|
|
|
Debt Instrument [Line Items] |
|
|
|
|
Debt instrument, maturity date description |
maturity dates ranged from June 26, 2023 to October 15, 2023
|
maturity dates ranged from April 4 to June 6, 2023
|
|
|
Payroll Protection Program [Member] |
|
|
|
|
Debt Instrument [Line Items] |
|
|
|
|
Borrowed amount |
|
|
|
$ 367,039
|
Debt interest rate |
|
|
|
1.00%
|
Paycheck Protection Programme [Member] |
|
|
|
|
Debt Instrument [Line Items] |
|
|
|
|
Borrowed amount |
|
|
$ 367,039
|
|
Minimum [Member] |
|
|
|
|
Debt Instrument [Line Items] |
|
|
|
|
Debt interest rate |
1.00%
|
|
|
|
Minimum [Member] | Merchant Agreement [Member] |
|
|
|
|
Debt Instrument [Line Items] |
|
|
|
|
Debt interest rate |
4.10%
|
|
|
|
Maximum [Member] |
|
|
|
|
Debt Instrument [Line Items] |
|
|
|
|
Debt interest rate |
10.00%
|
|
|
|
Maximum [Member] | Merchant Agreement [Member] |
|
|
|
|
Debt Instrument [Line Items] |
|
|
|
|
Debt interest rate |
100.90%
|
|
|
|
X |
- DefinitionAccrued interest rate percent.
+ References
+ Details
Name: |
PBIO_AccruedInterestRatePercent |
Namespace Prefix: |
PBIO_ |
Data Type: |
dtr-types:percentItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionNon convertible debt instrument amount.
+ References
+ Details
Name: |
PBIO_NonConvertibleDebtInstrumentAmount |
Namespace Prefix: |
PBIO_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionEffective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22(a)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-6
+ Details
Name: |
us-gaap_DebtInstrumentInterestRateEffectivePercentage |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:percentItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionContractual interest rate for funds borrowed, under the debt agreement.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22(a)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_DebtInstrumentInterestRateStatedPercentage |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:percentItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B
Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B
Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C
Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E
Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B
Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E
Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E
Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E
Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F
Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F
Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F
Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F
Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I
+ Details
Name: |
us-gaap_DebtInstrumentLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDate when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22(a)(2)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_DebtInstrumentMaturityDate |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDescription of the maturity date of the debt instrument including whether the debt matures serially and, if so, a brief description of the serial maturities.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22(a)(2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_DebtInstrumentMaturityDateDescription |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of the required periodic payments applied to principal.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_DebtInstrumentPeriodicPaymentPrincipal |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionMaximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.19(b),22(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionIncluding the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1
+ Details
Name: |
us-gaap_NotesPayable |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of realized and unrealized gain (loss) resulting from the difference between acquisition price and selling price or fair value of trading assets and trading liabilities, and from the firm's direct investment activity, conducted separately from customer trading activities, including, but not limited to, investments in private equity, alternative investment products, real estate, and exchanges and memberships.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 940 -SubTopic 320 -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481961/940-320-45-5
+ Details
Name: |
us-gaap_PrincipalTransactionsRevenue |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_TypeOfArrangementAxis=PBIO_MerchantAgreementMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=PBIO_PayrollProtectionProgramMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=PBIO_PaycheckProtectionProgrammeMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_RangeAxis=srt_MinimumMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_RangeAxis=srt_MaximumMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.23.3
Schedule of Related Party Debt (Details) - USD ($)
|
9 Months Ended |
12 Months Ended |
Sep. 30, 2023 |
Dec. 31, 2022 |
Defined Benefit Plan Disclosure [Line Items] |
|
|
|
Totals, Principle |
|
$ 731
|
|
Net, Principal |
|
$ 647,986
|
$ 634,885
|
Officers & Directors [Member] |
|
|
|
Defined Benefit Plan Disclosure [Line Items] |
|
|
|
Interest Rate |
[1] |
|
|
Totals, Principle |
|
$ 522,450
|
$ 521,950
|
Other Related Parties [Member] |
|
|
|
Defined Benefit Plan Disclosure [Line Items] |
|
|
|
Interest Rate |
|
12.00%
|
12.00%
|
Totals, Principle |
|
$ 126,050
|
$ 120,850
|
Related Party [Member] |
|
|
|
Defined Benefit Plan Disclosure [Line Items] |
|
|
|
Totals, Principle |
|
648,500
|
642,800
|
Discount, Principal |
|
514
|
7,915
|
Net, Principal |
|
$ 647,986
|
$ 634,885
|
|
|
X |
- DefinitionDebt instrument periodic payment principal gross.
+ References
+ Details
Name: |
PBIO_DebtInstrumentPeriodicPaymentPrincipalGross |
Namespace Prefix: |
PBIO_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionContractual interest rate for funds borrowed, under the debt agreement.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22(a)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_DebtInstrumentInterestRateStatedPercentage |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:percentItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionAmount of the required periodic payments applied to principal.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_DebtInstrumentPeriodicPaymentPrincipal |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
+ Details
Name: |
us-gaap_DefinedBenefitPlanDisclosureLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of liabilities classified as other, due within one year or the normal operating cycle, if longer.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.20) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_OtherLiabilitiesCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
v3.23.3
X |
- DefinitionContractual interest rate for funds borrowed, under the debt agreement.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22(a)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_DebtInstrumentInterestRateStatedPercentage |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:percentItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B
Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B
Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C
Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E
Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B
Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E
Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E
Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E
Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F
Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F
Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F
Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F
Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I
+ Details
Name: |
us-gaap_DebtInstrumentLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
srt_RangeAxis=srt_MinimumMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_RangeAxis=srt_MaximumMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.23.3
Debt (Details Narrative) - USD ($)
|
3 Months Ended |
9 Months Ended |
|
Sep. 30, 2023 |
Jun. 30, 2023 |
Mar. 31, 2023 |
Sep. 30, 2022 |
Jun. 30, 2022 |
Mar. 31, 2022 |
Sep. 30, 2023 |
Sep. 30, 2022 |
Dec. 31, 2022 |
Short-Term Debt [Line Items] |
|
|
|
|
|
|
|
|
|
Proceeds from Convertible Debt |
|
|
|
|
|
|
$ 4,336,665
|
$ 3,428,249
|
|
Fixed rate |
$ 2.50
|
|
|
|
|
|
$ 2.50
|
|
|
Deferred Costs |
$ 648,470
|
|
|
|
|
|
$ 648,470
|
|
|
Repayments of Senior Debt |
|
|
|
|
|
|
$ 2,462,269
|
|
|
Debt instrument maturity date description |
|
|
|
|
|
|
July 2020 to September 2024
|
|
|
Debt instrument, face amount. |
12,300,000
|
|
|
|
|
|
$ 12,300,000
|
|
|
Debt Instrument, Unamortized Discount |
744,393
|
|
|
|
|
|
744,393
|
|
$ 455,517
|
Payments on convertible debt |
|
|
|
|
|
|
2,462,269
|
1,086,946
|
|
Losses on extinguishment of debt |
|
|
|
|
|
|
$ 687,591
|
$ 10,000
|
|
Preferred stock extensions |
1,286,600
|
$ 1,397,000
|
|
|
|
|
|
|
|
Debt instrument, convertible price per shares |
|
|
|
|
|
|
$ 2.50
|
|
|
Convertible Debt [Member] |
|
|
|
|
|
|
|
|
|
Short-Term Debt [Line Items] |
|
|
|
|
|
|
|
|
|
Debt Instrument, Unamortized Discount |
$ 744,393
|
|
|
|
|
|
$ 744,393
|
|
455,517
|
Debt instrument, convertible price per shares |
|
|
|
|
|
|
$ 2.50
|
|
|
Common Stock [Member] |
|
|
|
|
|
|
|
|
|
Short-Term Debt [Line Items] |
|
|
|
|
|
|
|
|
|
Number of shares issued |
250,000
|
528,600
|
568,200
|
707,900
|
106,400
|
214,500
|
|
|
|
Preferred stock extensions |
|
|
|
|
|
|
|
|
|
Preferred Stock [Member] |
|
|
|
|
|
|
|
|
|
Short-Term Debt [Line Items] |
|
|
|
|
|
|
|
|
|
Preferred stock extensions |
6
|
$ 2
|
|
|
|
|
|
|
|
Three Lenders [Member] |
|
|
|
|
|
|
|
|
|
Short-Term Debt [Line Items] |
|
|
|
|
|
|
|
|
|
Payments on convertible debt |
|
|
|
|
|
|
$ 302,484
|
|
|
Three Lenders [Member] | Forbearance Agreements [Member] |
|
|
|
|
|
|
|
|
|
Short-Term Debt [Line Items] |
|
|
|
|
|
|
|
|
|
Payments on convertible debt |
|
|
|
|
|
|
272,500
|
|
|
Four Lenders [Member] | Forbearance Agreements [Member] |
|
|
|
|
|
|
|
|
|
Short-Term Debt [Line Items] |
|
|
|
|
|
|
|
|
|
Interest payable |
253,425
|
|
|
|
|
|
253,425
|
|
|
PBI Agrochem Inc [Member] |
|
|
|
|
|
|
|
|
|
Short-Term Debt [Line Items] |
|
|
|
|
|
|
|
|
|
Debt instrument, face amount. |
$ 352,188
|
|
|
|
|
|
$ 352,188
|
|
|
Minimum [Member] |
|
|
|
|
|
|
|
|
|
Short-Term Debt [Line Items] |
|
|
|
|
|
|
|
|
|
Debt interest rate |
1.00%
|
|
|
|
|
|
1.00%
|
|
|
Maximum [Member] |
|
|
|
|
|
|
|
|
|
Short-Term Debt [Line Items] |
|
|
|
|
|
|
|
|
|
Debt interest rate |
10.00%
|
|
|
|
|
|
10.00%
|
|
|
Convertible Debt [Member] |
|
|
|
|
|
|
|
|
|
Short-Term Debt [Line Items] |
|
|
|
|
|
|
|
|
|
Proceeds from Convertible Debt |
|
|
|
|
|
|
$ 4,300,000
|
|
|
Amortization of Debt Discount (Premium) |
|
|
|
|
|
|
2,621,523
|
|
|
Debt Instrument, Unamortized Discount |
$ 744,393
|
|
|
|
|
|
$ 744,393
|
|
|
Convertible Debt [Member] | Convertible Common Stock [Member] |
|
|
|
|
|
|
|
|
|
Short-Term Debt [Line Items] |
|
|
|
|
|
|
|
|
|
Fixed rate |
$ 2.50
|
|
|
|
|
|
$ 2.50
|
|
|
Convertible Debt, Fair Value Disclosures |
$ 1,832,757
|
|
|
|
|
|
$ 1,832,757
|
|
|
Convertible Debt [Member] | Minimum [Member] |
|
|
|
|
|
|
|
|
|
Short-Term Debt [Line Items] |
|
|
|
|
|
|
|
|
|
Debt instrument term |
|
|
|
|
|
|
1 month
|
|
|
Debt interest rate |
0.00%
|
|
|
|
|
|
0.00%
|
|
|
Convertible Debt [Member] | Maximum [Member] |
|
|
|
|
|
|
|
|
|
Short-Term Debt [Line Items] |
|
|
|
|
|
|
|
|
|
Debt instrument term |
|
|
|
|
|
|
12 months
|
|
|
Debt interest rate |
120.00%
|
|
|
|
|
|
120.00%
|
|
|
New Loan [Member] |
|
|
|
|
|
|
|
|
|
Short-Term Debt [Line Items] |
|
|
|
|
|
|
|
|
|
Debt interest rate |
10.00%
|
|
|
|
|
|
10.00%
|
|
|
Losses on extinguishment of debt |
|
|
|
|
|
|
$ 700,000
|
|
|
Ten Loans [Member] |
|
|
|
|
|
|
|
|
|
Short-Term Debt [Line Items] |
|
|
|
|
|
|
|
|
|
Proceeds from loans |
|
|
|
|
|
|
3,917,898
|
|
|
Increase in principal amount |
|
|
|
|
|
|
$ 4,067,898
|
|
|
Ten Loans [Member] | Common Stock [Member] |
|
|
|
|
|
|
|
|
|
Short-Term Debt [Line Items] |
|
|
|
|
|
|
|
|
|
Number of shares issued |
|
|
|
|
|
|
1,346,800
|
|
|
Ten Loans [Member] | Preferred Stock [Member] |
|
|
|
|
|
|
|
|
|
Short-Term Debt [Line Items] |
|
|
|
|
|
|
|
|
|
Preferred stock extensions |
|
|
|
|
|
|
$ 741
|
|
|
Short-term Non-Convertible Loan [Member] |
|
|
|
|
|
|
|
|
|
Short-Term Debt [Line Items] |
|
|
|
|
|
|
|
|
|
Amortization of Debt Discount (Premium) |
|
|
|
|
|
|
592,099
|
|
|
Debt Instrument, Unamortized Discount |
$ 514
|
|
|
|
|
|
514
|
|
$ 7,915
|
Proceeds from Short-Term Debt |
|
|
|
|
|
|
164,700
|
|
|
Original issue discount |
|
|
|
|
|
|
5,514
|
|
|
Proceeds from (Repayments of) Related Party Debt |
|
|
|
|
|
|
$ 159,000
|
|
|
Short-term Non-Convertible Loan [Member] | Minimum [Member] |
|
|
|
|
|
|
|
|
|
Short-Term Debt [Line Items] |
|
|
|
|
|
|
|
|
|
Debt interest rate |
12.00%
|
|
|
|
|
|
12.00%
|
|
|
Short-term Non-Convertible Loan [Member] | Maximum [Member] |
|
|
|
|
|
|
|
|
|
Short-Term Debt [Line Items] |
|
|
|
|
|
|
|
|
|
Debt interest rate |
120.00%
|
|
|
|
|
|
120.00%
|
|
|
X |
- DefinitionDebt original issue discount.
+ References
+ Details
Name: |
PBIO_DebtOriginalIssueDiscount |
Namespace Prefix: |
PBIO_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionStock issued during period value issuance of preferred stock for debt extension.
+ References
+ Details
Name: |
PBIO_StockIssuedDuringPeriodValueIssuanceOfPreferredStockForDebtExtension |
Namespace Prefix: |
PBIO_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 45 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org//1943274/2147482925/835-30-45-1A
Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.8) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
+ Details
Name: |
us-gaap_AmortizationOfDebtDiscountPremium |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionFair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.
+ References
+ Details
Name: |
us-gaap_ConvertibleDebtFairValueDisclosures |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionThe price per share of the conversion feature embedded in the debt instrument.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-5
+ Details
Name: |
us-gaap_DebtInstrumentConvertibleConversionPrice1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionPrice of the entity's common stock which would be required to be attained for the conversion feature embedded in the debt instrument to become effective.
+ References
+ Details
Name: |
us-gaap_DebtInstrumentConvertibleStockPriceTrigger |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFace (par) amount of debt instrument at time of issuance.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B
Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B
Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2
Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8
+ Details
Name: |
us-gaap_DebtInstrumentFaceAmount |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionNet increase or decrease in the carrying amount of the debt instrument for the period.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
+ Details
Name: |
us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionContractual interest rate for funds borrowed, under the debt agreement.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22(a)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_DebtInstrumentInterestRateStatedPercentage |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:percentItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionDescription of the maturity date of the debt instrument including whether the debt matures serially and, if so, a brief description of the serial maturities.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22(a)(2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_DebtInstrumentMaturityDateDescription |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionPeriod of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
+ Details
Name: |
us-gaap_DebtInstrumentTerm |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:durationItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount, after accumulated amortization, of debt discount.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 45 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org//1943274/2147482925/835-30-45-1A
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8
Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D
+ Details
Name: |
us-gaap_DebtInstrumentUnamortizedDiscount |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionThe carrying amount of deferred costs.
+ References
+ Details
Name: |
us-gaap_DeferredCostsCurrentAndNoncurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionDifference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 470 -SubTopic 50 -Section 40 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481303/470-50-40-2
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 470 -SubTopic 50 -Section 40 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481303/470-50-40-4
+ Details
Name: |
us-gaap_GainsLossesOnExtinguishmentOfDebt |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount of interest payable on debt, including, but not limited to, trade payables.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(15)(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 942 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03.15(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1
+ Details
Name: |
us-gaap_InterestPayableCurrentAndNoncurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionThe cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14
+ Details
Name: |
us-gaap_ProceedsFromConvertibleDebt |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionCash received from principal payments made on loans related to operating activities.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 25 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25
+ Details
Name: |
us-gaap_ProceedsFromLoans |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14
+ Details
Name: |
us-gaap_ProceedsFromShortTermDebt |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15
+ Details
Name: |
us-gaap_RepaymentsOfConvertibleDebt |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe cash outflow for a long-term debt where the holder has highest claim on the entity's asset in case of bankruptcy or liquidation during the period.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15
+ Details
Name: |
us-gaap_RepaymentsOfSeniorDebt |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
+ Details
Name: |
us-gaap_ShortTermDebtLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNumber of new stock issued during the period.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1
Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodSharesNewIssues |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleDebtMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_TitleOfIndividualAxis=PBIO_ThreeLendersMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_TypeOfArrangementAxis=PBIO_ForbearanceAgreementsMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_TitleOfIndividualAxis=PBIO_FourLendersMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
dei_LegalEntityAxis=PBIO_PBIAgrochemIncMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_RangeAxis=srt_MinimumMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_RangeAxis=srt_MaximumMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=us-gaap_ConvertibleDebtMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=us-gaap_ConvertibleCommonStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=PBIO_NewLoanMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=PBIO_TenLoansMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=PBIO_ShortTermNonConvertibleLoanMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.23.3
Schedule of Preferred Stock Outstanding (Details) - USD ($)
|
Sep. 30, 2023 |
Dec. 31, 2022 |
Class of Stock [Line Items] |
|
|
Total Convertible Preferred Shares |
$ 100
|
$ 1,098
|
Series A Junior Participating Preferred Stock, $.01 par value, 20,000 shares authorized, no shares outstanding |
100
|
1,098
|
Series D Convertible Preferred Stock [Member] |
|
|
Class of Stock [Line Items] |
|
|
Total Convertible Preferred Shares |
|
$ 3
|
Preferred stock, shares outstanding |
75
|
300
|
Series G Convertible Preferred Stock [Member] |
|
|
Class of Stock [Line Items] |
|
|
Total Convertible Preferred Shares |
|
$ 806
|
Preferred stock, shares outstanding |
80,570
|
80,570
|
Series H Convertible Preferred Stock [Member] |
|
|
Class of Stock [Line Items] |
|
|
Total Convertible Preferred Shares |
|
$ 100
|
Preferred stock, shares outstanding |
0
|
10,000
|
Series J Convertible Preferred Stock [Member] |
|
|
Class of Stock [Line Items] |
|
|
Total Convertible Preferred Shares |
|
$ 35
|
Preferred stock, shares outstanding |
0
|
3,458
|
Series K Convertible Preferred Stock [Member] |
|
|
Class of Stock [Line Items] |
|
|
Total Convertible Preferred Shares |
|
$ 68
|
Preferred stock, shares outstanding |
0
|
6,880
|
Series AA Convertible Preferred Stock [Member] |
|
|
Class of Stock [Line Items] |
|
|
Total Convertible Preferred Shares |
$ 86
|
$ 86
|
Preferred stock, shares outstanding |
8,601
|
8,601
|
Series BB Convertible Preferred Stock [Member] |
|
|
Class of Stock [Line Items] |
|
|
Total Convertible Preferred Shares |
$ 10
|
|
Preferred stock, shares outstanding |
858
|
0
|
Series CC Convertible Preferred Stock [Member] |
|
|
Class of Stock [Line Items] |
|
|
Total Convertible Preferred Shares |
$ 4
|
|
Preferred stock, shares outstanding |
401
|
0
|
Series H2 Convertible Preferred Stock [Member] |
|
|
Class of Stock [Line Items] |
|
|
Total Convertible Preferred Shares |
|
|
Preferred stock, shares outstanding |
0
|
21
|
Series A Junior Participating Preferred Stock [Member] |
|
|
Class of Stock [Line Items] |
|
|
Series A Junior Participating Preferred Stock, $.01 par value, 20,000 shares authorized, no shares outstanding |
|
|
Preferred stock, shares outstanding |
0
|
0
|
Series A Convertible Preferred Stock [Member] |
|
|
Class of Stock [Line Items] |
|
|
Total Convertible Preferred Shares |
|
|
Preferred stock, shares outstanding |
0
|
0
|
Series B Convertible Preferred Stock [Member] |
|
|
Class of Stock [Line Items] |
|
|
Total Convertible Preferred Shares |
|
|
Preferred stock, shares outstanding |
0
|
0
|
Series C Convertible Preferred Stock [Member] |
|
|
Class of Stock [Line Items] |
|
|
Total Convertible Preferred Shares |
|
|
Preferred stock, shares outstanding |
0
|
0
|
Series E Convertible Preferred Stock [Member] |
|
|
Class of Stock [Line Items] |
|
|
Total Convertible Preferred Shares |
|
|
Preferred stock, shares outstanding |
0
|
0
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13
Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef -Topic 272 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483014/272-10-45-3
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 272 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482987/272-10-50-1
Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(d)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(27)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3
+ Details
Name: |
us-gaap_ClassOfStockLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionValue of outstanding nonredeemable convertible preferred stock or outstanding convertible preferred stock that is redeemable solely at the option of the issuer.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3
+ Details
Name: |
us-gaap_ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1
Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_PreferredStockSharesOutstanding |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionAggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(21)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_PreferredStockValue |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=PBIO_SeriesDConvertiblePreferredStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=PBIO_SeriesGConvertiblePreferredStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=PBIO_SeriesHConvertiblePreferredStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=PBIO_SeriesJConvertiblePreferredStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=PBIO_SeriesKConvertiblePreferredStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=PBIO_SeriesAAConvertiblePreferredStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=PBIO_SeriesBBConvertiblePreferredStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=PBIO_SeriesCCConvertiblePreferredStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=PBIO_SeriesH2ConvertiblePreferredStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=PBIO_SeriesAJuniorParticipatingPreferredStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=PBIO_SeriesAConvertiblePreferredStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=PBIO_SeriesBConvertiblePreferredStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=PBIO_SeriesCConvertiblePreferredStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=PBIO_SeriesEConvertiblePreferredStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.23.3
Schedule Of Preferred Stock Outstanding (Details) (Parenthetical) - USD ($)
|
Sep. 30, 2023 |
May 01, 2023 |
Dec. 31, 2022 |
Series D Convertible Preferred Stock [Member] |
|
|
|
Class of Stock [Line Items] |
|
|
|
Preferred stock, par value |
$ 0.01
|
|
$ 0.01
|
Preferred stock, shares authorized |
850
|
|
850
|
Preferred stock, shares issued |
75
|
|
300
|
Preferred stock, shares outstanding |
75
|
|
300
|
Preferred stock, shares outstanding |
|
|
$ 300,000
|
Series H Convertible Preferred Stock [Member] |
|
|
|
Class of Stock [Line Items] |
|
|
|
Preferred stock, par value |
$ 0.01
|
|
$ 0.01
|
Preferred stock, shares authorized |
10,000
|
|
10,000
|
Preferred stock, shares issued |
0
|
|
10,000
|
Preferred stock, shares outstanding |
0
|
|
10,000
|
Series G Convertible Preferred Stock [Member] |
|
|
|
Class of Stock [Line Items] |
|
|
|
Preferred stock, par value |
$ 0.01
|
|
$ 0.01
|
Preferred stock, shares authorized |
240,000
|
|
240,000
|
Preferred stock, shares issued |
80,570
|
|
80,570
|
Preferred stock, shares outstanding |
80,570
|
|
80,570
|
Series J Convertible Preferred Stock [Member] |
|
|
|
Class of Stock [Line Items] |
|
|
|
Preferred stock, par value |
$ 0.01
|
|
$ 0.01
|
Preferred stock, shares authorized |
6,250
|
|
6,250
|
Preferred stock, shares issued |
0
|
|
3,458
|
Preferred stock, shares outstanding |
0
|
|
3,458
|
Series K Convertible Preferred Stock [Member] |
|
|
|
Class of Stock [Line Items] |
|
|
|
Preferred stock, par value |
$ 0.01
|
|
$ 0.01
|
Preferred stock, shares authorized |
15,000
|
|
15,000
|
Preferred stock, shares issued |
0
|
|
6,880
|
Preferred stock, shares outstanding |
0
|
|
6,880
|
Series AA Convertible Preferred Stock [Member] |
|
|
|
Class of Stock [Line Items] |
|
|
|
Preferred stock, par value |
$ 0.01
|
|
$ 0.01
|
Preferred stock, shares authorized |
10,000
|
|
10,000
|
Preferred stock, shares issued |
8,601
|
|
8,601
|
Preferred stock, shares outstanding |
8,601
|
|
8,601
|
Series BB Convertible Preferred Stock [Member] |
|
|
|
Class of Stock [Line Items] |
|
|
|
Preferred stock, par value |
$ 0.01
|
$ 0.01
|
$ 0.01
|
Preferred stock, shares authorized |
1,000
|
1,000
|
1,000
|
Preferred stock, shares issued |
858
|
|
|
Preferred stock, shares outstanding |
858
|
|
0
|
Series CC Convertible Preferred Stock [Member] |
|
|
|
Class of Stock [Line Items] |
|
|
|
Preferred stock, par value |
$ 0.01
|
$ 0.01
|
$ 0.01
|
Preferred stock, shares authorized |
2,000
|
2,000
|
2,000
|
Preferred stock, shares issued |
401
|
|
|
Preferred stock, shares outstanding |
401
|
|
0
|
Series H2 Convertible Preferred Stock [Member] |
|
|
|
Class of Stock [Line Items] |
|
|
|
Preferred stock, par value |
$ 0.01
|
|
$ 0.01
|
Preferred stock, shares authorized |
21
|
|
21
|
Preferred stock, shares issued |
0
|
|
21
|
Preferred stock, shares outstanding |
0
|
|
21
|
Series A Junior Participating Preferred Stock [Member] |
|
|
|
Class of Stock [Line Items] |
|
|
|
Preferred stock, par value |
$ 0.01
|
|
$ 0.01
|
Preferred stock, shares authorized |
20,000
|
|
20,000
|
Preferred stock, shares outstanding |
0
|
|
0
|
Series A Convertible Preferred Stock [Member] |
|
|
|
Class of Stock [Line Items] |
|
|
|
Preferred stock, par value |
$ 0.01
|
|
$ 0.01
|
Preferred stock, shares authorized |
313,960
|
|
313,960
|
Preferred stock, shares outstanding |
0
|
|
0
|
Series B Convertible Preferred Stock [Member] |
|
|
|
Class of Stock [Line Items] |
|
|
|
Preferred stock, par value |
$ 0.01
|
|
$ 0.01
|
Preferred stock, shares authorized |
|
|
279,256
|
Preferred stock, shares outstanding |
0
|
|
0
|
Series C Convertible Preferred Stock [Member] |
|
|
|
Class of Stock [Line Items] |
|
|
|
Preferred stock, par value |
$ 0.01
|
|
$ 0.01
|
Preferred stock, shares authorized |
88,098
|
|
88,098
|
Preferred stock, shares outstanding |
0
|
|
0
|
Series E Convertible Preferred Stock [Member] |
|
|
|
Class of Stock [Line Items] |
|
|
|
Preferred stock, par value |
$ 0.01
|
|
$ 0.01
|
Preferred stock, shares authorized |
500
|
|
500
|
Preferred stock, shares outstanding |
0
|
|
0
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13
Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef -Topic 272 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483014/272-10-45-3
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 272 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482987/272-10-50-1
Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(d)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(27)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3
+ Details
Name: |
us-gaap_ClassOfStockLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionValue of the difference between preference in liquidation and the par or stated values of the preferred shares.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(d)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
+ Details
Name: |
us-gaap_PreferredStockLiquidationPreferenceValue |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionFace amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_PreferredStockParOrStatedValuePerShare |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionThe maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_PreferredStockSharesAuthorized |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionTotal number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_PreferredStockSharesIssued |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionAggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1
Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_PreferredStockSharesOutstanding |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=PBIO_SeriesDConvertiblePreferredStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=PBIO_SeriesHConvertiblePreferredStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=PBIO_SeriesGConvertiblePreferredStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=PBIO_SeriesJConvertiblePreferredStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=PBIO_SeriesKConvertiblePreferredStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=PBIO_SeriesAAConvertiblePreferredStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=PBIO_SeriesBBConvertiblePreferredStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=PBIO_SeriesCCConvertiblePreferredStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=PBIO_SeriesH2ConvertiblePreferredStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=PBIO_SeriesAJuniorParticipatingPreferredStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=PBIO_SeriesAConvertiblePreferredStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=PBIO_SeriesBConvertiblePreferredStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=PBIO_SeriesCConvertiblePreferredStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=PBIO_SeriesEConvertiblePreferredStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.23.3
Schedule of Concerning Options and Warrants Outstanding and Exercisable (Details)
|
9 Months Ended |
Sep. 30, 2023
$ / shares
shares
|
Accumulated Other Comprehensive Income (Loss) [Line Items] |
|
Shares, Beginning balance |
17,586,591
|
Exercisable, Beginning balance |
17,570,591
|
Shares, Granted |
2,330,484
|
Shares, Exercised |
(117,552)
|
Shares, Expired |
(645,829)
|
Shares, Forfeited |
|
Shares, Ending balance |
19,153,694
|
Exercisable, Ending balance |
18,289,721
|
Stock Options [Member] |
|
Accumulated Other Comprehensive Income (Loss) [Line Items] |
|
Shares, Beginning balance |
1,307,822
|
Weighted average price per share, Beginning balance | $ / shares |
$ 0.72
|
Shares, Granted |
2,230,484
|
Weighted average price per share, Granted | $ / shares |
$ 1.50
|
Shares, Exercised |
(117,552)
|
Weighted average price per share, Exercised | $ / shares |
$ 0.69
|
Shares, Expired |
|
Weighted average price per share, Expired | $ / shares |
|
Shares, Forfeited |
|
Weighted average price per share, Forfeited | $ / shares |
|
Shares, Ending balance |
3,420,754
|
Weighted average price per share, Ending balance | $ / shares |
$ 1.23
|
Exercisable, Ending balance |
2,556,781
|
Warrant [Member] |
|
Accumulated Other Comprehensive Income (Loss) [Line Items] |
|
Shares, Beginning balance |
16,278,769
|
Weighted average price per share, Beginning balance | $ / shares |
$ 3.50
|
Shares, Granted |
100,000
|
Weighted average price per share, Granted | $ / shares |
$ 3.50
|
Shares, Exercised |
|
Weighted average price per share, Exercised | $ / shares |
|
Shares, Expired |
(645,829)
|
Weighted average price per share, Expired | $ / shares |
$ 3.50
|
Shares, Forfeited |
|
Weighted average price per share, Forfeited | $ / shares |
|
Shares, Ending balance |
15,732,940
|
Weighted average price per share, Ending balance | $ / shares |
$ 3.50
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482765/220-10-50-4
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20
+ Details
Name: |
us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionNumber of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionGross number of share options (or share units) granted during the period.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNumber of options outstanding, including both vested and non-vested options.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionWeighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionWeighted average price at which option holders acquired shares when converting their stock options into shares.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionWeighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionWeighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionWeighted average per share amount at which grantees can acquire shares of common stock by exercise of options.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNumber of share options (or share units) exercised during the current period.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_StatementEquityComponentsAxis=PBIO_StockOptionsMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.23.3
Stockholders’ Deficit (Details Narrative)
|
|
3 Months Ended |
9 Months Ended |
|
|
|
Apr. 13, 2023
USD ($)
shares
|
Sep. 30, 2023
USD ($)
$ / shares
shares
|
Jun. 30, 2023
USD ($)
shares
|
Mar. 31, 2023
USD ($)
shares
|
Sep. 30, 2022
USD ($)
$ / shares
shares
|
Jun. 30, 2022
USD ($)
shares
|
Mar. 31, 2022
USD ($)
shares
|
Sep. 30, 2023
USD ($)
Integer
$ / shares
shares
|
Sep. 30, 2022
USD ($)
$ / shares
shares
|
May 01, 2023
$ / shares
shares
|
Dec. 31, 2022
$ / shares
shares
|
Dec. 30, 2021
shares
|
Class of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Debt instrument, convertible price per shares | $ / shares |
|
|
|
|
|
|
|
$ 2.50
|
|
|
|
|
Debt instrument, convertible, threshold trading days | Integer |
|
|
|
|
|
|
|
5
|
|
|
|
|
Number of common stock for services rendered | $ |
|
$ 325,301
|
$ 172,400
|
$ 1,419,335
|
$ 167,375
|
$ 67,800
|
$ 77,700
|
|
|
|
|
|
Convertible debt issuances value | $ |
|
|
10,017,212
|
509,033
|
|
|
350,500
|
|
|
|
|
|
Options outstanding, shares |
|
19,153,694
|
|
|
|
|
|
19,153,694
|
|
|
17,586,591
|
|
Number of options, exercisable |
|
18,289,721
|
|
|
|
|
|
18,289,721
|
|
|
17,570,591
|
|
Extension of warrants for series AA preferred stock | $ |
|
|
|
|
|
|
|
$ 3,626,950
|
|
|
|
|
Interest expense | $ |
|
$ 4,338,759
|
|
|
2,034,021
|
|
|
$ 14,112,098
|
$ 6,448,771
|
|
|
|
Fair value of dividends paid in kind | $ |
|
$ 150,000
|
491,634
|
1,029,939
|
1,050,475
|
191,303
|
472,900
|
|
|
|
|
|
Shares isused for options exercised, shares |
|
|
|
|
|
|
|
117,552
|
|
|
|
|
Lender [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
Class of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Shares issued, price per share | $ / shares |
|
$ 0.69
|
|
|
|
|
|
$ 0.69
|
|
|
|
|
Issued For Services Rendered [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
Class of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Number of common stock for services rendered, shares |
|
|
|
|
|
|
|
|
190,500
|
|
|
|
Number of common stock for services rendered | $ |
|
|
|
|
|
|
|
$ 1,917,036
|
|
|
|
|
Conversion of Debt Extension [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
Class of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Convertible debt issuances shares |
|
|
|
|
|
|
|
|
140,200
|
|
|
|
Convertible debt issuances value | $ |
|
|
|
|
|
|
|
|
$ 350,500
|
|
|
|
Stock Issued During Period, Shares, New Issues |
|
|
|
|
|
|
|
203,613
|
|
|
|
|
Fair value of dividends paid in kind | $ |
|
|
|
|
|
|
|
$ 509,033
|
|
|
|
|
Debt Settlement [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
Class of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Shares isused for options exercised, shares |
|
|
|
|
|
|
|
117,552
|
|
|
|
|
Debt Extension [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
Class of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Stock Issued During Period, Shares, New Issues |
|
|
|
|
|
|
|
1,346,800
|
|
|
|
|
Fair value of dividends paid in kind | $ |
|
|
|
|
|
|
|
$ 1,671,573
|
|
|
|
|
New Common Stock Issuances [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
Class of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Stock Issued During Period, Shares, New Issues |
|
|
|
|
|
|
|
60,000
|
|
|
|
|
Fair value of dividends paid in kind | $ |
|
|
|
|
|
|
|
$ 150,000
|
|
|
|
|
Conversion of Preferred to Common Stock [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
Class of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Convertible debt issuances shares |
|
|
|
|
|
|
|
1,486,940
|
|
|
|
|
Series AA Preferred Stock [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
Class of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Fair value of dividends paid in kind | $ |
|
|
|
|
|
|
|
|
$ 1,714,678
|
|
|
|
Payment in Kind (PIK) Note [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
Class of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Stock Issued During Period, Shares, New Issues |
|
|
|
|
|
|
|
|
1,172,100
|
|
|
|
Fair value of dividends paid in kind | $ |
|
|
|
|
|
|
|
|
$ 2,196,278
|
|
|
|
Dividends Paid In Kind [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
Class of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Stock Issued During Period, Shares, New Issues |
|
|
|
|
|
|
|
142,767
|
|
|
|
|
Fair value of dividends paid in kind | $ |
|
|
|
|
|
|
|
$ 162,528
|
|
|
|
|
Accredited Investor and Consultants [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
Class of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Shares of restricted common stock |
|
|
|
|
|
|
|
9,717,035
|
|
|
|
|
Unvested Stock-Based Awards [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
Class of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Unvested stock based awards | $ |
|
$ 963,322
|
|
|
|
|
|
$ 963,322
|
|
|
|
|
Unrecognized compensation, period |
|
|
|
|
|
|
|
2 years 2 months 12 days
|
|
|
|
|
Closing stock price | $ / shares |
|
$ 0.20
|
|
|
|
|
|
$ 0.20
|
|
|
|
|
Options outstanding and exercisable intrinsic value | $ |
|
$ 0.00
|
|
|
|
|
|
$ 0.00
|
|
|
|
|
2021 Equity Incentive Plan [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
Class of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Common stock, capital shares reserved for future issuance |
|
|
|
|
|
|
|
|
|
|
|
3,000,000
|
Options outstanding, shares |
|
3,420,754
|
|
|
|
|
|
3,420,754
|
|
|
|
|
Series BB Restricted Preferred Stock [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
Class of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Shares of restricted common stock |
|
|
|
|
|
|
|
953
|
|
|
|
|
Series CC Restricted Preferred Stock [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
Class of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Shares of restricted common stock |
|
|
|
|
|
|
|
401
|
|
|
|
|
Restricted Stock [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
Class of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Shares of restricted common stock |
|
|
|
|
|
|
|
|
3,100,085
|
|
|
|
Preferred Stock [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
Class of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Preferred Stock, Shares Issued |
|
1,000,000
|
|
|
|
|
|
1,000,000
|
|
|
|
|
Number of common stock for services rendered | $ |
|
|
|
|
|
|
|
|
|
|
|
|
Convertible debt issuances shares |
|
|
401
|
|
|
|
|
|
|
|
|
|
Convertible debt issuances value | $ |
|
|
$ 4
|
|
|
|
|
|
|
|
|
|
Extension of warrants for series AA preferred stock | $ |
|
|
|
|
|
|
|
|
|
|
|
|
Fair value of dividends paid in kind | $ |
|
|
|
|
|
|
|
|
|
|
|
|
Common Stock [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
Class of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Number of common stock for services rendered, shares |
|
492,500
|
147,500
|
990,500
|
113,500
|
40,000
|
37,000
|
|
|
|
|
|
Number of common stock for services rendered | $ |
|
$ 4,926
|
$ 1,475
|
$ 9,905
|
$ 1,135
|
$ 400
|
$ 370
|
|
|
|
|
|
Convertible debt issuances shares |
|
|
|
203,613
|
|
|
140,200
|
|
|
|
|
|
Convertible debt issuances value | $ |
|
|
|
$ 2,036
|
|
|
$ 1,402
|
|
|
|
|
|
Stock issued during period, value, other |
|
|
|
|
|
|
|
95
|
|
|
|
|
Extension of warrants for series AA preferred stock | $ |
|
|
|
|
|
|
|
|
|
|
|
|
Interest expense | $ |
|
|
|
|
|
|
|
$ 3,715,204
|
$ 634,305
|
|
|
|
Stock Issued During Period, Shares, New Issues |
|
250,000
|
528,600
|
568,200
|
707,900
|
106,400
|
214,500
|
|
|
|
|
|
Fair value of dividends paid in kind | $ |
|
$ 2,500
|
$ 5,286
|
$ 5,682
|
$ 7,079
|
$ 1,064
|
$ 2,145
|
|
|
|
|
|
Shares isused for options exercised, shares |
|
|
|
117,552
|
|
25,279
|
|
|
|
|
|
|
Common Stock [Member] | Issued For Services Rendered [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
Class of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Fair value of warrants | $ |
|
|
|
|
|
|
|
$ 312,875
|
|
|
|
|
Common Stock [Member] | Debt Extension [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
Class of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Stock Issued During Period, Shares, New Issues |
|
|
|
|
|
|
|
|
25,279
|
|
|
|
Fair value of dividends paid in kind | $ |
|
|
|
|
|
|
|
|
$ 17,433
|
|
|
|
Common Stock [Member] | New Conversion Debt [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
Class of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Stock Issued During Period, Shares, New Issues |
|
|
|
|
|
|
|
|
368,500
|
|
|
|
Fair value of dividends paid in kind | $ |
|
|
|
|
|
|
|
|
$ 512,593
|
|
|
|
Common Stock [Member] | Payment in Kind (PIK) Note [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
Class of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Stock Issued During Period, Shares, New Issues |
|
|
|
|
|
|
|
170,306
|
|
|
|
|
Fair value of dividends paid in kind | $ |
|
|
|
|
|
|
|
|
$ 306,333
|
|
|
|
Stock Options [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
Class of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Options outstanding, shares |
|
3,420,754
|
|
|
|
|
|
3,420,754
|
|
|
1,307,822
|
|
Weighted average exercise price | $ / shares |
|
$ 1.23
|
|
|
|
|
|
$ 1.23
|
|
|
$ 0.72
|
|
Weighted average remaining term |
|
|
|
|
|
|
|
8 years 1 month 20 days
|
|
|
|
|
Number of options, exercisable |
|
2,556,781
|
|
|
|
|
|
2,556,781
|
|
|
|
|
Shares isused for options exercised, shares |
|
|
|
|
|
|
|
117,552
|
|
|
|
|
Exercisable Options [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
Class of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average remaining term |
|
|
|
|
|
|
|
7 years 9 months
|
|
|
|
|
Warrant [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
Class of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Number of common stock for services rendered | $ |
|
|
|
|
|
|
|
|
|
|
|
|
Convertible debt issuances value | $ |
|
|
|
|
|
|
|
|
|
|
|
|
Options outstanding, shares |
|
15,732,940
|
|
|
|
|
|
15,732,940
|
|
|
16,278,769
|
|
Weighted average exercise price | $ / shares |
|
$ 3.50
|
|
|
|
|
|
$ 3.50
|
|
|
$ 3.50
|
|
Weighted average remaining term |
|
|
|
|
|
|
|
2 years 5 months 1 day
|
|
|
|
|
Class of warrant or right, outstanding |
8,897,603
|
|
|
|
|
|
|
|
|
|
|
|
Extension of warrants for series AA preferred stock | $ |
$ 3,626,950
|
|
3,626,950
|
|
|
|
|
|
|
|
|
|
Fair value of dividends paid in kind | $ |
|
|
|
|
|
|
|
|
|
|
|
|
Shares isused for options exercised, shares |
|
|
|
|
|
|
|
|
|
|
|
|
Issuance warrants, shares |
|
100,000
|
|
|
277,500
|
|
|
100,000
|
277,500
|
|
|
|
Strike price, per share | $ / shares |
|
$ 3.50
|
|
|
$ 3.50
|
|
|
$ 3.50
|
$ 3.50
|
|
|
|
Fair value of warrants | $ |
|
|
|
|
|
|
|
$ 61,609
|
$ 280,608
|
|
|
|
Common Stock and Warrant [Member] | Issued For Services Rendered [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
Class of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Number of common stock for services rendered, shares |
|
|
|
|
|
|
|
1,630,500
|
|
|
|
|
Common Stock and Warrant [Member] | Conversion of Debt Extension [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
Class of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Convertible debt issuances shares |
|
|
|
|
|
|
|
1,258,742
|
|
|
|
|
Convertible debt issuances value | $ |
|
|
|
|
|
|
|
$ 1,293,270
|
|
|
|
|
Common Stock and Warrant [Member] | Payment in Kind (PIK) Note [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
Class of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Stock Issued During Period, Shares, New Issues |
|
|
|
|
|
|
|
4,094,121
|
|
|
|
|
Fair value of dividends paid in kind | $ |
|
|
|
|
|
|
|
$ 3,715,204
|
|
|
|
|
Series AA Preferred Stock [Member] | Debt Extension [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
Class of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Stock issued during period, value, other |
|
|
|
|
|
|
|
|
4,400
|
|
|
|
Stock Issued During Period, Shares, New Issues |
|
|
|
|
|
|
|
|
1,028,800
|
|
|
|
Preferred Stock [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
Class of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Convertible preferred stock, authorized |
|
1,000,000
|
|
|
|
|
|
1,000,000
|
|
|
|
|
Convertible preferred stock, par value | $ / shares |
|
$ 0.01
|
|
|
|
|
|
$ 0.01
|
|
|
|
|
Series BB Convertible Preferred Stock [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
Class of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Convertible preferred stock, authorized |
|
1,000
|
|
|
|
|
|
1,000
|
|
1,000
|
1,000
|
|
Convertible preferred stock, par value | $ / shares |
|
$ 0.01
|
|
|
|
|
|
$ 0.01
|
|
$ 0.01
|
$ 0.01
|
|
Preferred Stock, Shares Issued |
|
858
|
|
|
|
|
|
858
|
|
|
|
|
Series CC Convertible Preferred Stock [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
Class of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Convertible preferred stock, authorized |
|
2,000
|
|
|
|
|
|
2,000
|
|
2,000
|
2,000
|
|
Convertible preferred stock, par value | $ / shares |
|
$ 0.01
|
|
|
|
|
|
$ 0.01
|
|
$ 0.01
|
$ 0.01
|
|
Preferred Stock, Shares Issued |
|
401
|
|
|
|
|
|
401
|
|
|
|
|
Series BB Preferred Stock [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
Class of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Convertible preferred stock, par value | $ / shares |
|
$ 0.01
|
|
|
|
|
|
$ 0.01
|
|
|
|
|
Preferred stock voting rights |
|
|
|
|
|
|
|
The holders of Series BB Preferred Stock shall have the right to vote along with the holders of Common Stock in an amount equal to 10,000
votes for each share of Series BB Preferred Stock held
|
|
|
|
|
Number of shares converted |
|
|
|
|
|
|
|
10,000
|
|
|
|
|
Debt instrument, interest rate, stated percentage |
|
300.00%
|
|
|
|
|
|
300.00%
|
|
|
|
|
Debt instrument, convertible price per shares | $ / shares |
|
|
|
|
|
|
|
$ 2.50
|
|
|
|
|
Number of common stock for services rendered, shares |
|
|
|
|
|
|
|
92
|
|
|
|
|
Number of common stock for services rendered | $ |
|
|
|
|
|
|
|
$ 617,200
|
|
|
|
|
Convertible debt issuances shares |
|
|
|
|
|
|
|
741
|
|
|
|
|
Convertible debt issuances value | $ |
|
|
|
|
|
|
|
$ 2,683,600
|
|
|
|
|
Stock issued during period, value, other |
|
|
|
|
|
|
|
62
|
|
|
|
|
Series BB Preferred Stock [Member] | Preferred Stock [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
Class of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Stock issued during period, value, other |
|
|
|
|
|
|
|
58
|
|
|
|
|
Stock issued during period, value, conversion of units | $ |
|
|
|
|
|
|
|
$ 539,487
|
|
|
|
|
Series CC Preferred Stock [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
Class of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Debt instrument, interest rate, stated percentage |
|
8.00%
|
|
|
|
|
|
8.00%
|
|
|
|
|
Preferred stock remain outstanding percentage |
|
|
|
|
|
|
|
10.00%
|
|
|
|
|
Preferred stock, dividend rate, percentage |
|
|
|
|
|
|
|
75.00%
|
|
|
|
|
Outstanding shares, precentage |
|
50.00%
|
|
|
|
|
|
50.00%
|
|
|
|
|
Preferred stock liquidation Preference value | $ / shares |
|
$ 25,000.00
|
|
|
|
|
|
$ 25,000.00
|
|
|
|
|
Preferred stock, convertible, conversion price | $ / shares |
|
$ 2.50
|
|
|
|
|
|
$ 2.50
|
|
|
|
|
Debt instrument, convertible, threshold percentage of stock price trigger |
|
|
|
|
|
|
|
300.00%
|
|
|
|
|
Debt instrument, convertible, threshold trading days | Integer |
|
|
|
|
|
|
|
10
|
|
|
|
|
Debt instrument convertible benefically percentage |
|
|
|
|
|
|
|
4.99%
|
|
|
|
|
Stock issued during period, shares, other |
|
|
|
|
|
|
|
401
|
|
|
|
|
Stock Issued During Period, Value, Other | $ |
|
|
|
|
|
|
|
$ 10,017,212
|
|
|
|
|
X |
- DefinitionDebt instrument convertible benefically percentage.
+ References
+ Details
Name: |
PBIO_DebtInstrumentConvertibleBeneficallyPercentage |
Namespace Prefix: |
PBIO_ |
Data Type: |
dtr-types:percentItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionExtension of warrants for series AA preferred stock.
+ References
+ Details
Name: |
PBIO_ExtensionOfWarrantsForSeriesAaPreferredStock |
Namespace Prefix: |
PBIO_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionPercentage of outstanding shares.
+ References
+ Details
Name: |
PBIO_PercentageOfOutstandingShares |
Namespace Prefix: |
PBIO_ |
Data Type: |
dtr-types:percentItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionPreferred stock outstanding percentage.
+ References
+ Details
Name: |
PBIO_PreferredStockOutstandingPercentage |
Namespace Prefix: |
PBIO_ |
Data Type: |
dtr-types:percentItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAggregate intrinsic value of options outstanding and exerciasable.
+ References
+ Details
Name: |
PBIO_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableIntrinsicValue |
Namespace Prefix: |
PBIO_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13
Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef -Topic 272 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483014/272-10-45-3
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 272 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482987/272-10-50-1
Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(d)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(27)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3
+ Details
Name: |
us-gaap_ClassOfStockLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionExercise price per share or per unit of warrants or rights outstanding.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3
+ Details
Name: |
us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionNumber of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3
+ Details
Name: |
us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionNumber of warrants or rights outstanding.
+ References
+ Details
Name: |
us-gaap_ClassOfWarrantOrRightOutstanding |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionAggregate number of common shares reserved for future issuance.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_CommonStockCapitalSharesReservedForFutureIssuance |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionThe number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5
+ Details
Name: |
us-gaap_ConversionOfStockSharesConverted1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionPrice of the entity's common stock which would be required to be attained for the conversion feature embedded in the debt instrument to become effective.
+ References
+ Details
Name: |
us-gaap_DebtInstrumentConvertibleStockPriceTrigger |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionMinimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion.
+ References
+ Details
Name: |
us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:percentItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThreshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature.
+ References
+ Details
Name: |
us-gaap_DebtInstrumentConvertibleThresholdTradingDays |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:integerItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionContractual interest rate for funds borrowed, under the debt agreement.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22(a)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_DebtInstrumentInterestRateStatedPercentage |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:percentItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionAmount of cost not yet recognized for nonvested award under share-based payment arrangement.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionWeighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:durationItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of expense (income) related to adjustment to fair value of warrant liability.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 25 -Paragraph 13 -SubTopic 10 -Topic 480 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481766/480-10-25-13
+ Details
Name: |
us-gaap_FairValueAdjustmentOfWarrants |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount of the cost of borrowed funds accounted for as interest expense.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483581/946-220-45-3
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(3)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3
Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04.9) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (210.5-03(11)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483013/835-20-50-1
+ Details
Name: |
us-gaap_InterestExpense |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionPer share conversion price of preferred stock.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13
+ Details
Name: |
us-gaap_PreferredStockConvertibleConversionPrice |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionThe percentage rate used to calculate dividend payments on preferred stock.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.12-12A(Column A)(Footnote 3)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-2
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-12(Column A)(Footnote 4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column A)(Footnote 3)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column A)(Footnote 3)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6
+ Details
Name: |
us-gaap_PreferredStockDividendRatePercentage |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:percentItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe per share liquidation preference (or restrictions) of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(d)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3
Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-4
Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13
+ Details
Name: |
us-gaap_PreferredStockLiquidationPreference |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionFace amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_PreferredStockParOrStatedValuePerShare |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionThe maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_PreferredStockSharesAuthorized |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionTotal number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_PreferredStockSharesIssued |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionDescription of voting rights of nonredeemable preferred stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3
+ Details
Name: |
us-gaap_PreferredStockVotingRights |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionNumber of options outstanding, including both vested and non-vested options.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionWeighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionPrice of a single share of a number of saleable stocks of a company.
+ References
+ Details
Name: |
us-gaap_SharePrice |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionWeighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Subparagraph (e)(1) -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:durationItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionPer share or per unit amount of equity securities issued.
+ References
+ Details
Name: |
us-gaap_SharesIssuedPricePerShare |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionNumber of shares issued during the period as a result of the conversion of convertible securities.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1
Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29-30) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1
Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNumber of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.
+ References
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodSharesIssuedForServices |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNumber of new stock issued during the period.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1
Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodSharesNewIssues |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNumber of shares of stock issued attributable to transactions classified as other.
+ References
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodSharesOther |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTotal number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNumber of share options (or share units) exercised during the current period.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe gross value of stock issued during the period upon the conversion of convertible securities.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29-31) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionValue of stock issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29-31) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodValueConversionOfUnits |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionValue of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.
+ References
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodValueIssuedForServices |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionEquity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2
Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1
Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodValueNewIssues |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionValue of shares of stock issued attributable to transactions classified as other.
+ References
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodValueOther |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_ClassOfWarrantOrRightAxis=PBIO_LenderMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_StatementScenarioAxis=PBIO_IssuedForServicesRenderedMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_StatementScenarioAxis=PBIO_ConversionOfDebtMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_StatementScenarioAxis=PBIO_DebtSettlementMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_StatementScenarioAxis=PBIO_DebtExtensionMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_StatementScenarioAxis=PBIO_NewCommonStockIssuancesMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_StatementScenarioAxis=PBIO_ConversionOfPreferredToCommonStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_StatementScenarioAxis=PBIO_SeriesAAPreferredStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_LongtermDebtTypeAxis=us-gaap_PaymentInKindPIKNoteMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_LongtermDebtTypeAxis=PBIO_DividendsPaidInKindMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_VestingAxis=PBIO_UnvestedStockBasedAwardsMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_PlanNameAxis=PBIO_TwoThousandAndTwentyOneEquityIncentivePlanMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_AwardTypeAxis=PBIO_SeriesBBRestrictedPreferredStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_AwardTypeAxis=PBIO_SeriesCCRestrictedPreferredStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_StatementScenarioAxis=PBIO_NewConversionDebtMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementEquityComponentsAxis=PBIO_StockOptionsMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementEquityComponentsAxis=PBIO_ExercisableOptionsMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementEquityComponentsAxis=PBIO_CommonStockAndWarrantMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementEquityComponentsAxis=PBIO_SeriesAAPreferredStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=PBIO_SeriesBBConvertiblePreferredStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=PBIO_SeriesCCConvertiblePreferredStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=PBIO_SeriesBBPreferredStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=PBIO_SeriesCCPreferredStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.23.3
Subsequent Events (Details Narrative) - USD ($)
|
|
1 Months Ended |
3 Months Ended |
9 Months Ended |
|
Oct. 18, 2023 |
Nov. 05, 2023 |
Sep. 30, 2023 |
Jun. 30, 2023 |
Mar. 31, 2023 |
Sep. 30, 2022 |
Jun. 30, 2022 |
Mar. 31, 2022 |
Sep. 30, 2023 |
Dec. 31, 2022 |
Subsequent Event [Line Items] |
|
|
|
|
|
|
|
|
|
|
common stock, par value |
|
|
$ 0.01
|
|
|
|
|
|
$ 0.01
|
$ 0.01
|
Stock option number of shares granted |
|
|
|
|
|
|
|
|
2,330,484
|
|
Common Stock [Member] |
|
|
|
|
|
|
|
|
|
|
Subsequent Event [Line Items] |
|
|
|
|
|
|
|
|
|
|
Stock Issued During Period, Shares, Issued for Services |
|
|
492,500
|
147,500
|
990,500
|
113,500
|
40,000
|
37,000
|
|
|
Stock Issued During Period, Shares, Conversion of Units |
|
|
|
|
|
|
|
|
95
|
|
Common stock issued for debt extension, shares |
|
|
250,000
|
528,600
|
568,200
|
707,900
|
106,400
|
214,500
|
|
|
Minimum [Member] |
|
|
|
|
|
|
|
|
|
|
Subsequent Event [Line Items] |
|
|
|
|
|
|
|
|
|
|
Debt interest rate |
|
|
1.00%
|
|
|
|
|
|
1.00%
|
|
Maximum [Member] |
|
|
|
|
|
|
|
|
|
|
Subsequent Event [Line Items] |
|
|
|
|
|
|
|
|
|
|
Debt interest rate |
|
|
10.00%
|
|
|
|
|
|
10.00%
|
|
Subsequent Event [Member] |
|
|
|
|
|
|
|
|
|
|
Subsequent Event [Line Items] |
|
|
|
|
|
|
|
|
|
|
Convertible Debt |
|
$ 439,000
|
|
|
|
|
|
|
|
|
Share Price |
|
$ 2.50
|
|
|
|
|
|
|
|
|
Subsequent Event [Member] | Board of Directors Chairman [Member] |
|
|
|
|
|
|
|
|
|
|
Subsequent Event [Line Items] |
|
|
|
|
|
|
|
|
|
|
Stock option number of shares granted |
1,500,000
|
|
|
|
|
|
|
|
|
|
Numberof stock option exercise price |
$ 0.25
|
|
|
|
|
|
|
|
|
|
Number of years option vested |
3 years
|
|
|
|
|
|
|
|
|
|
Subsequent Event [Member] | Board of Directors Chairman [Member] | Two Thousand Twenty One Equity Plan [Member] |
|
|
|
|
|
|
|
|
|
|
Subsequent Event [Line Items] |
|
|
|
|
|
|
|
|
|
|
Common stock issued for debt extension, shares |
300,000
|
|
|
|
|
|
|
|
|
|
common stock, par value |
$ 0.01
|
|
|
|
|
|
|
|
|
|
Shares of common stock |
500,000
|
|
|
|
|
|
|
|
|
|
Subsequent Event [Member] | Mr Schumacher [Member] |
|
|
|
|
|
|
|
|
|
|
Subsequent Event [Line Items] |
|
|
|
|
|
|
|
|
|
|
Number of option vested percentage |
25.00%
|
|
|
|
|
|
|
|
|
|
Subsequent Event [Member] | Drs Ting [Member] |
|
|
|
|
|
|
|
|
|
|
Subsequent Event [Line Items] |
|
|
|
|
|
|
|
|
|
|
Number of option vested percentage |
25.00%
|
|
|
|
|
|
|
|
|
|
Subsequent Event [Member] | Lazarev [Member] |
|
|
|
|
|
|
|
|
|
|
Subsequent Event [Line Items] |
|
|
|
|
|
|
|
|
|
|
Number of option vested percentage |
25.00%
|
|
|
|
|
|
|
|
|
|
Number of option issuance percentage |
25.00%
|
|
|
|
|
|
|
|
|
|
Subsequent Event [Member] | Executive Officer [Member] |
|
|
|
|
|
|
|
|
|
|
Subsequent Event [Line Items] |
|
|
|
|
|
|
|
|
|
|
Numberof stock option exercise price |
$ 0.25
|
|
|
|
|
|
|
|
|
|
Subsequent Event [Member] | Series BB Convertible Preferred Stock [Member] |
|
|
|
|
|
|
|
|
|
|
Subsequent Event [Line Items] |
|
|
|
|
|
|
|
|
|
|
Stock Issued During Period, Shares, Other |
|
40
|
|
|
|
|
|
|
|
|
Stock Issued During Period, Shares, Conversion of Units |
|
505,000
|
|
|
|
|
|
|
|
|
Subsequent Event [Member] | Common Stock [Member] |
|
|
|
|
|
|
|
|
|
|
Subsequent Event [Line Items] |
|
|
|
|
|
|
|
|
|
|
Stock Issued During Period, Shares, Issued for Services |
|
278,500
|
|
|
|
|
|
|
|
|
Stock Issued During Period, Shares, Other |
|
455,350
|
|
|
|
|
|
|
|
|
Stock Issued During Period, Shares, Conversion of Units |
|
145,809
|
|
|
|
|
|
|
|
|
Subsequent Event [Member] | Minimum [Member] |
|
|
|
|
|
|
|
|
|
|
Subsequent Event [Line Items] |
|
|
|
|
|
|
|
|
|
|
Debt interest rate |
|
10.00%
|
|
|
|
|
|
|
|
|
Subsequent Event [Member] | Minimum [Member] | Executive Officer [Member] |
|
|
|
|
|
|
|
|
|
|
Subsequent Event [Line Items] |
|
|
|
|
|
|
|
|
|
|
Numberof stock option exercise price |
0.69
|
|
|
|
|
|
|
|
|
|
Subsequent Event [Member] | Maximum [Member] |
|
|
|
|
|
|
|
|
|
|
Subsequent Event [Line Items] |
|
|
|
|
|
|
|
|
|
|
Debt interest rate |
|
120.00%
|
|
|
|
|
|
|
|
|
Subsequent Event [Member] | Maximum [Member] | Executive Officer [Member] |
|
|
|
|
|
|
|
|
|
|
Subsequent Event [Line Items] |
|
|
|
|
|
|
|
|
|
|
Numberof stock option exercise price |
$ 1.50
|
|
|
|
|
|
|
|
|
|
X |
- DefinitionFace amount or stated value per share of common stock.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_CommonStockParOrStatedValuePerShare |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionIncluding the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1
+ Details
Name: |
us-gaap_ConvertibleDebt |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionContractual interest rate for funds borrowed, under the debt agreement.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22(a)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_DebtInstrumentInterestRateStatedPercentage |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:percentItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionGross number of share options (or share units) granted during the period.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionWeighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionMaximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.
+ References
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:percentItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNumber of shares issued under share-based payment arrangement.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionPrice of a single share of a number of saleable stocks of a company.
+ References
+ Details
Name: |
us-gaap_SharePrice |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionPercentage of vesting of award under share-based payment arrangement.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:percentItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionWeighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Subparagraph (e)(1) -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:durationItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1
Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNumber of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.
+ References
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodSharesIssuedForServices |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNumber of new stock issued during the period.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1
Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodSharesNewIssues |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNumber of shares of stock issued attributable to transactions classified as other.
+ References
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodSharesOther |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDetail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481674/830-30-50-2
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 855 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2
+ Details
Name: |
us-gaap_SubsequentEventLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_RangeAxis=srt_MinimumMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_RangeAxis=srt_MaximumMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_PlanNameAxis=PBIO_TwoThousandTwentyOneEquityPlanMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_TitleOfIndividualAxis=PBIO_MrSchumacherMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_TitleOfIndividualAxis=PBIO_DrsTingMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_TitleOfIndividualAxis=PBIO_LazarevMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_TitleOfIndividualAxis=srt_ExecutiveOfficerMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=PBIO_SeriesBBConvertiblePreferredStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
Pressure Biosciences (CE) (USOTC:PBIO)
Historical Stock Chart
From Jul 2024 to Aug 2024
Pressure Biosciences (CE) (USOTC:PBIO)
Historical Stock Chart
From Aug 2023 to Aug 2024